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People living with HIV (PLWH) accessing antiretroviral therapy (ART) report worse mental well-being 
than general populations and those with other chronic conditions.   
Aim  
To evaluate the effectiveness of a nurse-led palliative care intervention on the mental well-being of 
PLWH on ART in Kenya compared with standard care. 
Methods 
A randomised controlled trial (RCT) with longitudinal monthly follow-up over five time points and 
qualitative exit interviews was conducted.  The primary outcome was psychological quality of life 
(Medical Outcome Study-HIV), with secondary outcomes being psychiatric morbidity, worry and 
ability to share feelings.  Eligible participants were adults on ART reporting moderate to severe pain 
or other symptoms.  Analyses included ordered logistic regression at monthly time points and 
multilevel modeling to identify intervention benefit.  A purposive subsample of 30 participants 
across both study arms were selected for qualitative interviewing.  Thematic analysis explored active 
ingredients of the intervention and experiences of study participation.   
Results 
16% of all patients screened were eligible; 56% refused to participate.  120 patients were recruited 
(mean age 39, SD 8.9, 81% female) and equally randomised to each study arm.  Quantitative data 
analysis found significant benefit of the intervention in psychological quality of life (coefficient 0.59 
(CI 0.12-1.07), p=0.015), psychiatric morbidity (coefficient -0.50 (CI-0.96 to -0.03), p=0.035) and 
ability to share feelings (coefficient 0.92 (CI 0.28-1.56), p=0.005).  Qualitative analysis identified 
three active ingredients of the intervention: insight and understanding, medication and time.  
Unresolved physical, social and financial problems were identified as barriers to improvement.  
Aspects of study participation found to improve mental health and well-being were compassionate 




The intervention was effective in improving mental well-being through health information, symptom 
relief and enabling participants to articulate problems.  Aspects of study participation benefited 
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Despite much medical and scientific progress, HIV infection remains a significant and persistent 
problem, with approximately 35 million people living with HIV (PLWH) worldwide in 2012 (1).  
Infection erodes immunity, increasing susceptibility to infection, and if left untreated leads to 
premature death from opportunistic infections or AIDS-associated cancers (2).  Treatment consists of 
a combination of three medications that control virus replication, but are as yet unable to 
completely eradicate it (3).  Infection is highly stigmatised, with socio-cultural associations of 
immorality, promiscuity and deviance (4, 5).   
The experience of living with HIV has been revolutionised by recent medical advances in the field of 
HIV treatment and care, which have transformed the prognosis from a potentially imminent, 
physically painful and socially isolated death, to that of a chronic condition, manageable with a 
combination of medications and monitoring of immune functions (6, 7).  These developments have 
also reduced the infectiousness of HIV, thus reducing HIV transmission and prompting further policy 
changes to widen eligibility criteria (8).  This has led international stakeholders to declare the 
possibility of a future AIDS free generation (9, 10).   
Clinical research conducted in the UK, USA and sub Saharan Africa (SSA) has highlighted the 
persistent symptom burden experienced by PLWH on ART.  A cross sectional study conducted to 
assess the symptom burden of PLWH on ART in South Africa revealed continued high prevalence of 
psychological symptoms including sadness, irritability and worry, in addition to physical symptoms 
such as numbness and pain (11).  These findings have been replicated in clinics in the UK (12) and 
the USA (13, 14), all describing a similar situation of unaddressed psychological and physical 
symptoms in PLWH on ART.  Of prime concern is the prevalence of depression and anxiety in PLWH 
established on ART, which is greater than in the general population, and also greater than 
prevalence in patients with medically similar chronic conditions (15).   
Arguably related to this, HIV-associated stigma remains a significant challenge to PLWH and its 
reduction is a key concern of the HIV clinical, academic and activist communities, as it reduces HIV 
testing, access to treatment and treatment compliance, in addition to being negatively associated 
with quality of life and mental health and well-being (15-18).  It is important for enhanced quality of 
life for PLWH, and also clinically due to associations between poor mental health and non-adherence 
to treatment, which then leads to treatment failure (19).  A solution to these problems in terms of 
healthcare provision is therefore urgently needed.   
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Kenya is targeted in a recent UNAIDS and WHO policy document, which identifies thirty countries 
where they state that ART scale up should reach 90% of the eligible population by 2015 (9).  
Concerns have been raised that this will place increased strain on fragile healthcare systems, 
particularly in low and middle income countries (LMIC); which is especially a concern in the context 
of higher survival rates of PLWH which indicate provision of high quality services for a longer time 
period (20, 21).  Recent data reporting increased patient loss to follow up and pharmacies with 
inadequate supplies of medication for patient demand in the context of rapid programme scale up in 
Kenya have compounded these concerns (21).   
Therefore despite a growing body of knowledge on the symptom burden of PLWH on ART, there is 
limited evidence for the effectiveness of models of care to address these symptoms.  This is 
particularly troubling as the population of PLWH on ART is, firstly, continuing to grow with increased 
eligibility for ART will continue to require high quality, long term HIV treatment and care whilst 
stable on treatment (9), and secondly, is mostly being treated in the context of a rapid scale up of 
ART provision and in healthcare systems under strain in LMIC (21).  As Kenya has been appointed a 
target country in the Treatment 2015 policy document, is apparent that Kenya is at the forefront of 
developments which will shape the future of the HIV epidemic, and therefore especially as a LMIC, is 
an ideal context in which to trial a model of care for PLWH.   
Whilst a holistic approach such as palliative care has been suggested to improve the quality of life for 
PLWH (22), the effectiveness of such an approach has not yet been trialled experimentally, and thus 
there is no evidence base for programme development.  In SSA, holistic care for patients and families 
is provided through informal networks, traditional healers, or in medical contexts for patients 
diagnosed with life limiting conditions through palliative care (23).  Palliative care is a growing 
movement in SSA, with an increasingly skilled workforce and an increasing body of research 
evidence defining the need and justifying palliative care in SSA (23-26).  As such, the model of 
palliative care as a holistic and culturally appropriate approach is a potential solution to the problem 
of a model of care for PLWH to help manage the multidimensional needs of this chronic condition in 
Kenya and SSA.  
The aim of this thesis is to evaluate the effectiveness of a nurse-led palliative care intervention for 
PLWH on ART in Kenya, in terms of outcomes for mental health and well-being, and to identify the 
active ingredients and mechanisms of action associated with the intervention.  Through this 
research, a locally sourced, holistic solution to this growing problem is evaluated using a mixed 
methodology (27), with public health, academic and clinical implications and findings of relevance 




This chapter will describe the external macro and micro structures which influence the mental health 
and well-being of PLWH and the delivery of their care.  This will include a discussion of the 
international epidemiological and political context with a focus on Kenya and comparable LMIC in 
SSA.   
The chapter also includes an overview of the concepts used in this thesis: HIV and its treatment, 
mental health and well-being, mental health and HIV, and current models of care for PLWH.  It will 
conclude with a summary of the evidence which suggests a modified model of the palliative care 
approach may address the problems identified.  
1.1. HIV  
HIV belongs to a group of viruses called retroviruses and was first identified in the early 1980s.  
These first cases of HIV, before the virus was isolated, were detected when previously healthy 
individuals presented with immune deficiency and died of opportunistic infections (OI) (2).  The virus 
is transmitted through sexual contact or from mother to child during pregnancy, childbirth or 
lactation, or through sharing contaminated injecting equipment.  It replicates within the body in 
immune cells called CD4 cells, which become virus ‘factories’ before dying and releasing new copies 
of the HIV virus.  This death of CD4 immune cells leads to immune suppression and death if not 
interrupted.     
There are six classes of anti HIV drugs, called anti-retrovirals (ARV).  They work at different stages of 
the cell cycle to interrupt viral replication, demonstrated in Figure 1 in red type.  The first, most 
commonly used group are the nucleoside reverse transcriptase inhibitors (NRTIS: Zidovudine (AZT), 
Lamivudine (3TC)),  the second, the non-nucleoside reverse transcriptase inhibitors (NNRTI: 
Nevirapine (NVP), Efavirenz (EFP)) and the third, the nucleotide reverse transcriptase inhibitors 
(Tenofovir) which all interrupt the reverse transcriptase enzyme, essential in viral DNA replication.  
Protease inhibitors (PI: Nelfinavir, Lopinavir), often boosted by a low dose of Ritonavir, block 
protease, an enzyme essential in the maturation of the new virus cell.  Newer ARVs include 
Maraviroc, a CCR5 inhibitor which blocks the HIV virus from attaching to the CD4 cell thus preventing 
it from entering and replicating, and Raltegravir, an integrase inhibitor which blocks the action of the 
enzyme integrase in viral DNA reproduction (28).  Fusion inhibitors are less commonly used as they 
are administered by injection sub-cutaneously, but their mechanism of action is to prevent the HIV 
cell fusing with the CD4 cell, preventing the cell cycle from beginning. 
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Figure 1 HIV replication cycle, highlighting ART mechanisms of action (Source: Medscape.com) 
 
Antiretroviral therapy (ART) is a combination of three medications from more than one of these 
different classes of drug.  Working in combination, they suppress viral replication, addressing the 
many and various mutations which create viral resistance, and control the viral load.   
Diagnosis with HIV indicates the presence of HIV virus in the body.  High levels of HIV virus deplete 
the immune system as described, making the body more susceptible to certain cancers and OI, 
which when diagnosed in the presence of HIV are termed AIDS-defining diseases.  Having an AIDS 
defining disease means that the patient can be described as having AIDS, although this term is less 
commonly used, now that the progression from HIV to AIDS is reversible and no longer as 
predictable.   
1.1.1. Global HIV epidemiology 
By the end of 2012, it was estimated that 35.3 million people (95% confidence interval 32.2-38.8 
million) globally were living with HIV (29).  Worldwide incidence of HIV infection has fallen by 33% in 
adults and 52% in children since 2001, and was reported as 2.3 million in adults (1.9-2.7 million) and 
260 000 (230 000-320 000) in children in 2012 (29).  Since its peak in 2005, global AIDS-related 
mortality has fallen by 30%, from 2.3 million deaths in 2005 (2.1 million–2.6 million), to 1.6 million in 
2012 (1.4-1.9 million) (29).  This pattern of peak and subsequent decline in AIDS-related mortality 
occurred in North America and Western and Central Europe in 1995, and much later in SSA, in 2005, 
corresponding with the widespread introduction of ART (30).  The early benefits of ART in Europe on 
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new infections and mortality are clearly documented by the EuroSIDA cohort study, with the 
incidence of diagnosis with an AIDS defining illness falling by 8% per six month period from the 
introduction of effective ART in September 1998 to 2002 (31).  ART reached 9.7 million people in 
LMIC in 2012, representing 61% of all eligible patients under the 2010 WHO guidelines, and 34% of 
all eligible under the 2013 guidelines (29).   
This peak and subsequent decline in mortality globally has led to slight increases in prevalence in 
some areas and stable prevalence elsewhere, as people survive for longer due to the introduction of 
effective treatment (30).  The prevalence in SSA has declined, due to persistent high mortality and a 
25% reduction in incidence (30) which itself resulted from public health campaigns for behaviour 
change (19, 20).  
1.1.2. Antiretroviral therapy  
1.1.2.1. Eligibility and access to ART 
Since the introduction of highly active ART in 1996, made accessible in LMIC by 2004, progress has 
been made in increasing the proportion of eligible patients receiving ART (Figure 2).   
Figure 2 Percentage of eligible people receiving ART in LMIC, (according to 2010 WHO guidelines). Taken from UNAIDS 
2013 (29) 
 
In the past ten years international policy has increased the CD4 threshold for initiation of ART four 
times (2004, 2006, 2010 and 2013), due to research evidence indicating that initiation at earlier 
stages of HIV, before the immune system has been severely damaged, can lead to increased 
likelihood of survival and a decrease in complications (32-35).  In addition, new evidence indicates 
that when given as pre-exposure prophylaxis, or to HIV sero-negative sexual partners of HIV sero-
positive patients (known as treatment as prevention or TAsP), ARVs reduce the risk of transmission 
of HIV to almost zero (36, 37).  This has public health and epidemiological implications for the 
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reduction in incidence of HIV, and has led to the most recent guidelines recommending that 
treatment should be initiated for those with a CD4 count of less than 500 cells/cm3, those co-
infected with TB, or hepatitis B and those in sero-discordant relationships (33).  These changes have 
contributed greatly to increases in numbers of patients eligible for ART, placing pressure on 
healthcare systems to provide adequate care(21) (20).   
1.1.2.2. Medical outcomes of ART  
The introduction of ART prolongs life, leading to an increasing population of PLWH. People on ART 
are expected, once on effective treatment, to live socially and economically productive lives, 
managing HIV as a chronic disease.   
Analysis of mortality data in nine industrialised countries found that mortality rates of HIV positive 
patients, who have commenced ART and survived for the initial 6 months (when risk of death is 
higher), are comparable to that in patients with other chronic conditions (38).  In addition, causes of 
mortality in PLWH are no longer mostly due to HIV related infections or cancers (only 16.1% of 
mortality due to AIDS related illnesses in HIV positive cohort from Switzerland (39)).  Excess 
mortality might therefore be further prevented by earlier detection of HIV and timely initiation of 
ART.   
More recent data from the US and Canada describe how, while differences across baseline CD4 
count, race, gender and transmission risk group still occur, a person infected with HIV at age 20 on 
ART and living in the US or Canada can expect to live to the age of 70 (6).  Increases in life 
expectancy are not limited to the global north.  In 2011, a study from Uganda identified an almost 
normal Ugandan life expectancy (55 years), with variation due to immunity at diagnosis and ART 
initiation (7).  Data from South Africa has shown that provided patients initiate ART before their CD4 
count drops below 200cells/cm3, they can expect to live for 80% of the normal life expectancy in 
South Africa (40).   
These data suggest that, in the context of early initiation and easy access to ART, in the near future, 
AIDS will rarely be seen in the context of controlled HIV virus, and the pandemic will be no longer 
seen as a catastrophe (41).  However, whilst this era of HIV management is termed the era of 
treatment availability, with only 34% of the 28.6 million people currently accessing ART, according to 
the 2013 WHO guidelines (8, 29), some authors suggest it might better be termed the era of 
treatment possibility (41).   
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Improvements in life expectancy, whilst extremely positive, create new medical challenges for the 
HIV community.  The model of care for PLWH must now manage the co-morbidities, or 
complications as a result of ageing, opportunistic infections, and symptoms from previous more 
toxic ART regimens in addition to the psychological and social problems associated with HIV 
infection.  In addition, this must be provided successfully within the structural and social challenges 
of often fragile healthcare systems, to provide life-long treatment for millions of people (42).   
1.1.2.3. Implications of the recent changes to ART access guidelines 
In July 2013, UNAIDS, WHO, PEPFAR and the Global Fund launched a programme called Treatment 
2015.  The stated aim of this programme is to increase coverage of ART to reach a target of 15 
million eligible PLWH by 2015, as part of a global public health strategy to control the HIV pandemic 
(9).  This framework has identified 30 countries where there is unmet need for ART provision.  If 80% 
of people eligible for treatment within these countries are provided with ART, this will account for 
90% of the 15 million target (9).  With the introduction of treatment for prevention within the 2013 
initiation guidelines, and anticipated reduction in new infections (37), this programme aims to lay 
the foundation for the end of the AIDS epidemic (9).  Its authors describe benefits in terms of public 
health, economics, and social justice, and anticipate the prevention of an additional 3 million AIDS 
deaths and 3.5 million new infections by 2025, compared with the previous 2010 guidelines (9).   
The Treatment 2015 document states that the focus on provision of ART should not be at the 
expense of quality care, which should continue to be provided by efficiently streamlining HIV 
services with other services for chronic conditions and by increasing partnerships between 
institution and community care, rather than the provision of extra resources (9).  It advocates that 
funding should increasingly be provided by national governments and not international donors, 
which has raised concerns in the current economic climate that this may restrict the ability of certain 
countries to provide high quality holistic care (9).    The implications of this for theoretical models of 
HIV healthcare provision are addressed below. 
1.1.3. Current models of HIV healthcare provision for mental health and well-being 
Current HIV healthcare provision is described in international policy literature as consisting of three 
components: treatment, care and support. Treatment refers to the provision of ART by institutional 
providers, with care and support typically referring to psychological and social aspects of care:  “a 
comprehensive set of services, including psychosocial, physical, socio-economic, nutritional and legal 
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care and support” (UNAIDS) (43).  The 2010 UNAIDS strategy goes on to say that care and support is 
essential for well-being and should be offered from diagnosis and throughout the disease trajectory.   
In high income countries (HIC), HIV treatment guidelines emphasise the importance of psychological 
and social support of people with HIV, as part of the HIV care package, particularly with reference to 
ensuring good adherence to ART (44, 45).  These guidelines model good mental health and 
psychological well-being for all people with HIV, access to psychological support, involvement of 
PLWH/AIDS, support at diagnosis, assessment to identify needs, access to competent practitioners, 
co-ordination of support and evidence-based practice (45). 
Guidelines for HIV care and support (beyond provision of ART) in SSA are less consistent.  The 
Kenyan National Guidelines for ART include psychosocial care as an essential intervention for people 
with HIV, recognising the psychological and social impact of a HIV positive diagnosis (46).   In South 
Africa, the guidelines suggest annual health education updates, but only on nutrition and 
contraception, with a more comprehensive psychological assessment in the event of treatment 
failure and virological rebound (47).  The ability of the healthcare system in any country to provide 
holistic healthcare is dependent on political and economic support and the extent to which the 
resources available can address the burden of disease.  Psychological and social support of PLWH is 
often the more neglected aspect of care, as policy makers often assume that this will be provided by 
family members, more specifically women, particularly within LMIC (43, 48).  This valuable resource 
of care has become more precarious and strained, as the effects of HIV break down community and 
family units, increasing pressure on the remaining family members (49).   
Globally, the epidemiology of the HIV pandemic appears to be shifting from acute crisis to chronic 
management of disease (50).  This shift will require changes in healthcare provision in terms of care 
and support, in response to the changing needs of PLWH. Currently, due to persistent financial and 
logistical constraints, health systems often only provide the minimum of physical care and provision 
of ART in low resource settings (51, 52).  From a patient’s perspective, moving from crisis to 
chronicity requires economic and social support to return to previous standards of productivity, 
economic  contribution and positive mental health and well-being, after a prolonged period of ill 
health (50).  This is particularly relevant in light of international pressure on national governments to 
increase access to ART and a simultaneous decrease in resources provided to meet these needs.   
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1.2. Mental health and well-being 
1.2.1. Terms and definitions  
The concept of health was defined by the WHO in 1948 as “the state of complete physical, mental 
and social well-being and not merely the absence of disease or infirmity” (53).  In the context of this 
study three aspects of this definition are important in understanding mental health: positive mental 
health is integral to health, mental health is more than the absence of mental illness, and mental 
health is closely associated with physical health and well-being (54).   
The WHO elaborated on their definition of health in 2001 to further define mental health as “a state 
of well-being in which the individual realizes his or her own abilities, can cope with the normal 
stresses of life, can work productively and fruitfully, and is able to make a contribution to his or her 
community” (55).  This indicates that mental health and well-being contribute not only to the 
functioning of the individual but also to the community, and are more than the absence of 
psychopathology.  Mental illnesses such as major depression and anxiety are recognised 
consequences of unmet mental health needs.  In this thesis the framework for understanding these 
processes will be that developed by the WHO in collaboration with the Victorian Health Promotion 
Foundation and the University of Melbourne (56).  It describes the key determinants of mental 
health as: social inclusion, freedom from discrimination and violence and economic participation 
(56). 
1.2.2. Determinants of mental health  
It is argued that mental health is at a conceptual crossroads, where previously mental health was 
situated within the medical model, mental health promotion is now moving into a more 
multidimensional approach, embracing the social determinants of mental health (56).  In a similar 
way, 30 years ago cardiac health promotion care was firmly situated in the medical model, and now 
invokes advocacy of physical exercise, tobacco use cessation, nutrition and anxiety management 
(56).  Increasingly, academics and professionals within the field of mental health cite evidence that 
mental health and well-being are determined and should be addressed by tackling social, 
environmental and economic factors (56-58).  These factors are listed as: social inclusion and access 
to socially supportive networks; stable and supportive family, social and community environments; 
access to a variety of activities; having a valued social position; physical and psychological security;  
opportunity for self-determination and control of one's life; and access to meaningful employment, 
education, income and housing (56).     
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These factors have been incorporated into an evidence based framework for the promotion of 
mental health and well-being  as discussed by VicHealth (an Australian foundation for promoting 
good health and preventing chronic disease) in collaboration with WHO and the University of 
Melbourne (Figure 3) (56).   
Figure 3 VicHealth's framework for the promotion of mental health and well-being 
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This framework can be described as an intersectional approach, acknowledging the overlap and 
interdependency of social, psychological and economic determinants on positive mental health and 
well-being, developed on the basis of international research evidence of the effect of addressing 
these determinants (56).  This interdependence between the domains of well-being highlights why 
the framework is particularly appropriate for conceptualising positive mental health and well-being 
in this thesis, as it has resonance with the Biopsychosocial and holistic understanding of health and 
well-being, central to the palliative care approach on which the nurse-led intervention to be 
evaluated is based (59). 
The following sub-sections expand on each of the key determinants of health in the model adopted 
for this thesis.   
Background 
30 
1.2.2.1. Social inclusion 
A review conducted for the National Institute for Health and Clinical Excellence (NICE) in the UK 
identified a range of factors which were protective of mental health (57).  These included social 
capital and strong social networks, social inclusion, trust among community members and 
educational achievement (57).  Decreased social connectedness is negatively associated with quality 
of life, mediated by negative perceptions of stress and stressful experiences.   
To describe the effect of mental health and social networks, the model developed by Kawachi and 
Berkman is useful, and describes the direct mechanism of influence of social networks or ties on 
mental health (Figure 4)(60).   










Kawachi and Berkman describe how social networks can improve mental health through educating 
and informing an individual of health promoting behaviours, such as the effect of exercise in groups, 
or why it is important to stop smoking.  Social networks also increase positive affective states in the 
individual, by inducing feelings of belonging and security, in addition to increased self worth.  They 
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exercise, in addition to modulating neuro-endocrine responses to stress.  Being located within a 
social structure increases an individuals’ access to social support, such as informal psychological first 












Separate studies show that the presence of protective social factors such as belonging to social 
networks etc, is associated with individual factors identified as protective to positive mental health: 
feeling respected, valued and supported, and having a sense of hopefulness (57).  Individual level 
risk factors included lack of emotional resilience, genetic predisposition, family history of psychiatric 
disorder, childhood neglect or abuse, bereavement and being a long term carer (57). 
1.2.2.2. Freedom from discrimination 
The evidence suggests that a society which encourages freedom from discrimination,  diversity, 
freedom from violence and self determination and control over one’s life, is a society which is 
promoting positive mental well-being (56). 
Discrimination affects mental well-being in several ways.  Often it originates in stigma, which is 
defined as an attribute, behaviour or reputation which is socially discrediting (61).  Stigma is a 
complex and multifaceted concept, expressed and experienced differently in different cultural 
contexts.  It can be conceptualised as ‘enacted’ in the form of discrimination, ‘normative’ (a set of 
accepted values embedded in cultural norms), or ‘internalised’, meaning that the stigmatising 
messages are accepted (62). There are three functions of stigma in society: to exploit and dominate 
those in a less powerful position, to enforce social norms promote social stability; and to distance 
perceived threat of contamination, for example from infection or immorality (63).  Stigma highlights 
the perceived threat of diversity to physical security.   
When individuals are discriminated against, and their physical security or freedom from violence 
cannot be guaranteed, increased psychological and behavioural problems such as anxiety, 
depression, alcohol abuse and suicidal behaviour are reported (64).   
A recent systematic review and meta analysis of the literature found that experience of stigma and 
discrimination is associated with heightened stress response is related to non-participation in 
healthy behaviours and participation in unhealthy behaviours, and is strongly and consistently 
associated with psychological distress (65).   This effect has been documented in immigrant 
populations who experience discrimination on a racial basis (66-68), and in PLWH, (69-71). 
Discrimination can also reduce access to healthcare services and reduce compliance with treatment, 
as potential patients fearing the stigmatising label of a diagnosis, distance themselves from potential 
sources of help (72).  This exacerbates pre-existing problems and is a barrier to recovery. 
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1.2.2.3. Economic participation 
The effects of economic participation extend to the effects of work, education, housing and money 
on mental health and well-being (56).   
Unemployment was associated with psychological distress, in a cohort study from Canada (73), and 
in a meta-analysis of international literature on the effects of unemployment and lack of economic 
participation (74).  A separate review found that there is also evidence that those who are employed 
but who experience job insecurity also have increased psychological distress, psychosomatic 
complaints and physical strain (75).    
Findings from a study from the US identified that in areas of low unemployment, respondents with a 
college education who had previously been employed, reported the highest levels of depression and 
subjective physical health status, with two main causes: distress due to financial strain, or due to 
damage inflicted by unemployment status on participants’ sense of self (76).  Self-image and self-
efficacy were also apparent in evidence from New Zealand, where students with financial debt 
reported decrease psychological well-being when they perceived that they would be unable to 
manage the debt, associated with sense of control and self-esteem (77).   This association between 
psychological distress and perceived socioeconomic status and deprivation was also reported in two 
separate studies from the US (78) (79).    
Respondents from both urban and rural areas in South Africa described the practical side of life such 
as the importance of housing, money and a job, when asked to evaluate the concept of human well-
being (80), highlighting their understanding of the importance of economic and material 
participation to human well-being.   
1.2.3. Mental health and well-being in HIV  
Internationally, the experience of living with HIV is associated with a burden of unmet psychological 
and social needs.  A systematic review of mental health problems in HIV patients in India identified 
high prevalence of clinician-rated depression, post-traumatic stress disorder, general distress and 
anxiety, substance abuse and general psychiatric morbidity above population norms (81).  In Africa, 
a recent systematic review found 44% to 58% of all patients with HIV have psychological problems, 
most commonly depression (82).  Furthermore, mental health problems in PLWH were associated 
with poverty, unemployment and poor educational attainment (82).  A recent comparison of health 
related quality of life for adults living with and without HIV in the UK found that, despite being on 
ART and having an undetectable viral load those with HIV reported significantly worse health related 
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quality of life, more specifically  in terms of anxiety and depression, mobility, self-care, usual 
function and pain (83). 
In addition to impaired quality of life, unaddressed psychological and social problems have 
potentially severe clinical implications.  A recent meta-analysis of international data identified a 
strong and consistent negative association (n=95 studies, p < 0.0001) between depression and 
adherence (19).  Because patients must achieve optimal adherence (>95%) to control the virus and 
avoid viral resistance and associated outcomes (treatment failure, increased infectiousness, 
morbidity and mortality), this association presents a very real threat to the success of international 
progress in controlling the epidemic (3, 84, 85).   
Whilst regional and whole patient population reviews exist for depression, anxiety and experience of 
stigma in HIV patients, the international literature has not yet been systematically reviewed to 
examine the problems experienced by HIV positive patients, specifically established on ART.  
Understanding the extent of these problems in this growing cohort of PLWH on ART is extremely 
important both in terms of patient quality of life and the future implications for control of the 
pandemic.   
To review the data in the literature of the prevalence of psychological and social needs experienced 
by PLWH on ART, I conducted a systematic review of the peer reviewed literature, in line with the 
PRISMA statement (86) and guidelines from the NHS Centre for Reviews and Dissemination (87).  
This review was published in the International Journal of Nursing Studies and can be found in full in 
Appendix 3, where the full method including search strategy, search terms, inclusion and exclusion 
criteria, data management and analysis are reported (15). The results summarise the prevalence of 
anxiety, depression and experience of stigma in HIV positive people on ART.  The presence or 
absence of the experience of stigma was included as an indication of the social problems associated 
with a diagnosis of HIV. 
The data is reported using weighted mean prevalence calculated using a data quality score following 
Loney et al (88), attributing more weight to prevalence reported from studies of higher quality. 
1.2.3.1. Depression 
A total of 62 retained citations reported mean sample prevalence for depression (summarised in 
Table 1-1). The range of reported depression prevalence is illustrated in Figure 5 for all retained 
citations and by country income status. 
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Table 1-1 Summary of depression prevalence for all citations and by country income status 
Depression (all means weighted by data quality score following Loney (88)) 
 Mean (sd) HIC (sd) LMIC (sd) 
Point prevalence 
(n=14) 
33.60 (19.47) 25.81 (15.21) 41.36 (21.42) 
Included studies (89-102) (89-96) (97-102) 
Period prevalence 
of 1 week- 1month 
(n=41) 
39.79 (21.52) 40.96 (17.08) 38.69 (25.07) 
Included studies (11, 103-141) (104, 106, 107, 110, 
116, 118-124, 128, 133, 
136-138, 140) 
(11, 103, 105, 108, 109, 
111-115, 117, 125-127, 
129-132, 134, 135, 139, 
141) 
Period prevalence 
of 6 weeks to 
lifetime (n=7) 
23.61 (19.03) 49.0 (6.36) 15.99 (10.39) 
Included studies* (89, 99, 100, 
117, 122) 
(89, 122) (99, 100, 117) 
*Several studies contributed more than one prevalence period, e.g. lifetime, one year and 6 months, 
so numbers may not add up to total number of citations 
 
This review identified a weighted mean of point prevalence of depression in people with HIV on ART 
across the citations of 33.6%, with a higher point prevalence of depression reported in LMIC 
(41.36%) compared with HIC (25.81%).  Period prevalence, combining data over the past week to 
month was as expected, higher.  The period prevalence weighted mean was 39.8% in all retained 
citations, 41.0% in HIC, and 38.7% in LMIC.  Fewer studies reported rates for depression over the 
lifetime, or in the past 6 months, and so the data were merged to reports of depression in the longer 
term (6 months to lifetime).  The difference in reported 6 months to lifetime depression comparing 
HIC and LMIC is noteworthy, although there was strong potential for bias due to the small numbers 
of papers reporting this data.   
From the scatter plots several outliers are evident (Figure 5).  These outliers appear to originate in 
more homogenous and possibly more unusual samples than the general HIV population.  The data 
reporting 100% one-week period prevalence of depression was among mothers who were attending 
an outpatient clinic with their HIV positive children (113).  The sample reporting 92% one-week 
period prevalence of depression was composed of people who used to inject drugs (119).  The 
sample which reported 81.5% one-week prevalence of depression was composed of Rwandan 
women experiencing post-genocidal trauma (112).  All of these samples might be expected to 
experience more psychological distress.  Most other samples were more heterogeneous containing a 




Figure 5 Scatter plots to illustrate the range and distribution of reported prevalence of depression 
 
*All means weighted by data quality score ●=weighted mean 
Prevalence for each risk behaviour group (people who inject drugs, heterosexual women, men who 
have sex with men, former plasma or blood donors) was not disaggregated in the studies identified; 
therefore a comparison of these sub-groups was not possible.    
Analysis by measurement tool was possible only for point prevalence as period prevalence was not 
measured using standardised tools.  The most commonly used measures were the Beck Depression 
Inventory (BDI), the Centre for Epidemiological Studies Depression tool (CES-D) and the Hospital 
Anxiety and Depression Scale (HADS).  The range of prevalence and mean (again, weighted by data 
quality score) from the BDI, CES-D and the HADS data are presented in Figure 6.   Data from the 
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Figure 6 Range of 1-4 week period prevalence of depression by outcome measure 
 
*All means weighted by data quality score ●=weighted mean 
In this review, mean point prevalence of depression was 33.60% (sd 19.47) and 1-4 weeks period 
prevalence 39.79% (sd 21.52).  The data for longer period prevalence was sparse and therefore the 
mean is less likely to be representative of the population.   
The UK general adult population data for prevalence of depression ranges from 2.3% (142) to 8.1% 
(143).  General population data from Nigeria reports a 5.2% point prevalence (144), the USA 9.5% 
12-month prevalence (145), South Africa a 9.7% period prevalence for lifetime depression and 4.9% 
for the past 12 months (146), and in the Asia Pacific region figures stand at 1.3% to 5.5% current to 1 
month prevalence of depression (147).  The conclusion of this analysis is that prevalence of 
depression may be elevated in HIV positive people in comparison with international general 
population data.   
Whilst this review identifies prevalence of depression in PLWH as 33.6%-39.8%, depression in other 
chronic conditions, which are incurable, and have physical symptoms requiring long-term 
management are comparatively lower.  Patients with epilepsy for example, report a current or past 
year prevalence of 23.1% (148), multiple sclerosis patients (1 year period) 25.7% (149) and patients 
with diabetes a point prevalence of 28% in women and 18% in men (150). 
This review further found decreased point prevalence in HIC 25.81% (sd 15.21) compared with LMIC 
41.36% (sd 21.42)).  Our data suggest that depression is higher in HIV positive people than in the 
general population, and that depression is more burdensome in LMIC than in HIC.  This is compatible 
with recent international comparisons of the impact of depression on disability adjusted life years 
and years lived with disability, which indicate that the global burden of depression is higher in LMIC 
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1.2.3.2. Anxiety  
In total 14 papers reported the prevalence of anxiety in a study sample.  Data are summarised in 
Table 1-2 and the range of reported prevalence illustrated in Figure 7. 
Table 1-2 Summary of prevalence of anxiety for all retained citations and by country income status 
Anxiety (all means weighted by data quality score) 
 Mean (sd) HIC mean (sd) LMIC mean (sd) 
Point prevalence 
(n=6) 28.38 (17.07) 21.53 (22.91) 33.92 (10.64) 
Included studies (94, 95, 102, 109, 152, 
153) 
(94, 95, 152) (102, 109, 153) 
1-4 weeks period 
prevalence (n=8) 33.59 (21.07) 39.55 (24.64) 21.18 (14.28) 
Included studies (14, 120, 125, 129, 
132, 133, 139) 
(14, 120, 133) (125, 129, 132, 139) 
 
The mean point prevalence of anxiety was 28.38%; this was lower in HIC (21.53%) compared with 
LMIC (33.92%).  One to four weeks period prevalence was higher at 33.59%; this was higher in HIC 
(39.55%) compared with LMIC (21.18%). 
The highest prevalence of anxiety was found in a study of women in a French cross-sectional study 
(63%) (133).  Men in the same study reported a prevalence of 48% anxiety (133).  The lowest 
prevalence of anxiety (0%) was in a Thai sample (132).  The authors suggest that the low rate of 
anxiety could have been the result of strong social support among people with HIV/AIDS attending 
the clinic where recruitment occurred. 
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Figure 7 Scatter plots to illustrate the range and distribution of reported prevalence of anxiety 
 
*All means weighted by data quality score ●=weighted mean 
 
A recent systematic review identified a global prevalence of 7.3% anxiety in the general population, 
with a lower prevalence in African countries (5.3%) compared to Euro/Anglo cultures (10.4%) (154).  
The prevalence of anxiety disorders in the general population is 4.4% in the UK (142) and 18.1% in 
the US (145).  Whilst there is variation in these figures, they are all lower than the prevalence 
identified in this review amongst people with HIV on ART: 28.38% (sd 17.07) mean point prevalence 
and 33.59% (sd 21.07) 1-4 week period prevalence.  
The prevalence of anxiety among patients with HIV receiving ART identified in this review is also high 
in comparison with rates of anxiety among patients with other chronic conditions (diabetes 14%, 
cancer 15-23%, heart disease 10-50% (155)), suggesting that people with HIV/AIDS are at a higher 
risk of developing anxiety than other patients with chronic conditions, and the general population.   
1.2.3.3. Freedom from discrimination - Stigma 
Prevalence of stigma was reported in ten papers. Of these, seven reported an overall prevalence 
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Table 1-3 Prevalence of experience of stigma across all citations and by country income status 
 All data HIC LMIC 
Point prevalence 41.92%, 46%, 82% 41.92%, 46% 82% 
Included studies (128, 156, 157) (128, 156) (157) 
In the last 2 weeks 61.6% - 61.6% 
Included studies (158)  (158) 
From ‘during the past year’ 
to ‘ever’ 
38%, 25.3%, 83% 83%, 38% 25.3% 
Included studies (159-161) (159, 161) (160) 
 
The remaining three studies all used locally designed questionnaires, measuring different aspects of 
the experience of stigma.  A study in Zambia focused on the experience of stigma specifically related 
to ART, reporting a prevalence of 16% (162).  A national cross-sectional survey including HIV positive 
patients in France reported the percentage experiencing discrimination: 12.9% from relatives, 12.2% 
from friends and 16.3% from sexual partners (163).  A study conducted in Botswana in 2006, before 
widespread access to ART, found that 12% of HIV patients had not disclosed their infection status to 
anyone.  In the same study 27% of patients feared they would lose their job due to HIV, and 47% 
reported work-related difficulties due to HIV, mostly concerned with taking sick leave (164). 
However, it cannot be assumed that the same cultural understanding or social construct of stigma is 
being reported across studies.  In addition, differences between enacted, normative and internalised 
stigma are not differentiated in the retained citations (62).  Although elements of these constructs 
are described by the stigma scales used in the identified studies, the assumed interactions between 
stigma and the experience of discrimination are not made explicit.  For example, evidence suggests 
that the experience of stigma is often worse when patients have disclosed their serostatus, but 
levels of culturally acknowledged stigma in the society, which may dissuade people from disclosing 
and thus protect them from enacted stigma, have not been explored (156).   
To add to the complexity, PLWH in HIC may experience ‘compound’ or ‘layered’ stigma, which exists 
along pre-existing social fault lines, relating to sexual orientation, intravenous drug use, or 
commercial sex work (165, 166).  This creates difficulty when comparing experiences of stigma 
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between HIC and LMIC, where stigma is mostly associated with women and sexual morality, and 
raises the question of whether this kind of comparison is justified (167).   
1.2.3.4. Economic participation  
Prevalence data for economic participation for PLWH was not included in the systematic review, as 
the focus was on the psychological problems resulting from unmet mental health needs. However, 
the literature suggests that living with HIV is associated with decreased economic participation and 
economic hardship.  For example, a study from Kenya found in the 18 months preceding their death, 
a cohort of HIV positive tea pickers were less productive than their HIV negative counterparts, took 
more sick or annual leave and were allocated less strenuous tasks which were less remunerative 
(168).  This resulted in 16-17% decreased earnings.  A cohort study from South Africa identified that 
households affected with HIV reported poorer health and were less affluent than those who were 
not, with rapid decreases in income and expenditure over a period of 6 months in households with 
HIV positive members (169).  A epidemiological study in South Africa found that a HIV positive 
diagnosis increases the probability of being unemployed by 6-7%, with a greater effect seen in 
women, those in urban areas and those with less education, compounding pre-existing inequality 
(170).   
Whilst the majority of data describe the situation in SSA before the widespread availability of ART, 
there is some data describing the effect of ART on economic participation.  The effect of ART on the 
ability of PLWH to work and contribute economically was measured in a cohort of miners in South 
Africa in 2010 (171).  They report a “Y shaped” response in absenteeism in HIV positive workers.  
This means that they returned to work with absenteeism rates comparable with their HIV negative 
counterparts once established on ART (171).  Similar increases in economic productivity were 
reported in India in terms of economic participation, number of hours worked and individual income 
(172).  Economic analysis of the impact of ART programmes suggests a range of return on 
investment in terms of economic activity from 81% -287% of the programme costs (173).   
The literature describes the change from severe impact on employment and potential earnings 
before access to ART, to minimal impact if established on ART and in otherwise good health, without 
co-morbidities.  This suggests a mitigating or buffering effect of ART on the effect of economic 
participation on mental health and well-being. 
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1.2.4. Summary of literature and evidence regarding HIV and mental health 
The mental health and well-being of PLWH is impaired by their HIV positive diagnosis, with 
depression and anxiety higher in HIV positive people compared with the general population, 
particularly when they are physically unwell.  This is concerning, not only as this represents a serious 
impairment in quality of life, but also as there is an identified strong and persistent association 
between depression and non-adherence to ART (19).  Increased resistance to the available drug 
combinations due to non-adherence threatens the success of ART in terms of care for the resistant 
individual and of future options in primary and public health.  
In addition, the review found that over half of patients on ART report experiencing stigma and/or 
discrimination, which has repercussions for health-seeking behaviour, retention in healthcare 
services and quality of healthcare received, in addition to the impact on mental health status (17, 
174-176).   
Prevalence of HIV will increase in SSA as mortality decreases with increased access to ART, which will 
result in increasing numbers of patients accessing already stretched healthcare systems.  These 
patients will have medical needs for access to effective tolerable treatment to control their HIV virus 
and manage toxicities and opportunistic infections, in addition to increased risk of depression and 
anxiety and the difficulties of living with the virus in the context of continuing HIV related stigma.   
International experts have called for the integration of mental health-promoting interventions into 
routine HIV care to benefit both mental and physical well-being of patients (177).  Whilst these data 
highlight that this call is timely, pertinent and necessary, it is important to recognise that within a 
climate of increased pressure on governments to deliver on externally set targets for ART access, 
improving access to mental healthcare may be challenging.  Potential solutions must therefore be 
feasible in terms of the human and financial resources available and have proven relevant evidence 
of effectiveness within this context.  
There is therefore an urgent need to explore possible approaches to care in the context of increasing 
numbers of PLWH as a chronic condition, and therefore requiring long term management for 
complex psychological, social, and medical problems. 
1.3. Kenya 
This study is situated in Kenya, a country which borders Uganda, Somalia and Tanzania, and has a 
population of 44 037 656 (July 2013 estimate) and a median age of 18.9 years (178).  Selected 
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demographic and health statistics for Kenya are presented in Table 1-4, with South Africa and the UK 
data presented to enable comparison. 
Table 1-4 Comparison of demographic and health variables for Kenya, South Africa and UK  
Country Kenya South Africa UK 
Life expectancy at birth (2012) ◊ 69.4 53.4 80.1 
Maternal mortality 2010 
(/100 000 live births) 
360 300 12 






Under 5 mortality rate (/1000 live 
births)†2010 
85 57 5 
GDP per capita 2011 (current US$)  819 8090 38 918 
% GDP spent on healthcare in 2010 * 2.1 3.9 8.1 
◊Number of years a newborn infant could expect to live if prevailing patterns of age-specific 
mortality rates at the time of birth stay the same throughout the infant’s life 
†Probability of dying between birth and exactly age 5, expressed per 1,000 live births 
* Current and capital spending from government (central and local) budgets, external borrowings 
and grants (including donations from international agencies and non-governmental organizations), 
and social (or compulsory) health insurance funds, expressed as a percentage of GDP.  
Source: UNDP (179) and World Bank (180) 
 
The UNDP states that Kenya has a gender inequality rating equivalent with low human development, 
indicating that economic development and gender equality are significant challenges, a finding 
restated by a recent US report on human rights in Kenya (180, 181).  
1.3.1. HIV in Kenya 
HIV is the lead cause of mortality in Kenya, accounting for 29.3% of all causes of mortality (followed 
by perinatal causes 9%, pneumonia 8.1% and tuberculosis 6.3%) (182).  The Kenyan Government 
estimates HIV prevalence at 6.1% (1.6 million people) of the adult population, with 73% of all eligible 
PLWH on ART (2012) (183).  The 2012 Government report describes the HIV care policy as a 
comprehensive approach, with food by prescription for malnourished patients and access to pain 
relief for all (although it is conceded that morphine is rarely available) (183, 184).  The problematic 
shortage of health workers is also identified, in particular physicians (0.1 per 1000 people compared 
with 7.9 in the Euro zone), which may hamper the future success of any reforms (183).  
The epidemic in Kenya is described as generalised, and transmission predominately occurs within 
stable partnerships (38%), men who have sex with men (20%), sex workers, their clients and their 
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partners (18%) and casual sex (15%)(183, 185).  Point prevalence of HIV differs according to wealth, 
with increases from 4.6% in the lowest wealth quintile to 7.25% in the highest quintile (186).     
1.3.1.1. ART in Kenya 
The public health programme to distribute ART began in Kenya in 2003, but it was not until 2006, 
after a presidential declaration, that ART became free to the public and those eligible could access it 
in greater numbers (187).  More recently, Kenya has increased domestic investment in HIV 
treatment and prevention, doubling HIV related spending from 2008 to 2010 (30).  Despite this, 
more than 75% of funding for HIV programmes still comes from international sources, indicating 
continued reliance on international aid (30), which could be extremely problematic for Government 
and Kenyan PLWH should this aid be withdrawn at any time.  Kenya is named as a target country in 
the Treatment 2015 programme (9), and the Kenyan Government has adopted the suggested target 
of 90% coverage by 2015 (182). 
Currently in Kenya the recommendations for ART in adult patients are for first line therapy if their 
CD4 count is equal to or below 350 CD4 cells/mm3, at WHO stage 3 or 4, are co-infected with TB or 
Hepatitis virus with evidence of liver failure (46).  First line treatment is Tenofovir, Lamivudine and 
Efavirenz or Nevirapine, or Zidovudine, Lamivudine and Efavirenz or Nevirapine. Second line 
therapies are given when first line therapy fails, and substitute the Nevirapine or Efavirenz for a 
Ritonavir boosted protease inhibitor (46).  About 1% of urban Kenyans are currently accessing 
second line treatment (20).   
Recent data from a retrospective cohort study in Zambia estimate mean costs of ART range from 
$2.34 per month to $36.7 per month, depending on the regimen (188).  When costs beyond ART, 
such as co-trimoxazole or blood tests were entered into the calculation, mean monthly HIV 
treatment costs per patient was $243 (95% CI, $194-$293), ranging from $184 (95% CI, $172-$195) 
to $304 (95% CI, $290-$319) depending on clinic site (188).  This mean monthly treatment cost 
represents 21 323 Kenyan shillings at the time of writing, with Kenyan a minimum wage for unskilled 
labour of 5,218 per month (189).  This highlights the Kenyan reliance on internationally supported 
programmes which enable subsidised or free ART.   
Stavudine, which was previously included in all lines of treatment due to its high efficacy and low 
cost, has been phased out as per 2010 WHO guidelines because of the associated excessive 
toxicities.  Fixed dose combinations are used when available to decrease pill burden and make 
adherence easier, but are often more expensive (183).   
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1.3.2. Mental health and well-being in traditional cultures 
Although society is changing in many areas of Africa due to globalisation and industrialisation, it 
would be wrong to imagine that traditional beliefs concerning health and well-being have changed 
or been forgotten (190).  Traditional beliefs, although differently expressed in different places, are 
maintained at a deep level for many people, whilst changes due to globalisation affect the visible or 
more material aspects of life (190).   
Both disease and misfortune are seen as spiritual experiences in much of Africa, and therefore both 
are prevented and cured by the same practitioner – the medicine man (191).  Treatment is 
determined by suspected cause, with rational treatments for natural ailments, and a combination of 
supernatural and rational treatment for supernatural ailments (191).  The medicine man administers 
physical or spiritual (or psychological) treatment in the form of rituals or medicines made from 
plants, herbs, powders, roots, seeds, etc.  Treatment often involves a lot of time and personal 
attention, which develops trust and understanding between the patient and the medicine man 
(190).  Lambo, a Nigerian psychiatrist, describes how many African traditions understand mental ill 
health, and HIV infection itself to be as a result of natural, supernatural or spiritual factors (191).  
This understanding is based on a non-Western understanding of ‘reality’: in the western world, 
reality is concerned with things and mastery of things, whereas in traditional African culture where it 
is concerned with relations between people and other people and between all people and spirits 
(191).    
As a result of these differences in understanding about health and illness, interventions which are 
effective in a western environment may not be as well received, or as effective when delivered in a 
more traditional culture.  Fernando summarises how positive well-being in traditional African 
cultures includes a sense of unity in the spiritual and material worlds, combining empirical detail 
with elements of magic or fantasy (191).  The differences between understandings of positive well-
being in traditional African and Western cultures highlight the different basis on which each culture 
builds their understanding of ‘healing’ and ‘cure’, which may undermine the effectiveness of a 
culturally untranslated intervention.   
1.4. Models of care for PLWH 
1.4.1. Challenges with current models of care in SSA 
Clinics in SSA are often over burdened, attempting to provide high quality holistic care, with 
increasing clinical responsibility for increasing patient numbers in under-resourced settings (192).  A 
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retrospective cohort study from Kibera in Nairobi, Kenya found that 29% of patients dropped out of 
ART programmes for more than 90 days (20).  The authors suggest this could be the result of the 
recent scale up of ART provision by 300% over 2 years, which has led to increasing patient numbers, 
increasing complexity of care and decreased available workspace (20).  The increased pressures on 
healthcare systems due to the ART scale up are also evidenced in data from the WHO, which reports 
that 38% of countries (50% in SSA) reported ART stock-outs in 2010 (193).  This lack of consistently 
available ART is an indication of the serious threat to scale up success, and highlights the precarious 
nature of healthcare system capacity.    
1.4.1.1. Mental health as a area of neglect 
High patient burden also places pressure on clinics trying to comply with ART guidelines in Kenya, 
which recommend counselling and psychosocial support for all, in addition to a programme called 
prevention with positives, which covers sexual health and family planning (46).  Currently, the care 
offered to PLWH as described in section 1.1.3, is focused on viral control with referral to 
psychological or social support when problems are detected, often through a drop in medication 
adherence (47).   
In Kenya, this also reflects the training of healthcare professionals providing the care, most often 
nursing staff, which has a medical focus.  Undergraduate nursing students at the University of 
Nairobi, for example, are well trained in history taking, physical examinations, and health 
maintenance, but not in the importance of holistic care, communication skills, negotiating decision 
making or compassionate care (194).  It is unknown why this emphasis on medical skills exists. It is 
possible that this is a remnant from when nurses as a profession first worked in Kenya and other 
colonies, exporting the colonial era understanding of well-being using the biomedical model of 
medicine, with an emphasis on physical well-being, and the role of nurses being the assistant to the 
medical profession.  Nursing has developed as a profession, mostly since the development of the 
first nursing theories since Florence Nightingale, with Peplau’s model of interpersonal relations, 
which widened the focus of nursing care to nursing to patient centre care and the holistic approach 
(195).  There is evidence that a patient centred approach is preferable for patients and is effective in 
increasing patient satisfaction and symptom burden (196) 
This focus on the medical and physical aspects of well-being, at the expense of a holistic view of 
health, places the mental health and well-being of patients under threat.  This is particularly relevant 
when there are external pressures to focus solely on medical aspects of care such as ART provision.  
The excessive pressure and demands made on healthcare professionals in the delivery of care also 
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decrease the likelihood that the required resources for holistic patient centred care are made 
available.   
This has been recognised by the UK Consortium of AIDS and International Development (UCAID), 
who designed the HIV Care and Support Initiative, which identifies a global problem of psychological 
and social care as the “forgotten pillar” of the HIV response (48).  UCAID designed a road map, which 
charts the progress towards universal access to care and support by 2015 and contains guiding 
principles for care and support (197).  It has also conducted a mapping exercise looking at the global 
response to the epidemic in terms of care and support in 2013.  It describes the emergence of a new 
direction in strategy documents of agencies responsible for the coordination of the international 
response to HIV, such as WHO, UNAIDS and the World Bank (198).  The focus of the response has 
begun to shift from emergency response towards the chronic management of HIV, responding to the 
wider needs of PLWH and their communities, strengthening social protection and streamlining care 
with the management of other chronic diseases and child and maternity services.  This is a hopeful 
message in the context of Treatment 2015, which through increasing pressure on governments to 
focus on numbers of people on ART and numbers of AIDS related deaths, risks local decreases in 
financial and political support for the psychological and social care of PLWH in resource poor 
settings.  It is unclear however, what this shift might look like in different country contexts, and 
whether it is radical enough to address the unmet need currently experienced by PLWH.   
The identified burden of psychological and social problems reported by PLWH, demands a more 
concerted, holistic approach to care, and further academic study of its effectiveness for PLWH at the 
individual level and at the level of healthcare systems in countries such as Kenya. 
1.4.2. Holistic care  
First described by the South African philosopher statesman and prime minister Jans Smuts, holism is 
defined as the concept that living organisms are unified and indivisible, made up of parts which are 
both interdependent and interrelated (199).  Holism is often viewed as synonymous with the 
Biopsychosocial model of care, developed by Engel (200).  Engel argued that the pre-existing 
biomedical model was no longer relevant or useful for the tasks and social responsibility of medicine 
or psychiatry, and that it employed a mind-body dualism which disregarded the social, psychological 
and behavioural aspects of illness (201).  His extended model of holistic care is also in line with the 
WHO definition of health, which highlights the importance and interdependence of well-being in 
physical, social, psychological and spiritual domains (53).  An early study of the effect of holistic care 
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on patient outcomes found that the holistic approach improved patient mood, positive evaluation of 
care, and patient relatives’ views of medical personnel (202). 
1.4.2.1. Holism in chronic illness 
Patients with chronic conditions such as PLWH on ART or cancer, no longer face a predictably short 
life span, but continue to need extra support for themselves and their families, beyond what would 
be required in less complex or stigmatising medical conditions (203).  In cancer care, supportive care 
has been developed to meet the extra needs associated with the diagnosis of a chronic and 
potentially life-limiting condition.  Supportive care is defined by a recent systematic literature review 
and Delphi study as: 
 ‘The multi-disciplinary holistic care of patients with malignant and non-malignant chronic 
diseases and serious illness, and those that matter to them, to ensure the best possible 
quality of life. It extends as a right and necessity for all patients, is available throughout the 
course of the condition, concurrent to condition management and is given equal priority 
alongside diagnosis and treatment. It should be individualised, taking into account the 
patient’s past life experiences, their current situation and personal goals.' (204). 
This definition of supportive care includes multidimensional symptom control, supported decision 
making, increased patient professional communication and empowerment of the patient and their 
family in the self management of their condition (204).  Supportive care has links with and 
sometimes involves palliative care, as an approach to care which seeks to improve quality of life for 
patients and the families of patients with life limiting conditions, through multidimensional symptom 
control.    
In the context of care for PLWH in Kenya, supportive care in line with the recognised international 
definition is not adequately accessible for PLWH (204, 205).  This kind of care is more often provided 
informally by the community and family, but because of the stigmatising nature of HIV, or because 
the family itself is also in need of support, this does not always occur (198, 206).  When supportive 
care such as multidimensional symptom control and holistic person centred care is provided in 
Kenya, it is usually within the remit of palliative care (207).   
Regional and local bodies promoting palliative care within Kenya, and linking in with other palliative 
care associations in the region, have made much progress in the promotion of holistic, person-
centered care for people in the final stages of disease and at end of life (23).  The palliative care 
movement in Kenya is growing, increasing number of professionals with skills and knowledge in the 
management of multidimensional symptoms (207).  These professionals have much to offer PLWH, 
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particularly in terms of symptom control, patient centred care and patient education (9, 48).  Kenya 
was recently categorized as a 4a country by the International Observatory on End of Life Care, which 
means that palliative services in Kenya are at a stage of preliminary integration into mainstream 
service provision (26).  This specialism could prove a potentially viable source of high quality holistic 
care for these patients, which is currently not available.   
1.4.3. Palliative care approach as holistic care  
The WHO defined palliative care in 1992 as:  
‘an approach that improves the quality of life of patients and their families facing the 
problem associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and treatment of pain 
and other problems, physical, psychosocial and spiritual’(59). 
In Kenya, healthcare professionals providing palliative care are supported by the Kenyan Hospice and 
Palliative Care Association (KEHPCA), which has a mandate for advocacy, training and public 
education.  KEHPCA runs a regular training programme for physicians, nurses and allied health 
professionals to increase the body of knowledge regarding palliative care among generalist 
healthcare professionals and to increase the number of specialist practitioners in the country (207).  
KEHPCA works in close collaboration with the African Palliative Care Association (APCA), developing 
guidelines and standards, validating research tools for audit and quality control and promoting 
quality palliative care for all in need (23, 49, 208). 
1.4.4. HIV and palliative care 
Before the advent of widespread access to effective ART, palliative care was the mainstay of HIV 
care in the absence of curative treatment options (209).  Before the widespread availability of ART, 
in 2000, it was advocated as a public health approach by UNAIDS (210).  In resource poor settings, it 
was delivered through community members who were mobilised to care for the increasing burden 
of sick and infirm AIDS patients (211).  Evidence for the effectiveness of palliative care interventions 
in LMIC is sparse (212), however, holistic, supportive care models of HIV care which could be 
described as delivering care using the approach of palliative care do currently exist (213).  They 
receive relatively little attention and are mostly small scale and organised at a community level, 
often relying on minimally trained community based volunteers (211, 214).  Since the advent of 
increased access to ART, with the associated reduction in physical morbidity and mortality, 
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international interest and financial support has shifted to the push to improve access to life 
prolonging treatment (1, 9, 30, 215).   
1.5. Evidence for the effectiveness of palliative care interventions for 
positive mental health and well-being 
Palliative care guidelines recommend that care focus on physician-patient communication, 
assessment and treatment of pain and other symptoms, psychological, social and spiritual support 
and co-ordination of care (59, 216, 217).  However, within these guidelines, as palliative care is a 
patient centred intervention, the components of a consultation vary widely depending on patient 
need.  In order to evaluate the evidence for the effectiveness of palliative care in promoting mental 
health and well-being, it is necessary to first describe the common components of a palliative care 
consultation.   
 A recent analysis of data collected as part of a wider randomised trial of palliative care in lung 
cancer patients in the US documented that a palliative care consultation in the outpatient setting 
took a mean of 59.5 minutes (sd 28.6) (218).  This was divided between symptom management (25.7 
minutes (sd 15.8)), patient and family coping (19.6 minutes (sd 14.7)), and illness understanding and 
education (10.4 minutes (sd 7.6)) (218).   A phase II RCT of palliative care for lung cancer patients in 
the US, described palliative care delivered to their participants as a full medical, physical and 
psychosocial assessment, which led to recommendations for support in symptom control, education, 
counselling and home care (219).  These components can be summarised as symptom control, 
counselling and support and education and understanding.  The evidence for these interventions on 
mental health and well-being is summarised below, first for similar chronically ill patient populations 










Table 1-5 Evidence of the effectiveness for components of palliative care and whole palliative care packages on mental 
health and well-being of patients with chronic conditions and for PLWH 
Component of 
palliative care 
Evidence of effectiveness on mental health and well-being 
From the non-HIV literature 
(Cancer, asthma, mental health, 
stroke, diabetes, heart failure, 
COPD) 
From the HIV literature 
Symptom 
management  
 Decrease in asthma symptoms 
due to self management 
intervention associated with 
decrease in depression (220) 
 Improvement in physical 
symptoms management in COPD 
through pulmonary rehabilitation 
associated with decreases in 
depression and anxiety (221) 
 No evidence for effectiveness of 
an intervention identified but 
copious evidence of unaddressed 
physical symptoms alongside 
psychological distress (11, 12, 
222-224) 
Patient and 




 40 seconds of physician 
compassion reduced anxiety in 
breast cancer patients (225) 
 Counselling by minimally trained 
counsellors more effective than 
usual care for depression and 
anxiety in anxious or depressed 
women in Pakistan (226) 
 
 Community led health support 
associated with increased social 
support and decreased stigma in 
PLWH in Ethiopia (211) 
 Informal phone support groups 
improved self efficacy, help 
seeking and decreased social 
isolation for PLWH (227) 
 Participation in online support 
groups associated with improved 
mental health and well-being 
(228) 
 Interpersonal therapy for PLWH 
found reduced depression in 
intervention group in South Africa 
(229) 
 Group educational and 
psychological support effective in 
decreasing anxiety, depression 





Evidence of effectiveness on mental health and well-being 
From the non-HIV literature 
(Cancer, asthma, mental health, 
stroke, diabetes, heart failure, 
COPD) 





 Cochrane review identifies 
decrease in depression 
associated with increased patient 
education in stroke patients 
(231) 
 Advanced cancer patients 
reported decrease in depression 
with a nurse led psycho-
educational intervention in USA 
(232) 
 Patients with life limiting illness 
reported decrease in depression 
and increase in spiritual well-
being, through adult affective 
educational support programme 
in USA (233) 
 Systematic review identified 
improvements in psychological 
well-being in diabetic patients 
due to educational intervention 
(234) 
 Systematic review identified 
evidence for effectiveness of 
information, counselling, and  
testimonials for reducing HIV 
related stigma (235) 
 Emotional symptom self-care 
intervention reduced depression, 
anxiety and stigma in African 
American women (236) 
 Group educational and 
psychological support effective in 
decreasing anxiety, depression 
and perceived stress (230) 
Palliative care  
 Cancer, heart failure and COPD 
patients in USA, reported 
decrease in anxiety through 
advance care planning, 
psychosocial support, and family 
caregiver training (237) 
 Patients diagnosed with lung 
cancer reported decreased 
depression and improved quality 
of life compared to control (238)  
 Systematic review identified 
palliative care decreased anxiety 
in cancer patients (239) 
 Systematic review identified 
palliative care decreased in 
anxiety in HIV patients in UK and 
USA (review) (212) 
 Palliative care for PLWH 
associated with improved 




The evidence summarised in Table 1-5 describes the effect of relieving physical symptoms on mental 
health and well-being in patients with COPD and asthma, and highlights the lack of evidence in 
PLWH populations, despite numerous studies identifying evidence of unaddressed physical and 
psychological symptoms. There is evidence that providing psychological, social or spiritual support 
relieves psychological distress in breast cancer and mentally ill patients, in addition to PLWH.  
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Evidence for the effect of increasing illness understanding and patient education on psychological 
distress is strong in patients who have experienced stroke, cancer, diabetes and life limiting illness.  
In PLWH it has been found to reduce stigma, depression, anxiety and stress.   
This evidence suggests that a palliative care approach, with focus on holistic and patient centred 
care and the Biopsychosocial model of well-being is a plausible solution to the multidimensional 
problems reported by PLWH.  
1.6. Summary 
This chapter has discussed the epidemiology of HIV, recent advances in HIV care, concepts of mental 
health and well-being, and the changing healthcare needs of PLWH from acute management to 
chronic care.   
Due to the changes in eligibility for ART, the population of PLWH on ART will continue to grow, to 15 
million people at least by 2015.  This patient population experience increased prevalence of 
depression and anxiety compared to the general population, in addition to the social stigma of HIV.  
This adversely affects their quality of life, and also impacts on the potential effectiveness of the 
international ART roll-out.  International bodies continue to exert pressure on domestic 
governments to reach ambitious targets for increasing access to ART, in the difficult context of the 
global financial crisis, decreased access to international funding and increasing patient numbers.   
Supportive, holistic, patient centred care for PLWH, which is culturally appropriate and accessible to 
all who are in need, is suggested as a solution to this growing complex problem, particularly in this 
political, economic and epidemiological context.  Palliative care is a growing movement in SSA, with 
increasing numbers of locally trained professionals, guidelines and clinical outcome measures.  
Therefore palliative care offers a plausible solution; particularly as holistic care is not delivered 
elsewhere in healthcare.  Palliative care integrates care holistic care with the pre-existing expert bio-
medically focused disease management, drawing on the local skills and expertise of Kenyan palliative 
care professionals. 
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2. Aims and objectives 
2.1. Aim 
To evaluate the effectiveness of a nurse-led palliative care intervention on the mental well-being of 
HIV patients on ART in Kenya, and to explore active ingredients of the intervention and their 
mechanism of action and therapeutic aspects of participation 
2.2.  Objectives 
1. To determine baseline levels of mental well-being and to examine associations between baseline 
mental well-being and demographic and clinical characteristics among patients with HIV on ART 
enrolled in a randomised controlled trial (RCT) of a nurse-led palliative care intervention. 
2. To identify any effect of the palliative care intervention on mental health and well-being, 
comparing the intervention with standard best practice. 
This objective contains one null hypothesis: 
There will be no difference in psychological quality of life, measured by the MOS-HIV 
MHSS, in longitudinal analysis of difference between participants allocated to receive 
the intervention (nurse led HIV palliative care) and participants allocated to receive the 
control (standard HIV clinic care). 
3. To determine and describe participant experience and longitudinal response to participation in the 
study in terms of mental health and well-being, and to identify and explore associations between 
participant response and demographic and clinical characteristics. 
4. To identify and explore the existence of “active ingredients” and mechanisms of action of the 
intervention and therapeutic aspects and processes of study participation.
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3. Methods 1: Study design, rationale and methodological 
considerations 
3.1. Introduction 
This is a mixed methods study evaluating the effectiveness of a nurse-led palliative care intervention 
on mental health and wellbeing in HIV positive patients on ART.  In this chapter I describe and justify 
the study design and choice of methods for this study, exploring methodological considerations 
relating to conducting research using both quantitative and qualitative approaches.    
3.2. The study context: the TOPCare study 
This thesis was conducted as part of the TOPCare study, which is an RCT assessing the effect of 
receiving palliative care delivered by nurses experienced in the delivery of ART and trained in 
palliative care, on participant reported outcomes such as pain, symptoms and mental morbidity 
(ClinicalTrials.gov Identifier: NCT01608802).  The primary outcome tested by the TOPCare study was 
the effect of the nurse-led palliative care on patient reported pain and symptoms (241).  This thesis 
focuses on the psychological and social outcomes, which were the secondary outcomes of the 
TOPCare study.  Patients who were adult, HIV positive, on ART for more than one month and 
reported pain or symptoms of 3 or more on the APCA African POS (APOS) (0-5 scale) were eligible for 
inclusion.  The protocol for this trial was published in the peer reviewed journal, BMC Infectious 
Diseases and is available in Appendix 5. 
3.2.1. The study site 
The study site, Bomu Hospital, is in Mombasa, the second largest city of Kenya, located in the Coast 
region.  The hospital is within a constituency of Mombasa called Chamgamwe, which is on the 
Kenyan mainland (rather than Mombasa island), accessible to Mombasa island by the Makupa 
causeway (Figure 8).  Chamgamwe is an industrial area with an oil refinery and a port.  Residents of 
this area are mostly labourers in the refinery, the port or the nearby airport. The province of Coast is 
bordered by Tanzania to the south and the Indian Ocean to the east.  
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Figure 8 Map of Kenya, highlighting the Coast region,  and map of Mombasa with Chamgamwe indicated 
 
The 2009 census reported a population in Chamgamwe of 69 251 people, contributing to a total of 
523,183  people in Mombasa, and 38 610 097 people in Kenya (186).  Forty-six percent of Mombasa 
residents have piped water (compared with 30% overall in Kenya and 75.7% in Nairobi), 5.8% are 
connected to the mains sewers (8% in Kenya, 48% Nairobi) and 65% of households have access to a 
mobile phone (63% in Kenya, 88% in Nairobi) (186). 
Some images from Changamwe and Bomu Hospital can be found in Figure 9 and Figure 10.  
Figure 9 Changamwe   
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Figure 10 The registration room in the clinic where patients are registered and Dr Aabid Ahmed the executive director 
showing Dr Richard Harding around the hospital in December 2012 
 
Bomu Hospital is the flagship institution of the Mkomani Society, a philanthropic non-governmental 
organisation based in Mombasa.  It has a catchment population of 3.3 million people and sees 
300,000 patients annually.  The society, founded in 1979 on philanthropic values, currently runs four 
clinics, of which three provide medical care (205).  The Comprehensive Care Clinic (CCC) at Bomu 
hospital, which was our study site, has enrolled 28,000 HIV positive patients, of which 10,000 are on 
ART.  The clinic provides care for about 400 patients daily.  Details of the sources of funding and 
services provided at Bomu Hospital are described in Table 3-1. 
Table 3-1 Description of services available at the study site, the CCC and within Bomu Hospital (184) 
 
The CCC, where patients were recruited into this study, is a busy HIV clinic, open from Monday to 
Friday (205).  Care for HIV positive patients is provided free of charge, with a small fee for other 
Sources of funding Services provided 
 Centre for Disease 
Control 
 US Agency for 
International 
Development (USAID) 
 US President’s 
Emergency Plan for AIDS 
Relief (PEPFAR) 
 New York University 
 Project Sunshine 
 International 
Development Relief Fund 
 Kenyan Government - 
Ministry of Health 
 Volunteer HIV counselling and testing 
 Prevention of mother to child transmission 
of HIV 
 Maternal and child health 
 Community outreach 
 Diabetic clinic 
 Ear nose and throat clinic 
 Hypertension clinic 
 Surgical clinic 
 Gynaecology clinic 
 Paediatric clinic 
 Outpatient HIV clinic 
 TB clinic  
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services such as surgical or maternity care.  Basic essential HIV medications including ART and simple 
antibiotics are also free, but patients must pay for any medication outside of this list. 
3.2.1.1. Patient processing 
Upon arrival at the clinic patients are registered and self-select a waiting area, dependant on 
whether they are attending for an ART prescription refill and do not need medical attention, or have 
a complaint which they feel needs the attention of a medical officer.  Those attending for ART refill 
are seen by one of seven triage nurses, who perform a brief screen to decide whether the patient 
has any problems which should be addressed by the medical officer, or can be managed by the 
nurse.   
Once seen by a triage nurse or medical officer, patients receive their ART refill, and if appropriate are 
then referred for further support or investigations to relevant members of the multidisciplinary team 
such as clinical officers, nutritionist, family support workers and adherence counsellors.  There is also 
a team of tracers who work in the community to ensure the clinic staff maintain contact with 
patients who have defaulted from care or are in need of further support and to facilitate adherence. 
3.2.2. TOPCare study  
3.2.2.1. TOPCare participant flow 
Participant flow in the TOPCare study is described in Figure 11.  Potential participants were screened 
through two sets of criteria to verify that (1) they were adult, on ART for more than a month (not 
PMTCT or PEP), were cognitively able to consent and spoke English or Swahili, and then (2) to screen 
for a score of 3, 4 or 5 for pain or symptoms on the APOS (scale 0-5) lasting more than two weeks. If 
potential participants subsequently agreed to participate, they were randomised to receive either 
standard care or the intervention care package.   
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3.2.2.2. Contact points 
 
REFUSE 
Carry on receiving usual care, no entry into 
study X 
ACCEPT 
Take consent, allocate ID code, 
collect baseline (Month 0) data 
(Demographic, POS, MOS-HIV, etc) 
 Randomise n=120  
CONTROL (n=60) 
Carry on receiving usual care 
from clinic  
INTERVENTION: (n=60) 
Receive care from HIV nurse trained and 
supervised in palliative care  
BOTH INTERVENTION AND CONTROL:  
Collect data at month 0, 1, 2, 3, 4 
All patients receive reimbursement at each research appointment. 
APCA African POS 
Pain/symptoms 0, 1 or 2 




Problems acute, i.e. lasting for less 
than 2 weeks, no entry into study X 
 
Pain or symptoms 3, 4 or 5  
Problems not acute- Invite into 
study  
 
Screen for second criteria: POS pain and symptom items (past three days) 
Screen all patients with HIV attending the outpatient clinic: 
First criteria: 18+ years old, on ART for a month or more (not PMTCT or PEP), cognitively 
able to consent, speaks English, Swahilli if then proceed to second criteria 
INTERVENTION (n=20) and CONTROL (n=10) 
Optional qualitative interview after exiting the trial at month 4 
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The number of contacts with clinical and research staff for participants in the control and 
intervention study arms is depicted in Table 3-2.  Intervention participants received a minimum of 7 
contacts with the study nurses, compared with 4 with clinic staff for the control participants. 
Participants in both study arms were able to access healthcare when a problem arose outside of the 
scheduled contact points if necessary – patients in the intervention group arm with the study nurses 
and those in the control arm, with the clinic nurses. All participants in the study received five data 
collection appointments with the researcher.   
Table 3-2 Chronology of appointments for data collection and delivery of the intervention. 
3.2.2.3. Data collection  
The researcher administered the quantitative outcome measures at baseline and then monthly 
throughout the study period of five months.  Researcher recruitment, training and  data collection 
procedure is discussed in further detail in section 4.4.  The outcome measures used in the TOPCare 
study were a demographic questionnaire, the APOS, Medical Outcomes Study for HIV (MOS-HIV), 
General Health Questionnaire (GHQ 12), Client Services Receipt Inventory (CSRI) and questions on 
adherence to ART and sexual risk taking.  Examples of all measurement tools can be found in 
Appendix 6 
3.2.2.4. The intervention care package 
The intervention care package was delivered by two HIV specialist nurses from the standard care 
clinic, who received two weeks of palliative care practical training and ongoing clinical support.  They 
used a clinical assessment tool to assess and plan care, and referred complex cases to the local 









Baseline    
Within 1 week of first 
contact 
   
Within 2 weeks of first 
contact 
   
Month 1    
Month 2    
Month 3    
Month 4    
Methods 1: Study design, rationale and methodological considerations 
60 
hospice for ongoing support.  The minimum package of palliative care consisted of one visit within 
the first week following recruitment, one further visit within the second week, and then one visit per 
month for a minimum total of seven visits. 
Training  
The two nurses from the CCC who self-selected to participate in the study, each have many years 
experience in the clinic and were experts in ART care, adherence counselling and family planning.      
The palliative care training they received consisted of five days didactic training followed by five days 
of practical experience in a palliative care setting.  The training was provided by KEHPCA and 
included sessions on the principles of palliative care, mental health assessment and care, teamwork, 
pain assessment and management, spiritual and cultural issues, communication and counselling, 
sexuality, ethical and legal issues, self-care and stress management, breaking bad news, nutrition, 
symptom management, and the concepts of death, loss and bereavement.  The nurses then spent 
five days shadowing staff at the local hospice, an institution with a multidisciplinary team which has 
been delivering palliative care in this region since 2001.  The hospice routinely provides care for 
patients with life-limiting illnesses in the Mombasa region and offers out-patient services, home 
based care, hospital visits and day care.  They aim to provide support and training for families of 
patients in home settings, where they can be more comfortable, and to promote training and 
development for health care professionals, workers and volunteers in palliative care in the Coast 
province. 
Clinical supervision 
Clinical supervision was provided by the co-ordinator of the hospice supporting the project to the 
nursing staff delivering palliative care.  The co-ordinator of the hospice supported the staff from the 
point of training until the study closed.  This established a relationship of trust and support which 
continued throughout the study.  Initially, the clinical supervisor attended the study site twice a 
week to review all patient notes and offer solutions to problems the study nurses encountered 
during the course of delivering palliative care.  In particular, in the initial stages when the nurses 
were still building their skill-base and confidence and when cases were especially complex, each 
clinical decision taken would be jointly reviewed and discussed by the clinical supervisor and the 
nurses, encouraging skill development and problem solving.  The supervisor also encouraged the 
staff to be reflexive about the care, its impact on them in terms of stress and emotional burden and 
how they could manage this. 
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Complex cases 
Clinical cases which the nursing team felt unable to tackle or which required medications that could 
not be dispensed at the clinic, such as strong opioids, were referred to the hospice for further 
management.  Complex cases of pain or symptom management requiring specialist palliative care 
were also referred for co-management with hospice staff. 
Clinical assessment  
The clinical assessment sheet (Appendix 7) was designed as a prompt to ensure that participant 
assessment was holistic.  Its design was informed by assessment sheets currently in use by palliative 
care providers across SSA, and cover physical assessment, including pain, symptoms and activities of 
daily living; mental well-being, including family, economic and emotional well-being; and spiritual 
well-being. The final element of the assessment sheet relates to ART adherence and potential side 
effects and toxicities.  Every clinical assessment item was covered at every nurse-participant 
interaction, with a particular focus on the problems identified at previous sessions.  To track 
participant progress during the trial the nurse completed a tick box summary at the end of the 
assessment to highlight areas of concern, which were then recorded in the ongoing record.  The 
ongoing record was a summary document which facilitated progress-monitoring and ensure chronic 
problem follow up (Appendix 8).  In particular it was used to document problems identified by the 
participant and nurse during assessment and the action plan decided upon and subsequently revised 
on participants’ progress or deterioration. 
Intervention care package 
Intervention participants received the palliative care assessment and care a minimum of seven 
sessions with one of two study nurses over the four- month course of the study.  In addition to this, 
participants received the same standard HIV care delivered by the clinic nurses to participants in the 
control group. 
Further to the assessment described above, the study nurses employed a holistic patient centred 
approach according to the training they had received. They also facilitated couples counselling 
sessions as the need arose, or when requested by participants.    
The control – standard care 
Those participants allocated to the control group were seen by the CCC nurses and continued to 
receive standard HIV care in an identical way to the other patients in the clinic.  Once a month they 
attended the palliative care department to complete the study questionnaires.  In line with the CCC 
protocols, patients initially attend the clinic for ART repeat prescriptions every two months with 
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decreasing frequency once medically stable.  Because patients participating in the study were 
experiencing pain and symptoms and their CD4 counts did not exhibit an increasing trend, they 
attended the clinic once a month, in line with CCC protocol.   
3.3. Thesis study design  
This section will discuss the study design, the rationale for design decisions, provide a brief 
theoretical background of mixed methods research and discuss the methodological considerations 
for the study. 
This thesis uses a mixed methods sequential study design (242, 243), with mixed methods providing 
an expansive function, in order to evaluate effectiveness of the intervention care package (the 
‘what’), as well as reasons for any effectiveness (‘why’) in the context of participants’ experiences 
(‘whom’), (243, 244).  The mixed methods design included a quantitative data (phase 1) and 
qualitative data (phase 2) collection phases, with the findings from the qualitative data expanding on 
the results from the quantitative data analysis. (245).  Data integration occurred during the analysis, 
where the findings from the quantitative data were used to interrogate the qualitative data and 
draw meta-inferences (combined inferences from both types of data) and conclusions from both 
datasets.  This adds richness and comprehensiveness to the study conclusions, and reflects the 
complexity of the intervention under study. 
The thesis study design is depicted graphically in Figure 12.  Phase 1 was composed of longitudinal 
quantitative data collection over a period of four months, followed by phase 2, for a sub sample of 
the TOPCare study that was purposively selected and consented to participate in one qualitative 
interview.  Findings from analysis of data from each phase were used to address the objectives as 
illustrated in the map of the study design (Figure 12). 
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  Figure 12 Map of thesis study design 





MOS-HIV MHSS: Psychological quality of 
life 
GHQ-12: Psychiatric morbidity  
APOS: ability to share and worry 
CSRI: Service receipt  
 




(20 intervention 10 control) 
Purposive sub sample of Phase 1 sample 
 





1. To determine baseline levels of mental 
well-being and to examine associations 
between baseline mental well-being and 
demographic and clinical characteristics..  
 
2.To identify any effect of intervention  
 
 
3.To determine and describe patient 




4.To identify and explore the existence 
of “active ingredients” and mechanisms 
of action of the intervention and 
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3.3.1. Definitions of terms 
This section contains definitions of terms used in the analysis and reporting of data for this thesis. 
3.3.1.1. Active ingredient 
Evaluation of multifaceted person-centred interventions can be challenging, particularly when 
compared to the evaluation of a discrete drug intervention, because of the difficulty in isolating the 
different  aspects of the intervention that were effective (246, 247).  This study adopts the concept 
of an active ingredient developed by the MRC, namely the specific aspect or aspects of a complex 
intervention which make it effective (247).   
3.3.1.2. Mechanism of action 
Closely linked to the concept of an active ingredient is that of the mechanism of action.  This refers 
to the process or means through which an active ingredient exerts itself and interacts with other 
aspects of components of an intervention, the context and the participants, to produce and effect 
(247).  Understanding this mechanism is useful in refining the intervention, for example by isolating 
or enhancing the mechanism of action of the most active ingredients in an intervention.  
3.3.1.3. Mental health and well-being 
The description and understanding of the concept of mental health or well-being developed by 
Walker et al will be used in this thesis to capture the intersectionality of the social, psychological and 
economic determinants of mental health (56).  Their framework of the determinants of mental 
health is partially reproduced in Figure 3-6.  The use of this framework rather than a simple 
definition of mental health, serves as an evidence-based reminder of the complexity and 
intersectionality of the concept.   
Figure 13 Determinants of mental health or well-being (56) 
Key determinants of mental health 





Involvement in group activities 
Civic engagement 
Valuing of diversity 
Physical security 
Self determination and control 
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3.3.2. Mixed methods research  
This study evaluates the effectiveness of a nurse-led intervention on mental well-being, by 
quantifying and exploring changes in mental well-being throughout the study.  Meeting the study 
objectives requires the use of mixed methods research, defined as combining qualitative and 
quantitative approaches into one study or a series of multi-phased studies (248), or the integration 
of both quantitative and qualitative data collection and analysis (243).  The use of different types of 
data in the same study is increasingly common in research as it provides a more comprehensive 
account and more nuanced understanding, which is particularly important in the evaluation of 
complex interventions (247, 249).  However, the use of qualitative and quantitative approaches 
within the same research design creates an epistemological tension, discussed below. 
3.3.2.1. Evaluation of complex interventions  
The intervention under study for this thesis is a complex intervention as defined by the Medical 
Research Council (MRC) (247).  This means that it is context dependent and also made up of several 
interacting components, which themselves include measurable components and relatively un-
measurable components; for example, ‘nursing care’ includes administering medications wound 
care, and as well as tacit and routine elements that impact on the difficult to measure concepts of 
‘quality’ and ‘compassion’ (250). 
RCTs are an important and powerful tool in establishing the efficiency of clinical interventions 
however, it is recognised that the use of traditional RCT designed is flawed, particularly for the 
evaluation of complex interventions to improve health (246).  When evaluating the effectiveness of a 
simple intervention such as a medication, or a particular surgical technique, evaluation is focused on 
outcome.  When the same approach is applied to a complex intervention this often generates 
inconclusive or confusing results, because mechanisms of effect may not be sufficiently clear and 
uncomplicated to produce a clear outcome (251).   
In recognition of the importance of the complexities involved in evaluation, the MRC published 
guidelines for the evaluation of complex interventions in 2000 and revised guidelines in 2008 (246, 
247).  These guidelines specify that evaluation should include 5 steps. (1) preclinical, where theory is 
explored and hypotheses are chosen; (2) modelling, where the components of the intervention and 
underlying mechanisms which may predict effectiveness are identified; (3) exploratory trial, when 
constants and variable aspects of the intervention are described and a feasible protocol is 
developed; (4) definitive randomised controlled trial, where the intervention is compared with an 
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appropriate comparator, with defensible theoretical framework and adequate statistical power and 
(5) long-term implementation, where it is determined whether outcomes can be replicated in 
uncontrolled settings.  Qualitative data collection and analysis is advocated in steps 1 and 2, to 
inform the exploratory and definitive trial, which will produce evidence of effectiveness (247).   
Despite qualitative data input at the preclinical and modelling phases, if the underlying causal 
mechanisms of change differ from what was hypothesised and anticipated during these phases, 
there is a risk that a limited set of quantitative outcome measures might not be suitable to capture 
the effect of the intervention on their own (252).  To anticipate this study’s findings, a traditional 
RCT design using quantitative methods alone may have found that the intervention was ineffective, 
when in fact causation was more complex, involving the intervention’s context and interactions 
between different intervention components (253).   
Palliative care interventions are complex interventions because of the interacting components of the 
care package, the importance of context such as environment or disease, and also, because palliative 
care is patient centred, therefore components are delivered according to participant need creating 
many different combinations of treatment patients could receive (247).  Because of this complexity, 
evaluations incorporating qualitative data collection and analysis are particularly suited to palliative 
care research, as this approach is better able to provide both breadth and depth of inquiry in 
addition to providing an understanding of complex causal mechanisms (27, 254, 255).  It has been 
posited by some authors that this exploration of multiple causation and the effect of context would 
be possible with combinations of several RCTs such as multi arm or factorial RCT, calling this 
approach ‘realist trials’ (256).  However, the extreme demand of this approach on the available 
resources in terms of expense and time made this option less feasible for this study.  As a result, a 
mixed methods approach was selected, based on a critical realist philosophy. 
3.3.2.2. Philosophical basis - Critical realism 
Critical realism is a form of post-positivist philosophy, which posits that the world is complex and 
multidimensional, with many unobservable powers, structures and contexts which trigger reactions 
and responses in particular circumstances (257, 258).  Initially developed by Baskhar, critical realism 
argues that it is essential to understand the underlying mechanisms of causation, which are 
sometimes expressed and visible or measurable, in tangible events or outcomes, but also may be 
hidden and unexpressed (259).  Causation is understood to be complex, and mechanisms of 
causation are expected to vary under different circumstances and contexts, and are seen as 
‘tendencies’ and not ‘determinants’ of outcomes (253).   
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Critical realism divides reality into three strata: the empirical, which is the expressed visible 
outcomes, and the actual, which is what occurs whether observed or not, and the real, where the 
causal mechanisms operate (259).  For example, when looking at the sea, one might observe 
somebody surfing (strata of empirical reality).  One may or may not observe the waves, depending 
on whether they break or not, but we know that they occurs as they are necessary for surfing (strata 
of actual reality).  The waves are in turn caused by the currents in the sea (strata of the real).  In 
everyday life, causal mechanisms are more complex than portrayed in this example, and cannot be 
accurately described without contextual and supporting information which is not always available 
(for example, the ability of the surfer or weather).  This leads most research to offer a partial 
explanation for causality at best (260, 261).   
The unique contribution of critical realism to an understanding of social phenomena is to make the 
strata of their reality explicit, opening the possibility for their exploration (261).  Critical realism 
emphasises that our social world operates in an open system, and that it is crucial for research to 
emphasise the essential role of social and environmental context in causation (262).  (An open 
system is one which is vulnerable to context, where every element interacts with the environment 
and context and does not exist in isolation.)  If researchers ignore these strata of reality and the 
complexity of causal or generative mechanisms, they would treat society, which is an open system, 
as a closed system, and increase the risk of making false assertions of causality (260). 
Based on this theoretical understanding of how an intervention works, conclusions from critical 
realist research focus on causal mechanisms and context, and the way these relationships shape the 
outcome (258).  This moves evaluation research, including evaluation of nursing interventions, from 
“what works?”, to “what works, for whom and why?”, affirming the contribution of both 
quantitative and qualitative data collection and analysis (262).  In addition, without an 
understanding of the causal mechanisms, it is impossible to suggest reasons why an intervention is 
effective or not, and how any effect might have occurred (260).  This is particularly important when 
evaluating an intervention which may be adapted for another context and refined to enhance 
effectiveness or efficiency (260). 
3.3.2.3. Methodology - Critical methodological pluralism 
Critical methodological pluralism is a critical realist paradigm for mixed methods (263).  It is similar 
to pragmatism in welcoming a variety of methodological approaches and techniques, depending on 
the needs of the research question.  However, in critical methodological pluralism the methods must 
also fit the ontological perspective (263) in this case critical realism.   
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It is commonly thought that an ontological tension arises when mixed methods are used to evaluate 
complex interventions.  Qualitative methods often involve interpretivism and relativist assumptions, 
while quantitative approaches, are often based on assumptions of determinism and a successionist 
understanding of causality (253, 264).  Previously, these approaches were in direct conflict, and were 
thought to be incompatible, (244, 265).  This is resolved in critical realism.  Because critical realism 
accepts the possibility of linear causality within a closed system, it is compatible with the model of 
an RCT.  However, critical realism also accepts multiple causal mechanisms for an effect, and rejects 
the simplistic concept of direct cause and effect within a open system (253). As such critical realism 
is a sound ontological perspective for critical methodological pluralism.  
Critical methodological pluralism emphasises the importance of using appropriate and if necessary 
different methodological approaches within the study design.  Therefore, in order to evaluate this 
complex intervention, from a critical realist perspective, mixed methods have been chosen using the 
critical methodological pluralist paradigm, to gain breadth and depth of enquiry, and to understand 
the many causal mechanisms of action which many be occurring to create the outcome measured 
during this study. 
To summarise, it is acknowledged that the traditional RCT design is inadequate to evaluate the 
complex interventions, such as palliative care.  The addition of a qualitative component is 
recommended to increase understanding of context (246) and to increase the breadth and depth of 
inquiry (27).  The use of qualitative approaches in conjunction with quantitative approaches 
introduces an ontological tension, which is relieved by adoption of a critical realist philosophical 
basis and a methodological paradigm of critical methodological pluralism.  This enables the use of 
mixed methods to evaluate the complex intervention, with a clear ontological perspective.  
3.3.2.4. Contribution of mixed methods  
Mixed method evaluations of complex intervention focus on two key questions:  firstly, is this 
intervention effective in everyday practice, and secondly, how does the intervention work, i.e. what 
are the ‘active ingredients’ or what aspects are key to effectiveness or to the change observed and 
how do they exert their effects (244, 247, 266)?   
The aims and objectives of this thesis address both these questions (section 2, Pg 53).  Specifically 
objectives 1, 2 and 3 address baseline levels of mental health and well-being  and the evidence of 
effectiveness, and objective 4 addresses the existence of active ingredients and explores their 
mechanism of action, integrating mixed method data from both phases of the study (Figure 12).    
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The quantitative outcomes will contribute to an understanding of patterns or regularities in the 
sample, for example if mental health and well-being are associated with poverty or gender or 
education level (263).  Without quantitative measures it is almost impossible to detect taxonomies, 
trends or patterns that warrant further investigation.  Qualitative approaches become more useful 
when conducting an in depth study the patterns identified, or of respondents in specific 
circumstances, such as when describing the participant experience (objective 3) or identifying active 
ingredients for change (objective 4), or when underlying causal mechanisms are sought.   
This evaluation was conducted cross-culturally.  The literature strongly advocates that qualitative 
approaches to data collection and analysis be used in cross-cultural research, as it provides an 
opportunity for participants to express concepts which are important but may not be obviously 
relevant from the perspective on a cultural outsider (267). Qualitative approaches enable 
respondents to articulate their understanding of a topic from their own perspective, and not need to 
constrict and adapt their understanding to a framework devised by the cultural outsider (268).    
3.3.3. Research questions by objective and rationale for methodology 
3.3.3.1. Objective 1  
To determine baseline levels of mental well-being and to examine associations between baseline 
mental well-being and demographic and clinical characteristics among patients with HIV on ART 
enrolled in a randomised controlled trial (RCT) of a nurse-led palliative care intervention. 
The research question associated with this objective is:   
What is the baseline level of mental well-being of the participants enrolled in the TOPCare 
study, before the intervention was delivered?   
This objective will be addressed using the quantitative data from phase 1, to describe the outcomes 
from the MOS-HIV, the GHQ-12 and the APOS worry and ability to share items as measures of 
psychological quality of life, psychiatric morbidity and social well-being.  This data will also be 
analysed for association with demographic and clinical characteristics.   
3.3.3.2. Objective 2 
To identify any effect of the palliative care intervention on mental health and well-being, comparing 
the intervention with standard best practice. 
The research question for this objective is:  
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Does receipt of the intervention affect the psychological quality of life, psychiatric morbidity, 
worry and the ability of participants to share their feelings?   
Quantitative data from the MOS-HIV, GHQ-12 and the APOS worry and ability to share items will be 
analysed at monthly time points to identify differences between control and intervention 
participants.  The data will also be analysed using longitudinal analysis techniques to account for 
data clustering by participant.   
3.3.3.3. Objective 3 
To determine and describe participant experience and longitudinal response to participation in the 
study in terms of mental health and well-being, and to identify and explore associations between 
participant response and demographic and clinical characteristics 
The research questions for this objective are:  
How and why do participants respond to participation in the study, and receipt of the 
intervention?  
 Is this response different in participants with different demographic or clinical 
characteristics?   
Longitudinal summary measures (area under the curve) will be calculated for each participant from 
the phase 1 quantitative data, and will be analysed for association with demographic and clinical 
characteristics.  Any associations identified will be used to interrogate the phase 2 qualitative data 
for patterns of response across demographic and clinical characteristics.   
The qualitative data set will be analysed using thematic analysis with a focus on time, identifying 
descriptive themes to describe participant experience for both study arms before, during and after 
the study participation period.  This will be reported in terms of participant experience of 
psychological symptoms and social experience.   
This mixed methods approach will generate both process and outcome data to comprehensively 
address the objective.  
3.3.3.4. Objective 4 
To identify and explore the existence of “active ingredients” and mechanisms of action of the 
intervention and therapeutic aspects and processes of study participation 
This is a mixed methods objective which will address the following research questions: 
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What components of care were delivered as part of the intervention care package, and how 
did they differ from care received as in the standard care clinic?   
Which aspects of the intervention and of study participation were associated with therapeutic 
benefit, and what were the processes of change?  
To address this objective, data from the CSRI will be analysed to identify components of care 
delivered as part of the intervention care package, and compared with components delivered to 
those receiving standard care.  The components of care provided as part of the intervention will 
then be analysed for association with area under the curve calculated to address objective 3 
(longitudinal summative measure of well-being over time) to identify which components of care 
were associated with positive change in mental health and well-being. 
Qualitative data from phase 2 of the study will be analysed to identify the active ingredients of the 
intervention and their mechanisms of action (from participants who received the intervention care 
package) and therapeutic aspects and processes of study participation (from all participants). 
3.3.4. Methodological considerations 
3.3.4.1. Thesis situated within a wider trial 
Secondary outcome 
It is important to remember that this thesis and research question use the secondary outcome of the 
TOPCare trial, the primary being change in pain score.  It is reasonable to assume that if change in 
mental health and well-being was the primary outcome of TOPCare, the trial would have been 
designed differently. The statistical power of the sample was tested in the original study design to 
verify that there was adequate statistical power to detect a clinically significant change in the 
secondary outcome (MOS-HIV MHSS), but this will be rechecked for ensure statistical power for 
objective 2 of this thesis. 
Generalisability 
The sample for this thesis is taken from the TOPCare trial, which has inclusion criteria of moderate to 
overwhelming pain or symptoms, for two or more weeks, as measured by the APOS.  Thus, the 
findings can only be generalised to this population, a HIV positive population, stable on ART, but 
with persistent pain or symptoms.  To be classed as a stable ART patient means that the patient has 
been on the same regimen for some months, with decreasing trend in viral load and increasing CD4 
count, and no unmanaged symptoms or opportunistic infections. 
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Methodological limitations due to embedded nature of qualitative component 
Qualitative data collection conducted within a larger RCT risks having an auxiliary role, where the 
qualitative data is under conceptualised and added to the study design as an afterthought (264).  
This could be problematic if equal importance and thus attention was not attributed to data quality 
in each phase for both methodological approaches.  Plano Clark et al suggest that tensions can be 
avoided when research questions and a protocol for mixed methods data collection, analysis and 
interpretation, are clearly defined from the start and both components of the study are thus given 
equal priority and consideration in the study design (264). 
In this study, I carefully and fully developed the qualitative component as part of my thesis, but only 
after data collection for the wider the RCT had begun.  However, qualitative data collection tools 
were designed with the same attention to detail and rigor as quantitative data collection tools, and 
the sample was selected purposively to address the objectives. 
Further methodological limitations are discussed in the discussions section (Pg. 229) 
3.3.4.2. Cross cultural and cross-language research issues 
In the literature, cross-language and cross-cultural research is often critiqued for failing to recognise 
the impact of language on data quality, and underreporting steps taken to ensure cross-cultural or 
cross-language trustworthiness (269, 270).  A recent systematic review identified failure to 
acknowledge role of translator, failure to pilot test interview schedule and failure to describe 
interpreter credentials as most prevalent unreported limitations (269).  Additionally, when research 
is conducted in populations unfamiliar with research culture, concepts such as informed consent and 
even the concept of research (questions are asked with no expectation of response or action taken 
to address concerns raised) may be particularly concerning or confusing for participants (271).  
Concepts such as randomisation may not translate well, or may have cultural implications, for 
example associated with autonomy (271, 272).   
Im et al developed criteria for ensuring that research was been conducted in a rigorous and 
respectful way, and to address some of the concerns identified above (273).   They suggest the 
research topic must be culturally relevant, in that it must serve a need and improve the lives of 
participant members.  Context must be considered, meaning that the social structural context of 
participants, and the ways in which this might influence their responses must be considered.  
Appropriate communication, conceptualisations and translations should be used and there must be 
mutual respect for all aspects of the researchers’ and participants’ cultures (273).  Finally, the 
research must be flexible in terms of language and time taken for data collection.   
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By using local experienced and qualified researchers who supported the local population to 
understand and engage with the research, we hope to have addressed these challenges and 
concerns. The researcher and research nurses acted as key informants, providing information and 
cultural translation for myself as the analyst in London (274).  The qualitative data collection tools 
was piloted and subsequently amended and translators were selected based on their previous 
experience and on the quality of one interview transcript.  A forum of regular communication and 
meetings and a culture of openness was set up to facilitate this role, so that the study team could 
openly feed back to the study design team whenever they felt there was an issue of cross cultural or 
cross language confusion.  Further to this, to enhance transparency, all decisions and steps taken to 
increase cross language trustworthiness are reported in full in the analysis plan.   
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4. Methods 2: Protocol 
4.1. Introduction 
This chapter describes the study protocol detailing the procedures for data collection, sampling and 
recruitment.  This is followed by a description of each quantitative outcome measure, sample size 
calculations for the primary quantitative outcome, and a detailed analysis plan for each objective.    
4.2. Mixed methods matters 
Issues of sampling, the process of data integration, management of conflicting findings and data 
quality specific to mixed methods research are considered within the design and implementation, to 
ensure quality inferences can be made (275).  
4.2.1. Sampling 
Rigorous sampling in mixed methods research combines the requirements of quantitative with 
qualitative approaches whilst maintaining the data quality of both components and therefore the 
quality of the meta-inferences of the study (276).  As in all research, sampling in mixed methods 
research is determined by the research objectives, which also inform the sampling scheme (277).  
Quantitative probabilistic sampling is needed to generate findings which are generalisable to a 
population with similar characteristics (278).  Qualitative sampling techniques purposively sample 
for generation of theory, to explore unique, typical or extreme cases  or to achieve 
representativeness and transferability (276).  There remains a tension between the  focus of 
probabilistic sampling, which is to create breadth of information and the focus of qualitative 
sampling, which is depth of information on a smaller number of participants (278).  
In this study, sequential mixed methods sampling was performed to resolve this tension (278).  The 
sample for phase 2, the qualitative phase, is a sub-sample of the sample for phase 1, and was 
purposively selected based on study arm and response to the intervention in terms of MOS-HIV 
mental health summary score (MHSS).   
The samples were also of adequate size to enable statistical power to detect change in quantitative 
data and to identify and explore different experiences of the intervention and participation in the 
study.  This enabled the study to generate high quality findings from each phase and meta-
inferences from all phases, to meet the study objectives (276).   
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The sample for phase 1 was chosen using probabilistic sampling from attendees at the clinic who 
met the inclusion and exclusion criteria.  In total 120 participants were recruited based on the 
original TOPCare sample size calculations for the primary and secondary outcomes of the trial (241).  
From this, a sub sample of 30 participants was chosen purposively for the phase 2 qualitative data.    
4.2.2. Data integration 
In mixed methods research, findings from the analysis of each data type can be integrated at 
collection, analysis or interpretation (243). In this thesis the findings were integrated during all three 
stages.   
Firstly, integration during data collection was conducted using the results from the analysis of the 
quantitative data to inform sampling for phase 2.  MHSS was used to identify those who had 
responded to a clinically significant extent and those outliers or deviant cases who had responded in 
a different or counterintuitive way for inclusion in the sample for phase 2.  This is discussed in 
further detail in section 4.4.2.1. 
Secondly, findings from the quantitative data analysis were used to interrogate the qualitative data 
to met objective 3 (see Figure 12).  For example, and to anticipate, education was identified as 
associated with response to participation using quantitative analysis, and subsequently qualitative 
data on the participant experience were examined across levels of educational attainment (further 
details see section 4.6.5.2).   
The findings from phase 1 contribute to addressing all objectives.  The findings from phase 2 address 
objective 3 and 4.   
Thirdly, interpretation in the form of meta-inferences drawn from the results of data analysis from 
both phases, were made (248).  
4.2.3. Management of conflicting findings 
It is not expected that the findings from each type of data will necessarily converge.  Different 
methods and analytical approaches may produce data from the same sample which may converge, 
complement or diverge, particularly when the concepts under study are complex or multifaceted 
(279).   
If conflicting findings from the analysis of data from phase 1 or 2 are identified, they were treated as 
fundamentally different, in that they provide different types of insight or perspective on the same 
complex intervention (252).  By using a mixed methods approach, we increase the likelihood of 
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identifying divergent findings.  This indicates an increase in the scope, detail and depth of an inquiry, 
viewing the same encounter from different angles and highlighting different facets or aspects of the 
complex phenomenon (279, 280).  No data type or finding was privileged and all findings contributed 
to the meta-inferences of the study. 
To ensure that any divergences were not due to a lack of data quality in any of the phases, a detailed 
and rigorous data collection and analysis protocols (outlined on pages 81, 86, 91 and 97) have been 
designed and followed (252).   
The extent of divergence or convergence is sometimes used to indicate the external validity of 
findings, with convergence taken as strong evidence in favour of a finding, as a function of 
triangulation (279).  Triangulation is not always assumed to act as an indicator of validity, but 
denotes simply that different methodological approaches have been used to study one phenomenon 
(281).  Convergence of data from different sources could indicate shared bias rather than validity 
and therefore cannot be relied upon as a valid indicator of data quality (279).  Particularly in 
sequential study designs it cannot be used to validate findings, because of the potential for the data 
collected first to bias the second (277).  In this case the quantitative findings are being used to 
inform the qualitative interviews, and could affect the content of the interview.  Therefore, whilst 
useful in exploring diversity of response and to gain a deeper understanding of the mechanism of 
action, triangulation will not be used as a measure of validity in this study.   
4.2.4. Quality of mixed methods studies 
While standards for measuring data quality are well established in qualitative and quantitative 
research methodology, standards in mixed methods are less well developed (282).  However, 
O’Caithain et al have developed eight domains which will be used in this study to ensure the quality 
of the study design, data collection, analysis and inferences (283).  This framework covers the quality 
of study planning, design, data, interpretation, transferability, reporting, synthesizability and utility.  
The framework is presented in Table 4-1 with details of its application and relevance for this thesis. 
Table 4-1  Framework for data quality in mixed method research.  Taken from O’Caithain et al (283)  
Domain Description Application in this thesis 
Domain 1: 
Planning quality 
How well was the 
mixed methods 
aspect of the study 
planned?   
 
Was there a strong 
rationale for the 
use of mixed 
Data collection tools, sampling strategy and analysis plans for 
both phases of the study were planned and developed 
specifically to provide the mixed methods data required to 
address the study objectives.   
 
Mixed methods were required to evaluate the effectiveness of 
the intervention in terms of outcome and process, with 
qualitative data providing an expansive role.   
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Domain Description Application in this thesis 
methods?  
 





Data collection, analysis, reporting and initial disemmination 
activities were planned to overlap, reducing waste of nurse and 
researcher time, and fitting all activities into the time frame 
required by the project grant.   
 
Domain 2: Design 
quality 















The study has a sequential expansive design (243).  A map of the 
study design is reported in Figure 12. 
 
Validated outcome measues are used to measure quantitative 
levels of mental health and well-being. Qualitative method are 
used to examine active ingredients and therapeutic aspects of 
participation. 
 
Methods chosen will provide breadth and depth of enquiry, and 
will be used to provide compensation for each others 
weaknesses in this regard. 
 
Methods chosen will provide quantitative data on the 
magnitude and frequency of constructs and qualitative data on 
the meaning and understanding of constructs (284) 
 























There is a rigorous data collection and analysis plan detailing the 
choice of methods and rationale for these choices (sections 4.3, 
4.4 and 4.6).   
 
The study has been designed to maintain data rigor despite the 
time and logistic constraints of a mixed method study design (Pg 
62).   
 
Sample size calculations were performed to ensure adequacy for 
phase 1 (quantitative component). The phase 2 sample 
(qualitative component) of 30 participants, is considered 
adequate for data saturation (276, 285). 
 
Data analysis techniques for quantitative and qualitative data 
were chosen based on recommendations and guidance from the 
literature, to address the objectives and study aim (286-288).  
 
Analytic integration took place during the interrogation of the 
qualitative data by the quantitative findings to addresse 
objective 3.  To address objective 4, both quantitative and 
qualitative data were used, integrated to identify the active 












All findings were substantiated using the results of statistical 
analyses or text extracts from the qualitative interview 
transcripts. All statistical tests were tested for the violation of 
assumptions, and the results reported for transparency   
 
In the discussion, inferences were discussed within the context 
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of wider evidence.  Areas of divergence were explored more 
fully to understand the mechanism and extent of 
trustworthiness and reliability of the findings.   
 
The analysis process was constantly verified with my thesis 
supervisors, and will be published in the wider literature to 
ensure that any interpretations of the findings do not reply 
solely on myself (the researcher) and the research team. 
 
The credibility of interpretations was strengthened through the 
use of deviant case analysis which explored the possibility of 
other interpretations of the findings.    
 
Meta-inferences, were made whenever possible using both data 
sources when meeting objectives 3 and 4, without preference 
for either data type.   
 
Data divergences are openly explored (section 4.2.3.) 
 
 
Findings and inferences are reported by study objective to 





























The inferences will be transferable to populations of similar 
setting and context – HIV patients on ART reporting moderate to 
overwhelming pain or symptoms.   
 
The extent to which the inferences are transferable to other 
populations or disease groups is unclear, because the 
multidimensional and highly stigmatising nature of HIV infection 
means that differences in the effect of social context might be a 
barrier to ecological transferability.  
 
This population of HIV infected individuals was stable on ART 
and therefore reflects the majority of HIV positive people in the 
world in the near future, in accordance with the international 
progress of ART roll out (30).  Therefore there is good temporal 
transferability. 
 
The theoretical underpinning of the effectiveness of palliative 
care in caring for patients’ mental health and well-being needs is 
explained in section 1.5.  
 
Thick description of the sample, context and intervention will 












The protocol of the TOPCare study is published in an open 
access journal online to promote transparency and research 
quality.   The findings of the study will be adapted for and made 
available to patient groups, clinicians, members of the public 
and policy makers through a variety of means such as blog 
posts, articles in newsletters, professional interest body 
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websites and alerts on social media. 
 
The trial is reported in accordance with the CONSORT guidelines 
(289), will be submitted tof publication in peer-reviewed 
journals, regardless of whether a positive result is found, for 
academic integrity. 
 
The knowledge generated by this study reflects the mixed 
method approach, producing more evidence than two separate 
single method studies, due to the integration of data and meta-





Of sufficient quality 
for inclusion in 
systematic reviews 
Use of well validated outcome measures, reported clearly and 
transparently, increases the possibility that this data can be 
used in systematic review, to consolidate and develop the body 
of knowledge surrounding the mental health and well-being of 
PLWH on ART. 
 
Data collection, analysis and reporting is of high quality and 
conducted in accordance with international standards 
(CONSORT) 
 
Domain 8: Utility 
Findings are used 
by clinicians and 
policy makers 
Each finding and meta-inference from the study is associated 
with a recommendation for research, policy or practice to 
facilitate the dissemination process 
 
4.3. Preparation for data collection 
4.3.1. Selection, training and supervision of the researcher 
The field researcher who performed the data collection for this study is a Kenyan national from 
Nairobi.  She has considerable training and experience in conducting both quantitative and 
qualitative research to a high standard, and has been trained in researcher skills by staff from King’s 
College London (KCL) for previous projects. She has worked in the field of palliative care research 
since 2007 (5 years in 2011 when data was collected).  Before data collection began, she completed 
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Table 4-2 Training content for TOPCare researcher 
Topic 
Background to the TOPCare study  
Background and rationale for study 
Aims and objectives 
Timeline 
Study procedures : 
Screening of participants; Recruitment; Consent; Booking appointments; Distress protocol; 
Randomisation 
Ethics : 
Confidentiality; Data management and storage 
Measurement tools:  
APOS; MOS-HIV; GHQ-12; CSRI 
Routine reporting to KCL during the study : 
Reporting progress ; Importance of recording daily activity; Record keeping and data 
management 
Data entry:  
Use of data entry programme; Importance of accuracy and attention to detail 
 
During training, the researcher rehearsed data collection using the measurement tools in a mock 
interview, and had the experience of being asked the questions, to encourage reflective practice.  
She was also trained in interview techniques such as minimising bias when asking questions and was 
instructed and supported to maintain a professional demeanour.   
4.4. Data collection, management and entry 
As depicted in Table 4-3, data were collected from participants over a four month period through 
five data collection appointments.   
Table 4-3 Time points for data collection during the study 
Standard care participants Baseline t1 t2 t3 t4 
Post study exit 
(Sub sample of 
10) 
 Longitudinal quantitative 
data 
      
Semi structured interviews 
(sub sample) 
      
Intervention care package 
participants 
Baseline t1 t2 t3 t4 
Post study exit 




      
Semi structured interviews 
(sub sample) 
      
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The intervention participants also had clinical appointments with the nursing staff at these contacts, 
the frequency of which is graphically depicted in Table 3-2 on page 59.   
4.4.1. Phase 1: Longitudinal quantitative data 
4.4.1.1. Sampling and recruitment 
Details of the sampling and recruitment for the quantitative phase of data collection are also 
provided in the published TOPCare study protocol (290).   
Participants were registered at the Bomu Hospital comprehensive care unit (CCC) and consecutively 
screened.   The researcher visited the clinic daily at different times to recruit participants.  This was 
to ensure that if patients attending the clinic were different at different times or days (i.e. attending 
market or attending before or after work) they would have equal opportunity to be randomly 
selected for inclusion.  To begin screening, she used a random number table to select a number 
which corresponded with a participant on the register of participants currently in the clinic.  From 
this start point, participants were then screened consecutively for inclusion eligibility.  The first set of 
inclusion criteria was that patients were adult and HIV positive.  On finding a patient who met these 
criteria, she would apply the second stage of inclusion criteria and enquire whether they had been 
on ART for more than a month.  This was to exclude patients reporting symptoms common in the 
initial months of ART, due to side effects, toxicity or immune reconstitution inflammatory syndrome 
(291).  If patients had taken ART for more than one month, they were asked to rate their pain and 
symptoms on the APOS.  If they reported a pain or symptom severity score of 3, 4 or 5 from a 
possible score of 0-5 (with 5 being the worst case) for more than two weeks, (to exclude acute cases 
unsuitable for palliative care) they were taken through the consent process and information sheet to 
ascertain whether they would be interested in participating in the study.   
Randomisation 
Participants consented completed a baseline data collection interview with the researcher, were 
randomised to a study arm: to receive either the intervention care package or standard care 
(control).  Allocation to study arm was conducted by block randomisation.  In practice the researcher 
had three pots, each containing 40 slips of paper.  In each pot 20 slips were marked with an ‘I’ for 
intervention, and 20 with ‘C’ for control.  The participant blindly selected a piece of paper from a 
pot.  Each slip was discarded it after it had been selected.  Only one pot was used at a time.  Block 
randomisation ensured that the workload of the study nurses was manageable by limiting the 
amount of participants allocated to the intervention at any one time. 
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It was planned that the researcher would recruit five participants each week, therefore 6 months 
was planned for recruitment to be completed.  Participants were replaced if one dropped out of the 
study after providing only one data point.  Replacement participants were allocated to the study arm 
of the participant who prematurely left the study, and therefore were not entered into the 
randomisation process. 
4.4.1.2. Data collection 
Data collection was performed at monthly intervals by the researcher.  Each participant was 
allocated a participant pack, stored securely in the palliative care department.  Within the 
participant pack, each month was represented with a different coloured section to facilitate data 
collection and progress monitoring.  Each section contained the specific outcome measures to be 
completed, as not all were used at each appointment.  Participants were free to choose whether 
they conducted the interviews in English or Kiswahili or a mixture of both to ensure complete ease of 
understanding.  Participants who did not attend an appointment were contacted by the researcher 
and encouraged to attend.  There was a two week window after the scheduled appointment after 
which attendance and the data collected would be counted as the next scheduled appointment and 
the previous appointed recorded as a missing interview.   
Data collection took place in privacy in the office of the palliative care department within the 
medical centre, which is separate to the clinic.  On arrival to the department each participant would 
be given light refreshments before seeing the researcher.  The researcher completed each 
questionnaire in turn according to the schedule of questionnaires for each interview in the 
participants pack.  Questions were read aloud by the researcher for the participants to respond to, 
and written by the researcher in the participant pack, to minimise the effect of the varying levels of 
literacy in the sample.  Upon completion or termination of the interview, participants were given 
400 Kenyan shillings, equivalent of 5US$ at the time of the study.  This financial reimbursement was 
to ensure that transport costs were covered for all research appointments and that financial 
constraint was not a barrier to participation. 
The researcher was also responsible for data entry into an Epidata file containing an anonymised 
record for each interview conducted.  The researcher was requested to complete each record as 
soon as possible so that any errors or missing values could be identified and corrected. 
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Translation of study documents and cross-language trustworthiness 
Data collection tools, consent forms and information sheets were translated by the researcher 
(available in Appendices 6 and 9).  Some measurement tools had been translated and validated in 
previous studies, and these translations remained unchanged (208, 222).   
There are many procedures and recommendations for the translation of study documents and the 
pitfalls of failing to ensure good translation have long been recognised (292, 293).  A systematic 
review of quality of life measures produced a five-step guideline for translation and cross cultural 
adaptation of health related quality of life measures (293).   The guidelines recommend that several 
translations should be made in addition to back translations, multidisciplinary committee review, 
piloting of the newly translated documents and finally weighting the scores to each cultural context 
(293).  Unfortunately, a translation project of this magnitude was unfeasible and beyond the scope 
of this study and thesis due to time constraints.  Instead, the study data collection documents were 
translated by a researcher who was a native speaker, familiar with the measures, familiar with local 
language nuances of the Coast region of Kenya, and experienced in palliative care research.  This 
limitation will be further discussed in the discussion section 7.5.3.5. 
Quantitative data collection tools 
Data collection tools for the TOPCare trial include a demographic questionnaire, the APOS (208), the 
MOS-HIV (294), the GHQ-12 (295), CSRI (296), and some brief questions assessing risk behaviour and 
adherence.  For the purposes of this study, the MOS-HIV, the GHQ-12 and two APOS items (ability to 
share feelings with friends and family and worry) will be analysed for data on mental health and 
well-being.  The CSRI was used to monitor the content on the clinical encounters delivered by the 
study nurses, for comparison with standard care and to identify areas of effectiveness.  Examples of 
all quantitative data collection tools can be found in Appendix 6. 
Demographic questionnaire 
The demographic questionnaire collected data on gender, age, partner status, number of children, 
number of financial dependents, highest educational attainment and possession of a number of 
items which were taken as asset based indicators of wealth. These indicators were the materials of 
which floors, wall and roof of their home were made, their water source, fuel source and whether 
participants possessed a fridge, bicycle, television, car or radio.  Asset base approaches to 
determining wealth are commonly used in LMIC, as wealth and economic exchange may not be cash 
based and therefore estimates based on payment, salary or cash expenditure may be biased (297).  
This measure of wealth was developed for use in demographic health surveys by MEASURE DHS in 
collaboration with ORC Macro, for international use (297).   The variables of asset ownership are 
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analysed using principal-components factor analysis to create a continuous score, which is then 
divided into quintiles to represent relative socioeconomic status for analysis.  This method has been 
used widely in demographic health surveys as an indicator of wealth in Africa and elsewhere (298).   
Medical Outcomes Study – HIV (MOS-HIV) 
The MOS-HIV was developed from the initial Medical Outcomes Survey (MOS) in 1997 (294) and has 
been adapted from the MOS as a quality of life measure specific for HIV positive populations (299).   
The MOS-HIV is a 35 item self report quality of life survey, which assesses participant reported 
function and well-being in eleven subscales.  Item scores are then weighted to generate subscale 
scores measuring quality of life in terms of mental health (MHSS) and physical health summary 
scores (PHSS), which have also been validated in the African context (300, 301).  MHSS is being used 
in this thesis to measure psychological quality of life.  The MHSS is on a scale from 1-100 with a 
standardised mean of 50 for the general population.  Psychometric analysis of the MHSS indicates 
good internal consistency (0.94), test re-test reliability (0.6), sensitivity to change (p<0.001) and 
acceptable intra class correlation (0.53) (301).  It has been validated in the United States (301, 302), 
several European countries (303), Zimbabwe (304), Uganda (305) and Rwanda (306).  It is an 
appropriate choice of measure as it is disease specific and validated in populations from countries in 
SSA. 
MOS-HIV data is reported on a ranking system, generating ordinal data.  The raw scores for each 
sub-scale are transformed onto a scale of 0-100 according to guidance from the developers of the 
MOS-HIV (307).  Because the data generated is ordinal, and because the data is a subjective report, 
conservative measures should be used in the analysis, therefore the data was treated conservatively.  
Assumptions were always tested for each statistical analysis and if found to be violated for 
parametric statistical analysis, data was analysed using nonparametric techniques.   
General Health Questionnaire - GHQ 12 
The GHQ-12 is a measure of psychiatric morbidity, and is a reduced form of the GHQ-60 (295).  It has 
been validated in Nigeria, Kenya and Japan and is widely used in health research (308-310) and for 
screening in community healthcare settings (311-313).  It consists of 12 questions concerning 
concentration, worry, usefulness, decision making ability, feeling under strain, feeling helpless, 
ability to enjoy day to day life, ability to face problems, depression, self confidence, feelings of 
worthlessness and happiness (295).  Participants are required to rate each item on a Likert scale with 
the choice of: not at all, no more than usual, more than usual and much more than usual. 
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Following recommended practice, the chronic GHQ scoring method will be used to analyse the GHQ-
12 data for this study (CGHQ).  This method is designed for people living with chronic conditions, 
whose ‘no more than usual’ or baseline is likely to reflect levels of psychiatric distress higher than 
those expected in a well population (311, 314).   Using this method, a report of ‘no more than usual’ 
is taken as indication of chronic illness rather than good health (314).   
Because of the many versions of the GHQ (GHQ-60, GHQ-30, GHQ-28, GHQ-12 (315)) and the many 
different scoring methods (simple, Likert, CGHQ, GHQ (316)) comparison of results across studies is 
problematic.  The threshold for case definition varies depending on cultural context and disease 
group, and unless proportion of “caseness” is necessary for comparison purposes or to assess the 
mental health of the sample, and has been independently validated in a target population, this 
approach has limited value (316).  This study examined associations between high or low score and 
clinical and demographic independent variables, therefore raw score were used in the analysis of 
this data.  This score is a summation of the responses of all 12 questions in the GHQ-12 and ranges 
from 0-12, with 12 being the worst possible score, indicating a status of severe psychiatric morbidity. 
APOS items 
The APOS is a multidimensional palliative care assessment tool, adapted from earlier versions of the 
Palliative Care Outcomes Scale (POS) and validated for use in Africa (49, 208, 317, 318).  It is a seven-
item measure covering physical, psychological, social and spiritual dimensions of care.  There also 
are questions to ask of the carer of the participant which were not analysed in this study due to low 
availability of carers.  Participants respond verbally, or by using their hand to indicate the severity of 
each problem, with each finger counting as a point on the Likert scale, and a closed fist as 0.   Scoring 
is on a Likert scale of 0-5, from no problem to overwhelming problem for each item.  Four items use 
0 as the worst case scenario, where there are no problems.  Three items are scored in the reverse, 
where 0 represents best case scenario or no problems.  This ensures that care and attention is given 
to all questions.   
The APOS has good face validity and is responsive to change, has moderate internal consistency as 
expected in a multidimensional measure and takes 5-7 minutes to complete (208).   
Two items within APOS were used to address the objectives of this study: feeling worried and the 
ability to share feelings with friends or family.   
Client Services Receipt Inventory – (CSRI) 
The version of the CSRI used in this study is a modified version of a tool developed in mental health 
research, to assess cost and utilisation of mental health services (296).  The tool was modified to 
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create dichotomous outcomes reporting receipt or not of components of healthcare in four 
domains: spiritual, psychological, nursing/medical and social.   
4.4.2. Phase 2: Semi structured interviews 
4.4.2.1. Participants and sampling 
Preliminary analysis of the quantitative data showed that participants in both intervention and 
control groups reported benefit over the study period; therefore the sampling pool for phase 2 of 
the study included the full TOPCare sample of participants to understand the experience of 
participation in each study arm.  The sample was purposively chosen based primarily by allocation to 
study arm and secondly by participant experience in terms of response to participation in the study.   
The tension in sample size decisions in qualitative data collection and analysis lies between the need 
to be large enough to capture diversity of experience within the full sample, and small enough for 
detailed analysis to be feasible (285).  A sample size of 30 was chosen for this study, with the 
expectation that this would be sufficient to achieve data saturation without creating an unwieldy 
dataset (285).  In selecting the sample, participants who received the intervention were purposively 
oversampled (20 intervention participants) to explore variation in the active ingredients of the 
intervention.  Ten participants who received the standard care were also included to further explore 
the therapeutic aspects of participation, beyond receipt of the intervention.   
The participants were purposively sampled based on their quantitative response to participation in 
the study in terms of clinically significant change measured by the MOS-HIV MHSS, defined as a 
change in 10 points (307).  A binary variable was created, identifying those who improved by 10 
points or more and those did not.  In terms of clinically significant response to the study, the sample 
for phase 2 purposively included 10 of participants who did not report clinically significant 
improvement (n=6 from intervention group) in addition to 20 who did (n=14 from intervention 
group), to explore their experiences and any potential facilitators or barriers to benefit.  Further to 
this, deviant cases, reporting clinically significant deterioration during the study period, were 
purposively selected for inclusion.  This technique helps to create a fuller understanding of the 
process of change observed (319).   
Participants were selected a minimum of one month after exit so that they had received at least one 
appointment in the standard care clinic before the interview, and therefore all could compare their 
experiences in the study with standard care.  The time period also provided some time for the 
participants to reflect on their participation in the study and how it may have affected them.  
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Participants were not recruited beyond 9 months after study exit to minimise recall bias.  Potential 
participants were contacted by the researcher to enquire whether they would be interested and 
available to discuss their experience in the trial.  The recruitment consent and data collection of this 
phase was completed by October 2012 (patient information sheet and consent forms in Appendix 9).   
4.4.2.2. Data collection  
Selected participants were contacted by telephone and if they consented at this stage, a time and 
date was chosen for the interview at a convenient time.  On attending the palliative care department 
for the interview, they were given another information sheet detailing the purpose of this phase of 
data collection and details of data protection and their right to anonymity.  If they were still happy to 
proceed at this point, they were given another consent form to sign and the interview was 
conducted in a private place.   
Interviews were digitally recorded and lasted 20 to 60 minutes.  Participants received light 
refreshments and transport money as previously, for hospitality and to remove financial barriers to 
participation.   
Qualitative interview topic guide 
A topic guide was developed in collaboration with local and international researchers experienced in 
this area of study (Appendix 10).  It was piloted for flow and comprehensiveness with one 
participant prior to data collection.  It was amended slightly following the piloting exercise to re-
order the topics for improved flow.  It was structured chronologically to assess the participant’s 
perspective of their situation before, during and after their participation in the study, with different 
variations for control and intervention participants to reflect their different exposure.   
Initial questions asked participants about the quantitative data outcomes they had reported.  A 
graph presenting their psychological quality of life (as measured by the MOS-HIV MHSS) over the 
study period was created for each participant (example in Figure 14).  The researcher presented the 
graph and explained the data in an appropriate way, according to their level of educational 
attainment, ensuring understanding.   The participant was then asked if this appeared to be a true 
story of their journey or trajectory during the study period, and to describe what was happening in 
their life, which may have prompted the changes seen.  For example, if presented with Figure 14, the 
participant would be asked if they could remember something happening during the study period to 
explain the dip in psychological quality of life at time point 1.   
Methods 2: Protocol 
88 
Figure 14 Sample trajectory of an intervention participant as measured by MHSS, used in qualitative data collection 
 
All participants were asked why they thought their well being had improved or deteriorated, and to 
what they attributed any change (objective 4).  This was particularly relevant when interviewing the 
‘deviant cases’, whether they received the intervention or not.   
The topic guide then covered the participants’ physical, emotional, social and spiritual wellbeing 
before the study began.  They were asked to describe the effect their wellbeing had on their ability 
to perform the activities of daily living, such as work or other responsibilities.  The participants were 
then asked to describe their wellbeing during the study and after the study had ended, using the 
same pattern of questions (objective 3).   
After this account of experiences before during and after the study period, both study arms were 
asked about the experience of taking part in a research study.  They were asked how easy it was, 
how it made them feel, and how the experience of participating in the trial might have affected 
them emotionally, spiritually or physically (objective 4).  They were then asked about what they 
thought was the most important aspect of the intervention or of their participation in the study, 
what they attribute any benefit to and any additional comments they might have.   
Participants allocated to receive the intervention care package were asked additional questions 
about the experience of receiving the intervention.  This included components they found helpful or 
important to their well-being, which components they attributed improvement or deterioration to 
and the key differences they identified between the intervention care package and standard clinic 

















Monthly time points 
Change in MHSS over time for 
participant 154 
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Topic guide translation and cross-language trustworthiness 
The interview topic guide was translated into Kiswahili by the researcher in Kenya, who is a native 
Kiswahili speaker, but from Nairobi, where a slightly different Kiswahili is spoken in Mombasa.  The 
translation was checked by a Kiswahili speaker in the UK, who was from the same region in Kenya as 
the participants, and therefore was familiar with the linguistic forms and expressions of this area.  
Comments from the Kiswahili speaker in the UK were passed to the researcher, who refined the 
topic guide in light of potential misunderstandings highlighted.  This was done to increase the 
validity of the topic guide, in recognition of the potential loss of data quality when translation is 
inaccurate (272).   
As I do not speak Kiswahili, transcripts were translated into English prior to analysis.  Steps were 
taken to minimise any bias or loss of meaning as a consequence of translation (269).  Transcription 
and translation was performed by professional translators using the elance.com website.  Once the 
job was posted on the website, four translators offered their services.  All signed a confidentiality 
agreement before translating any audio files, to protect the identity of the participants’ involved 
(blank copy available in Appendix 11).  Once this agreement was signed, translators all transcribed 
and translated one file, the quality of which was checked and assessed by the researcher who 
conducted the interviews.  The two translators who provided the transcript of the highest quality, in 
terms of accuracy were chosen to translate the remaining files, first transcribing the interview 
verbatim (in Kiswahili) and then translating the document into English.   
The translators were given guidelines to follow when transcribing the documents.  These included 
transcribing verbatim, including pauses and non verbal communication such as laughing, highlighting 
sections which were unclear in the recording and requesting clarification and anonymising the data. 
The number of translators was minimised for more consistent translation and to increase internal 
validity of the translations (268).  Both chosen translators were native speakers and experienced in 
the translation of medical research and documentation from Kiswahili into English.  On completion, 
all transcripts and translations were checked by the researcher who conducted the interviews 
against the original audio recording, for accuracy and fidelity.  She made only a few simple 
clarifications and corrections, as the transcriptions and translations were deemed to be of a high 
quality. 
4.4.3. Data quality  
During the course of the study, Skype calls were held between the study site and the PI (Dr Richard 
Harding) and other senior investigators at KCL and in Nairobi, a minimum of once a month.  During 
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these calls the study team (researcher, two study nurses) would update the coordination team 
regarding numbers screened, recruited and exited for that month and discuss any matters arising 
(checklist for meetings in Appendix 2).   
In addition to this, throughout the study I was in almost daily contact with the researcher and 
research nurses, by email and phone.  The researcher entered recruitment data for each day’s 
screening activities into an Excel spreadsheet and sent to me weekly for checking.  The spreadsheet 
included the daily and weekly totals of numbers of participants screened, eligible, consented, 
randomised to each study arm and exited.  The file also contained a graphic which communicated 
study progress in terms of recruitment and participant exits to the study team.  Each week I would 
examine recruitment progress and the content of the database for consistency, coherence, values 
out of the specified or expected range and missing values.  I would request clarification and double 
checking of the original records if this arose.  In this way the data was maintained at the highest 
quality and the amount of avoidable missing data was reduced.  A screen shot of this excel file is 
available in Appendix 12. 
In July 2011, after the recruitment of 38 participants to the study, it became apparent that the 
recruitment and screening procedures were not being followed as detailed in the protocol.  
Recruitment was stopped while I travelled to the study site and conducted a rapid assessment of the 
situation.  I found that screening according to the protocol was difficult due to the pressures and 
structure of the clinic and its context.  For example, that there were seven clinic triage nurses, 
concurrently triaging patients.   
In close collaboration with the clinic management and staff and the study team we devised a way to 
recruit and consent participants within this context, respecting both the study protocol and the 
constraints of the clinic.  The intervention participants recruited to this point continued to receive 
the intervention as promised, but their research data was not retained.  Recruitment was restarted 
once these procedures had been clarified, confirmed and agreed with the clinic management and 
study coordinators.   
4.5. Ethical issues and approvals 
The TOPCare study was approved by the KCL ethics committee (Reference BDM /10/11-3) and the 
ethics board of KEMRI (Kenyan Medical Research Institute) (Reference KEMRI/RES/7/3/1) both can 
be found in Appendix 4.   
Additional ethical approval was sought and gained from KEMRI and KCL for the qualitative data 
collection interviews and analysis conducted for this thesis, again to be found in Appendix 4. 
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There was a distress protocol which was employed if a participant became distressed during the data 
collection.  The participant would be asked if they wanted to pause or stop the interview, and given 
time to regain composure before continuing if they so wished.  The participants were aware that 
they could terminate the interview at any time, and experience no consequences in terms of care or 
treatment.  Participants were made aware that if the researcher became concerned about their 
welfare (i.e. suicidal thoughts or abuse disclosed), she would first seek their permission and then 
refer to the study nurses or other appropriate external support.   
4.5.1. Ethical data management  
The consent forms and a list of participant ID numbers and names were stored separately to the 
study data to ensure anonymity.  The participant packs, recording the quantitative data, were stored 
in a locked filing cabinet during the data collection phase and were stored in the offices of the 
national palliative care association after data collection and data entry was complete. 
The audio file for each participant was sent to me at KCL and stored on my password protected 
computer, and backed up on the department server for security.   
4.6. Analysis 
The analysis plan explains how the datasets generated in phase 1 and phase 2 are presented and 
described and the analysis which was conducted to address each study objective. 
4.6.1. Phase 1: Longitudinal quantitative data  
The following sections contain an analysis plan for the description of the database generated in 
phase 1 of the study.  This includes analysis of recruitment, missing data, variable type and the 
characteristics of the sample and descriptive statistics for the demographic and clinical variables 
collected at baseline and baseline data for the APOS to describe their clinical status in more detail.   
Stata v10 was used for all analysis. The data flow was reported in accordance with the CONSORT 
guidance (289).    
4.6.1.1. Missing data 
Missing data was assessed as missing at random (MAR), missing completely at random (MCAR) or 
missing not at random (MNAR) in line with best practice (320).  The best case scenario is that data is 
MAR, or MCAR, which will have no bearing on the final outcome and therefore can be disregarded 
(321).  When data is MNAR this suggests a systematic missingness which may introduce bias, and 
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cannot be ignored in the analysis (321).   The effect of missing data on outcomes increases with 
extent of missingness and the extent to which it is MNAR (320).    
The missing data analysis in this thesis examined the number of items missing (single questions), 
number of units missing (missing all questionnaires for that time point), and the number of 
participants who exited the study prematurely, and reasons suggested for this if available.  This 
contributes to an assessment of implication severity of the missingness (320).  Because the sample 
became very well known to the researcher it was anticipated that reasons for missingness would be 
available and collected whenever possible in order to understand the extent of the problem of 
missing data in this dataset.  Missing data was summarised by study arm and number of data points 
missing as in Table 4-4.  
Table 4-4 Partial template for the summary of missing data 
Status at 
each month 





Missed single questions    
Missed single questionnaire    
Missed interview    
Premature exit    
Deceased    
Month 1 
Missed single questions    
Missed single questionnaire    
Missed interview    
Premature exit    
Deceased    
 
Management of missing data  
Because of the close monitoring of this data set as it was collected, large amounts of missing data 
were not anticipated.  The European Medicines Agency have issued guidelines on the management 
of missing data in clinical trials, and recommend if single items are missing within the dataset, they 
are imputed using the horizontal mean method, and if final data points were missing, they are 
imputed using last value carried forward (322).  This is in line with recommendations from the 
palliative care literature (305).   
An acceptable level of missing data is difficult to define in statistical terms as much depends on the 
nature of the data, the type of missingness and of the research subjects. Thompson and Levy suggest 
that aiming for less than 2% missing data means that the findings will be less susceptible to rejection 
on the grounds of bias from missing data (323).  However, they also recognise that this is a very high 
standard and is potentially an unrealistic expectation of many clinical trial datasets.   
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If more than two data points were missing for any one participant, or more than 5% of the data, list-
wise deletion was considered, i.e. removing all the data from all time points for the participants who 
exited prematurely or died.  List wise deletion, while simple and transparent, is problematic for two 
reasons: loss of statistical power and introduction of systematic bias (321, 324).  To assess the extent 
of bias introduced, if more than 5% of missing data was identified, list-wise deletion would be 
performed and the analysis repeated with this reduced dataset.  If the two analyses resulted in 
different outcomes, this suggests that the data was not MCAR and removing partial data would 
cause systematic bias.  In this case the partial dataset, before list-wise deletion, would be 
preferential, and should be used and these findings reported in the results.  If there were no 
differences in the findings, indicating no bias introduced as a result of list wise deletion, the 
database participants without complete data were removed and not included in analysis.   
If more than 10% of data was missing in this study, list-wise deletion would irretrievably compromise 
the statistical power of the study and intent treat analysis, therefore multiple imputation techniques 
would be explored (325).   
4.6.1.2. Variable type 
Decisions were necessary regarding the nature of some of the variables, to choose the most 
appropriate and valid analysis technique.   
Dependent variables 
As described in section 4.4.1.2 this dataset contains data on four dependent variables: psychological 
quality of life (from MOS-HIV MHSS), psychiatric morbidity (from GHQ-12) and worry and the ability 
to share feelings with friends and family (from APOS).  
Because all outcome measurement tools use a Likert scale to measure the subjective experience of 
living with HIV, the data is described as ordinal.  This means that the data is not expected to conform 
to the numerical normal distribution, and so it is expected that assumptions of parametric analysis 
techniques will be violated and analysis will be conducted using non-parametric techniques for 
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Independent variables 
Interval independent variables  
This dataset contains six independent numerical variables: age in years, number of children, number 
of financial dependents, CD4 cell count, number of days since HIV diagnosis and number of days on 
ART.   
Ordinal independent variables 
There are two ordinal variables in this dataset: highest educational level attained and wealth. 
Participants were asked to report whether they had never attended school, attended four years or 
less, completed primary school, completed secondary school or completed a diploma or higher level 
of education.  
Wealth is a numerical variable, containing data from the demographic questions, including the 
material your house is made from, the type of water source available to the household and about 
possession of certain items which indicate a higher socioeconomic status, in this case a fridge, a 
bicycle, a television a car and a radio.  These items were selected by the researcher, in collaboration 
with the study nurses as an indication of relative wealth in this population.  This data is weighted 
and transformed using an equation used in demographic health surveys, to generate a wealth 
variable, which will be divided into 5 quantiles and analysed as an ordinal data (297, 298).   
Binary independent variables  
There are four nominal binary variables in this data set - partner status, gender and receipt of TB 
treatment.  Partner status refers to whether they currently cohabit with a partner, whether married 
or not.  Receipt of TB treatment refers to whether they are currently receiving TB treatment, not 
whether they have ever received it.  In the data collection the question “Have you ever received an 
AIDS diagnosis?” was asked, but as all but one respondent had received this diagnosis (1/120), this 
question was omitted from the analysis.  
4.6.1.3. Intention to treat analysis 
The data was analysed using an intention to treat approach.  Regardless of protocol compliance or 
completion, with an intention to treat approach all available data are analysed for all participants 
according to the study arm allocation (326).  This is to ensure that available data from participants 
who withdrew from the trial prematurely are included in analysis, to reduce the possibility of bias in 
the treatment effect which could otherwise be distorted and appear more favourable than reality 
(327).   
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4.6.1.4. Sample size  
The primary outcome of this thesis is a statistically and clinically significant difference in the MOS-
HIV data: a measure commonly used, adapted to a HIV positive population, and validated in the 
cultural context.  It is essential to ensure that the TOPCare study sample had adequate statistical 
power to detect the clinically significant 10 point change (307).  I re-performed the calculations to 
assess the statistical adequacy of power with this sample size.   
Power to detect change in outcome scores depends on the magnitude of expected change, which is 
usually taken from previous research in similar groups (328).  There are no pre-existing thresholds 
for clinically significant change in the literature on which to base the sample size calculations for the 
GHQ, particularly when using the chronic GHQ scoring method, or the APOS item.  For this reason, 
despite their importance as secondary outcomes, no sample size calculations were performed for 
these outcome measures.  This avoided the risk of discarding data as statistically insignificant and 
therefore inconclusive, based on an untested and possibly arbitrary level of statistical significance 
(329), particularly when it might be more clinically useful to understand degrees of likelihood of a 
true causal effect (330).  Findings were instead discussed with careful interpretation of magnitude 
and direction of effect size, and knowledge of the clinical context to counter the risks of 
misinterpretation.   
The TOPCare study sample size was originally calculated using the APCA POS pain item as a primary 
outcome and the MOS-HIV as a secondary outcome for psychological well-being (290).  This was 
performed based on data from a study in a similar patient population also in Kenya, which cited a six 
point change in MHSS score as clinically significant (331).  This calculation identified the sample size 
required to detect a six point change as 56 patients per study arm with 80% power using the 
prescribed standard deviation of 10.  Subscale scores for mental health generated by the MOS-HIV 
are transformed onto a scale of 100, with 50 as the mean and a standard deviation of 10 points 
(307).  According to the developers of the MOS-HIV, a change of 10 points on a scale is “almost 
always likely to be meaningful”, interpreted here as clinically significant (307).   
Baseline data from the TOPCare trial report a mean score of 43 on the MHSS and a standard 
deviation of 10 for the whole sample.  Therefore, an anticipated final score of 53 (baseline plus 
clinically significant change) for the intervention, and 43 for the control, was used in these 
calculations.  It was anticipated that the sample will experience some regression to the mean, as 
they were recruited on the basis of moderate to overwhelming pain or symptoms, but as the sample 
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was randomly allocated to study arms, this should be equal in both arms and therefore can be 
disregarded in this calculation.   
The sample size calculation in Table 4-5 assesses the required sample size to detect a difference in 
means between control and intervention group, with 90% power and an acceptable alpha error of 
5%. 
Table 4-5 MOS-HIV MHSS sample size calculations 
 
These calculations indicate that a minimum sample size of 44 would have 90% power to detect a 
statistically difference of 10 points between the control and intervention study arms.  
In addition to analysing the data at monthly time points, as the data is longitudinal repeated 
measures on the same patients, analysis will also include longitudinal hierarchical modelling.  This 
longitudinal analysis approach appreciates the value of repeated measures over time, and also will 
adjust the data for bias introduced into the results due to data correlation by patient, which would 
otherwise invalidate the findings (332).  This technique will be discussed in further depth in section 
4.6.4.2.   
Sample size calculation for longitudinal analysis of repeated measures, correlated by patient is not 
straight forward as it depends on the size of the groups, the number of groups, and the intraclass 
correlation (ICC), which influences the design effect.  However, the literature on hierarchical linear 
modelling, also suggests that regardless of the level of correlation, an acceptable standard error can 
be generated from a minimum of 100 groups with 5 observations per group (333).    This indicates 
that the TOPCare study sample size, of 120 groups (participants) with 5 observations each will be 
sufficient. 
4.6.1.5. Baseline characteristics 
To increase familiarity with the dataset and examine the distribution of covariates between control 
and intervention study arm, the baseline characteristics were described in detail.     
This description of the whole sample and of the results of the randomisation will not include 
hypothesis tests because, if performed effectively, any difference observed in the distribution of 





SD Precision Power Total sample size (equally 
distributed by arm) 
43 53 10 95% 90% 44 
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identify whether randomisation was performed correctly, but whether the difference observed 
occurred by chance (335-337).  The important question is whether any observed difference between 
groups will bias the outcome (336, 338).  Covariates with strong prognostic value, if imbalanced at 
baseline could bias findings, but it is better to identify an imbalance at the study design stage rather 
than during baseline analysis, and to use stratified sampling to adjust for this effect (334, 336).      
If covariate imbalance was observed at baseline between control and study arm summary measures, 
and it was thought that these variables could have a strong prognostic effect on psychological and 
social outcomes, the variables were entered into multivariate models constructed during the 
analysis, to assess for effect.  If no effect was seen they were omitted for a more parsimonious 
model. 
4.6.2. Phase 2: Semi-structured qualitative interview data 
This section will outline the overall approach to and process of analysing the qualitative interview 
data, and steps taken to ensure data quality.  Specific analyses conducted to address each of the 
objectives will be described in detail in sections 4.6.5.2 and 4.6.6.  
The qualitative data was analysed using thematic analysis using the software programme Nvivo10 to 
manage the data.  Analysis was informed by a critical realist theoretical philosophy ( section 3.3.2.2) 
which acknowledges the existence of truth and objective reality external to the individual, but also 
that these concepts are shaped and perceived through the lens of social context, emphasising causal 
mechanisms and social process (244, 339).   
4.6.2.1. Presenting the sample and coding framework 
First, the mean, median, longest and shortest length of interviews was reported with comparison 
between control and intervention arm participants.  The transcription and translation process were 
briefly described.   
The baseline characteristics (age, gender, partner status, number of children, number of financial 
dependants, educational attainment, CD4 at baseline, TB diagnosis, AIDS diagnosis, ownership of a 
bicycle, fridge, TV , car or radio or and clinical improvement during study in terms of  MHSS) of the 
qualitative sample were summarised using descriptive statistics and presented in a table.  
The finalised coding framework was described, describing the major themes which emerged from 
the data.   
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4.6.2.2. Analysis approach 
In this study, thematic content analysis was used to systematically classify the data through coding 
and the identification of themes and patterns of meanings across a dataset (339, 340).  It is an 
iterative process, which requires careful and meticulous constant comparison between the data and 
the emergent coding framework, and openness on the part of the researcher to revise any analytical 
decisions made, in light of new information from the dataset.    
Following Hsieh, the specific type of thematic content analysis used in this thesis is directed content 
analysis, which takes the middle ground between open-ended inductive analysis, where there are no 
deductive codes at the outset, and more closed analysis in which all codes are predetermined, and 
analysis takes the summative form of counting (340).  A combination of deductive and inductive 
coding in directed content analysis can be used to validate or elaborate and extend a pre-existing 
theoretical framework (340).   
This use of thematic analysis in combination with the quantitative outcome data is in line with the 
critical realist paradigm of the thesis, which acknowledges both the empirical observable reality, but 
also the importance of subjective understanding and the importance of context in interpretation 
(262, 339).  The deductive codes were based on objective content of the intervention (assessment of 
physical, psychological, social and spiritual symptoms), whilst the inductive codes acknowledge the 
co-existence of the more subjective interpretation for each individual which emerged as these 
accounts were explored. 
The use of both deductive and inductive coding will ensure that unanticipated findings were also 
captured.  This is particularly important as the concepts of psychological quality of life, psychiatric 
morbidity and social well-being are complex and multifaceted, and therefore may be interpreted 
and understood in different ways by participants.   
4.6.2.3. Analysis process 
A project journal, in a memo in Nvivo, (extract available in Appendix 13) was created before analysis 
commenced for recording analysis decisions and emergent findings particularly relating to the active 
ingredients and their mechanisms of action.  Throughout the analysis, concepts arising from the data 
modelled and documented in the project journal.  This enhanced the trustworthiness of the findings, 
and the “auditability” of the analysis process (341).  The steps involved in the analysis are described 
below. 
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Familiarisation 
Before beginning any coding of the data, each interview transcript was read through, to become 
familiar with the data, whilst noting down interesting passages and thoughts (339, 342).  Patterns, 
concepts and meanings identified during initial reading were documented in the project journal for 
later exploration (339).   
Attributes and analytical categories 
To prepare for analysis, each interview transcript was assigned attributes depending on 
demographic and clinical characteristics of the participant who gave the interview, which would be 
used later in the analysis process.  These attributes were chosen based on the characteristics 
associated with variation in response in the literature and quantitative findings: gender, poverty, 
education and age by decade.  In addition participants were assigned a binary attribute based on 
presence or absence of evidence for clinically significant improvement in MHSS score during the 
study period (307).  These attributes were included to potential demographic influences on response 
so the intervention and participation in the study could be explored. 
To further prepare the data for analysis, ‘study arm’ and ‘stage of study’ were created as analytical 
codes.  This ensured that the data could be examined by either study arm and at any stage (before, 
during and after the study).  All of the data in each transcript was coded according to the stage of 
the study that the respondent was referring to in that part of the transcript and according to study 
arm.   
Coding framework  
The coding framework organises  structures and collates the codes, into major themes and sub 
themes (342, 343).  In this analysis plan, a code is a category assigned to the raw data, which 
captures the essence or otherwise summarises the content of the data (344).  Themes were defined 
as codes or collations of codes containing elements which represented a patterned response or 
concept within the data (287, 339).  The decision as to what constitutes a theme was based on 
significance and “keyness” in terms of addressing the objectives, and on the extent of repetition 
across the dataset (339, 343).  Following Barbour, to identify themes, the following questions were 
posed, with constant reference to the study objectives:  “Which codes are repeated? How do they 
relate to each other?  Do these codes relate as sub themes or associates in that they occur 
simultaneously?” (343).  Once identified, themes were grouped into major themes and sub-themes 
in a hierarchy, according to meaning and relationship to each other, to reduce the volume of data 
and structure it, making later analysis clearer and more transparent (339, 345).   
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Development of codes 
Deductive codes were identified from the literature and included in the wording of questions in the 
topic guide for the interviews, or otherwise arose from the results of the quantitative data analysis 
(343).  The literature used for identification of the deductive codes included the WHO definition of 
palliative care: physical, psychological social and spiritual well-being (59), and the systematic review I 
performed, which identified: sadness or depression and anxiety (15).  Coding was performed line by 
line, with the deductive codes applied as appropriate.  Additional themes not included within the 
deductive codes arose and were classified as new inductive codes (340).  The inductive codes were 
developed iteratively, using the constant comparison method, assessing whether the codes created 
were useful or would be more useful if broken down further (343).  This sometimes required 
broadening the scope of a code, to capture a concept more completely or encompass similar codes, 
or dividing and creating new codes if it was recognised that a concept was more complex, and 
required more detail (342).  Fine-grain analysis was also performed on themes of particular interest 
to the study (342).  For example, data coded at ‘psychological symptoms’ was explored in detail to 
identify fear, or worry or sadness for example, and then further examined to distinguish fear of 
death, fear of deterioration, fear of disclosure etc. (340).  As many new codes were created as 
necessary to reflect the nuances of the data (287).  Each code had a clear description attached, 
describing the content of the code to reduce overlap between codes and confusion in the coding 
process.   
Finalising and applying the framework 
Once no new codes were being identified or developed, the coding framework was finalised.  Once 
finalised, it was applied to each transcript again, to ensure that all data had been consistently and 
correctly coded.   
Interrogation of the data 
Once finalised, the findings of the quantitative data were used to interrogate the qualitative data 
using the attributes and analytical categories. 
This will be described in detail by objective in sections 4.6.5.2 and 4.6.6 . 
Presenting the results 
Findings were presented by objective.  Quotations from the transcripts were used to demonstrate 
evidence for interpretations of the data, and to ensure close proximity to the data was maintained.  
This increased transparency of the analysis process and prevented unfounded claims (339, 342, 346).  
Extracts were carefully selected to communicate or elaborate an aspect of the findings: as 
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explanation, to deepen understanding and enhance readability (346), and to present sufficient 
description to allow the reader to appreciate and understand the process which led to the findings 
presented (347).  Extracts were chosen from all interviews to ensure that all participants’ views were 
represented.   
Each extract will be reported with the corresponding participant identification number, gender, age 
and study arm.     
4.6.2.4. Data, analysis and inference quality 
In quantitative research, quality is marked by attention to internal validity, external validity, 
reliability and objectivity (348).  Lincoln and Guba developed similar criteria for trustworthiness to 
indicate data quality in qualitative research which includes: credibility, transferability, dependability 
and confirmability (341, 348).  Verification strategies to ensure trustworthiness in the data 
collection, analysis, findings and inferences, and are now discussed in turn with relation to this 
thesis. 
Credibility  
Lincoln and Guba define credibility as the naturalistic parallel to internal validity, and describe the 
following strategies to ensure credibility:  prolonged engagement in the field, persistent observation, 
triangulation, peer debriefing, referential adequacy and negative or deviant case analysis (341).  In 
this thesis, prolonged engagement in the field, and deviant case analysis were used to enhance 
credibility. 
Prolonged engagement in the field 
Prolonged engagement was conducted primarily with the study nurses and the researcher and 
myself, due to language and logistic constraints which prevented me from being physically engaged 
in the field.  I maintained close contact with the researcher, closely monitoring data collection, and 
also whilst conducting the analysis to ensure my understanding and inferences from the data were 
credible.  I also maintained close contact with the nurses, and benefited from their insight and 
extensive experience of the study population when making inferences from the data.  During data 
collection, I conducted an intensive week-long field visit, working closely with the nurses, their 
palliative care mentor and the researcher to deepen understanding of the study context. 
Deviant case analysis 
Deviant case analysis is the active search for those who respond differently, or are outliers in terms 
of response.  These participants were identified and examined in detail in order to add 
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understanding (349).  This facilitated the process of developing concepts or explanations for the 
phenomena observed, and refined the explanations for the phenomena (341).  Deviant cases 
identified during the quantitative data analysis will be purposively sampled, and their data examined 
in more detail, to find out why they responded as they did, and whether this data contributes to our 
understanding of the active ingredient and the mechanism of action.  In particular close attention 
was paid to the explanations they gave for their study trajectories; their reasons for decreases, non 
response particularly and any relevant contextual data (350). 
Transferability 
Transferability is analogous to reliability, and refers to the extent to which the findings are applicable 
to other contexts, settings or populations.  A mark of quality in terms of transferability is some level 
of transparency usually demonstrated by ‘thick’ description; Lincoln and Guba’s term for a detailed 
descriptive account of the sample, data collection procedures and study context (341).  In this thesis 
this descriptive account can be found in section 3.2, and within this analysis plan.   
Dependability and confirmability 
Dependability and confirmability are the analogues of external validity and objectivity (341).  These 
qualities in qualitative research are often described as auditability: to what extent is the decision 
trail transparent, coherent and logical?   
In this study, documented decisions, ideas, preliminary models and hypotheses based on the data to 
serve as an audit trail in the project journal (341, 342, 345, 351).  This audit trail will help to identify 
the development of ideas and models proposing mechanism of action and active ingredient which 
increases transparency, allowing an auditor to trace the process of decision making and determine 
whether the decisions were reasonable and consistent and therefore the findings trustworthy (351).  
The coherency of the decisions in relation to the evidence presented indicates confirmability. 
Having another researcher code the data concurrently, and checking inter-rater reliability is 
sometimes employed to increase the dependability of findings, however this is not an 
uncontroversial approach.  Whilst it may expand the scope of the coding, provide some kind of 
reassurance through triangulation, and ensure that any confusion or misunderstanding is clarified, 
the added value to the project is arguable, as each coder brings their own interpretive framework 
(345, 352).  This means that interpretation will be determined by the coders experience, theoretical 
background and discipline among other factors, which highlights the subjectivity acknowledged to 
be an integral part of qualitative research (352).  This does not detract from the value of the findings 
from each coder, but calls into question the added value of multiple coders and inter-rater reliability, 
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therefore whilst the potential value of this technique is recognised, it will not be used in this thesis.  I 
did however have input into finalising the coding framework, which was discussed along with the 
preliminary findings with the project team.   
I will now turn to each objective in turn, detailing how the analysis of the quantitative and 
qualitative datasets will meet the study objectives. 
4.6.3. Objective 1 
To determine baseline levels of mental well-being and to examine associations between baseline 
mental well-being and demographic and clinical characteristics among patients with HIV on ART 
enrolled in a randomised controlled trial (RCT) of a nurse-led palliative care intervention. 
The first step in meeting this objective was to determine the baseline levels of mental well- being.  
Baseline data for each outcome measure was presented in a scatter plot for MHSS and a percentage 
stacked bar chart for GHQ-12, APOS worry item and APOS share item, because of the difference in 
range of observations.  This will depict data for the whole sample and by study arm.  Summary 
statistics were also presented in a table for the entire data set and by study arm. 
Analysis was then performed as in Table 4-6 to identify independent demographic or clinical 
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Table 4-6 Analysis decisions for independent and dependent variables (326, 338). 
Independent variables Dependent variables 












CD4 at baseline 
Number of children 
Number of financial 
dependents 
Time since diagnosis 
(days) 
Time on ART (days) 
Ordinal* 





















*If any continuous variable is divided into quantiles after data type examination it will be analysed in 
objective one thus 
If any association was identified between independent variables and any of the dependent variables 
at baseline (p≤0.25), they were entered into a multivariate analysis to assess for any association, 
using ordered logistic regression for ordinal outcomes and multiple linear regression for interval 
outcomes (326, 338).  The assumptions of these tests were checked by assessing the normalcy of the 
distribution of residuals for linear regression (using Shapiro-Wilk test) and the proportional odds 
assumption for ordered logistic regression, which assumes that the coefficients which describe the 
relationship between the lowest and the higher categories have the same relationship between each 
group.  The findings of these tests were reported to ensure transparency.   
4.6.4. Objective 2  
To identify any effect of the palliative care intervention on mental well-being, comparing participants 
receiving the intervention and standard best practice. 
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4.6.4.1. Visual analysis over time and analysis at monthly time points 
The analysis was performed using the MHSS score from the MOS-HIV (psychological quality of life), 
GHQ-12 (psychiatric morbidity) and the APOS items (worry and ability to share feelings with friends 
and family).  For each dependent variable, the data was first presented in either a stacked bar chart 
or a line graph, depending on which would most clearly display the range of values and change in 
status over time in each study arm.  The MHSS score was presented using a line graph with the inter-
quartile range, and GHQ-12, APOS worry and APOS share were presented using percentage stacked 
bar charts, to enable visual analysis of the distribution and change in the distribution of the data 
over time.   
To examine response over time, intervention and control arms were compared at monthly time 
points to describe population level change in each study arm and to compare and identify whether 
one study arm improved quicker than the other (353).  This analysis was performed adjusting for 
baseline score.  Results were presented in a table with the coefficient for the difference between 
intervention and control study arms, 95% confidence interval for this coefficient and p value.  
Interval variables were analysed using linear regression, and ordinal variables were analysed using 
ordered logistic regression.  Assumptions were checked for all analyses.  If residuals for linear 
regression were not normally distributed, the variable was divided into quantiles and analysed using 
ordered logistic regression.  If the proportional odds assumption was violated in the ordered logistic 
regression, multinomial logistic regression was explored, which is a more flexible but less 
parsimonious approach.   
4.6.4.2. Analysis of repeated measures 
The data is longitudinal, collected over five months.  Because the observations are repeated 
measures, with five observations per participant, we know that the observations are not 
independent.  This means that the data is probably correlated or clustered by participant and if not 
taken into account during analysis, it is possible that any observable effect would appear stronger 
than it truly is.  To adjust for the effect of correlation, a hierarchical regression model was used.  As 
the dependant variables are ordinal, generalised estimating equations (GEE) is the best option to 
produce a population level average estimation of effect of study arm (354).   
To perform GEE it is necessary to first specify the correlation matrix and the link function of the data.  
The correlation matrix of this dataset was exchangeable, because we can assume that any two 
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observations from any one participant will have the same correlation (326).  The Gaussian link 
function for linear models was used to fit the data (355).     
If the residuals of this multilevel model were not normally distributed, hierarchical linear mixed level 
modelling was conducted using the Stata command GLLAMM (Generalized Linear Latent and Mixed 
Models).  This is a relatively novel analysis to analyse categorical or ordinal variables, accounting for 
correlated or clustered data over time (332, 356).   
To perform this analysis the distribution used, the link function, the number of integration points for 
each summation and whether adaptive or ordinary quadrature must first be specified (357).  For 
ordinal responses the link function is ordered logistic or ‘ologit’, with a binomial distribution (355).  
Adaptive integration is expected to perform better than Gaussian integration, particularly when intra 
class correlation (ICC) is high and cluster size is small, and with non-normal distributions as in this 
study (358).  Adaptive quadrature captures change in a slope when it changes rapidly, in a more 
reliable way that ordinary Gaussian quadrature (358).  The degree of accuracy is controlled by the 
number of integration points.  Increasing integration points increases accuracy but also 
computational burden, and increases the risk that the software will not achieve convergence, and 
therefore an accurate result (357, 358).  The recommended and default number of integration 
points is 8, which was used in this analysis (358).  The GLLAMM command operates more 
successfully if there are fewer categories of the dependent variable; therefore the outcomes were 
divided into four quantiles.  This would also enable comparison of the effect of the intervention on 
all dependent variables.   
The decision to analyse the data using multilevel modelling was verified by the ICC, which was 
calculated from the variance of the random intercept of each hierarchical model created and was 
reported alongside.   
This analysis was performed adjusting for baseline score.  Results were presented in a table with the 
coefficient for the difference between intervention and control study arms, 95% confidence interval 
for this coefficient, a p value and the ICC.   
Accepting or rejecting the null hypothesis 
Ho: There will be no difference in psychological quality of life, measured by the MOS-HIV MHSS, in 
longitudinal analysis of difference between participants allocated to receive the intervention (nurse 
led HIV palliative care) and participants allocated to receive the control (standard HIV clinic care). 
Analysis using GEE or GLAMM is the most appropriate and sophisticated analysis and therefore was 
used to accept or reject the null hypothesis using the MOS-HIV MHSS data, at p≤0.05.     
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4.6.5. Objective 3  
To determine and describe participant experience and longitudinal response to participation in the 
study in terms of mental health and well-being, and to identify and explore associations between 
participant response and demographic and clinical characteristics 
Mixed methods are required to meet this objective.  The analysis plan for the quantitative data will 
first be presented and then the analysis plan for the qualitative data, including the research 
questions stated in section 3.3.3.3.  A plan for the integration and presentation of the data in the 
results section will then be described. 
4.6.5.1. Phase 1: Quantitative data analysis plan 
To determine longitudinal response to the participation in the study, area under the curve was 
calculated for each participant.  This was then analysed for association with demographic and clinical 
variables. 
Area under the curve analysis 
Traditionally used in pharmacology research to assess uptake of drugs or bioavailability, the use of 
area under the curve (AUC) to assess treatment response in clinical trials is an increasingly popular 
approach (338, 359).  This is due to the ability of this technique to assess the improvement of each 
participant taking into account the longitudinal aspect of the data and any cumulative treatment 
effects, creating a mean score for the study period (360).  
Before calculating the AUC it is essential to assess the differences between each time-point in the 
data. If the time-points were equally spaced, with a standard deviation of less than half of the mean 
number of days between time-point, the more simple trapezoid method could be used.  If the time 
points were unevenly spaced, a more complicated method called the integration of regression would 
be used (360).   
The data was examined to calculate the mean time between appointments for all participants 
recruited to the study.  During data collection the researcher was instructed to make sure all data 
collection occurred within two weeks of the appointment date, and if this was exceeded, the data 
collection was to be recorded for the next time point.  It is therefore hypothesised that the time-
points will be evenly spaced so the trapezoid method is described here.   This involves calculating the 
mean score for baseline + time one, time one + time two, time two + time three and time three + 
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time four and summing these values to represent the area under the curve and therefore a mean 
value over time.  This was performed in Excel and then transferred into Stata for analysis 
Histograms displaying the distribution of area under the curve for all participants were reported for 
MHSS, GHQ-12 score and APOS worry and APOS share items. 
Analysis of association 
Multivariate regression analysis was performed to identify association between AUC for each 
dependent variable and the clinical and demographic independent variables, using linear regression 
for interval variables and ordered logistic regression for ordinal variables.   
To check analysis assumptions for linear regression, the residuals for each regression were tested 
using the Shapiro Wilk test for normality.  The assumptions for ordered logistic regression were 
checked using the proportional odds assumption.  If found that the assumptions were not met, 
multinomial logistic regression was performed.   
Multivariate models were constructed using the vselect command in Stata which lists the possible 
combinations of multivariate models with the corresponding r2 , Akaike’s information criteria (AIC) 
and Bayesian information criterion (BIC), an indication of the fit of the model and it’s parsimony 
(361).  A model with a relatively lower AIC and BIC and a higher r2, is a model which explains the 
variation in the data well, with less potential for error.   
Multivariate analysis was guided by the rule of no less than 20 subjects per variable in the 
model(326).  In the event of multiple tests of statistical significance, the Bonferroni method will be 
used to reduce the chance of alpha error (362).  This is a relatively conservative method of reducing 
the false positives in multiple statistical testing.  It has been criticised for increasing the rate of false 
negatives and reducing statistical power to unacceptable levels, and so clinical judgement will also 
be used to assess the appropriateness of applying this correction, if it is suspected that a type II error 
has occurred (363).  All analysis was adjusted by baseline score   
Presenting the results 
The final model for each dependent variable was presented in a table, presenting coefficients or 
odds ratios, 95% confidence intervals and p values for statistical evidence of effect.  A summary of 
the strength and directions of all associations identified was presented.  
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4.6.5.2. Phase 2: Qualitative data analysis plan 
Analysis of the qualitative data to address objective 3 is structured around the findings from the 
quantitative longitudinal analysis and the following research questions: 
How do participants respond to participation in the study and receipt of the intervention, 
and is this response different in participants with different demographic or clinical 
characteristics?   
Cultural understanding of the concept of well-being 
In acknowledging my cultural distance from this sample, I felt it was important before beginning the 
analysis to first understand what the participants of this study understood by the culturally and 
contextually dependent concept of well-being.  I recognise that this population have a very different 
experience of life, and of health and well-being to me, and therefore it was important to explore 
their understanding of the important aspects of well-being.  
I performed a text search within Nvivo 10, using the search terms ‘normal’ well’ or ‘better’, to 
identify all instances in the interview manuscripts where participants described what it meant to 
them to be normal, well or better and collated those extracts in a model.  I attempted to preserve 
the participants’ words, (once translated) as much as possible to retain fidelity to their descriptions 
and understanding of the concept.  This model will be presented before the results of the analysis 
for objective 3, to contextualise the findings, and enhance understanding of the cultural nuances of 
participants understanding of well-being.   
Analysis process 
A descriptive analysis of how participants responded longitudinally was conducted in terms of 
mental health and well-being before, during and after the study.   
Then the data were analysed according to participant response to the study (MHSS).  This was 
defined using suggested 10 point change in MHSS score as an indication of clinically significant 
change (307).  Participants who report an improvement of 10 points or more from baseline to final 
time-point were categorised into a binary variable of improvement.  Those who improved were 
compared with those who did not improve.  The group of participants categorised as not improving 
included those who did not improve or deteriorate to a clinically significant extent, as well as those 
who clinically deteriorated. 
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The qualitative results were presented in a narrative form by presence or absence of clinically 
significant benefit, study arm and by stage of study (before, during and after), with text extracts to 
substantiate any claims.   
The data were also analysed according to the clinical and demographic characteristics which were 
found to be significantly associated with longitudinal change in the quantitative AUC analysis.  The 
data were interrogated across these variables to highlight any exceptions and contradictions or 
nonconforming cases (patterns within the data) (343).  Due to small numbers in some of the 
characteristics (i.e. only 5 men) it was not always possible to look for patterns among those who 
reported clinically significant benefit or not.  It was anticipated that any patterns identified would 
elaborate or expand the quantitative findings, either through conflict or consensus.   
Some variables, for example education, had several categories, and therefore to facilitate the 
explanation of patterns within the data, the sample was divided into two groups: those with primary 
school education or less and those with secondary school or higher.  Wealth quintiles were 
combined to form a binary variable of relatively high or low wealth. 
The distribution across clinical and demographic variables were also presented first in a table and 
then in narrative form, with text extracts to substantiate any claims.  
The model of cultural understanding of the concept of well-being constructed using the descriptive 
phrases of ‘normal’, ‘well’ or ‘better’ was modified during the analysis as it became clear that 
associations between these descriptive phrases highlighted  the barriers and facilitators therapeutic 
change and clinically significant benefit.  This modified model was presented to facilitate 
understanding of the findings from the qualitative data analysis to address objective 3.   
4.6.5.3. Integrating and presenting the findings 
The findings from the quantitative and qualitative analysis for objective 3 were then presented and 
discussed, highlighting the qualitative explanation for findings from the quantitative analysis, and 
any incongruence or convergence in findings.   
4.6.6. Objective 4 
To identify and explore the existence of “active ingredients” and mechanisms of action of the 
intervention and therapeutic aspects and processes of study participation. 
Mixed methods were used to meet objective 4 integrating findings from analysis of the quantitative 
data from phase 1 and qualitative data from phase 2 of the study. 
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First, the components delivered as part of the intervention care package and how they differed from 
standard care was described.  Receipt of components of care was analysed for association with 
measures of mental health and well-being to identify the effective components.  Qualitative data 
from phase 2 was analysed using directed thematic analysis to identify active ingredients of the 
intervention and their mechanism of action and therapeutic aspects and processes attributed to 
study participation.   
4.6.6.1. Components of palliative care delivered as part of the intervention  
The CSRI measures services received by participants throughout the study, permitting comparison of 
service receipt by study arm.  Results were presented in a bar chart for visual comparison and then 
analysed as a binary variable indicating whether a participant ever received the service or not at any 
time point during the study period.  X2 tests were used to identify differences in service receipt 
between control and intervention groups.  Fishers exact test were used when there were less than 5 
observations in each cell (328).  A Bonferroni correction for 22 test to be performed during this 
analysis indicated that a threshold for significance of 0.002 would be a conservative indication of a 
statistically significant association (362).  However, because of the concerns that use of Bonferroni 
corrections leads to increased type II errors, a less conservative threshold of p≤0.01 will be used as a 
threshold for statistical significance (363).  The findings of this analysis were presented in a table 
reporting the test statistic and a p value.   
4.6.6.2. Active ingredients 
Phase 1 quantitative data analysis to identify the active ingredients of the intervention 
The analysis of longitudinal data to meet objective 3 included the calculation of AUC for each 
participant, for each of the following variables: psychological quality of life, psychiatric morbidity, 
worry and the ability to share feelings over the study period.  As the MHSS, GHQ-12 and APOS are 
non-parametric variables, and preliminary analysis indicated that assumptions ordered logistic 
regression were violated, binary logistic regression was used.  A binary variable for each AUC 
outcome variable was created, dividing the data at the median, into two quantiles.  This was used to 
indicate high or low AUC for each outcome variable and analysed for association with receipt of each 
component of care, adjusting by baseline score.  Logistic regression analysis then identified 
components of care associated with improvements in mental health and wellbeing, as measured by 
AUC for MHSS, GHQ-12, APOS worry and APOS share items.   
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The results will be presented in a table for each outcome, reporting the odds ratio, 95% confidence 
intervals and p value.  An adjusted value of p≤0.01 will be used as a threshold for statistical 
significance because of the increased risk of type II error due to multiple tests of significance (363).   
Phase 2 qualitative data analysis identifying the active ingredients of the intervention 
The terms ‘active ingredients’ and ‘mechanism of action’ are used when describing the intervention, 
as defined in section 3.3.1, in line with MRC guidelines (247).  Participants were asked directly in the 
interviews, what they attributed any change in their well-being to, and how this attributed aspect 
might have an effect.  This data was used as a starting point to identify any possible active 
ingredients of the intervention, with the rest of the interview data also examined.  It is recognised 
that whilst participants can produce leads for the researcher to pursue, through choice of language 
and overt or covert revelation of underlying assumptions, researchers have a duty to thoroughly 
explore any leads and critically examine participant suggested concepts or logic (343).   
Each active ingredient identified was created as a major theme.  These were explored, described 
using test extracts to substantiate findings.  
Summary of active ingredients 
Findings regarding the content of the intervention care package were integrated with the descriptive 
quantitative and qualitative data analysis regarding the active ingredients of the intervention. 
4.6.6.3. Therapeutic aspects of participation 
As well as the active ingredients it was hypothesised that there would be contextual factors or other 
aspects of participation in the study which might have therapeutic benefit, beyond receipt of the 
intervention.  These were explored in the qualitative data from participants in both the control and 
intervention group and are described using the terms “therapeutic aspects of participation”.   
Therapeutic aspects were created as major themes and sub themes.  To present the findings, each 
therapeutic aspect of participation was first presented in a percentage stacked bar chart.  Each bar 
chart represented the total number of text extracts found which contained data on a theme, 
presenting the percentage of each sub-theme demonstrate the different distribution of sub-themes 
across the study arms.  It was then described in a narrative using text extracts to substantiate claims.   
4.6.6.4. Mechanism of action and therapeutic processes of participation 
To identify the mechanisms of action of the active ingredients, and the therapeutic processes 
associated with the therapeutic aspects of participation, the data was examined whilst asking the 
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question: “What was actually occurring here?”  This question was repeatedly asked to examine why 
the identified ingredients and aspects were so powerful – why is communication reported to be so 
therapeutic?  Why it is that compassionate care was cited as a source of relief?  How might this 
aspect of ingredient exert its effect?  These questions helped to extract the underlying processes of 
how and why these aspects of care were reportedly so therapeutic to participants, whilst retaining 
close proximity to the data.   
The identified active ingredients and therapeutic aspects and processes of study participation were 
reported alongside their associated active ingredient or therapeutic aspect of participation, and then 
mapped onto the model of facilitator and barriers of mental health and well-being during 
participants experience of the study, which was created and then modified to address objective 3 
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5. Results 1: Description of the datasets 
5.1. Phase 1: Longitudinal quantitative data  
5.1.1. Recruitment and follow up 
Recruitment was conducted with fidelity to the protocol (section 4.4.1.1) from the end of July 2011 
to the end of February 2012.  The researcher recruited a mean of 3.9 participants each week (range 
1-8), approaching them in the CCC.  A total of 2070 participants were screened over the recruitment 
period.  Details of the recruitment statistics can be found in Table 5-1.   






























13% of total 
screened 










Thirteen percent of the total number of participants screened and 16% of all those on ART had pain 
or symptoms which had lasted more than two weeks and therefore were eligible for the study.  The 
percentage of those eligible that refused to participate appears relatively high at 56%.  Data on 
reasons for refusal was not formally collected, but informally the researcher was informed that 
participants often had difficulty taking time off work to attend the data collection interviews. 
The follow up flow of the study participants is depicted in a CONSORT diagram below (289).  Each 
data point represents a participant data collection appointment.   
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5.1.2. Missing data 
Over the trial period 6 participants prematurely left the trial representing 5% of the total sample 
(n=120).  Three participants died before the trial was complete, three withdrew prematurely (two 
Assessed for availability = 2070 
Randomised n= 120 
Excluded :  
406 were not on ART for ≥1 month 
1393 did not report pain or 
symptoms of 3, 4 or 5 on APOS 
151 declined to participate 
Randomised to intervention n= 60 Randomised to control n= 60 
Month 1:  
57 data points recorded 
2 participants did not attend 
1 participant deceased 
Month 1: 
60 data points recorded 
Month 2:  
56 data points recorded 
1 participant did not attend 
1 participant deceased 
1 participant migrated 
Month 2:  
59 data points recorded 
1 participant did not attend 
Month 3:  
52 data points recorded 
2 participants did not attend  
1 participant deceased 
1 participant migrated 
1 participant withdrew due to time 
constraints 
Month 3: 
59 data points recorded 
1 participant did not attend 
Month 4:  
54 data points recorded 
Month 4:  
57 data points recorded 
3 participants did not attend 
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moved away and one became less available due to work commitment).  Of those participants who 
remained alive during the study period, 98.1% of possible data was obtained.   
The sub sample of participants who left prematurely (n=6), were all allocated to the intervention 
study arm.  They had been diagnosed more recently and had received ART for a shorter time 
compared with the sample median, but otherwise there appeared to be little difference between 
these participants and those who remained in the study.  Due to the small numbers, it was not 
possible to perform analysis to identify whether there was any statistically significant difference 
between those lost to follow up and the remainder of the sample.  Table 5-2 contains the clinical and 
demographic details of three participants who died during the study period (attrition due to death or 
ADD) (255).   
Table 5-2 Demographic and clinical characteristics of participants who died during the study period 








Number of data points 1 3 2 
Gender f f f 
Partner status no no yes 
Age (years) 60 40 23 




Number of financial dependents 6 2 7 
Number of children 5 2 1 
Time since diagnosis (years) 5 <1 <1 
Time on ART (years) 5 <1 <1 
Poverty quintile  (1=higher, 5= lower wealth) 5 3 1 
Receipt of TB treatment no no no 
CD4 at baseline 358 524 403 
Mental health summary score (MHSS) at 
baseline  (MOS-HIV)  (1-100 range; 100 best ) 
12.95 36.79 56.80 
Physical health summary score (PHSS) at 
baseline (MOS-HIV)  (1-100 range; 100 best) 
15.38 15.94 47.20 
GHQ-12 score at baseline (Chronic scoring 
method, 0-12; 12 worst) 
11 12 0 
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Once it became apparent that all of the recorded deaths occurred in participants allocated to the 
intervention study arm, I launched an investigation with principal investigator (Dr Richard Harding).  
This involved close examination of the clinical records kept by the study nurses during delivery of the 
intervention, and interviewing the researcher and study nurses for further details to ensure that 
these deaths were not the result of receiving the intervention.  The subsequent narratives are the 
result of this investigation. 
The first participant who died was diagnosed with advanced cervical cancer.  She was randomised to 
the intervention group but only received one session of palliative care before death.  She would 
have been eligible for the hardship fund held by the hospital for those who were unable to afford 
chemotherapy, but her cancer was so advanced by the time it was diagnosed, it was decided by the 
medical team at the hospital that chemotherapy would have been ineffective.  She received 
nutrition counselling, advice about HIV and her relatives were counselled to support her.  She was 
admitted to the provincial hospital as she deteriorated, and was supported by the study team and 
the local hospice throughout, receiving opioid analgesia.  In collaboration with the local hospice, the 
participant and her family received counselling to prepare for death and the dying process.  As a 
result she decided that she wished to die at her parental home in a rural area.  This was facilitated by 
hospice staff in Mombasa in liaison with a hospice team near her parental home. She died at home, 
with her family, as she wished.  
The second participant was recruited to the trial with severe pain.  She received analgesia and 
underwent investigations which revealed in time that she also had advanced cervical cancer.  She 
would have been eligible for the hardship fund provided by the hospital, to pay for chemotherapy or 
radiotherapy, but her cancer had metastasised into other major organs and it was decided that this 
treatment could not be curative and would not be beneficial.  She received five palliative care 
appointments and attended three data collection appointments before she died.  As part of her 
palliative care she received counselling for ART adherence, psychosocial support and advice about 
the importance of hygiene and medication side effects.  She also received opiates and other 
analgesia for abdominal pain and advice on diet and exercise for constipation, related to opioid use 
for analgesia.  She was admitted twice to the inpatient ward at Bomu hospital.  After her first 
discharge she was readmitted when she attended her palliative care appointment and it was 
recognised by the study nurses that she was seriously unwell.  She continued to be given analgesia 
for pain management and was being considered for food by prescription due to her recent weight-
loss when she died of complications due to her cervical cancer at Bomu hospital.      
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The third participant who died whilst in the study was a woman who migrated after four palliative 
care appointments and two data collection appointments, and subsequently died in a rural area.  On 
enrolment, she reported painful legs and some nausea, but her main concern was her husband, 
whom she described as abusive and drinking too much.  She was otherwise well and managed a 
small income generation project.  As part of her palliative care she received nutrition counselling and 
advice on family planning and adherence to ART.  She had made great progress in her relationship 
with her husband, reporting that he had become more cooperative and supportive.  She was 
preparing to speak with her husband, with support and guidance from the palliative care team, to 
attempt to convince him to attend a session of couple’s counselling to encourage him to be tested 
for HIV.  She then became un-contactable by phone, and when visited by a community health 
worker who had been sent to trace her, it was confirmed by community members that she and her 
husband had decided that she should travel north to the rural area, to work on the family farm.  Her 
husband then reported to the palliative care team that whilst in the rural area she contracted severe 
malaria and died.   
Whilst there is cause for concern that all of the participants who died during the study were in the 
intervention study arm, there does not appear to be any evidence in the narrative data from the 
participant records that they were put at risk by the intervention (for example lack of access to care 
or over medication, or domestic abuse due to participation).  The other possibility is that the 
randomisation process was in some way compromised and that these participants were allocated to 
the intervention purposefully due to their visible need for palliative care.  The researcher had been 
trained and prepared through role play for this scenario to prevent this eventuality.  She was 
intensely supported throughout the recruitment phase of the study, with this potential temptation 
(to purposively allocate sicker participants to the intervention) in mind.  The research team were 
satisfied on the basis of this investigation that the randomisation procedure was performed 
according to the study protocol, and was not compromised. 
The remaining three participants who exited the study prematurely, (also all in the intervention arm) 
left the study due to migration or a lack of time to participate in the interviews, due to employment 
(attrition at random AaR) (255).  Their demographic and clinical characteristics are summarised in 
Table 5-3. 
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Table 5-3 Demographic and clinical characteristics of participants who exited the study prematurely 
Reason for exit 
Withdrew (migrated and 







Number of data points 3 2 3 
Gender m f m 
Partner status yes yes yes 
Age (years) 50 25 31 
Highest educational level 
attained 
Primary Primary Primary 
Number of financial dependents 10 3 0 
Number of children 4 1 1 
Time since diagnosis (years) <1 <1 <1 
Time on ART (years) <1 <1 <1 
Poverty quintile  
(1=higher, 5= lower wealth) 
1 4 4 
Receipt of TB treatment no no no 
CD4 at baseline 473 492 322 
Mental health summary score 
(MHSS) at baseline  (MOS-HIV) 
(1-100 range) 
20.72 48.85 44.78 
Physical health summary 
score(PHSS) at baseline (MOS-
HIV) (1-100 range) 
26.49 59.60 58.92 
GHQ-12 score at baseline 
(Chronic scoring method, 0-12; 
12 worst) 
8 3 8 
 
The first participant who withdrew prematurely reported severe generalised pain on enrolment.  He 
required a physician review and investigations.  He was treated with analgesia, antibiotics, received 
counselling on diet and ART adherence and was diagnosed with a stomach ulcer for which he 
received antacids.  The results of these investigations prompted further tests, by which time the 
participant had requested a referral to healthcare facilities in Tanzania, where healthcare is more 
affordable.  This participant was polygamous and also had a wife and family in Tanzania.  He 
attended six palliative care appointments and three data collection appointments before leaving.   
His Kenyan wife informed the study team that he had died of bone cancer diagnosed in Tanzania, 
after the study period had finished.   
Results 1: Description of the data 
120 
The second participant attended six palliative care appointments and two data collection 
appointments.  She reported some physical pain and other symptoms, but her main source of 
distress was her relationship with her husband, who was unfaithful and planning to marry a 2nd wife 
due to her HIV positive status.  Since he was HIV negative, he did not want to take risks by being with 
her.  She was offered advice on adherence, diet, sexual health and hygiene and given more 
information about HIV/AIDS.  She also received treatment for thrush and TB.  After her husband 
remarried, she decided to leave Mombasa to be taken care of by her mother.   
The final participant who withdrew from the study prematurely withdrew because he became 
employed and was concerned that if he took time off work to attend the sessions he might not be 
paid or might lose his job.  He was severely depressed at enrolment and socially isolated, describing 
himself as overwhelmed by the burdens of HIV and fears for the future.  He received psychological 
and emotional support, adherence and nutritional counselling and couples counselling with his wife.  
After the first session he reported feeling much better and began to take care of himself and look for 
paid employment.  His wife attended the clinic after he had missed three appointments, and 
reported that he had improved due to the support of the study nurses, had become employable as a 
result, and therefore had secured a job and was unable to take any time off to attend.  He attended 
four palliative care appointments and three data collection appointments.  
Again, while it might initially appear concerning that all participants who exited the study 
prematurely were in the intervention arm, all investigation of the clinical data and interviews with 
the study team do not suggest any compromise of the study protocol.  I am confident that the 
participants who died during the study period or exited prematurely were allocated to the 
intervention study arm randomly, and study participation did not cause their death. 
Missing items 
In the total of 600 data collection appointments which could have been attended,a total of 26 were 
not attended, therefore for these appointments there is no data for any outcome measure (26 
missing out of a possible total of 600: 4.3% missing).  Whilst the figure of 4.3% missing data is low, of 
this 4.3%, 21 of the 26 missing data points (81%) occur in the intervention arm due to increased 
attrition in this group.  Among the completed interviews, there was only one missing item (omitted 
or skipped question within the completed questionnaires).  All other attended data collection 
appointments had complete data. The distribution of missed single interviews is evenly distributed 
across control and intervention study arms (five missing single interviews in each).   
The distribution by study arm, and time-point is described in Table 5-4.   
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Missing data type Control Intervention 
Total control and 
intervention 
Baseline 
Missed question 1 0 1 
Missed single questionnaire 0 0 0 
Missed interview 0 0 0 
Premature exit 0 0 0 
Deceased 0 0 0 
Month 1 
Missed question 0 0 0 
Missed single questionnaire 0 0 0 
Missed interview 0 2 2 
Premature exit 0 0 0 
Deceased 0 1 1 
Month 2 
Missed question 0 0 0 
Missed single questionnaire 0 0 0 
Missed interview 1 1 2 
Premature exit 0 1 1 
Deceased 0 2 2 
Month 3 
Missed question 0 0 0 
Missed single questionnaire 0 0 0 
Missed interview 1 2 3 
Premature exit 0 3 3 
Deceased 0 3 3 
Month 4 
Missed question 0 0 0 
Missed single questionnaire 0 0 0 
Missed interview 3 0 3 
Premature exit 0 3 3 
Deceased 0 3 3 
Totals 
Missed question 1 0 1 
Missed single questionnaire 0 0 0 
Missed single interview 5 5 10 
Premature exit 0 3 3 (7 missed interviews) 
Deceased 0 3 3 (9 missed interviews) 
 
The minimal amount of missing data is largely due to the efforts of the researcher, who worked in 
close collaboration with the staff and management at the study site to contact participants who had 
not attended their data collection appointments.  Community tracers from the comprehensive care 
clinic, usually employed to ensure adherence to ART, were asked to enquire about participants who 
had not attended their appointments using their contacts and local knowledge.  This collaborative 
approach contributed to the minimal amount of missing data and subsequent high quality dataset.  
Management of missing data 
When one value was missing due to a participant missing a single interview and then returning to 
the study, single imputation was used: last value carried forward or the horizontal mean (320, 322).  
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For the 6 participants who left the study prematurely and therefore had more than one missing data 
point for all outcome measures, list wise deletion was not performed due to the small amount of 
missing data.  Once the single imputations had been performed, this left 16 missing data points, or 
2.7% missing data.  This small amount of missing data does not necessitate management (325).   
5.1.3. Variable type 
In terms of independent variables, age in years, number of children, number of financial 
dependents, CD4 count at baseline, time since HIV diagnosis in days and time on ART in days were all 
analysed as continuous data.  Education and wealth were analysed as ordinal variables, and gender, 
partner status and TB status were analysed as binary variables as detailed in Table 4-6. 
5.1.4. Characteristics of the sample 
The demographic and clinical characteristics of the sample are reported in Table 5-5.  Of the entire 
sample, the mean age was 39 years, and 81% were female.  Most achieved primary education and 
had more financial dependents than children.    
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Table 5-5 Demographic and clinical characteristics of the TOPCare sample 






Female n (%)   97 (81) 49 (82) 48 (80) 






Has a partner  (% yes) 63 60 66.7 
Median no. children (IQR)  2 (1-4) 2.5 (1-4) 2 (1-4) 
Median no. financial 
dependents (IQR)  
3 (2-5) 4 (3-5.5) 3 (2-5) 
Education 
Never been to school  






















Poverty quintile (5 quantiles 
of wealth), n (%) 


























Median years since HIV 
diagnosis  (IQR)  
3.5 (1.3-5.2) 4.7 (2.4-5.7) 2.6 (0.9-4.4) 
Median years on ART  (IQR)  2.5 (0.8-4.2) 3.0 (1.6-5.0) 1.6 (0.4-3.5) 
Median CD4 count  
(cells/mm3, IQR)  
358  (223-506) 343 (209-558) 359 (247-490) 
Receiving TB treatment 
(%yes) 
8 12 5 
WHO stage 
Stage 1  
Stage 2  
Stage 3  

















Participants allocated to the control arm were diagnosed and on ART for longer than participants 
allocated to the intervention arm.   
Figure 16 is a stacked bar chart displaying the distribution of baseline score by percentage from the 
APOS for each study arm to enable comparison.  In this figure, 0 indicates the worst outcome and 5 
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indicates the best outcome (scores for items 1, 2 and 3 have been reversed for ease of 
interpretation).   
Figure 16 Multidimensional well-being at baseline for TOPCare study participants, by study arm 
 
Whilst pain and symptoms appear to be very problematic for the sample at this point, it is important 
to remember that a pain or symptom score indicating moderate to severe pain or symptoms (0-2 in 
this figure) were inclusion criteria for the study.  Other than pain and symptoms, it appears over 50% 
of participants in both study arms experienced severe difficulty with getting enough help and advice 
to help their family and friends plan for the future and that over 20% in each arm reported that they 
had not been at peace at all over the past 3 days. Over 30% have severe difficulty sharing their 
feelings and approximately 50% in each study arm report high levels of worry.  More than 80% of 
participants report that they feel that their life is worthwhile.   
5.2. Phase 2: Semi structured qualitative interviews 
5.2.1. Sampling and sample characteristics 
Participants were recruited to the qualitative phase of the study a minimum of one month and a 
maximum of 9 months after they had exited the quantitative phase of the study.   
In terms of deviant case selection, there was only one participant who reported clinically significant 
deterioration, who also was alive at study exit.  This participant was purposively included in the 
qualitative sample.  The sample characteristics are described in Table 5-6 with reference to the 
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sample for the entire TOPCare dataset used in the analysis of the quantitative data, to enable visual 
assessment comparability.   
Table 5-6 Characteristics of sample for phase 1 and phase 2 of study  
Variable 
Phase 1 sample  
(n=120) 
Phase 2 Sample  
(n=30) 
Mean age (years, sd) 39.4 (8.7) 39.1 (6.9) 
Gender (% female) 81% 80% 
Partner status  
yes N (%) 
76 (63%) 17 (56.7%) 


















Education attainment N (%) 
None 






















Receiving TB treatment? Yes n (%) 10 (8.3%) 5 (16.6%) 
Received an AIDS diagnosis?  
Yes n (%) 
119 (99.2%) 30 (100%) 
Owns a bicycle? Yes n (%) 25 (20.8%) 8 (26.7%) 
Owns a fridge? Yes n (%) 30 (25%) 7 (23.3%) 
Owns a television? Yes n (%) 74 (61.7%) 18 (60%) 
Owns a car? Yes n (%) 5 (4.2%) 2 (6.7%) 
Owns a radio? Yes n (%) 76 (63.3%) 18 (60%) 
Clinically significant improvement 
reported on MOS-HIV MHSS? Yes n 
(%) 
62 (54.4%) 18 (60%) 
 
Participants in the sub-sample phase 2 appear to be similar to the sample for phase 1 in terms of the 
clinical and demographic variables (Table 5-6).  In order to describe levels of affluence within the 
dataset, in place of the distribution of poverty quintiles, which are somewhat abstract, the 
proportion owning a bicycle, fridge, television, car and radio are reported to demonstrate levels of 
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affluence in more concrete terms.  These variables also demonstrate the similarity between the 
samples for phases 1 and 2 in terms of affluence.  If experience of the study is associated with these 
clinical and demographic variables, this suggests that the variability of experience in the TOPCare 
sample should be captured within the sample for phase 2.   
The mean length of the interviews was 41.6 minutes (sd 11.8), with a median time of 40 minutes 
(range 26 -76 minutes).  They appear to be shorter in the intervention group compared with the 
control group, although the difference is very slight (38minutes v 41.5minutes).   
5.2.2. Transcription and translation 
One translator transcribed 16 of the 30 interviews, with the remainder translated by two other 
translators.  All translators were selected first on the basis of experience of previous experience of 
interview translation and secondly on the basis of the quality of one translation they provided.  After 
checking the manuscripts against the original recordings, minor adjustments for accuracy and 
comprehension were made by the researcher who conducted the interviews.  
5.2.3. Coding framework 
In the thematic analysis of qualitative data four major themes emerged: experience of healthcare, 
experience of research, living with HIV and sources of benefit.  Experience of healthcare included 
data on interactions with healthcare staff outside of the study and the experience of medication 
management beyond ART.  Experience of research encompassed participant descriptions of 
participation in the study, their understanding of the research and consent processes and 
descriptions of the content of the intervention.  Living with HIV encompassed participant 
descriptions of aspects of their lives which were affected by their HIV positive diagnosis.  Sources of 
benefit include participant descriptions of sources of therapeutic benefit from control and 
intervention study arms. They are depicted as active ingredients of the intervention, and therapeutic 
aspects of participation in the study.  The coding framework is depicted and discussed more fully 
below in Figure 17, Figure 18, Figure 19, and Figure 20.  
Figure 17 Coding Framework for ‘Experience of healthcare‘ 
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Experience of healthcare encompassed all data describing interactions with healthcare systems.  This 
included participant experiences of medications (not including ART) for symptoms management etc. 
which they received in the course of receiving healthcare from the standard care clinic and other 
providers such as the Government hospital.   
Figure 18 Coding Framework for ‘Experience of research’ 
 
The theme of experience of research encompasses data on participant understanding of consent and 
the reasons they gave for consenting to participate in the trial.  This was coded as it was realised that 
this was important to gain a deeper insight into the participant’s understanding of the research 
process, which affected their perceptions of the actions of the study team.  Participants sometimes 
misunderstood the practice of data collection as the researcher’s personal interest in them, because 
they lacked previous experience of research (discussed in fuller length in Discussion section).  This 
theme also encompassed data on the content of the intervention, and participant experience of 
interactions with the study team.   
Living with HIV (Figure 19) was the largest major theme, containing data on the experience of life 
with HIV in Mombasa.  The theme of ‘Living with HIV’ contained 5 sub-themes presented in Figure 
19: ART adherence, disclosure event, stigma, symptom burden, and financial burden.  The data 
coded at symptom burden and in the sub-themes of social and psychological well-being were 
examined and interrogated to address objective 3 as well as data coded under the theme of stigma, 
as stigma falls between the psychological and social domains, in that it influences and is influenced 
by both. 
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Figure 19 Coding framework for ‘Living with HIV’ 
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Participants were asked about their views on what was the most therapeutic or beneficial aspect of 
the study.  Their responses to this question and descriptions of why and how participants felt they 
had changed or improved during the study period, were coded at the major theme of ‘Sources of 
benefit’ (Figure 20). The sources of benefit are divided into active ingredients of the intervention and 
therapeutic aspects and processes of participation in the study.  
Figure 20 Coding framework for ‘Sources of benefit’ 
 
This data will be used to address objective 4, where the quantitative and qualitative data are 
analysed to explore and identify active ingredients and mechanisms of action of the intervention and 
therapeutic aspects and processes of study participation.  A list of definitions of themes and sub-
themes within the coding framework is included in Appendix 14. 
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6. Results 2: Results by objective 
In this chapter I present the results of data analysis described in section 4.6 to meet the objectives of 
the study.  These results are presented by objective and where relevant, according to study phase.  
The chapter closes with a summary of all findings by objective 
6.1. Objective 1  
To determine baseline levels of mental well-being and to examine associations between baseline 
mental well-being and demographic and clinical characteristics among patients with HIV on ART 
enrolled in a randomised controlled trial (RCT) of a nurse-led palliative care intervention. 
Baseline measures of mental health and well-being are reported below.  
6.1.1. MHSS 
The median MHSS score, inter-quartile range (IQR) and distribution for full sample and by study arm 
is presented in Figure 21 and Table 6-1.  This represents a median score slightly below the reference 
population cited by the measure authors Wu et al (307).  In the graph below, 0 is the worst possible 
score and 100 is the best possible score.  
Figure 21 Distribution of MHSS at baseline for full sample and by study arm 
 

















All sample     Intervention arm      Control arm 
Whole sample median MHSS (IQR) Intervention median MHSS (IQR) Control median (IQR) 
44.8 (IQR 36.97-53.78). 44.8 (35.9-55.1) 44.7 (39.8-52.1) 
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Bivariate analysis of MHSS with clinical and demographic variables at baseline is reported with test 
statistic, confidence intervals and p value (Appendix 15).  This bivariate analysis identified an 
association between MHSS score and gender, CD4 count at baseline and age in years, using p<0.25 
as a threshold for significance.  These variables were entered into the multivariate analysis.  The 
residuals of the linear regression model were not normally distributed (Shapiro Wilk test z=6.70 
p=<0.001) therefore MHSS was categorised into 6 quantiles of 10 points, to perform enable logistic 
regression.  
Table 6-2 Multivariate ordered logistic regression analysis to identify association between MHSS and independent 
variables at baseline (n=119) 
Variable Proportional log odds ratio 
(95% CI) 
P value 
Gender 0.31 (0.13,0.75) 0.01 
Age in years 0.98 (0.94,1.02) 0.30 
CD4 count at baseline  1.00 (1.00-1.00) 0.71 
 
This model analysis identified an association between MHSS and gender.  For women, the log odds 
of reporting better MHSS were 70% lower than that of men at baseline, holding CD4 count at 
baseline and age constant.  Tests for the proportional odds assumption prove insignificant (X2 
p=0.25) suggesting that the assumptions are met.   
Psychological quality of life as measured by MHSS was not associated with age, partner status, 
number of children, number of financial dependants, education, wealth, time since diagnosis, time 
on ART, CD4 count, and receipt of TB treatment in HIV positive patients on ART with moderate to 
severe pain or symptoms at baseline. 
6.1.2. GHQ-12 
The distribution of GHQ-12 score for the full sample and by study arm is reported in Figure 22 (best 
possible score 0, worst 12) and Table 6-3.  In the literature a score of 4, 5 or 6 is used as a threshold 
above which the respondent is identified as having psychiatric morbidity, depending on the context 
and sample (316).  
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Figure 22 Distribution of GHQ score at baseline for full sample and by study arm 
 
Table 6-3 Median and IQR GHQ-12 score for full sample and by study arm 
Full sample median GHQ score 
(IQR) 
Intervention median GHQ 
score (IQR) 
Control median GHQ score 
(IQR) 
6 (3-9) 6 (3-9) 6.5 (3-9) 
 
Bivariate analyses of associations between GHQ-12 score and baseline demographic and clinical 
independent variables are reported in Appendix 15.  The findings suggested some evidence for an 
association with GHQ identified psychiatric morbidity and older age in this sample (p=0.02).  There 
were no further associations identified therefore no multivariate analysis was performed.   
There was no evidence for an association between psychiatric morbidity and gender, partner status, 
number of children, number of financial dependents, education, wealth, time since HIV diagnosis, 
time on ART, CD4 count and receipt of TB treatment in HIV positive patients on ART reporting 







12 = worst 8 4 4 
11 8 4 4 
10 7 4 3 
9 14 8 6 
8 13 6 7 
7 8 2 6 
6 7 3 4 
5 7 3 4 
4 12 9 3 
3 15 6 9 
2 7 2 5 
1 6 3 3 


























Results 2: Results by objective 
133 
6.1.3. APOS worry item 
The distribution of the APOS worry item at baseline is presented in Figure 23 and Table 6-4.  The bar 
chart shows that distribution of worry across the study arms was similar, with the majority of the 
sample either reporting that at baseline they were worried all of the time or not at all.  
Figure 23 Distribution of APOS worry score at baseline for full sample and by study arm 
 
Table 6-4 Median and IQR of APOS worry item 
Whole sample APOS worry 
median (IQR) 
Intervention APOS worry 
median (IQR) 
Control APOS worry 
median (IQR) 
2.5 (0-5) 3 (0-5) 2 (0-5) 
 
Details of the bivariate analysis can be found in Appendix 15.  No associations were identified 
between worry and gender, age, partner status, number of children, number of financial 
dependants, education wealth, and time since HIV diagnosis, time on ART, receipt of TB treatment 
and CD4 count 
6.1.4. APOS share item 
The stacked bar chart presenting the distribution of APOS share item at baseline highlights 
considerable ceiling effect, with 53% reporting the highest possible score at baseline (Figure 24).   
Full sample Control Intervention 
5= worried all of the time 54 28 26 
4 1 0 1 
3 5 4 1 
2 14 3 11 
1 10 9 1 
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Figure 24 Distribution of APOS share item at baseline for full sample and by study arm 
 
Table 6-5Median and IQR of APOS share item at baseline for full sample and by study arm 
Whole sample APOS share 
median (IQR) 
Intervention APOS share 
median (IQR) 
Control APOS share median 
(IQR) 
5 (0-5) 4.5 (0-5) 5 (0-5) 
Details of the bivariate analysis can be found in Appendix 15.  No associations were identified 
between the ability to share feelings and gender, age, partner status, number of children, number of 
financial dependants, education wealth, and time since HIV diagnosis, time on ART, receipt of TB 
treatment and CD4 count.     
6.1.5. Summary of findings from objective 1 
The mean baseline MHSS was 44.8, lower than the reference group reported in the literature (307).  
MHSS was worse in women compared to men (p=0.02) at baseline.  There was no evidence of an 
association between MHSS and age, partner status, number of children, number of financial 
dependents, education, wealth, time since HIV diagnosis, time on ART, CD4 count and receipt of TB 
treatment in HIV positive patients on ART reporting moderate to severe pain or symptoms. 
Baseline GHQ score indicated some evidence of psychiatric morbidity in the sample, equally 
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psychiatric morbidity with age (p=0.02).  There was no evidence of any association between 
psychiatric morbidity and gender, partner status, number of children, number of financial 
dependents, education, wealth, time since HIV diagnosis, time on ART, CD4 count and receipt of TB 
treatment in HIV positive patients on ART reporting moderate to severe pain or symptoms.    
Neither worry or the ability to share feelings were associated with age, gender, partner status, 
number of children, number of financial dependents, education, wealth, time since HIV diagnosis, 
time on ART, CD4 count and receipt of TB treatment in HIV positive patients on ART reporting 
moderate to severe pain or symptoms.   
6.2. Objective 2  
To identify any effect of the palliative care intervention on mental health and well-being, comparing 
participants receiving the intervention and standard best practice. 
The data for the MOS-HIV MHSS, GHQ-12 and the APOS items is presented for visual assessment and 
familiarisation with the data and analysed at monthly time points to examine change over time, and 
using multilevel hierarchical regression model for repeated measures.  
6.2.1. Graphical depiction over time and analysis at monthly time points 
6.2.1.1. MHSS 
Summary measures (median and IQR) were used to graphically display the MHSS data (Figure 25).  
The line graph shows that both the median of the control and intervention study arm increased over 
time.  The intervention group reported earlier benefit at month 1, which attenuated at month 2 and 
increased at month 3.  By the final time point, they appeared similar.   
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Due to the interval nature of the MHSS variable, it was first analysed using linear regression.  The 
residuals of each regression were however not normally distributed, therefore the data was 
analysed using the MHSS data divided into 3 categories, using ordered logistic regression.  The 
results are displayed by monthly time point in Table 6-6 below.   
Table 6-6 Regression coefficients for effect of study arm on MHSS score at monthly intervals throughout the study 





Baseline (n=120) 0.29 (-0.44-1.02) 0.44 
Month 1  (n=119) 1.11 (0.35-1.86) <0.01 
Month 2 (n=117) 0.47 (-0.25-1.18) 0.20 
Month 3 (n=114) 0.75 (0.02-1.49) 0.04 
Month 4 (n=114)  0.74 (-0.03-1.51) 0.06 
 
Monthly time point analysis of the MHSS data showed statistically significant difference between 
control and intervention study arm at month 1 and some evidence of a statistically significant 
difference at months 3 and 4, with benefit in the intervention arm. 
6.2.1.2. GHQ-12  
The distribution of GHQ-12 scores (12 point scale) are presented over time in bar charts and by study 
arm (Figure 26). Visual assessment suggested improvement in psychiatric morbidity in both study 
arms over the study period.  As for the MHSS data, the intervention group improved more rapidly 
initially, with the initial difference between study arms attenuating over time.  A low GHQ-12 score 
indicates an absence of psychiatric morbidity.   
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Figure 26 GHQ-12 score over time comparing study arms (n=114) 
 
The GHQ-12 data were analysed in a multivariate model for each monthly time point, for effect of 
study arm on GHQ score.  The data for GHQ-12 were found to violate the proportional odds 
assumption of ordered logistic regression, and therefore scores were divided into three categories, 
which preserved the assumptions.  The model adjusts for baseline score (Table 6-7). 
Table 6-7  Ordered logistic regression for effect of study arm on GHQ score at monthly intervals throughout the study 
period, adjusting for baseline score (n=114) 
Time  
Coefficient 
 (95% CI) 
p value 
Baseline (n=120) -0.18 (-0.86 to -0.51) 0.61 
Month 1  (n=119) -0.85 (-1.54 to -0.15) 0.02 
Month 2 (n=117) -0.84 (-1.56 to -0.13) 0.02 
Month 3  (n=114) -0.58 (-0.30 to -0.14) 0.12 
Month 4 (n=114)  -0.51 (-1.25 to -0.23) 0.17 
 
The analysis demonstrated a statistically significant difference between control and intervention at 
months 1 and 2, with benefit to the intervention arm. 
6.2.1.3. APOS worry 
The distribution of worry score over time shows a similar pattern of decreasing worry over time in 
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intervention care package.  Scores have been reversed from original scoring for this graphical 
depiction to facilitate comparison with the other APOS item (ability to share). 
Figure 27 Distribution of APOS worry over time comparing study arms 
 
The APOS worry data were then analysed using ordered logistic regression, adjusting for baseline 
score.    
Table 6-8 Results of ordered logistic regression for effect of study arm on APOS worry score at monthly intervals 


























Monthly time point analysis showed a statistically significant difference at month 1 with benefit to 
the intervention arm, which attenuated and does not re-emerge at any subsequent time point.  
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6.2.1.4. APOS share 
The distribution of scores over time for APOS share suggested an immediate improvement in the 
intervention study arm from baseline, which was not seen in the control study arm (Figure 28).     
Figure 28 Distribution of APOS share over time comparing study arms (n=109) 
 
Once the improvement was made, most participants continued to report high levels of ability to 
share feelings in the intervention arm. The distribution appears to change little over time in the 
control study arm data.  Data distribution suggestive of a ceiling effect is maintained over time in 
both study arms.     
The APOS share data were then analysed using ordered logistic regression, adjusting for baseline 
score.    
Table 6-9 Results of ordered logistic regression for effect of study arm on APOS share data at monthly intervals 
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The results of the analysis demonstrated a statistically significant difference between control and 
intervention study arm at month one and month four.  Assumptions of the analysis were not 
violated at any monthly time point.  
6.2.2. Analysis of repeated measures  
This analysis was performed to assess for effect of study arm, whilst taking into account potential 
data clustering by participant and baseline score.  Initially analysis using GEE was performed, but the 
residuals of each regression were found to be not normally distributed, and therefore the results 
were invalid.   
GLLAMM was then performed, as a more robust technique with fewer assumptions for ordinal data.  
Each dependent variable was reduced to 4 quantiles to facilitate this analysis, which was performed 
using 8 quadrature points, a binomial distribution, the ordinal logistic regression link function (ologit) 
and correlation by participant.  The ICC was also reported, indicating the degree to which the 
repeated measures were found to be clustered by patient (higher score indicates increased 
clustering).   
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This model indicated that participants allocated to the intervention study arm reported higher 
MHSS, reduced GHQ 12, and increased APOS share in the ordered log odds scale.  No statistically 
significant difference was identified for APOS worry comparing intervention and control study arms.   
There was a statistically significant difference between the control and intervention arm, with 
respect to longitudinally analysis adjusting for data clustering, in terms of psychological quality of life 
(MHSS) psychiatric morbidity (GHQ-12) and the ability to share feelings (APOS share), but not for 
worry (APOS worry), with benefit to the intervention.    
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6.2.3. Null hypothesis 
The null hypothesis for psychological quality of life (MHSS) is stated below:  
There will be no difference in psychological quality of life, measured by the MOS-HIV 
MHSS, in longitudinal analysis of difference between participants allocated to 
receive the intervention (nurse led HIV palliative care) and participants allocated to 
receive the control (standard HIV clinic care) 
Longitudinal analysis showed a statistically significant increase (p=0.015) in MHSS in participants 
allocated to receive the intervention care package, thus the null hypothesis is rejected. 
6.2.4. Summary of findings from objective 2 
Analysis by monthly time point indicated statistically significant difference between study arms at 
month one for psychological quality of life (MHSS), psychiatric morbidity (GHQ-12), worry and ability 
to share, with benefit in the intervention arm.  At month two the difference persisted for psychiatric 
morbidity, but for no other outcomes.  At month three there was benefit in the intervention arm for 
psychological quality of life but no other outcomes, and at the final time point there was statistical 
evidence for benefit in the intervention arm for the ability to share feelings. 
Analysis of repeated measures identified a statistically significant difference between control and 
intervention groups in terms of psychological quality of life, psychiatric morbidity and the ability to 
share feelings, but not for worry.  The difference indicated benefit for the intervention arm for each 
outcome.  The null hypothesis of no effect was rejected. 
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6.3. Objective 3  
To determine and describe participant experience and longitudinal response to participation in the 
study in terms of psychological and social well-being, and to identify and explore associations 
between participant response and demographic and clinical characteristics 
Results of the quantitative analysis of phase 1 data will be presented first, followed by qualitative 
result of analysis of phase 2 data, ending with an integrated summary of the combined findings.  
6.3.1. Phase 1 data analysis of response to participation 
To identify which variables, in addition to study arm, had an effect on participants’ mental well-being 
area under the curve analysis was performed to examine association with demographic and clinical 
independent variables (see 4.6.5.1). 
6.3.1.1. Area under the curve  
Area under the curve analysis is a longitudinal summary of the measurements for each individual 
participant.  To decide whether the data is of adequate quality for the trapezoid method, the time 
between data collection appointments was analysed (Table 6-11).   
Table 6-11 Summary of time in between data collection appointments (n=112) 
Time interval  Mean (days) sd 
Time between T0and T1 29.2 5.1 
Time between T1 and T2 28.1 10.7 
Time between T2 and T3 30.6 10.8 
Time between T3 and T4 29.8 4.8 
 
Appointments were quite evenly spaced and therefore the trapezoid method could be used to 
calculate the AUC.   
6.3.1.2. AUC Distribution 
The AUC distribution for the MHSS suggested an almost normal distribution of results, with a slight 
negative skew.  The distribution of the GHQ-12 AUC data was skewed positively, indicating less 
psychiatric morbidity over the study period.   
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Figure 29 Distribution of MHSS AUC data  (n=114)    Figure 30 Distribution of GHQ-21 AUC data (n=114) 
 
Figure 31 Distribution of APOS worry AUC data (n=114)     Figure 32 Distribution of APOS share AUC data (n=114) 
 
The APOS worry AUC data was positively skewed.  As a low score indicated fewer problems in this 
item, this positive skew showed the low level of worry over the study period.  The APOS share data 
was negatively skewed.  This item was scored in the reverse, where a high score indicated fewer 
problems, thus this distribution indicated high levels of ability to share.   
6.3.1.3. Association with demographic and clinical independent variables 
MHSS AUC 
The results of the multivariate linear regression are reported in Table 6-12.  No Bonferroni correction 
was necessary as 4 variables were entered into the model, which meant there were 30 respondents 
per variable.  The residuals for this regression model were normally distributed (Shapiro Wilk z=0.87 
p=0.19). 
Table 6-12 Results of multivariate linear regression model of MHSS AUC and independent variables (n=114) 
Variable Regression coefficient (CI) p value 
Study arm 9.26 (2.18-16.33) 0.011 
Baseline MHSS score 2.03 (1.70-2.36) <0.001 
Poverty quintile -3.57 (-6.13- -1.02) 0.007 
Educational 
attainment 
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The adjusted r2 for this model was 58% indicating that study arm, poverty, educational attainment 
and baseline score account for 58% of the variability in MHSS AUC.  Allocation to the intervention 
group was associated with an increase of 9.26 AUC points, holding baseline score, poverty and 
education constant.  Each increase of baseline score was associated with an average increase of 2.03 
MHSS AUC holding study arm, poverty and education constant. 
For each increase in poverty quintile, there was an associated 3.57 points decrease in MHSS AUC.  
This suggested that an increase in poverty was associated with decrease in psychological quality of 
life, holding study arm, baseline score and education constant.   
For every increase in educational attainment, there appeared to be a corresponding 3.77 decrease in 
MHSS AUC, indicating that higher educational attainment was associated with poorer psychological 
quality of life, holding study arm and wealth constant.  This finding has marginal evidence for 
statistical significance. 
These findings suggested a significant predictive relationship between improved psychological 
quality of life and people who are richer, less educated and allocated to the intervention study arm. 
GHQ-12 AUC 
The residuals for a simple regression model were not normally distributed (Shapiro wilk test z=1.69, 
p=0.05), so this analysis was performed using ordered logistic regression, dividing GHQ AUC into 10 
categories.  The test for the proportional odds assumption indicates that this assumption had not 
been violated (X2 18.65 p=0.77).   






Study arm -0.88 (-1.55- -0.21) 0.010 
Baseline GHQ-12 score 0.35 (0.24-0.46) <0.001 
Poverty quintile 0.24 (0.001-0.47) 0.041 
 
Allocation to the intervention study arm was associated with a decrease of 0.88 in AUC ordinal 
category, or reduced psychiatric morbidity over time in the intervention group (p=0.01).  For every 
unit increase in baseline score, GHQ-12 AUC category increased by 0.35, when study arm and wealth 
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are held constant (p<0.001).  This suggested that those who began with increased morbidity did less 
well over the study period.  For each increase in poverty quintile, GHQ-12 AUC category increased by 
0.24 categories, indicating that increased poverty was associated with increased psychiatric 
morbidity holding study arm and baseline score constant.   
APOS worry AUC 
Analysis of the APOS worry item AUC showed that the assumptions of both linear regression and 
ordinal logistic regression were not met, as the residuals of linear regression were not normally 
distributed, and the assumption of proportional odds was violated.  Multinomial analysis was 
attempted but the results of this failed to report any trends or findings of any coherence.  Therefore 
AUC worry data could not reasonably be analysed and this data will not be reported. 
APOS share AUC 
The APOS share AUC data was analysed using ordered logistic regression because in the preliminary 
regression models, residuals of a linear regression model were not normally distributed (z=5.94, 
p<0.001).  The assumptions of ordered logistic regression were violated when this data was divided 
into 10 quantiles, but not when divided into 4, therefore 4 quantiles of APOS share AUC data were 
used (X2=145.59 p=0.06). 





Study arm -0.85 (-0.18-1.53) 0.013 
Baseline APOS share score 0.44 (0.28-0.60) <0.001 
Gender -0.91 (-1.79- -0.04) 0.040 
Highest educational 
attainment 
-0.59 (-1.01- -0.18) 0.005 
 
There was strong statistical evidence that allocation to the intervention arm (p=0.01) and higher 
baseline score (p<0.001) were associated with improvements in ability to share over the study 
period.  Female gender (p=0.04) and increasing educational level (p=0.005) were associated with a 
decreased ability to share over time, adjusting for allocation to study arm and baseline score.   
This suggests that those in the intervention study arm, those who began with higher ability, men and 
participants with lower education level reported increased ability to share during the study.   
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6.3.1.4. Summary of quantitative longitudinal response analysis 
The results of the quantitative analysis for association of outcomes with demographic and clinical 
variables show that over time, adjusting for the effect of study arm and baseline score: 
● Increased poverty was associated with worse psychological quality of life (p<0.01) and increased 
psychiatric morbidity (p=0.05).   
● Increased educational attainment was associated with worse psychological quality of life (p=0.04) 
and ability to share (p<0.01). 
● Male gender was associated with increased ability to share (P=0.04).  
● Increased psychological quality of life and ability to share and decreased psychiatric morbidity 
were all associated with allocation to the intervention study arm (all p=0.01).   
● Finally, better health status in terms of psychological quality of life, psychiatric morbidity and 
ability to share at baseline were associated with improvement in status over the study period 
(p<0.001 for all). This suggested that those who began the study with better mental health and well-
being, reported consistently better scores over time, adjusted for study arm and other variables.  In 
conclusion, baseline score was the strongest, most consistent predictor of outcome. 
6.3.2. Phase 2 data analysis of response to participation 
6.3.2.1. Cultural understanding of the concept of well-being 
The model which was constructed from the participants’ words and phrases used to describe what it 
meant to be normal, well or better, is presented in Figure 33. 
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Figure 33 Participants cultural understanding of the concept of well-being 
 
This model includes participants descriptions of what ‘well’ people are able to do, how they appear 
and how they are treated by others in society.  The model identifies a variety of different aspects of 
well-being, and highlights participant’s emphasis on physical and social function in their 
understanding of what it means to be well.  Among the most often repeated aspects were the ability 
to eat well and the ability to work, which may be related.   
To address objective 3, (determine and describe participant experience and longitudinal response to 
participation), the qualitative data is reported according to the time period referred to by 
participants (before, during or after the study), and by study arm.  
The majority of participants for phase 2 of the study reported clinical benefit in the quantitative 
outcome measures (Table 6-15).  Amongst those who did not report clinical benefit there are those 
who reported some positive or negative change but not to a clinically significant extent (10 point 
change (307)).  Only one participant, in the intervention group, reported clinically significant 
deterioration and remained alive at the end of the trial.   
The findings of the qualitative data analysis will be presented for both study arms before the study 
began, with separation by study arm and report of clinically significant benefit during and after the 
study (Table 6-15).   
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Table 6-15 Number and ID of participant with clinically significant benefit as measured by MHSS by study arm 
 Clinically significant 
deterioration 
(MHSS) 









097, 133, 156, 
159 
(n=4) 









108, 123, 139, 
147, 154 
(n=5) 
075, 106, 110, 114, 119, 
120, 125, 126, 129, 132, 
134, 135, 138, 144 
(n=14) 
 
6.3.2.2. At entry to the study 
This section provides an overview of the mental health and well-being of the entire sample at 
recruitment and entry into the study, as reported by participants at their exit interviews.  
Twenty-four participants reported that they experienced fear in their lives before recruitment to the 
study; mostly fear of death and deteriorating health.  Many thought that once diagnosed with HIV, 
deterioration and death was a certainty, and probably imminent:   
I just used to think that the next thing was death; that is what I believed.  I just used to see 
that I will just die because I had pains everywhere; I wasn’t healthy.  ID 075, female, 42 years, 
intervention 
Few knew others who had lived with HIV for a long time in the community, perhaps because of the 
relatively recent advent of widespread availability to ART:  
So I was in a depressive mood, because people always talked about the disease saying that 
one would have to die.  ID 110, female, 28 years, intervention  
Participants described anxiety because they assumed that it was impossible to get better and live 
normally as a HIV positive person:  
Interviewer: What did you fear most about your life? 
Patient: I was not sure if by using the drugs I could get helped and be able to live my normal 
life.   ID 107, female, 46 years, control 
Fears were associated with a lack of knowledge about the medication, and a lack of trust that it 
would be effective, sometimes based on experience of persistent complaints:   
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I could go to the doctor and I’d be told to take this medication. I’d take until completion and 
still no difference. I even started reasoning, “If I’m being given medication and I’m not 
improving even after completing the dose, what could be happening – will I really get well?” 
Then I got … I started getting worried.  ID 107, female, 46 years, control 
One time it’s headache, the other time it’s the stomach, then cold or is it malaria, I mean I 
was ever in poor health and I thought I’d go any time, never hoped of getting better. I never 
had a focused mind, I was very worried, because I wasn’t used to this – coughing then this 
and that and then that and all these were upon me and I’d never been used to this.  ID 125, 
female, 30 years, intervention 
They reported receiving little encouragement from health care providers and others in their 
community, often reporting a lack of hope for the future.  This lack of information, hope and trust in 
the therapeutic options led to fear and isolation: 
I mean that state of feeling you’ve no hope of life and you think you are soon passing 
away....It’s feeling that you are weighed down with too many thoughts because you don’t 
have anyone to give a helping hand.  ID 144, male, 32 years, intervention 
Participants also reported a fear of disclosure, associated with the fear that they might be shamed, 
socially isolated or discriminated against due to their HIV positive diagnosis:   
Initially, I had a lot of [hesitates] … friends but when I knew about my status I started fearing 
them – because I feared they [hesitates] might be discussing about me. So I started fearing 
them.  ID 110, female, 28 years, intervention 
I was worried that if I told him the truth then, he would be shocked and ask, “Mum where 
have you contracted this disease and Daddy is not alive?” so that got me so worried.    ID 126, 
female, 54 years, intervention 
Participants reported telling family and friends that they had TB, to explain weight-loss and obvious 
ill health, but to avoid people gossiping.  Secrecy was seen as the price for good relationships with 
the community:   
[In the community] we related well, because, you know, whatever issues you may have in 
your heart remain your secret. And there is no need of spilling them over to everyone for no 
reason.      ID 125, female, 30 years, intervention 
Patients often saw themselves as shamed: disliking themselves as a person, feeling unworthy, or not 
normal:   
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I was feeling isolated and I hated myself so much, I considered myself valueless and I felt like 
dying.    ID 135, female, 50 years, intervention 
Diagnosis with HIV was experienced as shameful, due to the socio-cultural associations of HIV with 
immorality and the associated stigma in this culture:   
 I was so afraid because in my entire life I never thought this disease would get me, I knew it 
was meant for some people with immoral behaviours within the community and I was living a 
straight, upright life even without a degree education.  ID158, female, 33 years, control 
Although she does not articulate exactly what she is afraid of, it is clear that this participant is 
experiencing an identity dissonance which has created fear.  Participants also experienced stigma in 
the form of open blaming and shaming from their families.  One participant reported how her 
brother had blamed her when she disclosed her HIV status, and described the associations of HIV 
with immorality: 
[He said] you went and took your own illness.  I told [you about] your husband, leave him, he 
will infect you with that illness; he likes a lot of women, now you see? Now you see?  ID 133, 
female, 40 years, control 
Participants also often blamed themselves for their diagnosis, expressing shame and guilt.  They 
expressed feeling abandoned by God, blaming God, but most often feeling shamed by the punitive 
purity codes associated with conservative religious practice:   
I felt guilty and responsible for my sickness so I felt like even if I cry to God he will never listen 
to me, but it wasn’t so.  Many people are positive and it is God who made it so.  ID 139, 
female, 42 years, intervention 
Once HIV serostatus had been disclosed, this sometimes led to the experience of discrimination and 
the exacerbation of the fears of participants who had not disclosed.  One participant described how 
this stigma affected her economic activity and ruined her business selling cakes by the road: 
They would say, “Hey, never buy buns from the lady with AIDS”. So I couldn’t do anything, I 
couldn’t sell anything – nobody would come to buy them.  ID 143, female, 36 years, control. 
Experiencing this discriminatory behaviour or enacted stigma sometimes discouraged participants 
from disclosing their status, which led to increased isolation and suffering.  Social isolation was a 
major cause of sadness; friends from before participants were sick had left, increasing their sense of 
vulnerability and isolation:   
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The way they used to talk about me, that I have this illness, and then they started isolating 
me.  At first we were together but when they knew I had that illness they started isolating me 
and that brought on the thoughts.  When I look around, I can’t find any companion.  ID 133, 
female, 40 years, control 
Some more specifically reported a lack of support in decision making and in managing their 
responsibilities, which highlighted their sense of isolation from the community:   
Let’s say, for instance, you need to eat but you don’t have the food. You look around and you 
don’t have anyone to help you. So you begin to lose … [hesitates] you feel hopeless.  ID 157, 
female, 48 year, control 
The lack of opportunity, or difficulties in securing income meant there was a lack of money to buy 
food, and therefore neither they nor their families would be able to eat well.   
Financial pressure was another oft-reported source of fear or anxiety.  Participants worried about 
their ability to meet the needs of those who depended on them, both now and in the future. 
Inability to fulfil their social roles in supporting their families or dependents, such as care taking or 
paid employment was perceived as shameful:   
Mostly, the children used to cause me distress, particularly the one who is in standard 8. Due 
to being constantly in poor health, I was wondering whether I would be able or in good health 
again to educate my children.  ID 106, female, 39 years, intervention 
Physical illness was also cited as a cause of shame, sadness and anxiety. Participants described 
sadness due to the constant burden of being ill and in pain, at seeing their children sick because they 
too were HIV positive and shame at the indignity of being physically cared for when incapacitated. 
The indignity for one woman was particularly painful: 
I thought ... these boys are bathing me and they see me totally undressed, of course, your 
heart, you persevere, but in your heart it hurts, it agonizes.   ID 133, female, 40 years, control 
Some participants reported instances of social support after they disclosed their status, for example 
the woman quoted above described how difficult she found it to receive support from a family 
member, who cared for her when she was extremely sick.  Often a young girl from the participant’s 
extended family would be sent to help with cooking, drawing water and cleaning clothes. 
Regardless of symptoms, belief in the inevitability and imminence of death was commonly expressed 
by participants and was described as a prevalent view in the community.  Five participants from the 
total of 30 that we interviewed reported that before the study began, they had experienced suicidal 
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ideation, either passively through giving up and fading away, or actively through suicide.  Two of 
these participants were allocated to the control and three to the intervention study arm.  They 
wanted to die because of their personal shame due to the discrimination they had experienced, 
stress due to ill health, suffering, financial pressures and out of a belief that there was no future for 
someone with a diagnosis of HIV:   
I had a lot of stress that affected me a lot, I lost appetite, secondly I lost the morale of taking 
my drugs and I felt wise if I could just die.  ID 077, male, 26 years, control 
.... thinking back when I used to be so ill, I saw it wise to kill myself with a rat poison 
[laughing] mixing it with a glass of water and drink it all [laughing] that was the devil in me 
advising me to do so, because there was no need staying on earth surface in so much pain 
and suffering. At times I felt like hanging myself.  ID 129, female, 43 years, intervention 
There were few reported differences in the mental health and well-being between control and 
intervention study arms at baseline.  A minority (n=4) did not report any problems with their mental 
health and wellbeing at baseline: 3 in the intervention arm and 1 in the control arm.  Triangulation of 
mixed methods data however revealed that one woman, when asked about her emotional state at 
the start of the study reported that she had no concerns or reasons to feel depressed, but gave 
some indications of distress in the quantitative measures.    
6.3.2.3. During the study 
Participant experience of and response to participation in the study is now examined by report of 
clinical benefit measured by MHSS, and by control and intervention study arm.  Participant 
explanations of their quantitative trajectories are integrated into this section of the results.   
Intervention participants reporting clinically significant benefit 
Intervention participants reported experiencing many processes of restoration or healing during the 
study.  Receiving the intervention increased their understanding of HIV, and their understanding of 
how care affected self worth, which was an empowering and normalising experience:   
Basically, through your counselling, as a matter of fact, without concealing anything, I really 
got helped. It picked me up from the ditch and placed me … [hesitates] I mean it exhumed me 
and brought me back to the world, you see what I mean.  ID 125, female, 30 years, 
intervention 
Participants were encouraged by the study nurses to see themselves as normal, just like any other 
person, which improved self esteem and self image: 
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It affected me because now I could do the things I was unable to do.  I started feeling normal, 
and I started to like myself.  All those things I never used to do.  ID 135, female, 50 years, 
intervention 
The concept of having HIV and being normal was clearly a strong message transmitted by the study 
nurses during the implementation of the intervention.  It was often mentioned by participants 
during interviews, and was described as a powerful and significant message to receive:   
I should laugh, eat, whatever am doing I should take it as normal and I will see myself as 
normal too.    ID 126, female, 54 years, intervention 
The participant quoted above contrasted the study nurse’s belief and statement that it was ‘normal’ 
to be HIV positive, with being advised to ‘behave normally’ when she received her diagnosis, in case 
people realised that she was HIV positive. 
Other participants described how their self-esteem, self worth and self acceptance were restored 
during receipt of the intervention, which positively affected their mental health and well-being: 
I started viewing myself like any other person, as you see me now, like am not sick at all I 
stopped worrying about myself and focused.  ID 129, female, 43 years, intervention 
...now I can say, “Well, this is just an affliction but there are others who are worse. ... I’m 
encouraged that this is something I can manage. It’s not like an accident or it’s not like 
anything fatal that cannot be managed ... now I feel that there is a way I can deal with 
myself. I know that if this happens, I can do this and alleviate my pain, alleviate my sufferings 
and I can take charge – I feel now I can take charge of my life and the things that I do.     ID 
134, female, 41 years, intervention 
I accepted myself, who I am and what I have in me.  ID 138, female, 40 years, intervention 
Participants often expressed their appreciation of being treated with respect and as equals by the 
study nurses, not as sick people:  
Whenever I come in here and see you I feel very happy; I feel I have seen my friends; sisters; 
so am grateful.  ID 075, female 42 years, intervention 
The sisters were so good to me and I loved them just as they loved me. And this gave me a lot 
of freedom.  ID 125, female 30 years, intervention 
This respect encouraged trust to form between participants and the study team, and reinforced the 
participants tentative rejection of stigmatising societal messages they had received, for example 
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messages that they were not worthy of equal treatment or inclusion in social activity.  Participants 
grew in strength and confidence, and increasingly rejected stigma throughout the study:   
Interviewer: and so after joining the study you stopped feeling shame and being stressed? 
Interviewee: I don’t even feel shame these days. ID 129, female 43, years, intervention 
I’m no longer scared because when I came here, I was told I can have a long life. But when I 
was there [at the CCC] I felt worthless. ID 132, female, 45 years, intervention 
Some used this increase in self confidence to disclose their status to their families for the first time, 
or to challenge family members who had excluded and isolated them due to their HIV diagnosis:  
I was scared when I first started this study, and my health was also not in a good condition 
when I started, but as I came here for the discussions I started feeling ok, because I became 
free and started living my life as normal. And when I told my family about my health, they 
also joined hands in supporting me. ID 135, female, 50 years, intervention 
Participants also described alleviation of anxiety and depression during the study.  They described 
how guidance and support from the study team and the act of disclosing and discussing their 
concerns relieved the emotional burdens they had been carrying:  
If you hadn’t taught me and been open with me, I’m very sure that I’d have given up in life. 
Right now I’m okay. I’m okay sister. I can feel it.  ID 138, female, 40 years, intervention. 
Participants began to see themselves as normal, worthy of interest and care. This relief of anxiety 
coupled with effective medication reduced physical symptoms and enabled the participants to 
reflect on their situation and begin to have hope for their future:   
Once the pain was off and … when I used to come here, we would talk with you and you 
would ask me the questions and I’d reflect back. You know, I would go over my … I’d reflect 
back, whatever that you had asked.  ID 134, female, 41 years, intervention 
Participants who had experienced suicidal ideation reported the alleviation of these symptoms due 
to the support of the study nurses: 
[The study nurse] started advising me on how to control myself during such hard time.  She 
told me to be reading the bible every time I feel like committing suicide, she even wrote a 
piece of bible verses to me and asked me to read them every now and then. Since then I have 
been so close to God and never had a bad thought again.  I dumped the rat poison in a pit 
latrine.  ID 129, female, 43 years, intervention 
Results 2: Results by objective 
155 
Control participants reporting clinically significant benefit 
Control arm participants described physical complaints which they experienced during the study, 
some of which were alleviated through care in the standard care clinic or elsewhere. The alleviation 
of these physical complaints improved their mental health and well-being, particularly when their 
ability to perform daily chores such as washing, cooking, carrying water or engaging in paid work 
were restored:   
I can do laundry for someone and he pays me, something that I never used to do. I couldn’t 
even take a bath on my own nor even eat, but right now I can light up my jiko [stove] and 
prepare a meal and eat on my own, it [participation in the study] has helped me a lot.  ID 158, 
female, 33 years, control 
Financial constraints continued to be challenging for participants during the study period.  
Temporary deterioration in psychological quality of life was attributed to financial constraints and 
the associated anxiety this caused.  Participants had no money for the medication, and the food they 
needed to heal:   
It is because of my life, considering that I have no money to take care of myself stressed me 
much.  I felt apart because even if I could be using drugs they could not help much because I 
wasn’t eating. And if the drugs weren’t working then the graph had to curve down because 
all the stress and problems over burdened me.  ID 130, female, 42 years, control 
The reimbursement for transport given to each participant was used by many for medication, food 
or to support the family.  This reportedly relieved some of the pressure associated with financial 
constraints:  
I’d get prescription from there and sometimes if I came here I’d be given something like bus 
fare. That bus fare would really help me – using it for fare and I’d use like a 100 shillings on 
the prescription. I can say that I used to benefit.      ID 107, 46 years, female, control 
Behaviour change was reported, and attributed to increased awareness of the importance of 
support, protected sex, and strict adherence to medication.  This was attributed to the persistent 
questioning from the researcher at the monthly data collection appointments. 
After joining the study I became more careful, if someone would come and tell me I look 
smart, I would say thanks, but without condom no way Sir. Love me or not we can’t have sex 
without condom because I know my own status so I control myself by using condom at my 
pleasure. ID 077, male, 26 years control 
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Many participants reported an improvement in mental health and well-being during the study which 
they attributed to participation in the trial, and in particular to the warm and open approach of the 
study team: 
Because the questions I was being asked and based on the reception I got, people were very 
free and they appreciated me – so that really encouraged me.  ID 107, 46 years, female, 
control 
I was ever sad, but when I joined the TOPCare study, everything started to resume to normal 
once again, because when I used to come here, everyone within the study was receiving me 
happily and this brought joy in my heart and I started being happy as well.  ID 077, male, 26 
years control 
One participant in particular clearly articulated how, during the study, she began to realise the 
importance of sharing her concerns, and that she was not the only person experiencing HIV 
infection.  This was a powerful experience for her, and she began to disclose her status to the people 
in the community:   
Yeah and when I started, I was … I just felt free because the first person I told my problem let 
me … [hesitates] made me to realise that they also had a problem like mine... I set myself 
free, I came to realise what I was doing … what I was thinking was wrong. Yeah after I came 
to realise that what I was doing was wrong, is when all the emotional problems ended.  ID 
143, female, 36 years, control 
She went on to access effective medication from the clinic, which relieved her emotional and 
spiritual distress as well as her physical pain.  She articulated how she realised that not being open 
about her status was destructive to her well-being, and how during the study, she grew in self 
awareness, and became more able to take care of her psychological and social needs: 
I came to realise who I am and I got to know myself better, and I came to know where I was 
getting everything wrong.  ID 143, female, 36 years, control 
Increased openness among control arm participants also led to improved social well-being and a 
perception of increasing levels of social support within the community:  
I was only close to my brother amongst my family members and because I wasn’t open to him 
either, we never had a good relationship but during the study I changed. I could go to his 
house and explain my condition to him, care free. So our relationship has revived and we are 
free to each other. ID 158, female, 33 years, control 
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Sometimes support from the family would be triggered by seeing others provide support.  One 
family, which had previously ostracised their HIV-positive member, witnessed the support network 
which had been created by the community and, feeling shamed, became more supportive.  
Participants reported surprise at the support they had received from their family and friends. 
Finding others who were also positive was an enormous source of support for many participants: 
What actually happened, from the day that I disclosed my status to my family and my friends, 
from that time, things started working for me – because they began supporting me, they 
began to be close to me and I found that we were the same and we were all sailing on the 
same boat.   ID 143, female, 36 years, control. 
Intervention participants reporting no clinically significant benefit 
As described earlier, six intervention participants reported no clinical benefit as measured by the 
MHSS, of which one reported clinically significant deterioration.   
When asked to explain why their quantitative trajectory reported deterioration in psychological 
quality of life, whether a temporary downward trend or an overall trend, all participants cited 
problems in other areas of their lives, such as unresolved physical pain, family and marital conflict, 
and financial pressures: 
Interviewer: we see here during the fourth month that you went down so fast, what 
happened here? 
Ahh!  I had stress because my daughter had a wedding ahead and we had disagreements 
with my husband over the wedding   I had to take all the responsibilities and include my 
family members to see if they could help me put things right, because I earn less at my place 
of work, so I was stressed.  ID 139, female, 42 years, intervention 
[My husband] caused me a lot of distress. Sometimes he beat me up. He would tell me that 
I’m the one who infected him with the disease. So I had a lot of troubles. That stress made me 
habitually ill.    ID 147, female, 34 years, intervention 
The illness I had in my stomach, when it starts to pain me, I lose appetite and since I don’t eat 
well I lack strength and my health deteriorate. ID 124, female, 37 years, intervention 
All participants did describe some therapeutic benefit from receipt of the intervention, which was 
sometimes captured as improvement in the quantitative outcomes, although not reaching clinical 
significance.  Those who did report some benefit described how once their physical complaints had 
been addressed, things became easier psychologically, which led to an increased sense of well-being: 
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You know once your body has relaxed you heart also settles down and subsequently 
everything gets restored.  ID 123, male, 44 years, intervention 
They described the emotional and social support they received from the study team and the comfort 
they found in realising they were not alone and isolated in their situation:  
So when I come here we talk and by the time I leave this place, I feel a little bit relieved. I 
know as long as this thing is here – I come here, I see people lining up here and feel as if I’m 
not alone. So many people are suffering from this disease.  ID 154, male, 32 years, 
intervention 
Some participants reported partial restoration of positive identity, changing from seeing themselves 
as sick because of their HIV diagnosis to opening up to the possibility that they might be able to live 
with HIV.  This involved some rejection of the concepts of being different to people who are HIV 
negative and the associated stigma: 
When I came here, I started feeling peaceful; I started feeling like a human being. I was able 
to do anything, even lifting a bag of cement, anything, I could handle any job and I started 
feeling in my heart that I can do anything such that if I got a job any time I’d be alright.  ID 
123, male, 44 years, intervention  
With the nurses, I have made me feel as if, though internally I know I’m HIV positive but on 
the other side I feel as if I’m no longer sick. I’m just like any other person out there who is not 
HIV positive because whenever I come here, I get my medicines. And I know if I take them as 
required I might have some more years to live.  ID 154, male, 32 years, intervention  
Only one participant reported a clinically significant deterioration.  This woman reported that her 
lack of employment and financial constraints were extremely preoccupying, and the cause of any 
deterioration observed:  
It was bad because I could...my mind could only think on how to get a job, how to get my 
daily meal and my life was just that way and I went on that way.  ID 124, female, 37 years, 
intervention 
She did however report that receiving the intervention was a positive experience for her, contrasting 
it with her experience in the standard care clinic, where they only give drugs and not time to talk:   
When you go to the ordinary clinics there is no time. Ah sister will sit down with you and tell 
you this and this…..they only give you drugs or push you in to see the doctor, but when you 
come here you have to talk first, you have to discuss is when…she gives you drugs, you see its 
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good when you come here because even if you have other ailment, the advice they will give 
you will make you feel much better. ID 124, female, 37 years, intervention 
 Perhaps because of the time spent talking and giving advice, she likened the experience of receiving 
the intervention to visiting the herbalist.    
It was good because when you go to the sister or a herbalist, and then he/she tells you to 
follow the instructions and everything will be ok. It’s obvious that you will leave that place 
feeling happy…so I used to leave this place feeling happy. 
ID 124, female, 37 years, intervention 
Control participants reporting no clinically significant benefit 
In a similar way to the intervention participants who reported no clinically significant benefit, the 
control participant often reported severe stressors in their lives.  Two participants reported 
unresolved physical pain, one reported experiencing what they described as a small stroke and one 
reported financial stressors and unemployment.  No participants in the control arm reported a 
clinically significant deterioration as measured by the MHSS. 
All participants reported appreciation for the study and benefit from participation.  This was usually 
because being asked questions during research assessments conveyed a sense of care and attention, 
which prompted self-reflection and self care.  Participants reported increasing in strength, self 
acceptance and understanding during the study: 
Things were just ok, because I had understood and accepted myself as I am; I was never 
ashamed any more but rather very open.  ID 97, male, 43 years, control 
It changed, I was okay because when I came here you gave me advice we talked nicely and 
you give me faith.... when I leave here also I leave with strength.  ID 133, female, 40 years 
control 
The experience of answering questions appears to have been an intimate experience, which made 
participants feel valued. 
It is because during my time in the TOPCare study, you used to ask me very important 
questions regarding my life and these are questions that I have never been asked before by 
any one since I tested positive, there is no one who have ever asked me how I feel nor how I 
live but when I came here you asked me all these. ID 159, female, 30 years, control 
The researcher’s interest in how the participants felt and how they lived was an important aspect of 
many participants’ experience of the study.   
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6.3.2.4. After the study 
Intervention participants reporting clinically significant benefit 
Participants described how participating in the study had changed their outlook on life, reporting an 
increase in enthusiasm, hope, self esteem and self worth:   
You guys, first and foremost changed my perception, to be precise. And then you taught me 
to take care of myself to live, plus, plus! ....The importance was my life. That is very 
important. The way you’ve taught me that life is more precious than the other stuff. ID 138, 
female, 40 years, intervention 
Everything started to work out… because I used to view myself like unworthy [hesitates] ...but 
when I stopped thinking it was alright…I had peaceful nights and my days were always good.  
ID 126, female, 54, intervention 
They described outward changes such as formalising relationships in marriage and joining a 
vocational training course in order to get a better job (ID 075), and beginning to make plans for the 
first time in years.  One participant described accepting her mortality and planning her legacy for 
future generations of her family: 
It’s important because I’m doing fine – though nobody will live here on earth for ever – I will 
leave my grandchildren with a place of their own where they can live peacefully and always 
say, “Our grandmother built this place for us”.  ID 132, female, 45 years, intervention 
Participants described improving in functional status, taking on work and providing for their families.  
This restoration of physical and social function was described as an important change for many 
participants:   
Since I came here and started using medicines from here, everything has now improved – I’m 
now able to dust the floor and do everything else.  I’m now well. I don’t get sick as often, I’m 
able to feed well, and there is nothing, not even worries. I’m also able to do my work as usual.    
ID 114, female, 48 years, intervention 
All of the participants in the intervention, who reported clinical benefit in the quantitative outcomes, 
described an appreciation of the study, which persisted after the study period.   
However, some participants reported that the improvements they made whilst in the study did not 
persist.  Worry, conflict at home and deterioration in physical health were cause for concern among 
the participants, as was no longer having access to effective analgesia:  
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I began using your drugs my health has been good, but now that I am back to the other clinic 
I am back to my earlier situation.... It is not good, not like when I was here.  ID 129, female, 
43 years, intervention. 
Participants reported that it was difficult to re-engage with the standard clinic.  They had to wait to 
be seen, sometimes for a whole morning, which they found difficult after the minimal wait that they 
experienced when participating in the study.  In addition, the volume of participants attending and 
the resulting time constraints meant that the interactions were necessarily shorter and focused on 
physical aspects of care.  Participants reported that they felt more judged and less supported: 
Because once I was at the C.C.C. [standard clinic] nobody used to take their time, sorry for 
saying but nobody used to take their time, umm, to teach you or at least to share with you 
your problems, you see. They just give you drugs and tell you after three months, come back. 
That’s it. They hardly take their time.  ID 138, female, 40 years, intervention 
For instance if someone dwells on one issue, such as, “Do you feed properly?” I may not be 
feeding well but you are not giving me any help, you see?  So if you ask me so and I tell you 
[they] say, “You don’t feed well and if you are not careful might contract T.B again.”  So such 
things offend me. ID 125, female, 30 years, intervention 
Other participants reported that they were able to communicate more confidently and openly with 
the staff in the standard care clinic, after the study had ended, articulating their problems and 
complaints: 
Interviewer: You’ve said that you are now bold, that you can now tell the doctor that you 
need this or that. You can now speak for yourself, why have you gained that transformation? 
Interviewee: It’s attributed to the instructions I received here – the way you told me never to 
conceal anything to myself, that I should be open and never fail to report a sickness.  ID 106, 
female 39 years, intervention 
 For some participants, specific changes, and the reasons why they experienced changes were less 
easy to identify: 
They built me psychologically and influenced the way I thought about life. I started taking it in 
another way.  ID 110, female, 28 years, intervention 
I’ve become stronger, I’m more inspired, you see. Now I can take charge. I mean I don’t seem 
to be very scared. You see … I don’t seem to be very scared now I can say, “Well, this is just an 
affliction but there are others who are worse”.  ID 134, female, 41 years, intervention 
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It has changed my thought, cleared my mind and my feelings also, I felt like one who matters 
in the society.... it made my heart stronger and I proceeded on with my normal life.  ID 135, 
female, 50 years, intervention  
They reported that they felt more optimistic and that their overall way of thinking about themselves 
had changed. 
Control participants reporting clinically significant benefit 
Participants allocated to the control also reported an increase confidence and ability to be open 
about their status, which they attributed to participation in the study:   
I came, I was received well, then we would be asked those questions but now I can see those 
questions and discussions have helped me - in the sense that if we were not having such 
forums, I wouldn’t have been helped and again I wouldn’t have had much freedom 
concerning my status. I would have continued to be timid.  ID 107, female, 47 years, control 
 After the study, many reported increased social integration; as they felt better about themselves, 
they felt better about interacting with their friends and neighbours.  Instead of hiding from visitors 
and isolating themselves, they welcomed the opportunity to interact as “normal”:  
I am a happy person right now and I pay them visits as well, I also feel that they see me living 
as normal and doing my own work without fear. Unlike before, I never used to talk to anyone 
even if they would pay me a visit and that bored them from coming but everything is normal 
right now.  ID 158, female, 33 years, control 
They reported the alleviation of emotional burdens, such that there were no longer any problems.  
Some also reported return to their previous physical and social functional status, earning money and 
maintaining their household:  
The good outcome is how I started doing my daily chores normally without any problem.  I 
was doing my simple house chores and I was also doing my business of salonist as usual, I 
had good health not bad.  ID 130, female, 42 years, control 
In addition, fulfilling their social role, whether earning money or taking care of family members, was 
made easier by experiencing less worry, and worrying less enabled them to better fulfil the role: 
It helped me because when you are not worried then you can attend to your responsibilities 
properly. You do your duties without any worries – working properly.  ID 157, female, 48 
years, control 
Results 2: Results by objective 
163 
The participant who previously described the benefits of openness during the study grew in strength 
and courage.  Although previously she had been forced to relocate her home and business due to 
stigmatisation and discrimination, she became more and more outspoken against the stigmatising 
views and discrimination she had experienced – rejecting them actively and openly.  By the end of 
the study she was working as an activist in the community, dispelling myths that HIV was caused by 
witchcraft and identifying people in the community who had not been tested for HIV and bringing 
them to the hospital for testing.  
Interviewer: And you are telling me this happened because of that time you were here with 
us? 
Participant: Yeah, that gave me the courage even to stand in front of anyone to share with 
them about myself.... I have a very good relationship because I have disclosed my status to 
them. They have even nicknamed me – you know me as [ID 143] they call me a minister. And 
do you know it’s a minister in charge of what? Minister for viruses!  And I have accepted it.  
ID 143, female, 36 years, control 
Other participants in the control arm also took on activist roles after the study finished.  In the case 
reported above, this was a new and socially approved role that she had taken on with much 
enthusiasm.  Another participant was less public, but no less confident in her new role (N.B. TB is 
often used as a euphemism for HIV as co-infection is common and having TB is less stigmatising): 
I visit a town clinic; where I normally go to take my drugs and when I get a new patient there, 
I call him sideways for a talk and advise him that T.B doesn’t kill, if you take your drugs and 
eat well you will just recover. Then I would leave them with my number and later on, they 
would pay me a visit at my place just in case they had numerous questions to ask.  I have 
realized that asking people questions in life helps them a lot, like it helped me, and I would 
also want to help people like I was helped.  ID 158, female, 33 years, control 
This participant experienced a restoration of positive identity, influenced by her physical status.  She 
had felt psychologically and physically unwell for a long time, describing herself as if she wasn’t a 
woman:   
I was so sickling and I was 30 years by then but I could not experience my periods for almost 
one and a half years - I was just like a man. But after coming here everything changed to 
normal and I can now have my periods as normal and also regained my feelings back.  ID 158 
female, 33 years, control 
Her participation in the study was a catalyst which enabled her to revert to what she saw as 
normality.  However, confidence was not sustainable for some participants, who lost the ability to 
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communicate openly when not explicitly given time to talk about their experiences or problems, 
when back in the standard care clinic:   
I feel like I have reverted to the usual situation because there is very little to talk about when I 
go there – you only talk about your pain if you are in pain, you get your medicines.  ID 157, 
female, 48 years, control 
Intervention participants reporting no clinically significant benefit 
Even though they reported no clinically significant benefit on the quantitative outcome measures, 
this group of participants expressed appreciation for the opportunity to be part of the study, and 
attributed participation with improvement in their holistic health and well-being:   
You know after recovering from this numbness, I have been able to take care of myself. I can 
do anything and this has given me the peace of mind because I can now work and make an 
income. I can do a lot of things and if I called in for some work I can now go and work even if 
it’s for a full week.  I now feel that my body is fit such that I can now lift a 50 kilogram bag of 
cement.  ID 123, male, 44 years, intervention 
Participants report difficulty engaging with the standard care clinic compared to the study nurses.  
They reported being unable to report problems in the standard care clinic afterwards, because of a 
lack of trust that they could help them resolve their issues, despite attending the clinic over a period 
of many years. 
I’m getting stressed again; reason being that he [husband] fights me all the time.... I felt that 
you are the ones who are capable of guiding me because even if I’d raise this issue with them 
… whenever I’m completely down with stress I prefer coming to talk to you.  ID 147, female, 
34 years, intervention. 
Participants cited a lack of time and inability to talk as a major barrier to creating a trusting 
therapeutic relationship with healthcare staff, which would enable them to disclose their concerns, 
and receive the support they required: 
Because – when I go there, we don’t have time to talk even though they are the same people 
I’m used to meeting every time. We don’t have time to share, but when I come to this side, 
we talk, share and if I have any problem I raise it up. ID 154, male 32 years, intervention 
Control participants reporting no clinically significant benefit 
There were four control participants who did not report clinically significant benefit from the 
quantitative outcome measures, but all reported qualitative benefit or appreciation on some level 
due to participation in the study: 
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I am so pleased with TOPCare because it gave me faith, courage and strength to convince 
myself that I am not alone in this struggle.  We are many, and because some people hide 
their situations and die early I learnt to be open and bold.  You always told me to just feel 
free.  ID 97, male, 43 years, control 
The financial reimbursement was also cited as a source of therapeutic benefit as it eased financial 
pressure in the family.  For two participants, this and talking to the researcher were the most 
therapeutic aspects of the study.  One participant described how he had grown in courage, which 
enabled him to interact with health care professional more directly.  He described the difference 
between his interactions before the study and after: 
I can’t withhold any weird feeling in my body; I have to face the doctor directly without 
hesitation. ID 156, male, 40 years, control 
Another participant describes the therapeutic process she experienced, in terms of self worth and 
hope for the future and the lasting impact of answering the questions of the researcher: 
Before joining the TOPCare study I used to think a lot, but since I came here and you used to 
ask me questions I would go home and think deeply about them; then I would see and 
convince myself that there is life beyond being sick. Because when one contracts this disease, 
he feels unworthy and sometimes I used to see no sense in living on this earth, but when I 
used to come here for the sessions and you gave me questions that got me thinking, I saw 
light beyond just being sick. ID 159, female, 30 years, control 
This extract articulates the transition many participants described or alluded to in terms of 
restoration of self worth and hope, and the way that participation in the study challenged their 
preconceived ideas about their self worth, associated with being diagnosed HIV positive.   
6.3.2.5. Independent variables 
In the quantitative findings, gender, education and wealth were associated with response to 
participation over the study period. The qualitative data from phase 2 was interrogated across these 
independent variables, looking at psychological symptoms and social problems over the study 
period.   
Gender 
 In the quantitative findings, women had worse psychological quality of life at baseline, but men 
benefited more in terms of ability to share their feelings over the study period.  Because of the lack 
of men in the sample who reported clinically significant benefit (n=1), comparison between those 
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who reported benefit and those who didn’t was not possible, so this analysis focused on the data for 
patterns in response between men and women over time.  
Table 6-16 Number and Ids of participants with clinically significant benefit by gender and study arm 
 
At entry to the study, differences were identified in the report of emotional and psychological 
problems between men and women. Women reported concern over social rejection and subsequent 
isolation, the ability to provide financially and emotionally for their children and fear, specifically 
about their health in the future.  Women also worried about their partner’s health, particularly 
partners who didn’t take their medication. They were concerned both for the health of the partner 
and worried about taking care of their partner when he became unwell:   
It used to bother me and even now it does, because we feel that if he’s taken ill, I’m the one 
who will suffer in caring for him. ID 119, female, 37 years, intervention 
All but one of the men (ID 077, who reported clinically significant benefit) reported that they did not 
experience any worry or sadness, apart from stress due to the severity and persistence of their 
physical complaints:   
There was a lot of pain on my legs, and indeed this affected my whole body making my 
situation very miserable. ID 123, male, 44 years, intervention 
Their concerns were more about the lack of cure for HIV or their material provisions.  They also 
reported acceptance of their HIV positive status. 
My worries were not because of the sickness, I was comfortable that I was positive.  ID 156, 
male, 40 years, control 
When queried about why one participant was so calm, he attributed it to trusting in God and in 
predestination (ID123).  It is difficult to extrapolate from these baseline differences whether these 
differences are between those who reported clinically significant benefit or not, or gender 
differences. 
 
Clinically significant benefit No clinically significant benefit 












107, 130, 143, 
157, 158, 
(n=5) 
075, 106, 110, 114, 119, 
120, 125, 126, 129, 132, 




108, 124, 139, 
147 
(n=4) 
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Improvement in mental health and well-being was often hindered by persistent physical symptoms 
or financial constraints, which were expressed differently across genders.  One man described how 
the anxiety of financial constraint was exacerbated by the lack of understanding displayed by other 
members of the family, who had expectations of being provided for:   
You know when you don’t have a job and you are married, you have a family, you have kids, 
meeting their expenses can sometimes be challenging, and this can also lead to a lot of 
anxieties within the family, especially when you try to explain to your wife the problems you 
are facing and she seems not to understand.  ID154, male, 32 years, intervention 
In terms of self image, women, much more than men, reported a change of perspective during the 
study period:   
Essentially, in that counselling, I was taught how to appreciate myself and never to look down 
on myself. I was also taught how to live with my children and the family in general, and that 
those things that look big and scary can be overcome. So the biggest things to me and the 
most intimidating were anxiety and stigma. So when I was told that all those amounted to 
nothing and advised to trust in God I suddenly started to see things in a clear perspective.  ID 
125, female, 30 years, intervention 
 Women often described some sort of restoration of self, of strength or of a sense of normality, 
attributed to the education and support they received through participation in the study: 
You enlightened me about this condition and the importance of my life. This made me to 
change and go back to my normal state and be like any other person. ID 106, female 39 
years, intervention 
I used to be taught that if I get sick…that I shouldn’t be troubled in my mind; I should feel 
normal like any other person and never dwell on the disease… [hesitates] as if I’m suffering in 
isolation. ID 119, female, 37 years, intervention 
Women described a process from feeling worthless and sometimes suicidal, to beginning to accept 
their situation and their HIV positive status and accepting themselves as a result:   
Interviewer: Why do you think you improved? 
Participant: Acceptance from within myself 
Interviewer: From yourself? 
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Respondent: Yeah, from within myself.  Acceptance – this is not the end. Surely, something 
good will come out of this. Surely I can do better than this. ID 134, female, 41 years, 
intervention 
They began to express compassion for others: considering how others might benefit from hearing 
about their experience and feeling concern for others who were discouraged and they described 
spontaneously counselling other HIV positive patients in positive living.  Women reported more 
incidences of stigma and shame than men; situations in which they felt embarrassed about their HIV 
positive status or avoided situations which would give people in the community cause to talk about 
them.   
I used to tell them that I have my sisters I visit at Bomu who have helped me psychologically 
and emotionally, though I would tell them that I suffered from T.B.  ID 125, female, 30 years, 
intervention 
The fear of and experience of enacted stigma, leading to shame and social isolation, was commonly 
reported amongst women. 
In summary, men reported more benefit in ability to share in quantitative terms, but reported few 
psychological or problems in the semi structured interviews.  It is possible that they were more 
reluctant to talk socially, outside of the study setting, compared with women, but found that they 
could share with the researcher, which was what was captured in the quantitative data.  The women 
reported more change in terms of self image, self esteem and positive self identity, which appears 
not to have been captured by the outcome measures included in this study.  This apparent 
divergence probably reflects the differing aspects of mental health and well-being measured by the 
differing methodological approaches. 
Education 
In the quantitative analysis, higher levels of education are associated with worse psychological 
quality of life and worse ability to share over the study period. 
Table 6-17 Distribution of clinically significant benefit across education and study arm in phase 2 
 Clinically significant benefit No clinically significant benefit 
Control Intervention Control Intervention 
Primary school 




075, 106, 114, 119, 125, 
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Amongst those who reported clinically significant benefit, those who had attained secondary school 
level education or higher reported increased openness as a valuable aspect of their participation.  
They appreciated the time and attention given to facilitate open exchanges between the study team 
and participants, and felt empowered to take charge of their healthcare: 
Now I feel that there is a way I can deal with myself. I know that if this happens, I can do this 
and alleviate my pain, alleviate my sufferings and I can take charge – I feel now I can take 
charge of my life and the things that I do. ID 134, female 41 years, intervention 
Those with less education reporting clinically significant benefit spoke more often about the 
importance of normalisation.  The palliative care nurses and the study team treated all participants 
with a non-judgemental attitude, warmth and acceptance; therefore those who received the 
intervention were regularly advised to see themselves as normal: 
They told me to talk my condition as a normal situation.  I shouldn’t be shocked. They said I 
should conduct myself like I used to.... and I should never feel different. So whenever I used to 
come here, they used to advise me on the same and I said to myself if this is how it is then I 
should not have any worries aha, so I stopped worrying at all. ID 126, female, 54 years, 
intervention  
Those in the control study arm appreciated the warmth and openness with which they were treated, 
which made them feel supported and worthy of support: 
In fact I liked the way you’d ask me how I was feeling and then I’d explain to you how I was 
faring. I really felt good – I’d feel the sense of liberation. And that made me cheerful. Because 
… [hesitates] you know sometimes you could just be there, in pain, or in distress or something 
of the sort and you don’t even have anyone to ask you, “How are you feeling?” ID 157, female 
48 years, control 
Participants with less education who did not report improvement reported persistent problematic 
physical symptoms, lack of social support and financial concerns:  
My health condition was ok, but then my only companion who was my mom felt sick, So I got 
confused because we were both sick and I was helpless.   It is at this point that my health 
started dropping down.  ID 97, male, 43 years, control 
That was brought about by stress, you know [I] am jobless and when I sit at home, I only think 
on how to get money and how I will be helping myself, that’s where the problem comes 
from....eeh...lack of job and basic needs in the house, my mind never settled. ID 124, female 
37 years, intervention 
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 Participants with secondary school education or more who did not report clinically significant 
benefit reported difficult life circumstances, such as marital discord or more commonly 
unemployment and financial concerns: 
Actually we had a problem with his [her son’s] dad.... He just turned to be a drunkard and I 
didn’t want that. He doesn’t care about taking care of the kids and what not.  So  ID 108, 
female, 37 years, intervention 
One of the major issues that I had at that time was financial constraint. I had suddenly lost 
my job following an unforeseen shakeup at my then workplace. I had no choice but to run 
here and there looking for a job. ID 154, male, 32 years, intervention 
The qualitative data does not clearly appear to explain why those with more education reported 
worse psychological quality of life and worse ability to share over the study period.  In the 
intervention study arm, those with more education attributed more importance to openness and 
equal exchange with the staff.  Those with less education attributed more importance to the 
normalisation of HIV.   
Wealth 
In the quantitative analysis, the wealthiest participants reported improved psychological quality of 
life and decreased psychiatric morbidity over the study period.    
It is important to note that although some participants were relatively better off they were still poor 
compared with others in Kenyan society, and still experienced financial constraints.  Qualitative data 
were interrogated for patterns comparing these groups, amongst those who reported benefit and 
those who did not. 
Table 6-18 Distribution of clinically significant benefit across wealth and study arm in phase 2 
 Clinically significant benefit No clinically significant benefit 
Control Intervention Control Intervention 
Lower 
wealth 
077, 130, 143,  
(n=3) 
075, 110, 120, 126, 








107, 157, 158, 
(n=3) 








Amongst participants who reported clinically significant benefit, there were few major differences in 
terms of problems and symptoms between those who were more or less wealthy.  Those less 
wealthy in both the control and intervention study arm more often reported appreciation for the 
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reimbursement for transport, which they used for school fees, food and other necessities.  This 
alleviated financial pressure and enabled them to concentrate on their well-being: 
During the times I used to come here and you gave me that [financial] support…I was thinking 
that now that I have gotten this support, what should I do to improve my health further so I 
started concentrating in order to get myself from that stress.  ID 130, female, 42 years, 
control 
Amongst those with higher levels of affluence, those who reported no clinically significant benefit 
reported more financial difficulties and appreciation for the transport reimbursement more often 
than those who reported benefit.  They also reported stressors in their social and familial life, such 
as marital discord or familial rejection due to their HIV diagnosis:  
I felt as if now my family had, you know, abandoned me.  Then after a while, my mother 
accepted the truth of the matter... and from that time onwards, any time I have a problem 
and call her she always chips in. If I need any assistance from my family they also chip in.  ID 
154, male, 32 years, intervention 
Those who were relatively less affluent reported persistent physical complaints, which they 
perceived prevented them from improving in other areas. 
6.3.2.6. Summary of qualitative longitudinal response 
The findings from the qualitative data analysis of participant experience and longitudinal response to 
participation in the study, in terms of mental health and well-being will now be summarised, 
followed by a discussion of the barriers and facilitators to therapeutic benefit. 
Before the study 
At baseline many participants reported fear.  Fear was health related, associated with ignorance and 
lack of adequate knowledge about HIV, mistrust of heath care professionals and medication and of 
the social consequences of disclosure of their HIV positive status – potential rejection and 
discrimination.  Participants also reported shame associated with their diagnosis of HIV and the 
blame they experienced from those in their community, from whom they did not receive acceptance 
or integration.  This social rejection and isolation caused sadness and reduced their social capital 
expressed through social support which further exacerbated their financial burdens.  This also 
caused significant stress and anxiety.  Participants were anxious about their ability to provide, 
fulfilling their social role both financially and socially for their families, both now and in the future.  
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Persistent physical illness was also cited as a source of anxiety and sadness, causing some to lose 
hope and express suicidal ideation. 
During the study 
During the study, those who reported benefit in the intervention arm described how they were 
empowered by the normalisation of HIV they experienced through their participation in the study.  
This normalisation positively affected their self esteem, self image and self confidence.  They 
described how important it was that they were treated with acceptance and respect, which 
alleviated their sadness and anxiety, and improved their self image.  They also described how 
receiving the right medication which addressed their physical complaints eased their psychological 
concerns that they would not be able to get better.  The control group appear to emphasise the 
associations of physical and psychological problems, describing how the conversations they had with 
the researcher when completing the outcome measures relieved their emotional burdens, which in 
turn reportedly relieved the burden of physical complaints.   
Those who did not report clinical benefit, in both intervention and control study arms reported 
intractable physical, social or financial problems, particularly those which meant that they could not 
fulfil their social roles, which directly or indirectly led to financial difficulties.  This in turn led to 
stress which was a barrier to positive mental health and well-being.   
Participants in the intervention arm, even when they did not report clinically significant benefit, 
described appreciation for the compassionate approach they perceived in the study team.  They 
appreciated being listened to, and the time taken to examine all aspects of their lives in a holistic 
way.  The control patients reported how important it was for them to have a forum to discuss how 
they lived and how they felt, how the care, attention and social support they perceived from the 
researcher prompted them to take better care of themselves.  They also described how the 
openness with which they were treated helped them also to be more open, and express themselves 
more freely. 
Longer term effects of participation 
After the study, those who reported clinical benefit in the intervention arm reported increased 
motivation and sense of hope: making plans for the future and considering their legacy.  They 
described the effect of improvement in their physical and social function and their appreciation of 
being able to fulfil their previous roles.  Those in the control arm reported increased self-confidence 
and ability to talk openly, which increased their opportunity for social interaction and decreased 
worry through sharing their emotional burdens.   
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Participants in the intervention benefitted from being reassured that they were normal: particularly 
those who were less well educated.  This appears to have been an important component of the 
intervention: being told that they should see themselves as normal and not sick, and being treated 
with respect, and not as stigmatised individuals.  
Whether they reported clinical benefit or not, all intervention participants described their 
dissatisfaction with the care they received in the standard care clinic in terms of interactions and 
opportunity to share emotional burdens.  They noticed the lack of therapeutic relationship in this 
context, which they attributed to a lack of available time to talk.  Participants in the control group 
described how they missed the opportunity to think and talk about their burdens as the study was 
now over. 
Those in the intervention group who did not report clinical benefit described how their holistic well-
being had improved and remained positive.  Participants in the control arm described how they had 
continued to feel free as they were instructed during the data collection sessions, and had increased 
in courage and hope as a result of their participation. 
Feeling free was a concept which was often mentioned by both study arms, and was a term used by 
the researcher when encouraging the participants to respond openly and honestly when completing 
the patient reported outcome measures.  It is possible that this term “freedom” was remembered 
and reported in the semi structured qualitative data interviews, because it did not appear to be a 
familiar concept in the lives of the participants.   
 
Model of barriers and facilitators to therapeutic benefit 
During analysis of the qualitative data to address this objective, associations emerged between the 
descriptive phrases participants used to describe well-being, which had been collated into the simple 
model of the participants understanding of the concept of well-being (Figure 33).  These associations 
highlighted the barriers and facilitators to therapeutic change experienced by the participants during 
participation in the study.   
For example, participants frequently reported that those who were ‘well’ had access to food and 
could eat well.  They described how those who were ‘well’ were able to work or had adequate 
financial support.  Through analysis of the participant experience, it became apparent that these two 
aspects of wellness were connected; if the family had adequate food to eat, it was seen as an 
outward sign that the provider of this family was fulfilling their social role, through paid employment 
or securing other financial support.  Eating well was also associated with physical well-being and 
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having the physical capacity to work, and therefore provide for the family.  Being unable to fulfil 
their social role was extremely distressing for many participants, and was associated with worry and 
sadness:   
Because, now I was weak, I couldn’t work. There was nothing that I could do for myself. I had 
to depend on somebody to do everything for me. And when they wouldn’t do it fast I’d get 
snappy and I’d get very annoyed you know... Because they were not doing it the way I’d want 
it done or the way I’d do it. So I’d feel, you see – they are looking down on me.  ID 134, female 
41 years, intervention 
The model was therefore modified to make the identified associations clearer.  Descriptive phrases 
which concerned similar aspects of a concept were combined and associations were inserted into 
the model using arrows to indicate direction (Figure 34).  Through identification of these themes and 
associations, the model consolidates and presents the facilitators and barriers to therapeutic 
benefit. 
In the model, descriptive phrases relating to physical well-being are presented in green rectangles, 
social well-being in blue diamonds and socio-relational and individual well-being in yellow circles.  
Financial support, which intersects with physical and social contributors of well-being, is presented 
in a red box.  This model appears to suggest a process of therapeutic benefit which echoes Maslow’s 
hierarchy of need: physical needs must be met first, which enable the fulfilment of social role which 
contributes to positive self image and mental health and well-being (364).   
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Figure 34 Facilitators and barriers of mental health and well-being during participants experience of the study 
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Poor physical health was described as a barrier to positive mental health and well-being.  This was 
explained by fears of future ill health and the implications this might have on the participant’s ability 
to fulfil their social role, whether that was care taking in the home or earning a living in paid 
employment.  Fulfilment of social role was also associated with feeling socially integrated and 
accepted, and also to positive self image.  Positive self image was associated with feeling open and 
shame free, accepting oneself and one’s HIV positive diagnosis and being treated with and feeling 
worthy of dignity and respect. 
6.3.3. Summary of quantitative and qualitative findings 
Improvement in mental health and well-being during the study period was dependent on the 
resolution of physical, social or financial concerns regardless of participant study arm.  Those who 
had overcome these reported improved mental health and well-being.   
Those whose physical problems were not addressed continued to suffer, reporting fear that they 
would not improve, and concern regarding their lack of understanding of why they continued to 
experience pain and symptoms.  Those who experienced social problems such as gender-based 
violence or rejection from their families continued to experience poor mental health and well-being.  
Those who benefitted from couples counselling during receipt of the intervention, or who 
challenged the stigma and discrimination they were subject to, experienced improved mental health 
and well-being.  Those who experienced continued financial constraint continued to experience poor 
mental health and well-being. 
Men reported fewer mental health concerns on recruitment; and appeared to be more comfortable 
with their HIV positive status.  This confirms the quantitative finding, that women had more 
psychological and social problems at baseline.  Quantitative data identifying increased ability to 
share over time in men compared with women was not explicitly explained by the qualitative data. 
Participants with more education appreciated the openness with which the study team interacted 
with the participants, whilst those with less education reported more appreciation from being 
reassured that they were normal, regardless of their HIV positive diagnosis. 
All participants reported experiencing financial constraint.   
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6.4. Objective 4  
To identify and explore the existence of “active ingredients” and mechanisms of action of the 
intervention and therapeutic aspects and processes of study participation.  
6.4.1. Components of palliative care delivered as part of the intervention 
A comparison of service receipt data by control and intervention study arms is depicted in a bar 
chart (Figure 35). 
Figure 35 Bar chart of participants who ever received components of care, by study arm 
 
This graph shows that those in the intervention arm appeared to have received more emotional 
support from staff, time to talk to staff about worries, visits from their pastor or imam, discussion 
about spiritual worries, emotional support for their families, skin disorder medication, discussion 
about the future, planning ahead for family, weak opioids, prayer with staff and constipation 
medication.  All variables were analysed to identify statistically significant differences between 
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X2 test and 
p value 
Visit from spiritual leader 63.3 (38) 68.3 (41) X2=0.33 p=0.56 
Discussion about spiritual worries 57 (34) 95 (57) X2=24.1 p<0.001 
Prayer with staff 12 (7) 25 (15) X2=3.56 p=0.06 
Emotional support from staff 80 (49) 100 (60) 
Fisher’s exact 
p<0.01 
ART adherence counselling 92 (55) 98 (59) 
Fisher’s exact 
p=0.21 
Time to talk to staff about worries 80 (48) 98 (59) 
Fisher’s exact 
p<0.01 
Emotional support for family 55 (33) 98 (59) 
Fisher’s exact 
p<0.01 
Discussion about pain 97 (58) 100 (60) 
Fisher’s exact 
p=0.50 
Discussion about symptoms 98 (59) 100 (60) 
Fisher’s exact 
p=1.00 
Non-opioid – paracetamol 100 (60) 98 (59) 
Fisher’s exact 
p=1.00 
Weak opioid – codeine 18 (11) 60 (36) X2=21.9 p<0.01 
Strong opioid – morphine 0 (0) 5 (3) 
Fisher’s exact 
p=0.24 
Help with breathing problems 83 (50) 75 (45) X2=1.26 p=0.26 
Anxiety medication 80 (48) 67 (40) X2=2.72 p=0.10 
Nausea medication 88 (53) 88 (53) X2=0.00 p=1.00 
Skin disorder medication 48 (29) 57 (34) X2=0.84 p=0.36 
Diarrhoea medication 18 (11) 22 (13) X2=0.21 p=0.65 
Constipation medication 12 (7) 27 (16) X2=4.36 p=0.04 
Discussion about future 22 (13) 67 (40) X2=24.6 p<0.01 
Planning ahead for family 22 (13) 65 (39) X2=22.9 p<0.01 
Nutrition support 18 (30) 18 (30) X2=0.00 p=1.00 
Financial support 7 (4) 5 (3) 
Fisher’s exact 
p=1.00 
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Statistically significant differences are evident between control and intervention study arm in 
discussion about spiritual worries, emotional support from staff, time to talk to staff about worries, 
emotional support for family, receipt of weak opioids, discussion about the future and support for 
the family in planning for the future.  All differences benefit the intervention arm.  Other than 
receipt of weak opioids, all variables indicate that the intervention group received more social, 
spiritual and emotional support. 
6.4.2. Active ingredients 
Active ingredients were identified through analysis of data from phases 1 and 2, the results of which 
are reported consecutively below. 
6.4.2.1. Phase 1 Quantitative data analysis to identify active ingredients 
Statistically significant associations between components of care and mental health and well-being 
in intervention arm participants are shown in Table 6-20.  As presented in Figure 35 and Table 6-19, 
almost all intervention group participants reported receiving emotional support from staff, ART 
adherence counselling, time to talk to staff about worries, emotional support for family, discussion 
with staff about pain and discussion about physical symptoms.  Due to this co-linearity, analysis of 
these variables was not possible.   
All of the participants who received discussion about spiritual worries, non-opioid analgesia, strong 
opioid analgesia and anti-emetics during the study period reported either high or low AUC for as a 
whole group, and therefore this analysis was unable to produce a valid odds ratio due to insufficient 
variation.  This is indicated with a ‘-‘ in the table.  This analysis indicate that all participants who 
received discussions about their spiritual worries reported high levels of psychological quality of life, 
low levels of psychiatric morbidity and low levels of ability to share feelings.  All participants who 
received paracetamol reported high levels of psychological quality of life, low levels of psychiatric 
morbidity and worry, but low ability to share feelings.  All participants who received morphine 
reported low levels of psychological quality of life, high levels of psychiatric morbidity and low ability 
to share feelings.  All participants who received anti-emetics reported high levels of psychological 
quality of life.  
The analysis also found a statistically significant association between a visit from a spiritual leader or 
receipt of codeine and increased odds of improved ability to share feelings with friends and family 
over the study period. 
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Table 6-20 Logistic regression for effect of receipt of each component of palliative care using AUC data  
Component of care 
Odds ratio, (95% confidence interval) and p value (n=54) 
MHSS AUC GHQ AUC APOS worry AUC APOS share AUC 
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The finding that a visit from a spiritual leader increases the odds of participant reporting high ability 
to share over the study period, whilst discussion about spiritual worries was associated with 
decreased ability to share is surprising and difficult to explain.  It would be expected that discussions 
with a spiritual leader would be about spiritual concerns and therefore the outcomes of the 
discussions would be the same regardless of where they were held.  It is possible that this is a 
chance finding. 
The other finding from this analysis which is interesting is the association between poor mental 
health and well-being and receipt of morphine.  Further examination of the data revealed that there 
were five prescriptions for morphine administered during the study period to three patients, one of 
whom was terminally ill and died before study exit.  It is important to also recall that this analysis is 
cross sectional and therefore no direction of causality can be suggested.   
6.4.2.2. Phase 2 Qualitative data analysis identifying the active ingredients 
of the intervention  
Three active ingredients were identified in the qualitative data: insight and understanding, taking 
time to talk, and medication.  These are discussed in turn with their associated mechanism of action. 
Insight and understanding  
The concept of insight and understanding was the most often cited active ingredient and was a 
major theme in the data with two sub themes: health education and counselling.  These sub-themes 
were often difficult to disentangle, as the terms appeared to be used interchangeably by some 
participants.   
Effective counselling was mostly concerned with what the study nurses termed “prevention with 
positive living”.  This is a component of the Kenyan care programme for PLWH, and encompasses 
advice on how to live with a diagnosis of HIV in a positive way.  Prevention with positive living also 
included basic guidance on reducing sexual transmission of the virus and how to interact with the 
community and with family regarding disclosure and management of discrimination:  
What benefited me most was the guidance on how to live positively, commitment to church 
and being prayerful. That I should always pray when faced with difficulty, eat well and will 
have a long life.  ID 132, female, 45 years, intervention 
Together with the study nurses, the participants were able to identify and address substantial unmet 
health education needs during the delivery of the intervention:   
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They counselled me and told me that it was important to observe my health status, especially 
on proper feeding. They also talked to me about sexuality and about my family.... It kept on 
improving because there were many things that I had not known about that the nurses 
taught me.  ID 120, female, 36 years, intervention 
The nurses helped me; yes, my needs were met because my needs included the need for 
advice; the importance of taking my medication.  ID 75, female, 42 years, intervention 
I was wondering what to do because she would insist, “Try to eat as much as possible, 
whatever is available. You don’t have to force yourself but little by little, make sure you don’t 
go hungry”. So I purposed to be keen on feeding well especially on food items known for 
boosting the blood in the body such as fruits – I fully devoted myself to the practice and by 
the time I was coming back the next time, everything was going up, up.  ID 125, female, 30 
years, intervention 
Having this information enabled the participants to make informed decisions regarding their 
healthcare: 
Initially, I didn’t take medicine at the right time. But when I came here, they told me that I 
needed to take medicines at the right time because that would help me. Then I ought to eat 
well, do some exercises, read the Bible and I’d live longer.  ID 110, female, 28 years, 
intervention 
Finally, participants described how, increased information increased their capacity to manage their 
own condition, and increased their belief in their own ability to cope: 
The questions that you [researcher] used to ask me have improved my physical well-being in 
such a way that when I come here, let’s say I talk to the other [study] nurse, we discuss more 
about the HIV epidemic.  I may be asked questions such as what leads to a person being 
infected and how to prevent. We’d also talk about the moral support I used to receive from 
you people.... I have made me feel as if, though internally I know I’m HIV positive but on the 
other side I feel as if I’m no longer sick. I’m just like any other person out there who is not HIV 
positive because whenever I come here, I get my medicines. And I know if I take them as 
required I might have some more years to live. ID 154, male, 32 years, intervention 
Mechanism of action: adequate information 
Having adequate information through increased insight and understanding empowered the 
participants to take their medications as prescribed and make decisions which would benefit their 
health.  It also reduced negative psychological symptoms such as sadness and fear, arising from a 
lack of knowledge of what they might face in the future.   
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Respondent: I was no longer anxious 
Interviewer: What freed you from anxiety? 
The advice that you gave me when I came here, such as about this disease – whether it would 
last or not last.... whether the disease is for life or not.ID 119, female, 37 years, intervention 
But after coming here, the advice that you gave me really supported me. I started thinking 
positively about my life and believed that I could have a long life.  ID 110, female, 28 years, 
intervention 
Having access to the information they need to look after themselves, was associated with alleviation 
of depression and fear: 
I was in depressive moods but later, owing to the constant guidance you gave to me and my 
realization of the worthiness thereof, I started getting committed in my mind and adhering to 
your instructions.  ID 106, female, 39 years, intervention 
Yes I used to cry... it used to seem like the end of the world to me [laughing]... But I came here 
and got good advice from you...ID 129, female, 43 years, intervention 
Counselling is available also in standard care, and it is interesting to consider why the provision of 
information was effective in palliative care but not in standard care.  I will return to this point in 
section 7.3.2.1. 
Medication 
Long standing symptoms such as numbness or pain resolved during receipt of appropriate 
medication through the intervention care package.  Relief of physical pain and distress contributed 
to an overall reduction of holistic distress, and a return to previous levels of physical and social 
function: 
Whenever you found me to be sick, you got me the required medication free of charge. That 
helped me and kept me going for a long time and I started appreciating myself again, you see 
what I mean? From that time my problems eased and from around half a month to a month 
and a half, I started to feel like I had resurrected. I felt like I’d come out of the grave. ID125, 
female, 30 years, intervention 
It is not clear whether the medications prescribed as part of the intervention care package were 
previously unavailable or inappropriately prescribed by the standard care clinic.  It could also be 
hypothesised that health education meant that medications were better understood and regimens 
therefore better adhered to:   
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I was distressed but I came here and was put under medication, got better and went on well 
with my work. Right now I have no problem at all and I feel that my life is much better.  I was 
helped with guidance, counselling and on the importance of sticking to medication … and I 
got healed.  ID 132, female, 45 years, intervention 
Mechanism of action: symptom relief 
Being pain- and symptom-free and experiencing physical health, meant participants could 
increasingly care for themselves and were able to earn a living and provide for their dependants, 
which alleviated stress and contributed towards their positive self-image. Participants reported that 
access to non opioid and mild opioid analgesia was associated with improvements in mental health 
and well-being:   
If I came for treatment, say today, for a new case, I think after giving me the medicines I’d be 
relieved the following day.... Yes, I’d be relieved. It didn’t persist.  ID 119, female, 37 years, 
intervention 
The pain eased because of the drugs that I took – the ones that I was given. They cleared off 
the numbness and once that was over the exhaustion also gave way...  But since I recovered 
from that numbness, I can now move around, I can go to work and I can do anything.  ID 123, 
male, 44 years, intervention 
Restoration of physical health also contributed to the process of normalising HIV infection, which 
improved mental health and well-being: 
To me, that was the most important thing because when I came here, my legs got well again 
and I started working, I felt like a normal human being.  ID 123, male, 44 years, intervention 
Taking time to talk 
The third active ingredient was taking time to talk.  The increased time to talk to the study nurses, 
helped the participants to articulate their needs, which meant that the advice they were given was 
more personalised, more often addressed the root cause of the symptom, and was therefore more 
therapeutic:  
I think I am better because I was listened to; I was helped.  I was given advice and so I left 
with something.  ID 108, female, 37 years, intervention 
The additional time the study nurses were able to spend time with the intervention participants 
compared favourably with the experience in the CCC, where increased patient numbers unavoidably 
means reduced patient-staff contact time:  
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When I go there [CCC], we don’t have time to talk even though they are the same people I’m 
used to meeting every time. We don’t have time to share, but when I come to this side, we 
talk, share and if I have any problem I raise it up.  ID 154, male, 32 years, intervention 
Here, we have more time with them; they will not see you in a hurry like the other place [CCC] 
because there are other people waiting; here you will be seen; you will explain your problem.  
ID 108, female, 37 years, intervention 
Time spent with the study nurses was structured according to the assessment sheets designed to be 
used as a guide to holistic assessment.  It is also possible that the time spent with the study nurses 
was therapeutic, because this time was structured according to this assessment.   
Mechanism of action: articulated concerns 
The mechanism of action of this active ingredient was that participants concerns were more clearly 
articulated, which enabled the study nurses to gain a greater understanding of the problems and 
increased the chance of them being addressed:   
There is a difference because here you have a lot of time to be with the doctor, to talk to 
him/her and to have them instruct you. But on the other side, not that the nurses are 
unwilling, but you personally feel condemned and say, “Ah there are others who are waiting 
to come in”. So you may be having issues that you’d want addressed but you feel, “Ah, I’ll 
raise when I come next time”. But here you feel free to ask anything without any problem.  ID 
120, female, 36 years, intervention 
As a result of being properly listened to, the nurses’ advice and the treatment prescribed was more 
personalised, appropriate and more effective: 
When you go to the ordinary clinics there is no time a sister will sit down with you and tell you 
this and this…..they only give you drugs or push you in to see the doctor, but when you come 
here you have to talk first, you have to discuss ….. You see it’s good when you come here 
because even if you have other ailment, the advice they will give you will make you feel much 
better.  ID 124, female, 37 years, intervention 
Their interactions with staff were therefore more fruitful, and addressed educational needs in a 
more targeted way, which affected physical and mental health and well-being.   
6.4.2.3. Summary of active ingredients   
Findings from analysis of the CSRI data from phase 1 showed that participants in the intervention 
study arm received more emotional support for themselves and their family, time to talk about their 
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worries (including the spiritual) discussions about the future and support for planning for their family 
in the future.  They also received more weak opioids (codeine) than those allocated to the control 
arm.  Further analysis identified statistically significant positive associations between the receipt of 
paracetamol, codeine and anti-emetics on components of mental health and well-being and a 
negative association with receipt of morphine.   
Discussions of spiritual worries appeared to be positively associated with psychological quality of life 
and negatively associated with psychiatric morbidity (both indicating improvement in well-being).  
Surprisingly, the association between discussion of spiritual worries and ability to share was 
identified as significant and negative, whereas a visit from a spiritual leader was significant and 
positive. 
Analysis of phase 2 qualitative data identified three active ingredients and the mechanism of their 
action.  These were increasing insight and understanding, which addressed unmet health 
information needs, medications, which relieved physical symptoms and taking time to talk, which 
helped participants articulate their concerns, enabling the nurses to tailor responses more 
appropriately to address participant problems.  
These mixed method findings converge with strong evidence to suggest that medications such as 
analgesia (paracetamol and codeine) and anti-emetics are associated with benefit in terms of mental 
health and well-being.  Table 6-19 shows that whilst almost all participants received paracetamol, 
more participants in the intervention arm received codeine.  This suggests that stronger analgesia is 
necessary in the medical management of these patients, and effective pain management has a 
beneficial effect on mental health and well-being.   
All but one intervention participant received all psychosocial components of care, including time for 
discussion and provision of emotional and social support, although their effect on the outcome 
measures was not able to be analysed in the quantitative data analysis. Time to talk and insight and 
understanding were found to be associated with benefit in the qualitative findings, suggesting that 
health education and counselling and time to talk are important active ingredients of the 
intervention. 
In summary, the active ingredients of the intervention identified through analysis of quantitative and 
qualitative data are effective medication, including analgesia, the provision of effective health 
education and counselling and increased taking time to talk:   
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Nobody had the time and chance to talk to me about how to take my drugs in a better way. 
So when I came here, you guys – what can I say? You counselled me and you taught me how 
to use my drugs in a better way.  ID 138, female, 40 years, intervention 
6.4.3. Therapeutic aspects of participation 
Analysis of the data from phase 2 of the study showed that participants in both intervention and 
controls groups reported benefit from participation in the study.   
These five themes which emerged during the analysis of qualitative data are described as 
therapeutic aspects of participation: compassionate care, the therapeutic benefits of talking, social 
support, patient reported outcome measures (PROMs) as prompts and material support.  They were 
often expressed slightly differently by participants allocated to receive either the standard care or 
intervention care package, therefore the similarities and differences between participants accounts’ 
from each study arm will be identified and discussed in the narrative report which follows along with 
their associated therapeutic process. 
6.4.3.1. Compassionate care, social support and communication 
These three therapeutic aspects of study participation were found, on closer examination, to be 
associated with the same therapeutic process, i.e. they exert their therapeutic power in a similar 
way, through trusting relationship.  For this reason, they will be reported consecutively in one 
section followed by a description of the action of the therapeutic process of trusting relationship. 
Compassionate care 
Compassionate care encompasses two sub themes: feeling treated well and being known.  The 
perception of the study team as compassionate appeared to be grounded in the non-judgemental 
attitude of the team members, which participants interpreted as openness and supportiveness.  This 
is well articulated by a woman allocated to the intervention arm:  
Interviewer: Why do you think this happened, like why were you able to open up? 
Respondent: The attention I received, the care, I mean, I would say the attention that I first 
received and the care. ID 134, female, 41 years, intervention,  
The graphic representation of the distribution of text extracts coded at the two sub-themes 
presented in Figure 36 shows differences in the way intervention and control participants 
experienced compassionate care.  It is important to note in the interpretation of this percentage 
stacked bar chart, and the ones which follow, that this is the total percentage of text extract coded 
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at a theme, and does not represent all participants included in the sample.  The chart is provided to 
indicate the relative importance of each sub-theme for participants, by study arm. 
Figure 36 Distribution of text extracts for sub-themes of compassionate care, by study arm 
 
Feeling treated well 
As shown in Figure 36 the most frequently reported aspect of compassionate care was appreciation 
of being treated well, which was described as being treated and spoken to in a caring, friendly, warm 
and respectful way: 
I used to be soothed such as being treated well, I mean I felt esteemed, that people here 
regarded me and treated me with respect.  ID 106, female, 39 years, intervention 
You’d feel that they were really caring. They were concerned, they were happy to see you – 
it’s not like you were a bother. It was not like it was something too big – like you were 
bringing in problems; no it was about helping one another. You see (hesitates) … I would look 
forward to, “Tomorrow I’m going to the clinic, yes, yes …”  ID 134, female, 41 years, 
intervention 
The way you treat people, talking to people nicely and knowing how they are proceeding 
health wise, so many things that make one feel better already.  ID 129, female, 43 years, 
intervention 
This view was also expressed by participants in the control: 
Another thing is the way you handle patients. For instance one may come here broken 
hearted and feeling down but you would encourage and give him the best, so many things 
contributed to this change.  ID 158, female, 33 years, control 
Control patients (n=18 
text extracts) 
Intervention patients 
(n=32 text extracts) 
Feeling treated well 12 29 
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So when I came here I feel it really helped me because I found … [hesitates] that day, I found 
people who were very free and they talked to me very nicely. The way I was received – I really 
appreciate.  ID 107, female, 46 years, control 
Intervention arm participants described the welcome they received from the study nurses as 
important to their well-being: 
Personal touch, the way they would welcome me, the way they would welcome you and 
you’d feel at home you know. You’d feel that they were really caring. They were concerned, 
they were happy to see you – it’s not like you were a bother.  ID 134, female, 41 years, 
intervention 
The care they received increased their sense of being at ease and that they were not a problem 
which was therapeutic: 
You know, whenever I came here I would feel at peace, you know. Not like some places you’d 
go and feel unsettled. Here you’d come and feel at home.  ID 138, female, 40 years, 
intervention 
Being known 
The perceived interest that the study team took in the health of the participants was noted, 
particularly by those allocated to the control arm.  They appreciated having someone check on their 
progress, and take an interest in their problems: 
There’s one thing that I have liked about this research, and that is when you would want to 
know about the progress of my health. That motivated me and made me to feel good.  ID 
157, female 48 years, control 
The most important thing is the way you were concerned with my life and daily activities, you 
used to ask if I have attended the clinic and so forth. And again the fact that the TOPcare 
study team is interested in knowing our progress as the patients is important to me as well. 
ID 158, female, 33 years control  
Compassionate care helped the intervention participants concentrate on expressing themselves, 
without fear of recrimination or negative reaction.   
Social support 
Social support was described as a therapeutic aspect of participation, with sub-themes of support 
from religious practice, peers and study team.   
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Figure 37 Distribution of text extracts for sub-themes of social support, by study arm  
 
From religious practice 
The importance of support from religious practice was described much more frequently by the 
intervention arm participants (cited by one control arm participant).  They described the 
connectivity and social engagement of religious practice as very helpful.  The study nurses 
encouraged the participants to engage in religious practice as part of the intervention, encouraging 
the participants to seek support from pastors or imams, attending public services if possible and 
read scriptures and pray in private:   
You know the other sister used to share the scriptures with me - from the book.   Yes, the 
Bible, as she read the word, those many thoughts I used to have would vanish from my 
mind....The pain also eased... Yes, I got relieved.  ID 144, male, 32 years, intervention 
Some participants reported attending services and feeling benefit from the social connectedness to 
their church family, or reading the Bible or praying and feeling connected to the Divine.  This 
connection was a source of comfort and of strength:   
[Now] I go to church always. It has helped me because whenever I go to church I feel happy 
and peaceful.  ID 126, female, 54 years, intervention 
From peers 
Befriending peers as a result of participation in the study was important for many participants, but 
more frequently for those in the control group.  They began to see that there were many people 
who had experienced similar things to them, from the diagnosis and medical care to stigma and 
discrimination.  As a result of increasing courage which she attributed to participation in the study, 
Control patients (n=11 
text extracts) 
Intervention patients 
(n=22 text extracts) 
From religious practice 1 14 
From peers 6 1 
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one participant described how she had disclosed her HIV positive status, which led to the discovery 
that she had peers. 
What actually happened, from the day that I disclosed my status to my family and my friends, 
from that time, things started working for me – because they began supporting me, they 
began to be close to me and I found that we were the same and we were all sailing on the 
same boat.  ID 143, female, 36 years, control 
Participants reported increasing strength from the knowledge that there were many people in the 
same situation, whether they had made contact with them or not. 
The more I used to come here for questioning the more I got encouraged, to get that advice 
that I should not worry, as I am not alone in this sickness.  We are many despite the fact that 
we don’t know each other encouraged me the more.  ID 97, male, 43 years, control 
From the study team 
Participants in the intervention study arm described the study team (researcher and two nurses) as 
friends from whom they received social support which they described as therapeutic:   
It was more personal and attached. I mean you would feel that there was a link... The nurse 
was feeling for you, she was relating to what you were going through. She was concerned, 
there was some concern. You would feel that there was someone who was there to help you 
to mourn with you. You see, you were not all alone.  ID 134, female, 41, intervention 
They also described the palliative care nurses as ‘buddies’ or ‘helping hands’, from whom, even after 
study exit, they anticipated a supportive friendly response.  One participant from the intervention 
study arm reported how she returned to the palliative care nurses for comfort after study exit when 
she felt frightened about the anticipation of a pap smear test. 
The sense of care which the participants perceived from the study team was important for 
participants in both study arms.  They described how they developed feelings of friendship between 
themselves and the study team and grew to enjoy their company:  
They have changed me a lot because as I came here frequently, I became social to those 
people who used to interview me and I wish I would continue with the sessions and even if 
not so, then I would love to have some talks with them about life.  ID 159, female, 30 years, 
control 
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Yeah you don’t take us as if – these are sick people, you know. You treat me like a fellow 
human being, like your sister, like your … you know, friend – genuine friend. That’s more 
important.  ID 138, female, 40 years, intervention 
Interactions with the study team and, for those in the intervention group, with the study nurses was 
described as supportive by many participants, and contrasted with their experiences interacting with 
staff in the CCC: 
There was a link, there was a bond, there was something – I mean that feeling that she’s with 
you. There was feeling. The nurse was feeling for you, she was relating to what you were 
going through....You would feel that there was someone who was there to help you to mourn 
with you. You see, you were not all alone. So, but unlike at the C.C.C., you see you are many 
and it’s like, “This is your medication go over there and take”.  ID 134, female 41 years, 
intervention 
Communication 
The theme of the communication contained four sub-themes: open communication, talking to share 
and relieve burdens, freedom in communication and being listened to.   
Figure 38 Distribution of text extracts for sub themes of communication, by study arm  
 
Open communication 
For participants, openness was an essential aspect of communication, both in terms of the way 
questions were asked and the way participants felt when they were answering them.  Essentially, 
participants perceived the researcher’s accepting attitude as communicating her personal 
acceptance, which was a powerful experience for many participants who were socially isolated or 
Control patients (n=48 
text extracts) 
Intervention patients 
(n=65 text extracts) 
Open communication 19 24 
Talking to share and relieve 
burdens 
16 15 
Freedom 11 14 
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who had experienced stigma or discrimination.  The acceptance and openness which was built 
between the researcher, study nurses and the participants facilitated the disclosure of previously un-
discussed topics:   
The way I’m talking to you now there are things that I cannot talk with other doctors or other 
sisters out there. Here I’m free.  ID 138, female, 40 years, intervention 
Communication provided space for the participants to organise their thoughts and the opportunity 
to explore their current situation and reflect on how they would like to respond to their current 
situation, an opportunity they may otherwise not have had: 
When I used to come here, we would talk with you and you would ask me the questions and 
I’d reflect back... So I would think about it – reflect, reflect about it... and once I’d reflected, 
I’d sit down over and think now, something should change.  ID 134, female, 41 years, 
intervention 
The open communication during data collection appointments was also appreciated by participants, 
who described how the open way in which the questions were asked encouraged them to express 
themselves, which made them feel liberated: 
Coming here has really helped me, especially for that freedom and I feel liberated.... Yes it has 
helped me to express myself. ID 107, female, 46 years, control 
Every time that we talked, I’d have relief from pain. Because the questions you used to ask 
were about things affecting me psychologically. So whenever you asked a question and after 
I’d provide the answer - that problem would get out of my life. ID 110, female, 28 years, 
intervention 
Sharing burdens for relief 
Participants often described the psychological relief felt after sharing a problem: 
I also shared my problems as they occurred - you know, you don’t solve problems by keeping 
them to yourself but by sharing with other people. That way, you feel a bit of relief.  ID 154, 
male, 32 years, intervention  
You know when you are being asked such questions, you feel like your mind is being set free. 
So I used to feel like … basically, say, as I was leaving here, I felt as if something … [hesitates] 
that also contributed in improving my psychological well being. It really helped it to improve.  
ID 120, female, 36 years, intervention 
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Participants allocated to the control study arm, who were only completing the outcome measures 
during data collection appointments and not receiving counselling, also reported benefit from 
communication:  
When I started coming here, the worries started going down because I found somebody 
whom I could tell my problems and when I started doing that then the depression started 
going down.  ID 143, female 36 years, control 
You helped by asking me several questions on what was affecting, I felt like someone was 
helping me to carry my burden, I had problems with solving my issues but whenever I came 
here and you advised me all was ok, and I found it simple to solve them.  ID 130, female, 42 
years, control 
Feeling free  
The safe and welcoming therapeutic environment enabled intervention arm participants to express 
themselves freely and openly:   
I was scared because I have never had an opportunity like this to explain myself and I have 
never been questioned like this before, but as times went by, I started talking freely and 
stopped being scared and I was much happy because you told me a lot of things in a free 
manner…so I became much free to you unlike at the beginning of the study.  ID 135, female, 
50 years, intervention  
The sisters were so good to me and I loved them just as they loved me. And this gave me a lot 
of freedom. So there was a difference – here I had more freedom than the other place.  ID 
125, female, 30 years, intervention 
The study team encouraged participants to express themselves freely and interacted with them in a 
way which was perceived as free and open by the participants:   
It also helped me because when I started going there I used to be afraid but after coming 
here and got to be asked the questions, I started answering expressly, I found it to be of much 
help because I started  feeling free... The type of questions that I was being asked and the 
way I was being asked, freely it also made me to feel free...  ID 107, female, 46 years, control 
Participants were treated with respect and were asked to decide which language they wanted to 
conduct the appointment in.  This made self expression easier for some: 
It was easy because first of all, one would use a language of their [own] choice. You didn’t 
have to use the language preferred by the nurse. Then you’d feel the sense of freedom. It was 
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easy because it would be between you and the doctor alone. It was private.  ID 120, female, 
36 years, intervention 
Beyond the content of the discussions, participants described benefit from verbally expressing their 
concerns:   
Every time that we talked, I’d have relief from pain. Because the questions you used to ask 
were about things affecting me psychologically. So whenever you asked a question and after 
I’d provide the answer - that problem would get out of my life. Yeah.  ID 110, female, 28 
years, intervention 
Being listened to  
Participants also described their appreciation of having somebody take time to listen to them:   
Psychologically, you know you need somebody who you can share your problems with, at 
least he’s your buddy, him or her, and you feel settled down.  ID 138, female, 40 years 
intervention 
For intervention arm participants, being listened to was akin to taking time to talk, described as an 
active ingredient of the intervention missing in standard care:  
It was never meaningful [in the CCC] because when you get here you have to talk and discuss 
is when you proceed to treatment… and there, is all about presenting your card to the doctor 
and you receive drugs that’s all.  ID 124, female, 37 years, intervention 
Mechanism of action: trusting relationship 
Without trust, participants cannot begin the vulnerable task of rebuilding a sense of positive self-
image.  Trust is defined in the literature as the mututal understanding that no party will exploit 
another’s vulnerability and is recognised as essential to human well-being (365).  Trust is formed 
between individuals on the basis of social interaction, where one expects the other to act in a non 
harmful way, without established contractual obligation (366).  . 
Many participants in the study were subject to stigma and discrimination on a daily basis (see page 
171), which undermined their sense that they were worthy of time and attention, of friendship and 
of being treated with dignity and respect, which contributed to a negative self image.  This was 
compounded by the lack of time available for the nurses in the CCC to show their interest and to 
adequately discuss participants’ problems.  Having a trusting relationship counteracts the effect of 
stimatising messages received by the participants from their immediate and wider communities, 
which were damaging to their positive self image, mental health and well-being.  The therapetic 
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process described by the participants is a shift from seeing themselves negatively, through 
internalisation of stigmatising messages, to seeing themselves as normal – just like anyone else.   
Compassionate care 
Compassionate care and its two sub-themes (feeling treated well and being known) communicated 
to participants that they were worthy of being treated with dignity and respect in the context of a 
trusting relationship, which contributed to positive self image.   
Based on how we started, the way you showed me the importance, you enlightened me 
about this condition and the importance of my life. This made me to change and go back to 
my normal state and be like any other person.  ID 106, female, 39 years, intervention 
I started viewing myself like any other person, as you see me now, like am not sick at all I 
stopped worrying about myself and focused.  ID 129, female, 43 years, intervention 
As previously described, being encouraged to treat themselves and see themselves as normal, and 
worthy of being treated with respect within a trusting relationship, despite the diagnosis of HIV was 
extremely important for many participants.  This effect was more marked in the intervention 
participants, who were repeatedly told that they were normal by the palliative care nurses.  
Participants’ emphasis on the benefits of being told that they were normal suggests participants 
experienced feelings of abnormality.  Similarly, the extent to which participants repeatedly reported 
appreciation for the compassion and care from the study team suggests that this was not in 
abundance in other areas of their lives.  This lack of feeling normal and compassion from others 
contributed to participants’ feelings of negative self-image, fuelled by the experience of stigma and 
discrimination.   
Social support 
Receiving social support and forming trusting relationships communicated to the participants that 
they were worthy of trust, social integration and acceptance, which contributed to a positive self 
image:  
It helped me because when we used to discuss I felt we were more close.  ID 124, female 37 
years, intervention 
 As described in the findings from objective 3 (page 148) many participants experienced social 
rejection or feared that they would experience rejection if they disclosed their status: 
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I used to feel all alone because I struggled with everything on my own, I used to feel that 
telling anybody my problem wouldn’t help instead they would only laugh at me and isolate 
me the more.  ID 129, female, 43 years, intervention  
Strong, trusting relationships built with the study team and subsequently with their peers and with 
others through religious practice, improved self image, and enabled them to access their previously 
un-accessed agency: 
It’s true because even now, at the moment, I can stand in front of people and open up but 
before I came here I couldn’t do that...… The way I used to come here and you’d speak to me 
made me realize that there was no need of keeping things to myself anymore.  I resolved to 
speak out so that I could be helped in whichever way....  When I started coming here, the 
worries started going down because I found somebody whom I could tell my problems and 
when I started doing that then the depression started going down. ID 143, female, 33 years, 
control 
This increased trust, social acceptance and support appeared to offer a counter-narrative to the 
social rejection participants feared they would meet in the community.  Social stigma in the form of 
discrimination was described as a normative aspect of culture and, when internalised, had evident 
damaging effects on the participant’s positive self image:   
I felt guilty and responsible for my sickness so I felt like even if I cry to God he will never listen 
to me. ID 139, female, 42 years, intervention 
I never use to view myself as normal and at times I used to ask myself what I would do to be 
like others because I had no meal, I had stress, drugs are required and I had no money. ID 
130, female, 42 years, control 
Participants reported isolating themselves from potential sources of support, particularly when 
describing their experiences before recruitment to the study, and living in fear of the reaction of 
their friends and family if they discovered the HIV positive diagnosis:   
What if my relatives got to know about my status before I had disclosed it?  What about my 
beautiful daughter, how she would react? Such things. Those were my worries.  ID 143, 
female, 33 years, control 
The rebuilding of self image occurred through the experience of developing trusting relationships, 
and participants began to reject the stigmatising messages that they were abnormal, inferior or had 
reason to be shamed and keep their diagnosis secret: 
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I was scared when I first started this study, and my health was also not in a good condition 
when I started but as I came here for the discussions I started feeling ok, because I became 
free and started living my life as normal and when I told my family about my health, they also 
joined hands in supporting me.  ID 135, female 50 years, intervention    
The most important thing to me was the fact that I realized how to stay contented with this 
disease, not to be afraid or despise myself but to look upon everything as usual and trust in 
God.  ID 097, male, 43 years, control  
It is because when you used to ask me questions, I used to feel much free inside … I felt like a 
very normal person without any form of illness, I felt so good eh.  ID 126, female, 54 years, 
intervention 
Through rebuilding self image and sense of worth, by means of positive, trusting, supportive 
relationships and social interaction, the participants were able to overcome their fear and engage 
with those in their community. 
I think [people engage socially now] because I am a happy person right now and I pay them 
visits as well, I also feel that they see me living a normal and doing my own work without 
fear. Unlike before, I never used to talk to anyone even if they would pay me a visit and that 
bored them from coming but everything is normal right now.  ID 158, female 33 years, 
control 
Communication 
Aside from the content of the interactions, which are captured elsewhere (section 6.4.2.2), the 
findings of this analysis show that in receiving compassionate care and social support, control and 
intervention group participants were able to build a trusting relationship in which they were able to 
verbally express themselves in a therapeutic way.  Communication also exerted its therapeutic 
power because of trust.   
The combination of trust, adequate time and the confidentiality of the study team interactions with 
participants created a unique environment for the participants to discuss their problems freely and 
openly.  Because of the stigma of HIV and the associated secrecy, participants described finding it 
difficult to find a safe forum in which to discuss their concerns, or plans for self-care: 
Because if you seek advice from anyone – you ask them, “Is it okay for me to do this”, they’ll 
start talking ill about you everywhere.  ID 107, female 46 years, control 
Participants felt safe to express themselves openly, without fear of judgement, which enabled them 
to process their experiences and emotions, and begin to accept their situation without shame:   
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The most important thing was … most important thing of being here was being able to 
express myself. To accept what has become of me and to say that this is what is happening 
but I can overcome it. This has been very nice and then a forum of expressing my innermost 
feelings and fears. ID 134, female, 41 years intervention 
But after being spoken to every so often, I went over it and accepted that it was only a 
condition that would come to pass and that I’d go back to my normal life.  ID 106, female, 39 
years, intervention 
6.4.3.2. PROMs as prompts 
While both control and intervention participants reported using PROMs as a prompt to reflection, 
identification of problems and self care, this was especially common in the control arm participants 
possibly because they did not receive any other explicit input.  Figure 39 presents the number of 
participants in each arm who reported using the PROMs as prompts, to illustrate these differences. 
Figure 39 Distribution of participants referring to PROMS as prompts, by study arm 
 
The questions, asked at each data collection appointment were described as a mind exercise, 
without which improvement would have been slower:   
Sitting down to be asked questions made me better, because were it not for those questions it 
would have taken me a lot of time to get back to my normal psychological status. So asking 
those questions acted like exercising my mind.  ID 120, female, 36 years, intervention  
That someone was interested in the extent of support they received, or the frequency with which 
they attended the clinic or took their medication, was taken as an indication of the importance of 
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I told you that I sometimes I would forget. You asked me “why” and since you asked that 
question “Why” … I went back home and adhered to the prescription and I have never 
skipped taking medicine apart from the day I had an operation.  ID 107, female, 46 years, 
control 
Once the pain was off and … when I used to come here, we would talk with you and you 
would ask me the questions and I’d reflect back. You know, I would go over my … I’d reflect 
back, whatever that you had asked. So I would think about it – reflect, reflect about it … ID 
134, female, 41 years, intervention,  
Others described adhering more closely to their prescribed ART or other health promotion messages 
so that they could report positive news to the researcher at the next appointment, with a clear 
conscience.   Some control arm participants perceived therapeutic benefit from completing the 
PROMS, similar to the experience of receiving counselling:   
There are some questions amongst the questions that you used to ask me, that I have never 
been asked by anyone before in life, not even with my family member. There are some 
questions that my family members have never asked me since I contracted this disease and 
those questions that you asked me made to learn that there is life even after being positive.  
ID 159, female, 30 years, control 
In terms of health education, many control arm participants had gaps in their knowledge – about 
HIV, healthy eating and nutrition, family planning and protected sex and the importance of adhering 
to ART.  Some described how the PROMS helped them think, and increased their suspicions that 
there was something they should have been doing which they were currently not.   
They could ask me every time if I was using a condom, so I suspected there was a mess in not 
using a condom so I decided to use it.  ID 156, male, 40 years, control 
This also highlights the lack of basic knowledge in the patients attending the standard care clinic.   
Therapeutic process: self care 
Participants reported using the PROMS to prompt self-care, as a trigger for health promotion, self 
care and a structure for self reflection, which continued once they left the data collection 
appointment.  
To be honest when I first came here and sat down with you for a discussion I felt different… 
the discussion we used to have made me feel at peace and I got rid of all the bad thoughts I 
had, on my way home ... so I started helping myself to change step by step.  ID 130, female, 
42 years, control 
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6.4.3.3. Material support 
All participants in the trial were supported materially in two ways: light refreshments on arrival at 
the research centre, and reimbursement for travel expenses (US$5).   
Figure 40 Distribution of text extracts for sub-themes of material support, by study arm 
 
Participants in both arms reported appreciation for the refreshments.  For some this was seen as an 
extension of the hospitality of the research visit, as a sign of dignity, respect, affirmation or support: 
Interviewer: What did they do for you to feel treated well or soothed? 
Respondent: First and foremost when I came here I’d be appeased with biscuits and 
juice....then I would be given the fare and then I’d be given good medicines.  ID 106, female, 
39 years, intervention 
In Kenyan culture, receiving guests with light refreshments is seen as basic hospitality and not to do 
so in social situations would be an insult to the guest.  It is possible that this gesture of hospitality 
and understanding of social norms, laid the foundations for the development of the therapeutically 
beneficial relationships with the study team that participants described. 
The reimbursement for travel expenses was often used by participants to support other expenses, 
such as to purchase a higher quality of food or to provide for some of the needs of their families.  
Some reported using the money to pay school fees or to contribute towards to costs of a wedding:  
As it was, I couldn’t go on with my work at that time because I wasn’t in good health.  So 
after getting that transport money, I would use it for transport and then I’d have some to buy 
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some food items. So that helped a great deal and that’s why I was continually motivated.  ID 
120, female, 36 years, intervention 
I stopped being worried, feeding well, as well as helping me financially to buy the food so that 
I could feed well.  ID 114, female, 48 years, intervention 
I will go there and they’ll reimburse my fare – that fare I’ll use it … something else that’s small 
that may be I was lacking – I can buy … maybe I can buy even some fruits and what have you 
on my way home. So I’d feel, “Huh, there is something. There is something to look forward to.  
ID 134, female, 41 years, intervention 
The control participants also reported using the travel reimbursement to buy tonics or medications 
they might otherwise not have been able to access.  This relieved the financial burden they were 
under to some extent, and was cited by many as a source of therapeutic benefit:  
I’d get prescription from there and sometimes if I came here I’d be given something like bus 
fare. That bus fare would really help me, using it for fare and I’d use like a 100 shillings on the 
prescription. I can say that I used to benefit.  ID 107, female, 46 years, control 
The transport reimbursement alleviated thus financial burden which was a source of stress and 
therefore a barrier to positive mental health and well-being in both study arms.  This was also 
evident in the data from a participant in the intervention group who reported clinically significant 
deterioration, which she attributed to persistent financial pressures, that she could not see a way of 
alleviating. 
Therapeutic process: relief of financial strain 
Financial strain was a source of concern for many participants therefore this small alleviation of the 
constraint was cited by many as a reason for their reduction in anxiety.  In addition to relieving 
financial constraint, this financial support enabled participants to be more self determining, 
increasing their ability to access items which were important to them which were otherwise 
unavailable.  
This improved the ability of participants in both study arms to fulfil their social role in provision for 
their family, and in turn improved their self image as a provider, or contributing member of the 
social group.  Fulfilling this role in a way which was socially expected contributed towards 
improvements in self image and positive mental health and well-being. 
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6.4.4. Summary of active ingredients and therapeutic aspects of participation  
The mechanism of action of the identified active ingredients and therapeutic processes of the 
aspects of participation identified in the analysis of qualitative data, are mapped onto the model 
created to address objective 3, illustrating the barriers and facilitators to therapeutic benefit (Figure 
34).  The actions of the active ingredients and therapeutic processes are mapped using coloured bars 
to highlight the processes affected. 
The mechanism of action of the active ingredients appears to improve physical well-being, by 
management of symptoms through provision of effective medication, improving health promoting 
behaviours through education and counselling and addressing the problems of patients through 
providing time to articulate symptoms and concerns.  This improvement in physical well-being 
enables the participants to fulfil their social role.   
The process of the therapeutic aspects of participation appears to have had effects on social role and 
self image.  Building trusting relationships increased participants’ feelings of social acceptance and 
integration, acceptance of self and decreases their feelings of shame and the need to isolate 
themselves.  The trusting relationships also gave the participants an experience of being treated 
with dignity and respect.  This enhanced participant self image which led to improved mental health 
and well-being.  Self-care through use of PROMs as prompts increased physical well-being and 
increases independence. And the provision of material support enables participants in both study 
arms to fulfil their social role and expectations and increased self determination, in that they could 
chose how the money was spent, which contributed to physical and mental health and well-being.   
Having good physical health and fulfilling one’s social role promotes positive self image and positive 
mental health and well-being in this sample. 
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Figure 41 Mechanism of action of active ingredients and therapeutic processes of therapeutic aspects of participation 
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6.4.5. Summary of findings from objective 4 
Active ingredients of the intervention care package received by those allocated to the intervention 
study arm (identified through quantitative and qualitative data analysis) were insight and 
understanding (which encompasses counselling and health education), medication, and taking time.  
Insight and understanding relieved anxiety and depression associated with ignorance about HIV and 
about the future which would be possible if participants adhered to their ART.  It also enabled 
participants to make better decisions about their self care; for example, improving their diet.  
Medication relieved physical symptoms, which were a great sources of anxiety for many participants 
who were recruited on the basis of moderate to severe pain or other symptoms.  Taking time for 
discussion during the palliative care appointments enabled the intervention group participants to 
articulate their symptoms and concerns and therefore receive a more targeted and appropriate 
treatment response. 
Therapeutic aspects of participation in the study, experienced by participants in both study arms, 
were compassionate care, communication, social support, PROMs as prompts and material support.  
Compassionate care, social support and the communication exerted their therapeutic process were 
through trusting relationship, which enabled participants to rebuild their self image which had been 
damaged, in part by stigma and discrimination.  The PROMs provided a structure for participants to 
reflect on their well-being and were used to trigger self care behaviours and highlight health 
promoting behaviours they should adopt.  Material support increased the participants’ ability to 
provide for their families and relieved anxiety caused by financial constraint. 
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6.5. Summary of all findings by objective 
6.5.1. Objective 1 
To determine baseline levels of mental well-being and to examine associations between baseline 
mental well-being and demographic and clinical characteristics among patients with HIV on ART 
enrolled in a randomised controlled trial (RCT) of a nurse-led palliative care intervention 
At baseline, psychological quality of life as measured by the MOS-HIV MHSS, was found to be worse 
than in the reference population (44.8 compared with 50 (307)), and worse in female participants 
compared to men (p=0.02).   
The median score for psychiatric morbidity is approximately the threshold for “caseness”, indicating 
that half of the sample had some level of psychiatric morbidity at baseline. 
Baseline analysis showed that 45% of the sample was worried all of the time and 35% were not able 
to share their feelings with friends or family at any time in the past 3 days.   
There were no associations between psychiatric morbidity, worry or ability to share feelings and age, 
gender, partner status, number of children, number of financial dependents, highest educational 
attainment, CD4 count at baseline, receipt of TB treatment, previous AIDS diagnosis or wealth. 
6.5.2. Objective 2 
To identify any effect of the palliative care intervention on mental health and well-being, comparing 
the intervention with standard best practice. 
Monthly time point analysis identified early statistically significant difference between control and 
intervention group in all outcomes (p≤0.02).  These differences attenuated for psychological quality 
of life, psychiatric morbidity and worry, with no significant difference between control and 
intervention groups by trial exit.  The difference in ability to share feelings also narrowed into 
insignificance at month in ability to share, but then widened at the final time point to reach 
statistical significance again. 
Analysis of repeated measures, adjusting for data correlated by participant identified a positive 
effect of the intervention on psychological quality of life, psychiatric morbidity and the ability to 
share feelings, but not worry. 
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6.5.3. Objective 3 
To determine and describe participant experience and longitudinal response to participation in the 
study in terms of mental health and well-being, and to identify and explore associations between 
participant response and demographic and clinical characteristics. 
Analysis for association between  are under the curve for mental health and wellbeing outcomes and 
clinical and demographic variables found a positive association with wealth and mental health and 
well-being in terms of psychological quality of life and a negative association with psychiatric 
morbidity.  Increased educational attainment was associated with decreasing psychological quality 
of life and ability to share feelings.  Male gender was associated with increasing ability to share 
feelings.  Allocation to the intervention group was associated with improved psychological quality of 
life, ability to share and improved psychiatric morbidity.  The strongest and most consistent 
predictor of outcome in each dimension of mental health and well-being was baseline score.   
Analysis of qualitative data found that barriers to receiving benefit in terms of mental health and 
well-being from the intervention were unaddressed physical, social or financial problems.  Physical 
problems were pain and other symptoms and social problems were rejection or gender based 
violence.  Participants described building their self image through participation in the study, and 
increasingly rejecting the HIV associated stigma they encountered. 
6.5.4. Objective 4 
To identify and explore the existence of “active ingredients” and mechanisms of action of the 
intervention and therapeutic aspects and processes of study participation. 
Active ingredients of the intervention, identified through integration of findings from quantitative 
and qualitative data analysis, were insight and understanding, medication and taking time to talk, 
particularly about psychosocial issues.   
Therapeutic aspects of study participation were identified as compassionate care, the therapeutic 
benefit of talking, social support, PROMs as prompts and material support.  The processes through 
which these therapeutic aspects exerted their power were through increases in trusting 
relationships and through using the PROMs as a structure for self-reflection and education, thus 
improving physical health and alleviating strain on mental health and well-being.  Material support 





This section will summarise the main findings from the quantitative and qualitative analyses by 
objective, and then discuss and situate the active ingredients and therapeutic aspects of 
participation within the relevant literature.  Limitations of the study and the findings will then be 
discussed, in addition to ethical implications and future work, in terms of both clinical and academic 
practice. 
7.1. Main findings 
This study, for the first time, describes the considerable psychological burden experience by PLWH 
on ART, with moderate pain or symptoms.  It has found that a nurse-led palliative care intervention 
benefitted participants through health education and counselling, medication and providing time to 
talk, particularly in the context of a socially stigmatising condition.   The study also found that 
aspects of participating in the study were therapeutically beneficial for participants in both study 
arms: being treated with compassion, social support, communication, using the PROMs as prompts 
to self-care and receiving material support. 
Barriers to improving mental health and well-being were unmet physical, financial and social needs.  
This echoes the seminal theory of Maslow, where physiological need (air, food, water) must be 
realised before higher needs for safety (employment, family resources), love and belonging 
(friendship, family, sexual intimacy), esteem (self respect and respect of others) and self 
actualisation can be recognised and addressed (364).   
In this chapter, these key findings will be discussed and considered more fully, with reference to the 
wider evidence and in the context of the aim of the study, restated in Table 7-1. 
Table 7-1 Study Aim 
 
To evaluate the effectiveness of a nurse-led palliative care intervention on the mental well-being of 
HIV patients on ART in Kenya, and to explore active ingredients of the intervention and their 
mechanism of action and therapeutic aspects of participation 
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7.2. Effectiveness of a nurse-led intervention on mental health and well-
being of HIV patients on ART in Kenya 
We found evidence that the intervention was effective in terms of the quantitative measures of 
psychological quality of life, psychiatric morbidity, worry and the ability to share.  These findings are 
now discussed with reference to the wider literature.  
7.2.1. Psychological quality of life 
At baseline, the median score for psychological quality of life, as measured by MHSS, was lower than 
the reference median in the literature (50), indicating worse psychological quality of life (307).  
Comparison with findings from research in other HIV positive populations indicates that this figure is 
similar (Table 7-2), despite our sample being recruited on the basis of moderate to severe pain or 
other symptoms. 
Table 7-2 Comparison of MHSS in this study with other study sample 
Source Country Year 
MOS-HIV MHSS 
(possible range 1-100) 
Study sample Kenya 2012 44.2 (7.7) (median and IQR) 
He et al (367) 
Stangl et al (368) 
Chariyalertsak et al (369) 
Ion et al (370) 











43.6 mean (sd 9.7)  
40.0 mean (sd 11.2) 
53.4 (mean) 
49.2 mean (sd 10.7)  
52.0 median (IQR 44.2–57.9) 
 
Women were found to have worse baseline psychological quality of life compared with men.  This 
finding has been replicated in other studies of PLWH in Canada (370), Cuba (372) and Uganda (373).  
This also mirrors data for the general population, where women are found to have increased rates of 
anxiety and mood disorders, (although men have higher rates of externalising and substance use 
disorders) (142, 374, 375).  These gender differences have been partially attributed to gender 
inequality, as a narrowing of difference has been reported where women have increased role 
equality (374).  
In comparison with those receiving standard care, participants allocated to receive the intervention 
care package reported significantly improved psychological quality of life one month after baseline 
(T1 of 5 time points) and significant difference was also found at month 3 (p=0.04) and month 4 
(p=0.06) with benefit in the intervention arm.  Longitudinal multi level analysis of repeated measures 
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found a statistically significant difference between control and intervention group participants with 
benefit in the intervention arm.   Thus the null hypothesis of no effect of the intervention was 
rejected. 
Analysis of MHSS AUC (longitudinal summary) showed some evidence of an association between 
higher psychological quality of life and decreased educational attainment (p=0.089).  Contrastingly, a 
study from Italy found that increasing education was associated with improvement in MHSS in an 
observational cohort of PLWH on ART (376), a finding also reported in two separate studies from 
Uganda (373, 377), and the USA (301).  The results from the analysis of the qualitative data suggest 
that those with less education reported appreciation from being reassured that they were ‘normal’ 
more frequently than those who had attained higher levels of education.  This could explain this 
counterintuitive finding.   
A positive association between wealth and psychological quality of life was identified in analysis of 
AUC data in this study.  This finding is replicated in other research with PLWH in Uganda (373), USA 
(378) and Zimbabwe (379).  In the general population low socioeconomic status is also associated 
with poorer outcomes in terms of anxiety and mood disorders (375).  This suggests that low 
socioeconomic status could be a barrier to benefiting from this intervention. 
7.2.2. Psychiatric morbidity 
The median baseline GHQ-12 score was 6 points, when analysed using the scoring system for those 
with chronic conditions.  As previously discussed, because four different versions of the GHQ 
questionnaire and three different approaches to scoring the data are evident in the academic 
literature, there are few comparisons available for the data from this study.   
Table 7-3 Comparison of GHQ-12 score in this study with other samples 
Sample Country Year GHQ-12 score (possible range 1-12) 
This study sample Kenya 2012 6 median (3-9) 
Mixed population with chronic 
symptoms (380) 
Italy 1993 7.46 mean (sd 3.02) 
Community sample (311) UK 1988 8.6  mean 
 
It appears that our score of a median of 6 (data was not normally distributed) is lower than other 
samples, indicating a comparatively low level of psychiatric morbidity (Table 7-3).   
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Monthly time point analysis found initial significant difference between control and intervention 
groups at months 1 and 2 (p=0.02 for both), with benefit to the intervention group, which was not 
apparent at later time points.  Longitudinal multilevel analysis of repeated measures found a 
significant difference between study arms for GHQ-12 score (p=0.035) with benefit in the 
intervention group.   
Analysis of association with clinical and demographic variables showed that GHQ-12 was positively 
associated with poverty (p=0.04) suggesting that higher levels of economic deprivation are 
associated with increasing GHQ-12 score, and by implication high levels of psychiatric morbidity.  
This is similar to the findings for psychological quality of life, and is in line with the wider evidence 
that morbidity is associated with poverty and socioeconomic difficulty (375). 
7.2.3. Worry 
Baseline levels of worry as measured by the APOS indicated that one half of participants were 
worried all the time (54/120) and one third were not worried at all (34/120).   
The APOS is a relatively new measure and thus there is little published data with which to compare 
this score.  A cross sectional study of PEPFAR funded clinic patients in South Africa and Uganda 
reported a median score of 2 for worry, compared with 2.5 from this study (222). 
Monthly time point analysis showed a significant difference in worry at month 1 (p-0.01) but at no 
other time point.  Longitudinal analysis of repeated measures indicated no difference between 
control and intervention group.  There were no association between any clinical or demographic 
variables and AUC analysis for worry.   
Nurse-led palliative care has been found to decrease worry or anxiety in patients with advanced 
cancer (381).  The distribution at baseline, (with more than 70% at either end of the scale) suggests 
that there may have been some difficulties experienced by the sample in interpreting and 
responding accurately to this question.   
7.2.4. Ability to share feelings 
At baseline 53% of participants reported that they were able to share their feelings with friends or 
family at all times in the past three days.  The median of 5 reported in this study (0=worst, 5=best) 
suggests that this sample were considerably more able to share their feelings at baseline than the 
sample from South Africa and Uganda cited above, who reported a median score of 3 (222).  
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Monthly time point analysis found statistically significant benefit in the intervention group at month 
1 and the final time point of month 4.  Longitudinal analysis of repeated measures found statistically 
significant difference between control and intervention arms for the ability to share feelings, with 
benefit in the intervention group. 
AUC analysis for association of ability to share over the study period with clinical and demographic 
variables found benefit in men compared with women, and a negative association with educational 
attainment.   
Whilst the APOS item of ability to share feelings does not describe availability of social support, it is a 
measure of utilisation of social and emotional support.  It is possible that at baseline, when no 
difference between men and women was noted, men were not sharing their feelings, but perceived 
that their level of sharing was adequate.  The qualitative data analysis found that men reported no 
worries or concerns, which could indicate a reluctance to talk about feelings or that they were 
accurately describing their state of mind.  During the study, as indicated in data from phase 1 and 2, 
they began to share their feelings and reported increased disclosure of their HIV status and increases 
in social and emotional support.   
A large cross sectional study of the general population in Norway found that increasing receipt of 
emotional support is associated with lower prevalence of depression, an effect which was stronger 
in women compared with men (382).  A general population based cross-sectional study in Beirut, 
Lebanon identified a similar trend, where social support was protective of self-rated health for 
women but not for men (383).  This suggests that social support in the form of sharing feelings may 
not have been important for men in our study before recruitment, but once the study commenced, 
they began to share with the study team.  This does not necessarily indicate that this was beneficial 
for their mental health and well-being, as evidenced by the lack of effect seen on psychological 
quality of life and psychiatric morbidity in this study. 
There is little published data exploring the association between education level and social support.  
A cross sectional study from Nigeria found that PLWH who had poor social support also had low 
levels of education and poor quality of life (103).  Cross sectional data from women living with HIV in 
the USA found that increased social support was associated with social capital variables including 
educational level (384).  However, this evidence does not explain why those with increased 
educational attainment reported worse ability to share feelings over the study period, and therefore 
this finding warrants further investigation.   
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7.3. Sources of benefit: Active ingredients and therapeutic aspects of 
participation 
Active ingredients were identified by intervention participants as therapeutically beneficial aspects 
of the intervention care package, through analysis of the quantitative and qualitative data, and will 
be discussed in the context of the wider evidence.  Therapeutic aspects of participation, common to 
both study arms will be discussed subsequently.   
Attention to the causal mechanisms of the active ingredients and therapeutic aspects of 
participation was primed by the critical realist approach taken in this thesis, (described in section 
3.3.2.2, Pg 66), which draws attention to the importance of underlying mechanism which drive 
observable changes.  Each causal mechanism and process discovered through data analysis is 
described after a discussion of the corresponding active ingredient or therapeutic aspect of 
participation. 
7.3.1. Active ingredients of the intervention and their mechanism of action 
7.3.1.1. Insight and understanding and adequate information  
The theme of insight and understanding encompassed two sub-themes, health education and 
counselling, which were described by participants as an important source of therapeutic benefit, 
both in terms of content and delivery.   
The need for health information found in the baseline quantitative data was met by health 
education and counselling delivered as part of the intervention care package.  This alleviated 
participants’ fears associated with uncertainty and their future, due to living with HIV.  
In the literature, there is pre-existing evidence for the effectiveness of psycho-educational 
interventions in the reduction of depression and anxiety in mental health and cancer research (226, 
232, 233).  In palliative care research, cancer patients who received advanced care planning, which 
includes discussion with patients about the future, were found to have decreased depression (238) 
and anxiety (237).  Findings from the HIV literature that group educational and psychological support 
are effective in decreasing anxiety, depression and perceived stress, has led to the widespread use 
of peer support groups for PLWH (230).  There is overlap between the active ingredient of insight 
and understanding and the therapeutic process of trust.  Evidence suggests that when delivered in 
the context of little or no trust, health information has only a slight or even a negative effect (366).   
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Qualitative data describing health education illiteracy in this population, for example about the 
importance of adherence to ART and protected sex, are concerning.  These findings suggest areas for 
improvement in the use of peer support and the need for communication skills training for staff in 
the standard care clinic.   
7.3.1.2. Medication and symptom relief 
Quantitative analysis of data regarding service receipt found a statistically significant difference in 
the receipt of weak opioids (codeine) between study arms.  This may suggest that pain is less well 
managed in the standard care clinic.  Receipt of paracetamol was associated with benefit in all 
quantitative outcomes, indicating that the availability of non-opioid analgesia is essential to holistic 
health.   
The qualitative data described how analgesia adequately relieved pain for the majority of 
participants, which alleviated the associated fear and anxiety that their distressing physical 
symptoms would never be resolved, and that they would not be able to work or provide for their 
families in the way they wished. 
These findings suggest that a more consistent prescription of mild opioid analgesia would be 
beneficial for relief of pain and holistic well-being, in line with the WHO recommendations (385).  A 
recent pharmacy stock audit of 120 PEPFAR funded health centres in East Africa found that 73% 
were well stocked with non-opioid analgesics (suggesting that 27% were not), 21% had codeine and 
only 7% of pharmacies were stocked with strong opioids (386).  In the same study, of the pharmacies 
who reported that they did stock these medicines, stock-outs were common, with 47% reporting 
stock-outs of non opioid analgesia tablets, 33% reporting a stock-out of weak opioid tables and 100% 
reporting stock-outs of strong opioids (386).  This suggests that even when prescribed, problems in 
the supply chain mean access to adequate pain relief may continue to be a problem. 
Lack of consistent access to analgesia and other medications for symptom control is an additional 
barrier to improvement in mental health and well-being for PLWH in this context.  Introduction of 
the WHO pain ladder as a widely used and inexpensive approach to pain management should be 
made routine (385), in addition to improvements to the supply chain to prevent stock outs of 
essential medicines.  
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7.3.1.1. Time to talk and articulated concerns 
Analysis of quantitative differences determined that study participants receiving the intervention 
care package received more psychosocial care than those in the standard care arm.  Psychosocial 
care included emotional support for the individual and their family, and time to discuss concerns, 
spiritual worries and planning for the future.  Qualitative data analysis showed how having time to 
talk about their problems was extremely important for therapeutic benefit reported by those 
receiving the intervention, and was notable in its lack when they returned to standard care.  
Psychosocial care is neglected in many healthcare settings internationally, despite its importance for 
patients.  A recent RN4cast study of nursing levels and their implications on care quality and safety 
was conducted in the UK and in eleven other European countries (387, 388).  The UK research 
findings showed that due to a lack of time 87% of nurses omitted certain essential nursing tasks, 
most frequently those related to psychosocial care.  Comfort care or time for patients to talk was 
omitted by 66% of nurses in the UK and 53% of nurses across the other European countries (387, 
388).  The high levels of unmet need at baseline in this study ( 
Figure 16, Page 124) indicate that there are significant unmet psychosocial needs in this sample.  
This potentially indicates a routine neglect of psychosocial care in the standard care clinic. In 
conjunction with the RN4cast data, this demonstrates a pattern of inadequate provision of 
psychosocial care across international settings.  The evidence suggests that a lack of time to interact 
with patients may be an important constraint (388). 
Evidence suggests that when time is constrained, nurses prioritise medical tasks to process patients 
through the system to prepare them for medical discharge (388), most clearly seen when staffing 
levels are low (387).  As the standard care clinic is extremely busy (400 patients/ day, see Table 3-1, 
page 56), it is likely that the neglect of psychosocial care is due to increased workload and 
subsequent time constraints. 
Another explanation for this neglect of psychosocial care is the lack of importance placed on holistic 
well-being by health care professionals working in the standard care clinic.  A study from the UK 
found that when patients in primary care presented with unexplained physical symptoms and even 
when they suggested potential psychosocial causes, GPs were preferentially more likely to suggest 
physical investigations and interact with a low level of empathy (389).  These findings suggest that 
even when patients present with physical symptoms recognised as expressions of unmet 
psychosocial need, they are not managed appropriately and referred to appropriate care, even in a 
relatively well resourced healthcare setting of a UK GP practice.  As discussed in the background 
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chapter of this thesis, nurses trained in Kenya receive a comprehensive training package, including 
training on chemistry, microbiology, haematology, anatomy and pharmacology, in addition to 
sociology, psychology and hospital and community nursing (194).  However, this comprehensive 
course, while commendable, neglects communication skills, person-centred care and the importance 
of managing the holistic experience of illness, focusing instead on diagnosis and management of 
disease. This focus on medical management in nurse training does not appear to prepare nurses to 
care holistically for their patients.   
The evidence base for the effectiveness of psychosocial support in the management of physical 
outcomes in chronic conditions is established and psychosocial support is now mandated as part of 
supportive cancer care (390, 391) and coronary care (392).  The findings of this study indicate that 
psychosocial care and support is unacceptably under-addressed in the care of PLWH. 
7.3.2. Therapeutic aspects and processes of participation 
7.3.2.1. Compassionate care, social support, communication and trust  
As described in section 6.4.3.1, trust can be seen as the therapeutic process associated with 
compassionate care, social support and communication.  In this section each therapeutic aspect will 
be discussed with reference to the wider evidence, and then the proposed interactions between 
these aspects of the study and trust, to suggest a theoretical process facilitated by trust which led to 
improved mental health and well-being. 
Compassionate care 
The Latin origins of the word compassion are to “suffer with”, expressed by those who are witness 
to suffering, and through this experience of ‘being with’, feel motivated to alleviate the pain they 
witness (393).  A definition from the nursing literature states that: “compassionate care is an 
interaction in which one person recognises and responds to the need or suffering of another by 
giving physical or emotional comfort” (394).  Suffering can be physical, social, psychological or 
spiritual in nature. 
Participants in this study described experiencing the study team’s compassion, and the positive 
effect that this had on them during their participation in the study.  They described being treated 
well: with respect and dignity and with attention to their personal needs and wants, including the 
need to be known by their health care provider.   
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Participants described a lack of a compassionate approach in the standard care clinic, which is not 
unusual in health care systems under pressure to deliver care to high numbers of patients.  A study 
in a paediatric ward in Tanzania implemented an intervention to improve relationships between 
staff and parents (395).  The study reported that despite much effort on the part of the ward staff, 
relationships did not significantly improve, owing to systemic problems in the working environment: 
poor inter-staff relationships and low responsiveness of the hospital management to their 
complaints and difficulties at work (395).  Participants in a study from Nigeria, Tanzania and Uganda 
reported that harsh, uncompassionate treatment from staff was a common reason for HIV patients 
non-attendance at clinic for appointments, leaving patients feeling angry, humiliated, and 
disengaged from treatment (396).     
“Being known” was an expression of compassion important to many participants.  They felt cared for 
when the study team knew to ask about their family, or remembered important things about them 
such as their previous health complaints.  A qualitative study of communication needs in breast 
cancer patients found that patients wished their doctors to know them as individuals, which often 
meant having a conversation about something unrelated to their diagnosis (such as family) or 
making the patient feel special in another way (397).  Patients with breast cancer in a Canadian 
phenomenological study described being known as key to building trusting relationships with their 
physicians, which was found to be essential in countering feelings of vulnerability associated with 
illness and expressed by all patients (398).   
Facilitators of and barriers to compassionate care in healthcare were reported in a review published 
by the Kings’ Fund in the UK in 2009 (393). The authors identified dealing with and preventing staff 
stress and burnout and ensuring support from the wider organisational structure of hospital care as 
ways to encourage compassionate care (393).  More recently, Watters et al conducted a qualitative 
enquiry into the presence or absence of compassionate care as experienced by patients and staff in 
the healthcare setting (399).  They identified that compassionate care was facilitated by effective 
and supportive inter professional teams, role modelling by other members of staff, personal factors 
such as beliefs values and compassion capacity, high nurse-to-patient ratios and supportive 
managers who are aware of individual staff needs (399).  Barriers to compassionate care were a high 
workload, personal factors such as fatigue or stress, managerial requirements such as audit and 
meeting targets and variance from normal care pathway (399).  These findings support the evidence 
from Tanzania cited above, that managerial support is essential to creation of a compassionate care 
culture in healthcare (395).   
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Compassionate care in the standard care clinic was notably lacking when compared to the 
participants’ experience of the intervention and engagement with the study team.  Evidence 
suggests that receiving compassion is associated with a reduction in anxiety and improvement in 
mental well-being (225) in addition to improved control of diabetes and cholesterol and increases in 
patient and family satisfaction (400).  
It is possible that the lack of compassion observed by participants was due to lack of time available 
for clinicians and the lack of support from management, to take time to provide this care.  However, 
studies have shown that compassionate care is being delivered in similar clinical environments in 
SSA.  In a qualitative study of staff and patients in rural clinics in rural Zimbabwe patients described 
staff as friendly and reported that staff listened to them, acknowledging that their HIV was “more 
than a medical condition” (401).   This was reportedly extremely therapeutic. 
Expressing compassion, whilst a normal human response, is described as a potentially painful 
experience for the person expressing compassion, as they ‘suffer with’ the sufferer (393).  This 
highlights the need for support for staff in order to facilitate the provision of compassionate care.  
Time is required to be compassionate, which requires support, commitment and role modelling from 
high level management, and reductions in staff workload to prevent  stress, fatigue and burnout 
(393).   
Social support  
Receiving compassion from the study team built trust in their relationship with participants, which 
was perceived and described by participants as a source of social support.  Findings further suggest 
that this support encouraged participants to build relationships with their peers and participate in 
religious practice in a way they had previously been unable to do, and from which they also gained 
therapeutic benefit.  Participants described receiving social support from the study team and seeing 
them as friends, with a mutual exchange of affection.  They described disclosing their status to 
peers, exchanging peer support and engaging with religious practices, all of which were associated 
with improved mental health and well-being.   
These findings are mirrored in the extensive literature on social support and mental health and well-
being.  Kaplan et al, in their seminal paper on social support and health(402), summarise evidence 
which suggests that a perceived lack of social support or any change or decrease in social support 
can result in psychological, and in some cases physical ill health.  They describe how having adequate 
social support enhances self-esteem and provides affirmation and a place to express negative 
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emotions (402).  High levels of emotional and tangible social support have frequently been found to 
be associated with low levels of depression and anxiety (382).   
Communication 
Participants expressed the importance of openness in interactions with the study nurses and 
researcher.  They spoke of feeling free and being interacted with in a free way, which encouraged 
them to respond in an equally free and open manner.  They also reported disclosing to others after 
speaking to the research team, potentially an effect of being empowered by this positive experience 
of talking openly and without shame 
It is likely that the researcher emphasised the importance of talking freely for data collection.  It is 
essential that the interviewee understands that information that they might wish to convey is 
acceptable and interesting to the researcher, who works to create an atmosphere of openness and 
acceptance where interviewees do not fear judgement when disclosing their personal, intimate 
experiences (403).  In an attempt to reduce interviewer bias, researchers in qualitative research are 
advised to sustain a “empathic neutrality whereby the researcher uses personal insight while taking 
a non-judgemental stance” (403).  To a stigmatised and marginalised individual, it is possible that 
this message could be read as, ‘my experience is acceptable and therefore I am acceptable’.  In this 
way, the research process contributes to the feelings of increased self worth and acceptance 
reported in the qualitative data.   
The interaction between researcher and interviewee, described as free communication and non-
judgemental acceptance has similarities with the concept of positive unconditional regard described 
by Rogers et al (404), in which therapists are encouraged to express neither approval nor 
disapproval, simply acceptance.  Rogers describes unconditional positive regard as essential for 
therapeutic personal change.  The trust built through the therapist’s unconditional positive regard of 
a client seems to have also been built during the study between researcher and participant, with 
therapeutic consequences. 
Effective and sensitive communication could have implications for holistic well-being; due to both 
the way in which information was given and the benefit of the information itself.  Participants in this 
study described the positive effects of being listened to, and sharing their burdens with the 
researcher on their mental health and well-being.  The work of Payne et al, exploring communication 
and in primary care, found a positive approach such as that demonstrated by the study team, was 
associated with patient satisfaction (196).  Similarly, in a recent systematic review, high quality 
communication between physician and patient was found to positively influence emotional health, 
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resolve symptoms, improve function and pain control (405).  When functionally and subjectively 
measured, skilful quality patient physician interaction which increases patient control and includes 
positive affect and health information has been found to be associated with better health status 
(406).   
It is apparent in the findings of our study that participants felt too unsafe to discuss their problems 
amongst their community.  Similar findings have been reported from a study of PLWH in South 
Africa, which identified the need for a safe forum where PLWH could exchange information about 
how they could apply health information to their lives, within the context of a stigmatising condition 
(167).  Participation in our study created a similar space and opportunity to reflect on the experience 
of living with HIV.  Campbell et al suggest that reflection and review, create the beginnings of critical 
thinking and facilitate the shift from victim to empowered actor, and help PLWH to develop the 
confidence to engage with and positively influence their environment (165, 167). 
That the high quality communication skills of the study team enabled participants to express 
themselves freely, which was therapeutic in itself, but also created a therapeutic relationship, in a 
similar way to unconditional positive regard, and positively influenced mental health and well-being, 
through increases in patient control (section 7.3.2.2, page 221) and the provision of health 
information (section 7.3.1.1, page 213).   
The therapeutic process of trust 
Whilst it is apparent that compassionate care, social support and communication were therapeutic 
aspects of participation in the study, it is essential to understand why this was the case.  I believe 
that these aspects of participation were therapeutic because they enabled trusting relationships to 
be formed, within which participants were able to rebuild their self image and improve their mental 
health and well-being.   
Trust in relationships with healthcare providers was examined in a qualitative study of patients with 
chronic conditions (Lyme’s disease, breast cancer and mental illness) (407).  Study findings showed 
that expressions of caring, concern and compassion were the most important aspects of a trusting 
relationship, with listening as centrally important (407).  Provision of emotional support (defined as 
demonstrations of love, caring, esteem and value, encouragement, empathy and sympathy) has 
been postulated as the mechanism through which social relationships enable the distressed person 
to express their emotions, and have their feelings validated, thereby bolstering self-esteem (408).  It 
is suggested in the literature that peer support is particularly important for offering relevant and 
appropriate coping assistance and supplying advice, appraisal and feedback, as an individual’s hope 
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increased with the knowledge that there were others who have coped successfully (408).  
Participants in this study described the study team as friends, which implies that they saw them as 
peers to some extent, which may in turn explain the extent to which social support was received 
through participation in the study. 
Participants also described how aspects of participation in the study built trusting social 
relationships, first with the study team, and then beyond.  There is evidence that trust may be the 
key to accessing support from pre-existing social networks.  A study conducted by Grace et al into 
social support in undergraduate students describe reliance on social support as dependent on levels 
of interpersonal trust, where those with high levels of interpersonal trust perceive more social 
support from friends and family, and use these sources of support to withstand stressors (409).  
Those with low levels of interpersonal trust were more likely to use maladaptive coping such as 
avoidance or substance abuse.   
This evidence suggest that in fostering trusting relationships, through compassionate care, 
communication and the provision of social support, further support was accessed, which decreased 
the use of more negative coping mechanisms such as avoidance and isolation, and improved mental 
health and well-being.   
7.3.2.2. PROMs as prompts and self-care 
During the study participants described how they used the PROMs as a prompt to self-care, 
suggesting that the PROMs exert their therapeutic benefit through reminding or highlights actions 
which could promote health that the participants could engage in, or areas of well-being which the 
participants had not before considered, which they subsequently reflected and then acted upon.  
This was explicitly described by participants in areas such as protected sex and medication 
adherence, where responding to the PROMs was used to identify gaps in health education which 
acted as a catalyst for behaviour or attitude change.   
The increased motivation for self-management is encouraging, particularly as HIV transitions into a 
chronic condition, in which patients are required to adhere to medication, adapt their behaviour in 
response to symptoms, adjust to social and economic consequences and interpret and manage their 
symptoms for the rest of their lives (410).  It is recognised in the literature that patients with chronic 
conditions need increased access to appropriate health information including information on 
diagnosis and implications, treatments and consequences, potential impact on their future, sources 
of support, and coping and adjustment strategies, to enable them to manage their condition (410).  
This suggests that as HIV becomes increasingly recognised as a chronic condition, care may shift to 
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one of shared responsibility, based on patient need, and suggests a patient centred approach, with a 
sense of ownership and control will be necessary.  This approach has been adopted in the 
management of chronic conditions such as diabetes, hypertension and angina (411-413).   
The unanticipated therapeutic benefit of completing the PROMs indicates that patients are able to 
recognise, and when promoted, address the gaps in their knowledge of HIV and healthy lifestyles.  
Some participants also benefited from having a forum or structure, from which they were able to 
reflect and take steps to manage their own mental health and well-being.  Finally, these results 
highlight the potential use of a simple short tool to have significant therapeutic benefits, which could 
be used to increasingly empower PLWH to manage their condition.   
7.3.2.1. Material support and relief of financial strain 
Findings from the qualitative analysis suggest that material support in the form of light refreshments 
and financial reimbursement for travel expenses relieved anxiety for participants in both the control 
and intervention study arm.   
One possible causal mechanism for this observable effect is the relief of economic hardship.  
Participants described how they were able to purchase item they would otherwise have not been 
able to afford.  It is difficult to extract whether the relief they reported was simply because they 
didn’t have to worry about these things anymore, or because the extra financial support meant that 
they had more of a sense of personal control, which we know from the literature is associated with 
self-esteem and mental health and well-being.  This effect has been shown in research from New 
Zealand (77), China (414) and the USA (79).  In the USA, personal control was found to mediate the 
relationship between financial stress and chronic poor health, depression and reduced social and 
emotional functioning (79).  Research conducted among older African-American people with HIV 
found that financial strain was a significant predictor of life satisfaction (415). 
Another potential causal mechanism for this effect is the sense of care and belonging that the 
material support engendered. Similar findings have been reported in an anthropological study of 
financial reimbursements for research participants in Kenya (416).  Participants reported that the 
tangible material transfer made them feel cared for, in a similar way to the participants of our study.  
Findings of the anthropological study described how being in a research study made participants feel 
they belonged with or were being taken care of by the research foundation, and led to a sense of 
attachment and care which improved their mental health and well-being.  The authors suggest that 
“monetary transactions and other transfers of material value are experienced as part of wider 
connections and collectives, larger possibilities and hopes” (p.53) (416). 
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7.3.2.2. The effect of therapeutic processes on stigma and shame 
Participants in this study described feeling shamed, socially isolated and in some cases suicidal due 
to the HIV-associated stigma and discrimination they experienced.  The building of trust between 
participants and the study team appears to have counteracted this shame by verbally and non-
verbally normalising the diagnosis, and teaching the participants that they are worthy of being 
treated with dignity and respect, and should therefore treat themselves as well.   
Internalised stigma, where the socio-culturally sanctioned stigmatising messages are incorporated 
and accepted by the stigmatised, often manifests as shame (70, 417-419).  A definition of shame has 
been generated from evidence from women in the USA who describe it as: “An intensely painful 
feeling or experience of believing we are flawed and therefore unworthy of acceptance and 
belonging” (420).   
Some participants described how during the study they became more able to resist shame and 
stigma and discrimination, either passively or actively.  As described in section 6.3.2.4, participants 
who had previously isolated themselves to avoid discrimination began to reject these stigmatising 
messages.  This occurred internally at first as participants acknowledged privately that messages of 
immorality or dirtiness were untrue.  Increasingly, some participants began to engage with the 
community and not avoid contact with those they thought may discriminate or stigmatise them.  The 
full extent of this resistance was reported by participants who described challenging those who 
expressed discriminatory views, and in some cases forging a new role of HIV activist in their 
communities.   
Participants had difficulty identifying what it was that catalysed this change.  They described the 
change in their behaviour as due to something which occurred during the interactions with the 
researcher during data collection and with the study nurses during receipt of the intervention.  The 
data suggests that these interactions, through the building of trust, somehow enabled participants 
to rebuild their self-image, which had been eroded by stigma and discrimination, and thus reject the 
stigmatising messages. 
The theory of shame resistance developed by Van Vliet contributes to an understanding of how 
participation in the study could have led to an increased resistance to stigma (421).  The theory was 
developed using a grounded theory approach, with data from adults in Canada who had experienced 
and partially overcome a significant shaming episode (such as being caught and convicted of 
shoplifting or being accused of rape).  Van Vliet describes five processes through which resistance 
Discussion 
224 
occurred: connecting, refocusing, accepting, understanding and resisting (421).  I will now discuss 
these processes with reference to the findings of this study. 
‘Connecting’ describes the movement from social isolation to connection.  This involves finding allies 
who can be supportive, socialising with others through participation in community activities, talking 
with others (particularly about experiences of stigma and shame and being accepted and normalised 
in this), connecting to a higher power and repairing relationships (421).  In the current study the first 
allies were the study team, who were able to talk with participants, and provide a forum within 
which participants could express themselves without judgement (therapeutic aspects of social 
support and communication see section 6.4.3.1).   
‘Refocusing’ describes shifting energy and attention from the source of shame or stigma to personal 
goals and self care behaviours, focusing on personal strengths and qualities, and working on self 
improvement.  Participants reported increasing self care during the study, often prompted by use of 
the PROMs during data collection.  They also described shifting attention from others to themselves, 
and learning to ignore those who wished to talk and gossip about them. 
‘Accepting’ involves a move from avoidance towards facing the reality, including acceptance of one’s 
feelings and expressing them (421).  Participants often spoke about the importance of accepting 
their diagnosis and their situation, partially associated with receiving normalising messages from the 
study team.  They also benefitted from communicating their feelings (sharing burdens for relief see 
section 6.4.3.1).   
‘Understanding’ refers to learning about external factors such as extenuating circumstances and 
separating from shame and developing insight into the underlying reasons for one’s actions and 
behaviours (421).  Participants demonstrated this when they described how they had come to 
realise that anyone could become infected with HIV, and that it was normal, and therefore 
acceptable.   
The final process is ‘resisting’, which concerns the rejection of stigmatising or otherwise negative 
judgements and asserting and challenging those who persist in those judgements (421).  This is most 
clearly described by the participant in the control group (ID 143) who moved from discrimination 
victim to activist, bringing people who had discriminated against her into the clinic for HIV testing.  
Other participants described resistance in more gentle terms: reaching out to family members who 
had previously rejected them, deciding not to be ashamed, disclosing their HIV status to the 
community, and offering to be a support to those newly diagnosed.  This resistance describes the 
forging of a new identity as an HIV positive person in society, without shame, whether as an activist 
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or as a normal person who interacts with their immediate and local community, regardless of the 
discrimination or stigma they may face.   
This phenomenon of forming a new identity is also described in the work of Soskolne, who 
conducted a narrative analysis of the life stories of HIV positive women in South Africa (422).  The 
author describes how the women who were more resistant to stigma had negotiated a new, positive 
self identify, which helped them cope with stigma related anxiety (422).  A qualitative inductive 
exploration of illness narratives and adherence among PLWH in South Africa suggests that adequate 
practical, emotional and social support is essential for individuals to forge new ‘stigma resistant’ 
identities (423).  These narratives revealed how participants required a sense of being valued or 
supported by others in order to forge a new identity which empowered them to manage the stigma 
they were facing (423).  With wider support, PLWH were able to express their emotions, make sense 
of their diagnosis and move towards a problem solving approach toward managing their health, 
whereas those with fewer social and emotional resources were less able to adjust and cope (423).   
Evidence from the literature and from this study suggests that if PLWH are provided with social 
(social support), emotional (compassionate care, time to talk) and practical support (material 
support) they may be able to resist HIV-associated stigma.  This has resonance with Van Vliet’s 
model of shame resistance.   
7.4. Summary of therapeutic benefit  
The intervention care package had a statistically significant effect, improving psychological quality of 
life, psychiatric morbidity and ability to share feelings with friends and family, compared with 
standard care. It did not have a statistically significant effect on the extent to which participants 
worried.  Longitudinal summary measures showed that those with higher levels of education 
demonstrated poorer psychological quality of life, lower levels of ability to share feelings and 
increased psychiatric morbidity over time, and those with higher levels of wealth reported higher 
psychological quality of life and lower psychiatric morbidity over time. Men also reported improved 
ability to share over time. 
Active ingredients of the intervention were identified as insight and understanding, medication and 
taking time to talk, with the associated mechanisms of action of adequate information, symptom 
relief and articulated concerns.  Therapeutic aspects of participation in the study were identified as 
compassionate care, social support, therapeutic benefit of talking, PROMs as prompts and material 
support, with their respective processes of trust, self care and relief of financial strain.  These 
ingredients and aspects contributed to positive mental health and well-being. 
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Unmet physical, social and psychological needs were identified as barriers to therapeutic benefit.  
Many participants receiving standard care reported that nursing staff did not have time to talk to 
patients about their concerns and problems, which often remained unaddressed.  Increased 
allocation of time may result in the alleviation of these concerns and problems, but further research 
is warranted to explore how to better meet patients’ needs in standard care.  
Based on Table 1-5, created to summarise the evidence in the literature for the effectiveness of 
aspects of palliative care interventions on mental health and well-being, the contributions of the 
findings from this study are summarised in the same way in Table 7-4, for the effectiveness of 
palliative care for PLWH.  
Table 7-4 Summary of evidence for the effectiveness of nurse-led palliative care intervention 
Component of 
palliative care 
Evidence from this study for effectiveness of palliative care on mental 
health and well-being 
Findings from quantitative data 
analysis 
Findings from qualitative 
data analysis 
Symptom management  
Receipt of codiene associated with 
increased odds of reporting high 
ability to share. OR 4.46 p= 0.01 
Active ingredient:  
Medication 
Patient and family 
support: psychological, 
social or spiritual 
Findings reported in Table 6-19 
indicate that almost all participants 
in the intervention study arm 
received emotional support for 




Time to talk 
Illness understanding 
and patient education 
- 
Active ingredient:   
Insight and 
understanding  
Time to talk 
 
 
Within the context of an environment designed to promote well-being, patients with extraordinary 
needs cannot be satisfied with standard medical and nursing care.  In this respect, it appears that the 
experience of receiving palliative care for PLWH in Kenya is similar to that of other patients receiving 
palliative care in other countries and contexts, as described by patients receiving specialist palliative 
care in the UK in the work of Jarrett, Payne et al, who reported that the most valuable aspects of 
receiving palliative care were pain control and someone to talk to (424).   
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7.5. Study reflections 
7.5.1. Sample characteristics 
Table 5-5 describes the sample characteristics for the TOPCare trial phase 1 data.  This sample is 
younger than the usual palliative care population, and is 81% female.  Whilst this is not usual for a 
palliative care sample in HIC, it does reflect the epidemiology of the wider HIV pandemic, particularly 
in LMIC.  Those infected are usually young, and female (29).   
In addition, participants report a median of 2 children and 3 financial dependants.  This indicates 
that they have responsibilities to provide for people beyond their nuclear family.  Whilst this is usual 
in Kenyan society, it is worth bearing in mind when considering the importance of social role to 
mental health and well-being in the findings of this study.  Participants knew that if they were unwell 
or otherwise unable to provide, there would be a wider network of dependants who would also 
suffer.  In light of this, it is unsurprising that social role was so integral to positive mental health and 
well-being.   
7.5.2. Reflections on the framework of mental health and well-being 
The framework for mental health and well-being in this study was developed by the WHO, University 
of Melbourne and VicHealth in Australia (section 1.2.2, Pg. 28).  This framework described the 
determinants of mental health and well-being as social inclusion, freedom from discrimination and 
violence, and economic participation. 
This thesis has found further evidence for social inclusion as a determinant of mental health and 
well-being.  Social support from the study team, peers and religious practice were reported as a 
therapeutic aspect of participation in the study.  Supportive relationships were described by many 
participants as extremely important, where they could rebuild self-image and personal strength.   
The second determinant described was freedom from discrimination, which includes physical 
security, self determination and control over one’s life.  As participants progressed they were able to 
resist HIV-associated stigma, ensuring their physical security, which occurred in parallel with reports 
of improved mental health and well-being.  There were anecdotal reports among the intervention 
arm participants that receiving couples counselling from the study nurses reduced incidence of 
domestic abuse, although this was not an active line of enquiry during the study.  In addition 
participants reported that material support increased their ability to contribute and provide for their 
family’s’ needs, increasing their sense of control over their lives, and thus improving their mental 
health and well-being. 
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Economic participation is the final determinant of mental health and well-being including the 
importance of work, education, housing and money.  Work, education housing and money were 
extremely important to our participants, potentially because they lived in the context of poverty.  
Participants expressed gratitude that the intervention improved their well-being such that they were 
able to work, and earn money, which improved their mental health and well-being. 
The findings from this study support and extend the use of the VicHealth framework for 
understanding mental health and well-being, and its promotion among this sample. 
7.5.3. Methodological limitations 
There are several possible limitations to the findings of this study, each of which will be discussed in 
turn. 
7.5.3.1. Missing data  
All participants who left the study before the end of the trial period were in the intervention arm of 
this study. Whilst this has been explored in great depth in section 5.1.2, it would be remiss not to 
reflect on it at this point as a potential limitation.   
Field workers from a study conducted in Kenya reported finding it highly distressing to follow study 
protocol in the absence of the people who wrote it (425).  They described ethical dilemmas, where 
they were required to withhold care from patients in need, in order to comply with standard 
operating procedures, increasing the temptation to provide care whilst knowing that this would 
compromise the study (425).  We anticipated these dilemmas, and the pressure on the researcher, 
particularly at the point of randomisation.  The researcher and I discussed in person how important 
it was that the randomisation was conducted correctly, and the implications for the data and future 
research if it was compromised.  However, it is impossible to be certain without being present that 
the randomisation was not compromised, and visibly sicker patients who subsequently died 
preferentially allocated to receive the intervention. 
At the present time, based on a full investigation of the available data for each person, the research 
team as a whole is accepting that this occurred by chance, but should this not be the case, it would 
have implications for the validity of our findings.   
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7.5.3.2. Inability to analyse APOS worry item 
Due to the data type and distribution of the AUC for the APOS worry item, it violated the 
assumptions of linear and ordinal regression models, and therefore could not be analysed. This 
means that I was unable to test for any association between worry over time and demographic and 
clinical variables.   
7.5.3.3. High ineligibility rate 
Of the total sample of patients screened for inclusion in the study, 16.2% of patients were stable on 
ART and reported pain or physical symptoms scored at 3 or above on the APOS and therefore were 
eligible for inclusion in the trial.  For all patients, including those where were not on ART, this figure 
decreases to 13%.     
These findings of this study can only be extrapolated to PLWH with moderate to severe unresolved 
pain or other symptoms.  The eligibility rate indicates that this is a relatively small group of patients.  
Had the eligibility criteria more closely reflected the holistic nature of palliative care, and screened 
for the presence of social, psychological or spiritual problems, the eligibility rate may have been 
higher, and may have more closely reflected the need for holistic care in this patient population.  
Informal communications with the study nurses, who have extensive experience of working with this 
population, indicate that this would be the case.   
7.5.3.4. Refusal rate 
The refusal rate (55.72%) appears to be relatively high compared to studies in similar populations in 
Sub Saharan Africa (30% (426), 12% (427), 3% (428)).  A study conducted in the same region of Kenya 
as the current trial explored the concept of informed consent in a trial with 100% consent rate (429).  
They conclude that many participants consented to participation due to fears of inferior treatment if 
they refused, or because they assumed that there would be direct therapeutic benefit, despite the 
randomised controlled trial study design (429).  This paper also reported that if potential participants 
refused to participate, often it was because they anticipated little personal therapeutic benefit for 
the personal cost to them, either financially or in time (429).  In the light of these findings, our 
comparatively high refusal rate of 55.7% may not be a cause for concern. 
This refusal rate should also be examined in light of the fact that the researcher in the TOPCare 
study was instructed to guide the participants through the information sheet slowly, answer 
questions and specifically advise participants that there would be no consequences to refusal to 
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participate.  A report into informed consent for a diabetes clinical trial in the Navajo tribe in the USA 
revealed that, counter-intuitively, careful explanation of the risks and benefits designed to increase 
trust in the research process was in fact associated with increased mistrust (271).  The extent of the 
detail of the discussions with the research team in this case reportedly lead to embarrassment and 
confusion on the part of the tribes’ people and contributed to a high refusal rate (271).  It is possible 
that the highly detailed, careful approach to the consent process affected prospective participants in 
this study a similar way, which could partially explain the increased refusal rate.  It is also possible 
that due to the clear explanation to participants at consent, participants were aware of the costs to 
them and therefore did not consent if they would be unable to attend and participate fully in the 
study.   
The researcher was also instructed to explain clearly that should the participant be randomised to 
the control arm, they would continue to receive the same care in the clinic as previously but would 
be expected to attend five data collection interviews, each lasting approximately 45 minutes.  
Participants had a good understanding of the costs and benefits of participation, financial and 
otherwise, and the very real possibility that they may not receive the intervention.  Informal data 
gathering by the researcher suggests that the majority who refused to participate were dissuaded by 
the time commitment required, because they would be unable to take time off work to attend the 
appointments.  This is also supported by the minimal attrition rate, which suggests that those who 
consented to participate were aware of the demands on their time and were able to fulfil them. 
It is possible that the participants felt that this research was too costly, either in terms of time taken, 
financially due to missed work opportunities or emotionally due to the sensitive nature of the 
subject.  Respondent burden is defined as a subjective phenomenon of physical, psychological or 
financial hardship associated with participation in research (430).  It is more problematic in 
situations where questions may be sensitive, stressful to answer or the process could be demanding 
in terms of interview time or frequency.  It is important to bear in mind that this study was 
conducted in an outpatient setting, and the patients in this population have roles and 
responsibilities to fulfil outside of the study setting.  Research fatigue has been found to be 
associated with a lack of practical change seen from previous research engagements (431).  The 
study site for this trial is very experienced in conducting research and it is a possibility that this 
population are research experienced, increasing the chance of respondent burden or fatigue.  
Unfortunately no data were formally collected on reasons for refusal to participate.   
A study in Ethiopia exploring the process of informed consent found that having a stigmatising 
condition reduced the likelihood of consent, as participants feared further stigmatisation as a result 
Discussion 
231 
of their participation (432).  As HIV is a stigmatising condition, it is likely that this contributed to 
refusal for some potential participants. 
Finally, in interviews for phase 2, participants were asked why they consented to participate in the 
trial.  Most participants interviewed for phase 2 reported that they consented because they wanted 
to be helped.  It is possible either that those who refused were not experiencing the same level of 
need, or that those consenting had very high levels of need.  Therefore, the refusal rate may impact 
on the quality and generalisability of the findings because those who refused to participate were 
different to those who participated.  Those who consented did not perceive that the demands made 
on them by their roles and responsibilities prohibited them from participating in terms of time, and 
therefore may have been less socially connected, less physically able or different in other ways 
associated with taking on responsibility, or may not have been in paid employment as much.  Those 
who consented also had high levels of need and wanted to be helped, which may not reflect the 
nature of the wider clinic population.   
Should this concern be justified, then in a sample with less need at baseline, who were working and 
therefore less financially constrained, and with more social responsibility and therefore less socially 
isolated, the effect of the intervention may have been not as strong, or even detectable.    
In summary, the refusal rate may be a positive reflection of the extent of the information given prior 
to consent, which meant potential participants were able to make an informed decision about their 
participation.  Other contributing factors could be research fatigue, respondent burden, or the 
stigmatising nature of HIV.  There is however evidence to suggest that those who refused to 
participate may be different to those who consented, indicating further constraint on the 
generalisability of findings.  
7.5.3.5. Cross cultural research  
International best practice in cross language research includes back translation of any translated 
documents to verify internal validity, ensuring that concepts which may be difficult to translate, 
especially culturally bound concepts such as mental health and well-being, are accurately conveyed 
in the translated versions (293).  Due to time and logistical constraints, back translation was not 
undertaken.  This may have introduced some systematic bias and reduced the internal validity, as we 




In addition, 27 qualitative interviews were conducted in Kiswahili, transcribed and translated into 
English for analysis.  It is important to acknowledge that some detail, nuance and inflection may 
have been lost in this translation, in addition to the cultural distance between participants and me as 
the analyst.  This cultural distance means that I may have misinterpreted the data.  According to 
Ingvarsdottir et al, the process of translation includes three ‘coherence systems’, or means for 
understanding and constructing accounts: those of the researcher, the participant and interpreter.  
Whilst on a verbal level there may appear to be agreement and comprehension, it is impossible to 
be sure that there is concordance between all three parties (433).   
The challenges experienced when collecting and analysing data in a different language are similar to 
those experienced in secondary data analysis, primarily because of the cultural distance between 
myself as the analyst and the researcher (274).  Temple et al suggest that interviews conducted in 
the physical absence of the analyst, and in a language that the analyst cannot understand, are 
actually ‘third hand data’ (274).  This may mean that the data lose meaning or are contaminated 
with unjustified interpretation as they undergo collection, interpretation and analysis processes.   
In addition, in a similar way to secondary data analysis, during data collection the analyst cannot 
influence the interaction between researcher and participant, and is not as involved or situated 
within the social context of the research participants and data collection (274).  This may limit the 
lines of enquiry available to the analyst, and inductive themes which emerge may not be able to be 
fully explored, suggesting that the findings may not be complete.   
To mitigate for these effects, I presented initial findings to the Kenya study team, senior hospital 
management and 80 of the 120 participants who were contactable six months after data collection 
closed (section 4.4.3).  This was done using a power point presentation, translated into Kiswahili by 
one of the study nurses.  The participants then asked questions and commented on the findings.  
This was primarily a dissemination exercise, to feedback the preliminary findings to participants as a 
sign of our respect for the participants and the time and effort they put into sharing their 
experiences with the study team, but it was also to verify that the preliminary findings were 
consistent with their experiences.  Feedback was extremely positive.  Participants communicated 
how much they appreciated participating in the study with the senior management of the hospital 
and with the research team from the UK.  They asked that the study continue and be made available 
for all patients in the standard care clinic.  They also asked for more opportunities to talk and for 




7.5.3.6. Transferability of findings  
There are two difficulties with the transferability of these findings. Firstly, this trial tested a palliative 
care intervention, for which experience of chronic pain or symptoms (more than 2 weeks) was used 
as an indication of palliative care needs and thus eligibility.  This cut off was used because the 
primary outcome of the trial was difference in pain; therefore participants with pain were recruited 
to the trial.  This is a limitation of the findings in terms of transferability to other HIV positive 
populations who do not have unmanaged pain or symptoms.  The 16% eligibility rate for this trial 
from in-clinic screening indicates that the findings may not be transferable to the remaining 84% of 
patients who did not have severe to moderate pain or symptoms.  
As previously mentioned, if eligibility for palliative care was defined in this study based on less 
biomedical criteria, it is anticipated that more patients would have been eligible, as the study nurses 
recognised that many patients with or without pain or other symptoms experience social and 
psychological distress.  This suggests that the findings may be more transferable than it initially 
appears, although this warrants further investigation.  
Secondly, the trial was conducted within the context of a country with an established palliative care 
movement.  As previously reported, Kenya has been rated 4a by the International Observatory of 
End of Life care, which means that palliative care services are relatively well developed and are 
beginning to be integrated into mainstream services (26).  This highlights the limitations of the 
findings in terms of transferability to other countries without similarly well developed palliative care 
services, or other holistic care options.  Countries such as Mozambique, which reported a HIV 
prevalence of 11.1% in 2012, and only isolated provision of palliative care might struggle to see 
similar results without the wider support of local expertise in palliative care developed over the past 
decades in Kenya (26, 29).  Should this study be replicated in such an environment, it would be 
possible to identify the contribution of the palliative care infrastructure on the outcomes we 
observed, beyond the holistic philosophy of care.   
7.5.3.7. Regression toward the mean  
The participants recruited to the TOPCare study were recruited on the basis of them reporting a pain 
score of at least 3 on a scale of 0-5.  This relatively high level of pain or symptoms is likely to be 
associated with some level of psychological distress, as is well documented in the HIV literature (223, 
434).  Therefore, if the sample began with higher than normal levels of psychological distress, it is 
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reasonable to assume that this sample would experience some improvement in mental health and 
well-being due to regression to the mean, and not necessarily due to treatment effect.   
Regression to the mean is a statistical phenomenon which describes change in observations from 
the same individual which are not due to the effect of an intervention, but due to natural change 
over time because of the extreme value of the first observation.  Extreme values are described as 
such because they are unusual in the population, and will be therefore caused by a rare combination 
of factors, which due to their rarity, may not occur again in the same combination (435).  If the two 
observations taken from the same individual were uncorrelated, we would expect the second 
observation to be much closer to the population mean, but as these measures are correlated, 
because they are from the same person, the change is less but the direction the same, towards the 
mean.  The further the observation is from the population mean, the stronger the effect of 
regression toward to mean (435).   
To assess for regression to the mean, I compared the data from this study with similar dataset from 
a three month observational study in Kenya of 696 participants taken from PEPFAR funded clinics, 
who reported pain and symptoms on the APOS in addition to the MOS-HIV (331).  MHSS data from 
this study for the participants reporting a pain score of 3, 4 or 5 at baseline (n=151) reported a mean 
change over the observation period of 11.32 MHSS points, which is greater than the 10 points which 
denote clinical significant change (307) .  This suggests that these patients improved over time 
without a specific intervention for their mental health and well-being, due to regression to the 
mean, or other unmeasured contextual factors.  (These patients received clinical management of 
their HIV (99%), a package of health promotion for people living with HIV (94%), with less reported 
receiving psychological support (58%) (331)).   
Mean change in the TOPCare study was 10.32 MHSS points in the control study arm and 12.41 in 
those receiving the intervention care package.  If we assume that the difference seen in the PEPFAR 
data is due to regression towards the mean, in the absence of any other explanation, we must also 
attribute some of the change seen in the TOPCare study data to regression towards the mean.  
However, for the TOPCare study data we have data from mixed methodological approaches, which 
provide evidence to suggest that although the effect seen may be partially due to regression to the 




7.5.3.8. Other possible sources of bias 
Trial effect 
Therapeutic benefit from participation in a trial is a recognised phenomena, and one of several 
referred to in the literature as the Hawthorne effect (436).  Therapeutic benefit from participation 
indicates that participation in a trial improves outcomes for both control and intervention study 
arms, caused by environmental factors such as a study team with a compassionate approach, a 
sense of participation in something important, or pride in being chosen for a research project (436).  
This effect has been identified in medical, education and management research (437, 438).   
It may appear that the sample for the TOPCare study experienced the Hawthorne effect, as 
participants reported improved outcomes in control and intervention study arms.  However closer 
examination of the qualitative data revealed that the therapeutic benefits described could be 
attributed to specific  aspects of study participation, and not simply due to feeling special, observed 
or chosen as a research participant.  The qualitative data helped to elucidate this fact, therefore 
highlighting the benefit of a mixed methods study design for the evaluation of complex interventions 
(439). 
Incidental benefit due to time spent with participants 
The staff team at the study site see approximately 400 patients per day, and depending on the 
presenting complaint, clinical appointments are about 5 minutes long.  The control study arm 
received five of these appointments over the four month study period.  The intervention group 
received a minimum of seven appointments, each lasting from 45 minutes to an hour of one on one 
time with an experienced HIV nurse trained in palliative care.  This means that including data 
collection interviews, the intervention group received a minimum of 540 minutes or 9 hours of 
contact time, whilst the control group received about 250 minutes or just over 4 hours.   
When studying the mental health and well-being of a known stigmatised group it is reasonable to 
assume that the group, who received a minimum of nine hours of contact time over four months, 
would respond more positively than a group who received about 4 hours, of which 25 minutes were 
with a health care professional, over four months.  Participation in the study, and responding to the 
questions in the outcome measures was meant to be simply a data collection exercise.  However in a 
stigmatised and socially isolated population, interaction with a friendly, accepting, non-judgemental, 
professional researcher has therapeutic impact, as seen in the findings of the therapeutic aspects of 
participation.   
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This highlights that there were in fact three levels of participants of interest to this study: the 
intervention participants who received the intervention and 5 interviews with a researcher, the 
control participants who received standard care and 5 interviews with a researcher, and the 
participants at the clinic who received standard care and whose outcomes we could not measure 
without most likely affecting them.  Indeed an interesting and important question is the extent to 
which it is possible to measure mental health and well-being outcomes in a socially isolated and 
stigmatised, minimally literate population, without introducing bias.  Potentially, non-participant 
observation of clinical encounters could be used to explore this group, without affecting their 
outcomes through social interaction.  This approach may help to gain insight into this unstudied 
group    
Systematic bias 
Recall bias affects all studies which rely on participant memory and retrospective data collection 
methods.  The extent of recall bias is affected by the type of knowledge, its importance to the 
participant and the time elapsed since the event (440).  Recall bias was mitigated in this study by 
limiting the time between study exit and qualitative interview.  Recall bias is also associated with 
social desirability, with data more likely to be recalled by participants if it is socially desirable.  
Social desirability bias can be separated into two components: self deprecation and other 
appreciation (441).  This bias reflects the respondent’s tendency to deny socially undesirable traits 
and emphasise more desirable traits, particularly from the imagined perspective of those whom they 
respect or wish to impress.  Participants in this study reported that they were concerned about how 
the study team viewed them, primarily because they liked their company.  One participant expressly 
described how she felt she should report benefit, even if she did not experience it, because she did 
not want the researchers and study nurses to become discouraged by her lack of progress.  It is 
possible that others acted similarly.    
The researcher collecting the qualitative interview data was seen by participants as part of a team 
which provided the care.  Should the respondent want to please the interviewer, who was seen as 
an educated but approachable person, and potentially the person responsible for bringing palliative 
care to the clinic, they may well have spoken about their experience in a more positive light.  To 
counteract this possibility, participants were told that the interviewer was interested in their 
experiences and that there was no right or wrong answer to the questions she was asking.  She was 
also trained to minimise social desirability, by maintaining a neutral stance and approach to 
participants, and not asking leading questions during qualitative interviews.  Social desirability could 
have been further mitigated by having a different researcher collect the quantitative and qualitative 
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data, thus reducing the connection with the intervention and trial.  This was not possible due to 
financial and logistical constraints.   
Interviewer bias, where the data collected is affected by the interviewer, may also be a concern for 
this study, however this was reduced in recruiting the interviewer due to her experience in the field, 
and extending her training in interview technique, including how to minimise systemic bias in health 
systems research (440).  Interviewer bias may still have affected the data collected, as previously 
discussed, even an open and non judgmental affect can have an effect on the participants if they are 
not used to openness and not being judged.   
In this study, participants participating in the qualitative interviews were interviewed at the location 
they received the intervention or where they completed the research questionnaires.  It is likely that 
the data will have been affected by recall bias, particularly those for whom the study was uneventful 
or those for whom there was a bigger time delay between exiting the trial and participating in the 
interview.  This might have been mitigated further, by reducing the time between trial exit and 
qualitative interview.   
7.5.4. Ethical Considerations 
7.5.4.1. Palliative care delivered by outpatients clinic nurses 
Informal communication with the nursing team indicates that the study nurses had difficulty 
maintaining emotional distance from the participants to whom they were delivering palliative care.  
Previously in their careers, there had been no time in a clinic encounter to interact meaningfully with 
their patients, and therefore they had never listened to patient concerns and difficulties in any 
depth, and had never before experienced the intimacy this created.  They reported difficulties 
managing their personal feelings as a result, and described grieving for participants who died during 
the trial in a way they had never before, feeling deep sorrow and relying on each other for support.   
During the palliative care training which the study nurses received in preparation for delivering the 
intervention, personal care was taught and discussed, acknowledging the difficulties associated with 
increased exposure to human distress, suffering and death.  In addition, the nurses had support from 
an experienced palliative care professional who guided them through the personal and professional 
challenge of delivering palliative care for the first time.  It appears that this training and support was 
insufficient to prepare the nurses to healthily manage the emotional labour of caring for participants 
with severe emotional pain.   
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While it is normal and human for nurses to feel sadness at the death of a patient, the extent to 
which these nurses described their grieving was concerning, particularly with the longer term view 
of widening access to supportive or palliative care to all HIV positive patients.  When palliative care is 
delivered in established centres, a wider community of practitioners is immediately available for the 
novice for learn from and be guided by.  The experience of the nurses in this study suggests that 
increased support should be made available, in addition to more time preparing staff for the death 
of patients who will become known to them. 
However, it is also important to note that despite this difficulty, the nurses also reported feeling 
much more fulfilled by their role as palliative care nurses during the study. They felt rewarded by the 
relationships they made through which they saw the participants improve, due in part to their 
efforts.     
7.5.4.2. Care beyond the study period 
Unlike other trials of palliative care interventions, patients who exited this trial were expected to 
continue to live with their condition for many years.  This meant that the needs which were 
identified and addressed by the intervention would no longer be addressed once they returned to 
standard care, and may remain unaddressed for many years.   
This was problematic for eight participants recruited to receive the intervention care package, who 
continued to require a higher level of analgesia than was available at the standard care clinic after 
trial exit.  To address this, the research team worked with the local hospice to source the 
appropriate medications to these patients for a maximum of two months, by which time the 
symptoms had resolved.  Regardless, the patients are now aware that there is another way of 
addressing their medical treatment and care needs, namely palliative or holistic care, which could 
create distress if they felt the standard care was inadequate. 
7.5.4.3. Financial reimbursement 
Participants reported gratitude for the financial reimbursement they received, ostensibly for travel 
expenses.  However, they reported using the money for purchasing higher quality food, medicine 
and health tonics and supporting their family financially.  This raises two issues. 
First, participants allocated to standard care therefore may have purchased medicines and tonics, 
which were inaccessible to patients in standard care who were not participating in the study.  Whilst 
this does not strictly fit the definition of trial contamination, if these medicines and tonics were 
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effective, the comparative treatment effect of the intervention may be reduced, and the possibility 
of a type II error increased (442).  
Second, financial reimbursement appears to have affected participants’ mental health and well-
being.  Essentially, reimbursement was identified as a therapeutic aspect of participation, which was 
not its primary purpose (replacing travel expenses).  This therapeutic effect was likely due to the fact 
that the amounts distributed were considerably more than needed to cover their travel.   
Participants received a flat rate, regardless of distance travelled.  This approach is recommended by 
national research councils (425), but has also been criticised for being usually excessive, 
inappropriate, unaffordable to those unfunded by industry sponsors and ultimately unfair to 
participants who are paid the same amount but who incur different costs, depending on the distance 
travelled (443).   Our participants received 400 Kenyan Shillings.   Minimum daily wage for an 
unskilled employee outside of Nairobi or other major cities in Kenya was 264.50 Kenyan shillings in 
2013 (403.80 for semi-skilled or assistant role, 562.96 for skilled such as baker or general clerk) 
(189).   The TOPCare study offered almost the equivalent of a day and a half’s wages to reimburse 
participants for their transport costs.  This seems excessive, and yet was recommended by local 
stakeholders and cleared by the Kenyan and London based ethics committees.      
It is universally recognised in trial communities that giving participants money to reimburse for 
transport is not the zero sum transaction described in research protocols, but a transfer of net value 
to the study participant (416, 444).  This transfer usually occurs in a context where, in comparison to 
the research institution, the individuals participating in the research are extremely poor (425).  
Molyneux et al. conducted a study to support the development of guidelines for benefits and 
payments for research participants, and found that whilst it is generally agreed that benefits and 
payments should ensure that participants should be compensated for expenses, excessive payments 
or incentives distort the decision making processes, as those in poverty may participate against their 
better judgement (425).  In addition, they highlighted cases where women had returned home with 
their transport money given by the research facility, which had disrupted gender roles within the 
household and led to conflict (425).  Molyneux et al. recommend that payments be set based on 
distance between the research facility and residential zone, and should include a small amount to 
compensate for a drink or snack for the journey (425).   This approach, whilst introducing a layer of 
complexity to transport reimbursements, would reduce the therapeutic effect of this extra money 
and clarify the effect of the intervention. Currently we cannot be sure how much of the therapeutic 
effect seen is due to the alleviation of financial constraint. 
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A further potential problem from this excessive reimbursement of travel expenses is that it could 
potentially have acted as an inducement for participants to consent.  Should it have become 
common knowledge within the clinic that reporting pain or symptoms meant inclusion in the study, 
which guaranteed small but regular source of income for the next five months, this could have 
influenced decision to participate, or even encouraged participants to falsify symptoms to ensure 
recruitment.  To prevent this effect, at recruitment, participants were only told of the amount they 
would be reimbursed after completing the baseline interview.  In addition, the refusal rate of 56% 
would suggest that this effect was not significant. 
It is difficult to address this issue, without addressing the issues of the wider context of the trial 
(poverty, social deprivation), and it is morally difficult to stipulate that people who have financial 
difficulty should not be helped in case this decreases the effect of the intervention.   
7.5.4.4. Informed consent 
Participants in research are vulnerable to potential exploitation, particularly when experiencing pre-
existing vulnerabilities such as illiteracy, sickness or poverty (445, 446).  A lack of appreciation of the 
differences in culture and life experience and disparities in wealth has been a barrier to 
understanding the ethical dilemmas of research conducted in LMIC by privileged researchers from 
more HIC (445).  Informed consent is essential to preserve the dignity, safety, privacy and human 
rights of research participants, and remains an important but complex issue in cross cultural 
research (445) 
The study team was clear that an ethical approach to consent was essential.  Actions taken include 
providing prospective participants with culturally and language appropriate consent materials and a 
Kiswahili speaker to discuss the risks and benefits in detail.   
In the context of this study, many reasons were given for consenting to participate in response to 
questioning during the phase 2 qualitative interviewing.  Many participants reported that they had 
high levels of unmet informational need, which they hoped to address through study participation.  
They also reported that they had unresolved symptoms and pain, which influenced their decision to 
participate. Whilst they were well informed of the study content and requirements, their ability to 
make a decision may have been unfairly influenced by this unmet need. 
Informed consent is a very difficult aspect of a study.  As suggested previously, providing increased 
information, which would be the preferred route in HIC, could be confusing for people with different 
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cultural and educational backgrounds.  On reflection it is my opinion that in the informed consent 
procedure adopted in this study was as high quality as was possible. 
7.6. Future work 
7.6.1. Clinical contributions 
The study findings are discussed below, in the context of improving the clinical care. 
7.6.1.1. Palliative care for PLWH in Kenya 
Baseline data from this study identified unmet psychosocial and spiritual need at recruitment, 
indicating that the holistic needs in patients with life limiting conditions in the clinic study site are 
not being met.  This could be a result of the medical focus of the undergraduate nurse training 
curriculum for nurses attending the University of Nairobi described previously (194), or a general 
lack of prioritisation of psychosocial needs due to the dominant biomedical discourse among staff 
and the necessary rationalisation of staff time due to the volume of patients (see Section 1.4.1.1, Pg 
45).  This would be compatible with findings from a study by Gott et al, that the dominance of the 
biomedical discourse and its associated focus on ‘cure’ as the only legitimate approach to care is a 
barrier to the delivery of holistic palliative care at any time but the terminal phase of life (447).   
In an organisation where this philosophy of cure as the only legitimate form of care is strongest, it is 
likely that the perspectives of professionals from primary health (448) and nursing (199), with a 
more established record of holistic multidimensional approaches to care, are less well received.  In 
these environments, palliative care as a medical speciality which has moved beyond the biomedical 
domain, to a less cure-focused, more patient-centred view has much to contribute to patient well-
being (449).   
The implementation of a short training package in palliative care for the clinic staff may help staff 
recognise the importance of attending to patients’ psychosocial problems, and how this contributes 
to holistic well-being in PLWH.   
7.6.1.2. Peer educators as treatment navigators 
Participants reported both that they had difficulty articulating their problems in the standard care 
clinic, and an appreciation of being treated with compassion and being known by the study team. 
Peer educators could meet these needs relatively inexpensively.   
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Peer educators do currently exist in the standard care clinic, but their role is limited to health 
education provision for a small number of patients.  Their role should be extended to support 
patients as a ‘treatment navigator’ and to monitor patient progress and well-being.  They could meet 
with the patient before they met with a healthcare professional to discuss their holistic well-being.  
This would serve as a space or forum to discuss their experiences of HIV (167), and also fulfil the 
needs of being known, listened to, talk to relieve burdens, and to engage in open communication.  
With some training, peer educators could use a PROM such as the APOS as a springboard for 
discussion, and to assess the patients quickly and efficiently to identify areas of potential need.  They 
could monitor and track previous problems and support the patient in accessing necessary support, 
and in preparing patients’ questions for a clinical encounter with a nurse or medical officer.  This 
would assist the patients in articulating their problems, to make sure they were resolved. Following 
our findings regarding the benefits of a non-judgemental approach, the peer educators should also 
be trained in patient empowerment methods, and in being non-judgemental and maintaining 
patient confidentiality. This position would not need much training, but should be paid to denote the 
importance of the role. 
Potential patients who might benefit from these services could be identified by the nursing staff, to 
whom most of the patients are familiar, but ideally patients could also self-refer to the peer 
educators to ensure that all who felt they needed help could access it.  This intervention would 
encourage patients to take care of their holistic well-being needs and not simply manage the 
physical aspects of HIV.  This would entail a shift in clinic culture which would require support from 
those in senior management. 
The proposed peer educator intervention could be simply evaluated through simple cross sectional 
study, screening multidimensional wellbeing in a random sample of the clinic population not 
accessing the peer support/trackers, and comparing it to those who were receiving the supportive 
service.  
7.6.1.1. Use of traditional healers 
When participants described having time to talk about their problems, some compared it to visiting 
a herbalist, or traditional healer.  This is common in SSA, where most people visit traditional healers 
in parallel with biomedical practitioners (450), where the perceived role of the physician is to relieve 
symptoms, and the traditional healer to explain the cause (451).   
Traditional healers outnumber biomedical practitioners in most countries in SSA, particularly in rural 
areas, and therefore represent an accessible and knowledgeable community resource (451, 452).  
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They routinely provide informal patient-centred care, which is culturally accepted and delivered in 
the context of their understanding of indigenous knowledge systems and models of helping (450, 
452, 453).   
Traditional healers should be explicitly and openly integrated into healthcare provision as 
community contact points.  They could provide a listening service to PLWH, to help them articulate 
their problems, and referring directly to the clinic when beyond their level of expertise.  Mutual 
respect between traditional and biomedical practitioners, lacking in many previous programmes, 
should be a priority for programme managers to ensure optimal benefit from both approaches 
(450). 
7.6.1.2. Material support in the context of poverty 
Although in our study, the financial reimbursement of travel expenses was intended to be a zero 
sum transfer, to reduce barriers to participation in the trial, the amount given was excessive and 
created surplus to be used to alleviate distress associated with financial constraint, after travel was 
reimbursed.   It effectively became part of the intervention, albeit received by all participants and 
not only those allocated to the intervention arm.  This is unsurprising, as financial constraint is 
recognised as a determinant of mental health and wellbeing in the literature, as discussed in section 
1.2.2.3 (56).  Participants in sample were relatively poor, as demonstrated in Table 5-6, (4% owned a 
car, 21% owned a bicycle and 25% owned a fridge). This highlights difficulty of conducting research 
in a non-exploitative way in the context of poverty.  In addition for palliative care, if care is to be 
holistic, potentially interventions which improve participant’s socio-economic status, should be 
considered.   
Recent evidence suggests that the provision of food security and food assistance can have a positive 
impact on treatment adherence for PLWH, who are co-infected with TB (454).  It is possible that in 
this study, as in ours, the provision of material support relieved financial constraint and the 
associated mental health distress, and enabled participants to engage in their health and well-being.   
These findings should inform future interventions and research in this population, and researchers 
should bear in mind the therapeutic impact of relieving financial constraint as an additional source 
of benefit to their intervention.  An evaluation of the effectiveness of an economic intervention 
would be pertinent to our findings that relief of material suffering improved psychological well-
being, and would reflect the wider literature on the social and environmental determinants of health 
and well-being (73, 79, 415). 
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7.6.1.3. Medication  
Our study has identified the unmet need for mild to strong opiates for pain control in this sample of 
PLWH.  It is therefore essential that adequate pain relief be made consistently available, both in 
terms of an improved supply chain to prevent stock-outs in Kenya, and in terms of financially 
accessibility.   
A recommendation from this study is that clinical staff in HIV settings are trained in the use of the 
WHO pain ladder, which is simple to use and recommends inexpensive medication to control pain 
(385).  This should improve care provided the pharmacy is stocked accordingly. Training should also 
be provided to hospital staff responsible for the supply chain of essential medicines to prevent stock 
outs.  This is not an expensive addition to current care, but merely optimisation of existing 
structures, which is particularly important when making recommendations for changes in healthcare 
in LMIC. 
7.6.1.4. Compassionate care 
Our findings indicate that compassionate care is not widely practiced in the standard care clinic, 
probably largely due to the heavy patient load and lack of time.  In light of our findings on the impact 
of a compassionate approach on patients, and the wider literature on the subject, this should be 
addressed as a matter of urgency by the senior management of the clinic.  It would entail a shift in 
culture, increasing the priority and routine of delivering care with a compassionate approach, and 
would require staff training to promote compassionate, patient focused care encounters.  As this 
sometimes can take more time, structural reorganisation may be necessary for nurses to enable 
patients to be listened to, and an opportunity to feel respected and treated with dignity.   
The structural reorganisation would require commitment and continuing support for clinic staff from 
senior management, to ensure that changes made were implemented.  It could be evaluated using 
routine data collected from the clinic such as ART adherence rates, attendance rates, and loss to 
clinic follow-up in the community.  In addition patient’s satisfaction with care could be assessed 
using   a simple indicator on leaving the clinic.  Due to low levels of literacy, this could achieved by 
placing a token or slip of paper in one of three boxes: satisfied, ambivalent or dissatisfied with care 
received in the clinic today.  Should there be many patients reporting dissatisfaction, this could be 
explored through qualitative interviewing.   
The use of a measure of patient rated clinician compassion or empathy such as the Jefferson Scale of 
Physician Empathy (JSPE) (455) or the CARE measure (456) could be used considered and if found 
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favourable, employed at regular intervals.  Although it is recognised that empathy and compassion 
are not synonymous, our study participants perceived expressions of empathy as compassionate, 
and therefore evidence from patient rated empathetic consultations would be informative for 
practice development in the absence of a tool to rate compassion.   
7.6.1.5. Routine screening and one off holistic care encounter 
The study found benefits to intervention participants compared to those receiving standard care 
after one month, possibly due to the initial high intensity of palliative care appointments in the initial 
weeks of the study (Table 3-2).  As a result, screening and a one-off holistic care appointment may 
be effective for improving holistic well-being of patients attending the clinic.  A screening tool, such 
as the APOS, could be used to assess for multidimensional needs of patients attending the clinic, 
with referral to a holistic service for those reporting distress, where time could be taken and a 
holistic assessment of well-being performed.   
To evaluate this intervention, a similar approach to the TOPCare trial design could be used.  A 
random sample of patients should be screened, and if problems were identified in any dimension, 
participants should be randomised to receive either a brief one off palliative care encounter or 
standard care.  All patients would be screened again after a few months to evaluate the 
effectiveness of this intervention.  Short term palliative care interventions such as this have been 
trialled in patients with multiple sclerosis, and found to reduce symptoms and caregiver burden 
(457). 
7.6.1.6. PROMs as a prompt in practice 
The importance of the PROMs as a prompt for participants, particularly those not receiving the 
intervention could be another potential area for an intervention.  Patients waiting in the clinic to be 
seen by the nurse or medical officer should use the time to complete a simple PROM, such as the 
APOS as a short, concise holistic assessment tool. 
This could serve as a prompt to remind the patient to address problems when they are seen by the 
nurse of medical officer, and also as a simple data collection exercise.  If resources were available, 
patients could complete these using an electronic device, which could read the questions to them 
through a headset, to avoid problems with low literacy.  They would record their response using the 
touch screen, which would be stored as routine data, used to track patient progress and improve the 
clinical care.  Patients could request print outs of their progress to act as a further prompt for self-
reflection and self-care.   
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To trial the effectiveness of this simple intervention on patient outcomes, other routinely collected 
data such as CD4 count or adherence data could be compared for those randomly allocated to 
complete the PROMs with those not.  This would allow the evaluation of the effect of completing the 
PROMs separate from the effect of the social interaction with the researcher described during this 
study. 
7.6.2. Implications for policy 
Findings from this study provide evidence that should be integrated into HIV care guidelines, for the 
promotion of holistic well-being for PLWH.   
All patients should be screened for multidimensional needs at regular intervals.  This, with 
appropriate referrals and treatment, will prevent early signs of mental distress developing into 
severe mental illness, which will have an impact on treatment adherence and the future success of 
ART in controlling the HIV pandemic (19). 
Health education should be increased, and provided at all times and in diverse ways which are 
appropriate for the range of patients, adapted to their level of literacy, anxiety and time availability. 
It should be delivered only after time has been spent listening to patients, to ensure that the 
information provided is timely and appropriate, and should be delivered in a context of trust, which 
will increase information retention and the likelihood of a positive outcome.   
Appropriate analgesia should be available and accessible for patients at all times in the clinic 
pharmacy.  Steps should be taken to prevent stock-outs of analgesia included on the WHO pain 
ladder, which is an effective and inexpensive approach to pain management (385). 
Patients should have access to specific social support networks for PLWH as a forum to discuss their 
experience of HIV in a non-judgemental environment, free from the effects of stigma.  Our findings 
indicate the importance of social and emotional support and the potential to learn from others in 
the same situation.  The stigmatising nature of HIV means that a safe and non-judgemental forum to 
discuss their experiences is rarely available, and evidence suggests that this could benefit patients in 
terms of health education and social and emotional support (167). 
Material support should be made more available, consist of more than simply financial 
reimbursement, and be more responsive to the local context and need.  This would mitigate the 
additional constraints placed upon a family with a member living with HIV/AIDS, particularly if the 
affected member is the main breadwinner, and could contribute towards the extra costs incurred 
through illness, such as medication not covered by basic clinic care.  It would also alleviate 
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psychological distress.  Creative income generating programmes should be explored for this patient 
population, to mitigate the effects of sickness due to HIV on family life.  This may involve 
collaborations with community-based organisations in the area, working in areas such as 
microfinance, rolling loans or projects that increase skills and employment options for PLWH.   
Senior hospital management should provide leadership and support for clinicians to develop a more 
patient centred, respectful, caring and non-judgemental approach to care.  This may involve 
increasing staff numbers to reduce workload, stress and burnout, role modelling a compassionate 
approach to patient care and improving team-work in clinics.  Clinical supervision or peer debriefing 
would also recognise and mitigate any negative effects of the emotional labour of this approach to 
nursing. This would increase staff and patient quality of life, mental health and well-being, and 
patient reported satisfaction with care.   
7.6.3. Academic and theoretical contribution 
7.6.3.1. Stigma  
HIV associated stigma is a major barrier to the success of the international effort to curb the spread 
of HIV, and thus the eradication of stigma is recognised as an important goal for international donors 
and other bodies working in the field of HIV (10, 16, 18, 458).  The findings in this study, and the 
novel mapping of findings regarding stigma and stigma resistance onto a pre-existing theoretical 
model of shame resistance, demonstrate the importance of further developing and testing a 
theoretical framework of shame resistance theory among stigmatised PLWH.   
There is evidence that interventions designed to enhance self compassion, in which participants 
explore the concepts of self-criticism and self-compassion in a group context, can enhance resistance 
to HIV-associated stigma (459).  One study found that a group therapy intervention resulted in 
significant reductions in anxiety, depression, feelings of inadequacy, self criticism, self persecution, 
hatred of self, social comparisons, seeing others as “shamers” and submissive behaviour and 
significant increases in self reassurance and self compassion (459).  This appears to follow the shame 
reduction theory described by Van Vliet, in which those who are shamed reframe their experience, 
and begin to separate themselves from the shaming experience, and in the process recover (421).   
Self-compassion and shame resistance interventions should be further developed and evaluated in 
terms of their impact on the experience of stigma and the ability of people with HIV to resist stigma 
and shame.  If the proposed mechanism for the reduction of HIV associated stigma is verified and 
sustained, the implications for PLWH, both in terms of public health and individual health, are 
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considerable.  People at risk and those who suspect they may be positive, would test earlier, and 
more frequently.  This would lead to those eligible accessing treatment earlier, which would lead to 
a reduction in infectiousness, and could prevent transmission to other uninfected people.  Retention 
in care would be easier as patients would not fear being seen at the clinic and inadvertently 
disclosing their status.  Patients would freely disclose their status and therefore access the 
emotional and tangible social support they need to cope with sickness.   
7.6.3.2. Refining the wider trial study design 
The primary outcome of the TOPCare trial was reported pain.  The secondary outcome of the trial 
and the primary outcome of this thesis was psychological quality of life.   
To study the effect of an intervention on mental health and well-being, particularly in socially 
isolated populations, the trial design must minimise the effect of increased social interaction beyond 
receipt of the intervention.  If this is not adjusted for in the study design, as we have found, it is 
difficult to separate out the effect of the intervention from the effect of social interaction through 
participation in the study.  
One possible solution could be to identify the control and intervention arm patients and begin 
collecting repeated measurements of observational data on their holistic well-being before initiating 
an intervention.  This would allow for any changes due to study participation increasing social 
contact to be measured in both study arms.  After one month, the intervention and trial could be 
initiated and therefore any intervention effect more clearly identified.    
7.6.3.3. Ability to share and educational attainment 
The findings show an association between increased ability to share and decreased educational 
attainment.  This finding conflicts with the wider literature on social support and education, and as 
such warrants further investigation in this population.   
7.6.4. Methodological contributions 
This study demonstrates the use of mixed methods to evaluate a nurse-led intervention for PLWH in 
SSA.  To the best knowledge of the study team, this is the first study to evaluate a palliative care 
intervention integrating findings from both quantitative and qualitative methodological approaches 
on a HIV positive sample. The use of mixed methods enabled exploration not only the outcomes of 
the intervention, but also the processes and mechanisms by which these outcomes arose.  In 
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identifying the processes, and in essence, what was effective and why, the intervention can be more 
easily adapted and replicated for different clinical contexts and patient populations.   
Five quantitative data analysis techniques were used to analyse the quantitative data: linear 
regression, ordered logistic regression, logistic regression, area under the curve and multi-level 
modelling.  Each technique has its own advantages and disadvantages, and contributed to 
addressing the study objectives.  As the data were highly non-parametric, ordered logistic regression 
was used when assumptions were not violated.  Use of non-parametric statistics is relatively rare in 
the published data, even when data are subjective measures and collected using an ordinal scale.  
This approach produces a more conservative result, thus maintaining the integrity of the study and 
increasing the likelihood that any associations identified are not the result of statistical error.  
Monthly time point analysis generated comparison data, enabling between arm comparisons at each 
time point, and the identification of the effect of palliative care after one month of intensive 
support.   
The use of multi-level modelling of ordinal variables has not been previously used on APOS data and 
therefore is a novel contribution of this thesis to the research field.  It enabled the analysis of 
repeated measures, adjusting for the bias which would be created by correlation of data by patient.  
In creating a longitudinal summary measure through the use of AUC, analysis of association between 
longitudinal change and clinical and demographic variables was possible. 
In addition this study provides a detailed description of the content of a patient-centred palliative 
care encounter for PLWH, for each appointment, based on patient need.  Palliative care for PLWH is 
relatively under-researched within the wider palliative care research context, and as such this data 
was never before been collected and reported in such detail.  In addition, this highlights the 
contribution of palliative care for PLWH, and identifies components that could be added to standard 
clinic care to improve holistic outcomes. 
The findings also highlight that the traditional view of the researcher as independent observer is 
flawed.  The identification of PROMs as prompts to self-care leading to improvements in mental 
health and well-being demonstrate these difficulties and perhaps the impossibility of collecting 
outcome data from a complex intervention without influencing the outcome.  In addition the impact 
of context on outcome is described through the participants’ reports of the importance of material 
support in the process of therapeutic benefit, thus highlighting the value of acknowledging the open 
system in which the intervention was delivered (244, 263).   
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The use of mixed methods is recommended for the development and evaluation of complex 
intervention such as palliative care (27).  In this case it enabled a detailed examination of the 
experience of receiving a palliative care intervention, and an exploration of the associations 
observed in the quantitative outcome measures, through integration and thus expansion in the 
qualitative data, in addition to exploration of active ingredients and their causal mechanism.  This 
integration of methods creates a richer understanding of the participant experience and adds to the 
work of Plano-Clark, O’Caithain and Curry, who advocate for the use of mixed methods evaluation in 
health services research (242), particularly as in this case, interpretive qualitative methods within an 
RCT (264).   
Following this, the study also highlights and attempts to resolve the ontological tension underlying 
the use of a traditional RCT design in identifying complex causation (244, 261).  If evaluation of the 
effectiveness of the intervention were based solely on the quantitative data analysis, we would be 
unaware of the contribution of compassion, social support, communication PROMs as prompts and 
material support to the outcomes observed.  The use of critical realist theory as a philosophical basis 
to resolve the ontological tension inherent in mixed methods research is also a relatively novel 
contribution.  It has much to offer the science of evaluation research in palliative care, openly 
acknowledging that outcomes of social interaction are complex, context dependent, and usually 
have multiple causal mechanisms, of which we can identify only some (244, 261).  This approach 
describes reality as composed of the empirical, real and actual domains (see section 3.3.2.2), which 





This study found that a nurse-led palliative care intervention for PLWH on ART was effective 
compared with standard care in improving psychological quality of life, the ability of participants to 
share their feelings and in reducing psychiatric morbidity, but had no effect on levels of worry.  
Barriers to therapeutic benefit were persistent physical, social or financial problems.  The active 
ingredients of the intervention were identified as health education and counselling, medication, and 
providing time to talk to enable participants to articulate their problems. 
These findings suggest that simple additions of health education, access to medication and allocating 
time to talk and articulate problems could be sufficient to address many of the mental health and 
well-being problems experienced by PLWH.  These interventions could be achieved economically, 
through minimal staff training and optimising pre-existing supply chains for medication.  Time for 
participants to talk could be created through extending the role of peer educators, or integrating the 
expertise of traditional healers into the care delivered.   
Participation in the study was therapeutic beyond receipt of the intervention.  Participants in both 
study arms described benefit from experiencing compassion, social support, communication and 
material support and through using the PROMs as a prompt to self care.  These therapeutic aspects 
of study participation were effective through establishment of a trusting relationship, first between 
the study team and the participants, and then amongst the community, and through increases in 
feelings of personal control and thus self esteem and self-image.   
These therapeutic aspects of participation highlight the current low level of trusting relationships 
and social support described by PLWH, possibly due to HIV-associated stigma.  This study found that 
trusting relationships led to a rebuilding of self-image, the forging of stigma resistant identities and 
improvements in mental health and well-being.  A theoretical contribution of this study was to map 
this rebuilding process onto pre-existing theories of shame resistance, extending the theory to HIV-
associated stigma.  Should a model of care based on this theory of resistance to stigma be proven 
effective, the implications for PLWH could be significant, as it would improve access to HIV testing, 
treatment, medication adherence and the social emotional and physical well-being of PLWH.   
This study also made four methodological contributions.  First, the study demonstrates the value of 
mixed methods in the context of an RCT, which although generally recommended, is still relatively 
novel in palliative care research.  Each methodological approach contributed to a sophisticated 
understanding of the complex intervention, and the influence of contextual factors on its 
implementation and effectiveness.  Secondly, the paradigm of critical realism was found to be a 
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useful stance from with to conduct mixed method research, resolving the ontological tension, and 
contributing an emphasis on contextual factors and underlying causal mechanisms, which helped to 
identify and conceptually integrate the findings.  Thirdly, the use of multilevel modelling to analyse 
repeated measures has never before been used on APOS data.  This analysis can be done effectively 
to adjust for the potential bias created by correlation of repeated observations by patient, and 
should be used in future research, to generate more rigorous findings using the APOS data.  
Fourthly, this study has deepened understanding of the methodological complexities of conducting 
an RCT in context of social need, such as poverty and social isolation due to stigma.     
This study has shown that a nurse-led palliative care intervention is an effective model of care for 
meeting the holistic needs of PLWH on ART, describing the effect of health education, medication 
and time to articulate problems, intrinsic to the palliative care approach.  The participants’ 
appreciation of compassionate care, social support, communication, prompts to self-care and 
material support highlights the difficulties of conducting research in a population with complex 
needs, related to poverty, stigma and social isolation.   
The findings of this study represent a novel contribution to the evidence base for the development 
and evaluation of a holistic model of care, which helps to meet the multidimensional needs of PLWH 
experiencing HIV infection as a chronic condition, particularly within the constraints of healthcare 
systems in LMIC.  Furthermore, the findings of this study support efforts to increase resistance of 
PLWH to stigma and discrimination, with associated benefits for public health as well as individuals’ 
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Appendices 
Appendix 1 – Timeline of PhD and TOPCare study 
Date TOPCare trial event My timeline 
09/2010 Study designed  
Funding grant submitted 
 
10/2010 Funding granted Ethics approval 
submitted 
 
11/2010   
12/2010 Ethics approval granted from Kings 
and KEMRI in Kenya  
 
01/2011 Study nurses appointed and 
trained 
 
02/2011 Study documents developed and 
standardised operating procedures 
finalised 
 
03/2011 Ethics approval granted from South 
Africa  
Study launch in Cape Town South 
Africa 
Training researchers 
Started PhD  
Finalise TOPCare study documents  
 
04/2011 Recruitment starts in Kenya Monitoring recruitment 
05/2011   
06/2011   
07/2011 Recruitment in Kenya stops and  
recommences 
Visit to Mombasa to resolve 
matters arising during recruitment  
08/2011   
09/2011  Design qualitative component of 
study 
10/2011   
11/2011  Apply for ethical approval for 
qualitative data collection 
12/2011   
01/2012 Apply for extension of trial period 
to Kenyan and Kings ethics 
submitted 
 
02/2012 Recruitment and data collection 
starts in parallel South African 
study site 
 
03/2012 Approval for extension of study 
period granted  
 
Kings ethics approval for qualitative 
data collection granted 
04/2012   
05/2012  Kenyan ethics approval for 
qualitative data collection granted 
06/2012 Qualitative data collection begins 
in Kenya 
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07/2012 Quantitative data collection 
complete 
PhD upgrade successfully 
completed  
Recruitment for transcription and 
translation of qualitative data 
begins 
08/2012   
09/2012 TOPCare study protocol paper 
submitted to BMC Infectious 
diseases  
Analysis of quantitative data 
commences 
10/2012 Qualitative data collection 
complete 
 
11/2012 TOPCare study protocol published 
in BMC infectious diseases 
Translation of qualitative data 
complete Analysis of qualitative 
data commences 
12/2012 Dissemination of preliminary findings to patients and staff in South Africa 
and Kenya 
01/2013   
02/2013   
03/2013   
04/2013   
05/2013  European Association Palliative 
Care Conference – poster 
presentations 
06/2013  Systematic review submitted to 
International Journal of Nursing 
Studies 
07/2013   
08/2013   
09/2013  AIDS Impact conference – oral 
presentation 
10/2013   
11/2013   
12/2013 Recruitment data paper submitted 
to BMC research Notes 
 
01/2014   
02/2014  Systematic review published online 
in the International Journal of 
Nursing Studies 
03/2014   
04/2014  RCN International Research 
Conference – oral presentation 
05/2014   
06/2014   
07/2014  Submit PhD 
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Report over past 2 weeks  
1. How have things been going? 
 
 
2. Have you met any problems? 
 
 
3. How many days were you recruiting for? 
 
 
4. Report for last 2 weeks. 
Number of patients screened by triage nurse. 
 
Number scoring 3-5 on pain/symptoms. 
 
Number assessed against exclusion criteria 
 
Number invited into study 
 
Number refused  
 
Number new enrolled 
 
Number randomised to intervention 
 
Total enrolled from start 
 
Total number completed 
 
 
5. Triage nurses 
Did they have any problems? 
 
Did they report number screened? 
 
 
6. Data Entry 
Has data been entered for all these patients? 
 
Have you made a backup? 
 
7.  Plans for the next month. 
How many days a week do you plan to recruit? 
 
How many patients do you plan to recruit in the next month? 
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Appendix 3 – Systematic review paper 
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Appendix 4 – Ethical approvals 
Ethical approval form from KEMRI 
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Ethical approval form from Kings College London 
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Ethical approval from KEMRI for qualitative data collection 
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Ethical approval from Kings College for qualitative data collection 
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Appendix 6 - Data collection tools 
Demographic questionnaire 
   ANSWER 
D1 Gender 1=Male 
2=Female 
 
D2 Age  
 
  
D3 Has a partner 1=Yes 
2=No 
 
D4 How many people are you 
financially responsible for? 
  
D4a How many children do you 
have? 
  
D5 What is the highest level of 
education you have attended? 
0=No school 




5=Degree or higher 
 
D6 Date enrolled in care at this 
facility 
 
_ _ / _ _ /_ _ 
D7 Date of HIV diagnosis  
_ _ / _ _ /_ _ 
D8 Date of ART initiation  
_ _ / _ _ /_ _ 
D9 Most recent CD4 count  
 
D10 Date of most recent CD4 count  _ _ / _ _ /_ _ 
D11 WHO stage   
D12 Date of WHO stage recording  _ _ / _ _ /_ _ 
D13 Received AIDS diagnosis 1=Yes 
2=No 
 
D14 Receiving TB treatment 1=Yes 
2=No 
 
D14a Does your immediate family 




D15 What is the main material used 
to make the floors of your 
house? 








D16 What is the main material used 
to make the walls of your 
house? 
0=Thatched/straw 
1=Mud and poles 
2=Un-burnt bricks 
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7=Wood timber 
8=Burnt bricks with cement 
D17 What is the main material used 










D18 What type of toilet do you use 
at home?  
1=Private flush 
2=Private VIP latrine  
3=Private traditional pit (covered) 




D19 What is the main source of 
drinking water for your house? 
0=Bottled 
1=Piped inside house 








D20 What type of fuel does your 











9=No food cooked in household 
 
 Does anyone in the household 
own a...? 
  
D21 Bicycle 1=Yes 
2=No 
 
D22 Refrigerator 1=Yes 
2=No 
 
D23 Television 1=Yes 
2=No 
 
D24 Car  1=Yes 
2=No 
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The APOS & ECOG 
 ASK THE PATIENT Questions 
1-7 
POSSIBLE RESPONSES ANSWER 
P1 
 Please rate your pain (from 0 = 
no pain to 5 = 
worst/overwhelming pain) 
during the last 3 days 





5 = Overwhelming. The worst pain you can imagine 
 
P2 
Have any other symptoms (e.g. 
nausea, coughing or 
constipation) been affecting 
how you feel in the last 3 days? 





5 = overwhelmingly 
 
P3 
Have you been feeling worried 
about your illness in the past 3 
days? 





5 = Worried all of the time 
 
P4 
Over the past 3 days, have you 
been able to share how you are 
feeling with your family or 
friends? 





5 = Yes, I’ve talked freely 
 
P5 
Over the past 3 days have you 
felt that life was worthwhile? 





5 = Yes, all the time 
 
P6 
Over the past 3 days, have you 
felt at peace? 





5 = Yes, all the time 
 
P7 
Have you had enough help and 
advice for your family to plan 
for the future? 











Physical function of patient 
Rated by the interviewer 
 
0= fully active, able to carry on all pre-disease performance 
without restriction 
 
1=Restricted in physically strenuous activity but ambulatory 
and able to carry out light work, e.g., light house work, office 
work 
 
2=Ambulatory and capable of all selfcare but unable to carry 
out any work activities. Up and about more than 50% of 
waking hours 
 
3=Capable of only limited selfcare, confined to bed or chair 
more than 50% of waking hours 
 
 
Appendix 6 – Data collection tools 
314 
4=Completely disabled. Cannot carry on any selfcare. Totally 





Ask THE CARER Questions 8, 9 and 10 ONLY if consent given by 
patient and carer 
 
P8 
How much information have 
you and your family been 
given? 





5 = As much as wanted 
7 = N/A, no carer/consent not given 
8 = Carer not present at time of interview 
 
P9 
How confident does the family 
feel caring for ____? 





5 = Very confident 
7 = N/A, no carer/consent not given 
8 = Carer not present at time of interview 
 
P10 
Has the family been feeling 
worried about the patient over 
the last 3 days? 





5 = Worried all of the time 
7 = N/A, no carer/consent not given 
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The MOS-HIV 
No. QUESTION POSSIBLE RESPONSES ANSWER 
I would like to ask you a few questions about your health.   






M2 How much bodily pain have you generally had during 








M3 During the past thirty days, how much did pain interfere 
with your normal work, including both work outside the 
home and housework? 
1=Not at all 
2=A little bit 
3=Moderately 
4=Quite a bit 
5=Extremely 
 
The following questions are about activities that a person might do during a typical day. Does your health 
now limit you in the following activities? And if so, how much? 
 1=Yes, limited a lot 
2=Yes, limited a little 
3=No, not limited at all 
M4A The kinds or amounts of vigorous activities you can do 
like digging, fetching water from a well, carrying a load, 
splitting firewood, running, lifting heavy objects or 
engaging in strenuous sports 
 
 
M4B The kinds of moderate activities you can do like washing 












M4E Walking a moderate distance, like the length of a 
football pitch or taking a village walk 
 
 
M4F Feeding, dressing or bathing yourself or ability to use 
the latrine   
  
The following questions are about work. Does your health now restrict you in doing the following kinds of 
work? 
M5 Does your health keep you from working at a job, doing 
work around the house or attending school? 
1=Yes 
2=No  
M6 Have you been unable to do certain kinds or amounts of 
work, housework, schoolwork, because of your health? 
1=Yes 
2=No  
For each of the following questions, please tell me the answer that comes closest to the way you have been 
feeling. 
 (Interviewer must begin by reading this introductory 
question to the patient) 
 
How much of the time during the past 30 days: 
1=All of the time 
2=Most of the time 
3=A good bit of the time 
4=Some of the time  
5=A little of the time 
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6=None of the time 
M7 Has your health limited your social activities, like visiting 
with friends or family? 
 
 
M8A Have you been a very nervous person? 
 
  
M8B Have you felt calm and peaceful? 
 
  
M8C Have you felt depressed? 
 
  
M8D Have you been a happy person? 
 
  
M8E Have you felt so depressed that nothing could cheer 
you up? 
  
M9A Did you feel full of life and energy? 
 
  
M9B Did you feel totally without energy? 
 
  
M9C Did you feel tired? 
 
  
M9D Did you have enough energy to do the things you 
wanted to do? 
  
M9E Did you feel weighed down by your health problems?   
M9F Were you discouraged by your health problems?   
M9G Did you feel despair over your health problems?   
M9H Were you afraid because of your health? 
 
  
M10A Did you have difficulty reasoning and making decisions, 
for example, making plans or learning new things? 
  
M10B Did you forget things that happened recently, for 




M10C Did you have trouble keeping your attention on any 
activity for long? 
  
M10D Did you have difficulty doing activities involving 
concentration and thinking? 
  
 Please tell me the answer that comes 
closest to describing whether the 










M11A You are somewhat ill 
 
  
M11B You are as healthy as any other person you 
know 
  
M11C Your health is excellent 
 
  
M11D You have been feeling bad recently 
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M12 How has the quality of your life been 
during the past thirty days? That is, how 
have things been going for you? 
1=Very well, could hardly be better 
2=Pretty good 
3=Good and bad parts bout equal 
4=Pretty bad 
5=Very bad, could hardly be worse 
 
M13 How would you rate your physical health 
and emotional condition now compared to 
thirty days ago? 
1=Much better 
2=A little better 
3=About the same 
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GHQ-12 
  Have you recently…  ANSWER 
G1 
Been able to concentrate on whatever you are 
doing? 
1=Better than usual 
2=Same as usual 
3=Less than usual 
4=Much less than usual 
 
G2 Lost much sleep over worry? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G3 Felt that you were playing a useful part in things? 
1=More than usual 
2=Same as usual 
3=Less so than usual 
4=Much less than usual 
 
G4 Felt capable of making decisions about things? 
1=More so than usual 
2=Same as usual 
3=Less so than usual 
4=Much less capable 
 
G5 Felt constantly under strain? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G6 Felt you couldn’t overcome your difficulties? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G7 
Been able to enjoy your normal day-to-day 
activities? 
1=More so than usual 
2=Same as usual 
3=Less so than usual 
4=Much less than usual 
 
G8 Been able to face up to your problems? 
1=More so than usual 
2=Same as usual 
3=Less able than usual 
4=Much less than usual 
 
G9 Been feeling unhappy and depressed? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G10 Been losing self-confidence in yourself? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G11 Been thinking of yourself as a worthless person? 
1=Not at all 
2=No more than usual 
3=Rather more than usual 
4=Much more than usual 
 
G12 
Been feeling reasonably happy, all things 
considered? 
1=More so than usual 
2=Same as usual 
3=Less so than usual 
4=Much less than usual 
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Adherence and risk 
  Possible responses ANSWER 
R1 
Have you had sex in the past two months? 1=Yes 
2=No [go to question R4] 
 
R2 
Have you had sex without protection in the past two 
months? 
1=Yes 




Have you had sex without protection in the past four 






How many doses of ART have you missed in the past 
seven days? 
Write the number. If none 




Client services receipt inventory 
 
Area of care . 
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Area of care . 
In the past month have you received..? 
8= Don’t 
know ANSWER 




















 SOCIAL  
C19 
Discussion with staff about your future if you were to  














Financial support ie. Access or help with accessing funding or benefits, 
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Appendix 7 –Clinical assessment sheet  






Ask the patient to show where their pain comes on the scale of 0-5 
 
 
0  1  2  3  4  5 
 
Important questions to ask the patient 
Where is the pain (there may be more than one pain) 
When did it start? 
What does it feel like? (eg. stabbing, cramping, burning etc) 
Timing – is the pain there all the time or does it come and go? 
 Does the pain cause you to wake up at night? 
Treatment – has any treatment been tried and has it helped? 
Change – what makes it better or worse (eg movement, eating, time of day etc)? 
Cause – what do you (the patient) think is causing the pain? 
 
 
Pain assessment comments: 
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Body chart   

















Could you list the five worst symptoms you 
have experienced in the past five days? 
 
 
For example: nausea or vomiting, pain, lack of 
energy, lack of appetite, constipation, 














   
 
Body chart assessment comments: 
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Activities of daily living  
 Independent Needs 
assistance 
Dependent 
Bathing    
Dressing    
Toilet    
Mobility     
Continence    







Understanding of illness and consequences  
What do you understand by your illness? 
What does your family understand? 
What is your main distress? 
What is your family’s main distress? 
What are your expectations? 
What are the family’s expectations? 
Activity of daily living assessment comments: 
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Has the illness affected any close relationships? (this may include sexual issues) 





Family support (discuss)  
















Understanding of illness assessment comments: 
Economic situation assessment comments: 
Family support assessment comments: 
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Emotional assessment  
Over the last two weeks have you been  
bothered by: 
little interest or pleasure in doing things 
feeling depressed or hopeless 
feeling sad 
feeling worried 
trouble falling asleep or sleeping too much 
feeling tired or having little energy 
poor appetite or overeating 
feeling irritable 
feeling bad about yourself – that you are a failure or have let yourself or your family down 
trouble concentrating on things 
moving or speaking so slowly other people could notice, or being very fidgety and  
restless feeling nervous 
thoughts that you would be better off dead or of hurting yourself in some way 
If you have been bothered by any of these problems, how difficult have they made it for you to do 
your work, take care of things at home, or get along with other people? 






Emotional assessment comments: 
 




Faith – What do you believe has brought meaning to your life? Do you have a faith or belief?  
Importance – How important is your faith or spirituality to you?  How is it important? 
 
Importance of religion/faith or belief system in life (please circle) 
Great   Moderate   Unimportant   Nil 
 
Community – Are you part of a religious or spiritual community?  If you don’t have a community, 
would it help you if you found one? Do you pray with others? Does it help you?  Would you like to 
give us your religious adviser contact number so we can assist you in contacting them? 
Peace - Are you at peace with your faith or belief? Are you at peace with your family? 
Address or Application – Can we help in any way? How would you like me to address these issues in 
your healthcare?  How do these issues impact your current situation? Do you have any fears or 
concerns regarding your spirituality which we may be able to address? Has your illness in any way 










Spiritual assessment comments: 
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ANTI-RETROVIRAL THERAPY 







  Yes No  
1 Is the patient experiencing uncontrolled pain?   
2 Is the patient experiencing unresolved physical problems (including 
problems with sleeping, appetite, nausea, bowel, breathing or fatigue)? 
  
3 Does the patient have problems with daily living activities?   
4 Does the patient have any concerns about their understanding of their 
illness? 
  
5 Does the patient have problems with family relationships or support?   
6 Does the patient have financial or legal concerns that are causing distress or 
require assistance? 
  
7 Does the patient have psychological problems that are interfering with 
wellbeing or relationships? 
  
8 Does the patient have concerns about spiritual or existential issues?   
9 Does the patient have problems taking, tolerating, or adhering to ART?   
 
Antiretroviral therapy assessment comments: 
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Appendix 8 - Ongoing record 
     Patient’s name _____________________________ 





































































































Appendix 9 – Patient information and consent forms for phase 1 and 2 
329 
Appendix 9 – Patient information and consent forms for phase 1 and 2 
TOPCare trial Patient Information Sheet 
REC Reference Number: BDM/10/11-13 
You will be given a copy of this Information sheet 
We would like to invite you to take part in this original research project.  You should only participate 
if you want to; choosing not to take part will not disadvantage you in any way. Before you decide 
whether you want to take part, it is important for you to understand why the research is being done 
and what it will involve for you.  Please take time to read the following information carefully and 
discuss it with others if you wish.  Ask us if there is anything that is not clear or if you would like 
more information. 
What is the purpose of the study? 
We want to find out whether providing extra care and support makes people with HIV feel better if 
they are taking antiretroviral therapy (anti-HIV drugs, also known as ART). It is called the TOPcare 
Trial, standing for ‘Treatment and Outcomes in Palliative care’.  
Why have I been chosen? 
We are asking every patient to take part who is aged over 18, has HIV, is taking antiretroviral 
therapy, and has severe pain or symptoms. We hope for 120 people at this facility to take part. You 
were chosen because you told the triage nurse that you had pain or symptoms which were severe or 
worse.  
Do I have to take part? 
No, you don’t have to take part. You are free to withdraw at any time, and you don’t have to give a 
reason. If you are one of the people chosen to receive care and support and you decide to withdraw 
from the study, you will still have the care and support for all the time you would have been in the 
study. You can also decide to remove all data about you from the study, up until July 2012. After that 
time it will no longer be possible to identify which data is yours. 
What will happen if I take part? 
You will be given this information to keep if you wish and asked to sign a consent form to show that 
you have agreed to participate. The research assistant will ask you to complete seven 
questionnaires, which will take about 40 minutes altogether. Then you will be asked to take a piece 
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of paper from a bag which will indicate whether you are going to receive ordinary care or extra care 
and support. Half the people in the study will get extra care and you have exactly the same chance 
as everyone else. 
If you are in the ordinary care group, you will be asked to complete five or six questionnaires each 
month for four months with the research assistant, which will take about 30 minutes. Your care will 
be exactly the same as the normal care provided at the clinic. If you are in the extra care and support 
group, you will be assigned to a new nurse who has training in extra care and support. You will also 
be asked to complete the same five or six questionnaires once a month for four months with the 
research assistant. After four months the research will be over and you will continue to receive the 
standard care offered at this clinic. 
The questionnaires are about how you feel and what care you have had. Some of the topics are  
Physical problems like pain or symptoms 
Whether you are worried 
Whether you have problems working 
Whether you feel happy or unhappy 
What kinds of care you have received from the clinic 
 
While taking part, there is a slight risk you may get anxious or embarrassed. You can ask to take a 
break or withdraw from the study at any time. Everything you say will be completely private unless 
the interviewer thinks you or your family’s safety is at risk, in which case they may have to tell your 
care team.  
Are there any other effects of being in the study?  
If you choose to participate, we will provide US $5 to pay for your transport to get to the facility. 
When we finish the study, we will give copies of the final report to the facility and arrange that you 
can have a copy if you want. If we find that extra care and support does help people taking ART, then 
we will provide training for all the nurses at this clinic, so that all the patients will be able to get extra 
care and support. This will happen after the end of the study. 
Will my taking part in this study be kept confidential? 
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All the information which we collect during the interview will be kept strictly confidential and 
anonymous. You will not be identified in any way, and your personal details (for example name and 
address) will be kept separately from the information you give. We will NOT let anyone have any 
information that could identify you. Any information you give us will NOT be kept with anything that 
could identify you (like your name or address). You may withdraw your data from the project at any 
time up until July 2012. 
What happens to the results of the research study? 
We will add your results with those from 119 other people at this facility to find out whether people 
receiving extra care and support have better outcomes over time. We may also share the 
anonymous data with other researchers.  
Who is organising the research? 
This study is being organised by King’s College London (UK). The Kenyan and King’s College London 
Research Ethics Committees have reviewed this study and approved it for your protection.  
Who can I contact? 
If you’d like to talk to someone about the study, or get more information, or if you have experienced 
any harm as a result of this study, please contact: 
Dr Richard Harding (Principal Investigator) 
Department of Palliative Care, Policy and Rehabilitation 
Cicely Saunders Institute, Kings College London 
School of Medicine at Guy’s, Kings and St Thomas Hospitals 
Bessemer Road, London UK, SE5 9RJ 
Tel: +44 (0) 20 7848 5518 
Dr Zipporah Ali (Country Study Coordinator) 
National Coordinator, Kenya Hospices and Palliative Care Association 
Chaka Court, Off Argwings Kodhek Road, Next to Chaka PLACE, Hurlingham 
P.O Box 20854-00202, Nairobi, Kenya 
Tel: +254 (20) 2729302 
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Consent Form 
REC Reference Number: BDM/10/11-13 
Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
Thank you for considering taking part in this research. The person organising the research must 
explain the project to you before you agree to take part.  If you have any questions arising from the 
Information Sheet or explanation already given to you, please ask the researcher before you decide 
whether to join in. You may take a copy of this Consent Form to keep and refer to at any time. 
I consent to the processing of my personal information for the purposes explained to me.  I 
understand that such information will be treated as strictly confidential and will be handled in 
accordance with the terms of the UK Data Protection Act 1998. 
I understand that if I decide at any time during the research that I no longer wish to participate in 
this project, I can notify the researchers involved and withdraw from it immediately without giving 
any reason. Furthermore, I understand that I will be able to withdraw my data at any time up to July 
2012 
I agree that the research team or other researchers may use my data for future research and 
understand that any such use of identifiable data would be reviewed and approved by a research 
ethics committee.  (In such cases, as with this project, data would not be identifiable in any report). 
Participant’s Statement:  
I _____________________________________________ (Participant’s name) agree that the 
research project named above has been explained to me to my satisfaction and I agree to take part 
in the study. I have read both the notes written above and the Information Sheet about the project, 
and understand what the research study involves. 
Signed_____ __________________ Date_____________ Researcher’s signature here indicates 
        witness to thumbprint 
Researcher’s Statement: 
I ________________________________ confirm that I have carefully explained the nature, demands 
and any foreseeable risks (where applicable) of the proposed research to the participant.  
Signed ___________________________________ Date__________________  
Please tick  
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Patient Information Sheet for qualitative interview 
         You will be given a copy of this Information sheet 
As a patient who has participated in the TOPCare study, we would like to invite you to take part in 
one extra interview.  You should only participate if you want to; choosing not to take part will not 
disadvantage you in any way. Before you decide whether you want to take part, it is important for 
you to understand why the research is being done and what it will involve for you.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information. 
What is the purpose of the study? 
We want to find out about your experience of receiving care in this study, and whether it has had 
any impact on your life, your relationships, your family or your own wellbeing. We will use this 
information to plan care for this clinic and others like it. 
Why have I been chosen? 
We are asking patients who have completed the TOPCare study.  We hope for 25 people at this 
facility to agree to participate in this extra section.  
Do I have to take part? 
No, you don’t have to take part. You are free to withdraw at any time, and you don’t have to give a 
reason. You will continue to receive treatment at your clinic either way. 
What will happen if I take part? 
You will be given this information to keep if you wish and asked to sign a consent form to show that 
you have agreed to participate. The research assistant will ask you some questions about your 
experience of receiving care while you have been part of this study.  This interview will take from 15 
minutes to an hour, depending on how much you have to say.  The interview will be recorded with 
your permission.  None of the people providing you with care will hear the recording, just the 
research staff. Your personal details (e.g. name and address) will not be given to anyone and your 
answers will be kept separately. We will use all responses to write up reports on how we think 
receiving care affects people and what is the most important part of this care.  Nothing you say will 
be identified as coming from you 
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You will be asked to do this interview ONCE.   
While taking part, there is a slight risk you may be asked about things that could make you feel 
anxious or embarrassed. You can ask to take a break or stop the interview at any time. Everything 
you say will be completely private and confidential unless the interviewer thinks you or your family’s 
safety is at risk.  If this happens, they may have to tell someone in your care team who can ensure 
safety.  This will not be done without discussing it with you first.   
Are there any other effects of being in the study?  
If you choose to participate, we will provide US $5 to pay for your transport to get to the facility. 
When we finish the study, we will give copies of the final report to the facility and arrange that you 
can have a copy if you want. You will also be informed about a meeting where you will have an 
opportunity to hear about the findings of the study and ask questions of the research team in 
person.   
Will my taking part in this study be kept confidential? 
All the information which we collect during the interview will be kept strictly confidential and 
anonymous. You will not be identified in any way, and your personal details (for example name and 
address) will be kept separately from the information you give. We will NOT let anyone have any 
information that could identify you. Any information you give us will NOT be kept with anything that 
could identify you (like your name or address). You may withdraw your data from the project at any 
time up until December 2012. 
What happens to the results of the research study? 
The findings from the study will go together with the findings from the larger trial that you were also 
part of.  This will help us to understand if people receiving extra care and support have better 
outcomes over time and what this experience is like. It will help people to understand what works in 
terms of care and why.  We may also share the anonymous data with other researchers.  
Who is organising the research? 
This study is being organised by King’s College London (UK). The Kenyan Medical Research Institute 
and King’s College London Research Ethics Committees have reviewed this study and approved it for 
your protection (BDM/10/11-31) 
Who can I contact? 
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If you’d like to talk to someone about the study, or get more information, or if you have experienced 
any harm as a result of this study, please contact either of the following:  
Dr Richard Harding (Principal Investigator) 
Reader in Palliative Care 
Department of Palliative Care, Policy and Rehabilitation 
Cecily Saunders Institute 
Kings College London 
School of Medicine at Guy’s, Kings and St Thomas Hospitals 
Bessemer Road 
London UK, SE5 9RJ 
Tel: +44 (0) 20 7848 5518 
Dr Zipporah Ali (Country Study Coordinator) 
National Coordinator, Kenya Hospices and Palliative Care Association 
Chaka Court, Off Argwings Kodhek Road, Next to Chaka PLACE, Hurlingham 
P.O Box 20854-00202, Nairobi, Kenya 
Tel: +254 (20) 2729302 
The Secretary, (Country Ethics Committee)  
National Ethics Review Committee, KEMRI 
P.O Box 54840-00200, Nairobi, Kenya 
Tel: +254 (020) 2713349/2722541 
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Consent Form for Qualitative Interview 
REC Reference Number: BDM/10/11-13 
Please complete this form after you have read the Information Sheet and/or listened to an 
explanation about the research. 
Thank you for considering taking part in this research. The person organising the research must 
explain the project to you before you agree to take part.  If you have any questions arising from the 
Information Sheet or explanation already given to you, please ask the researcher before you decide 
whether to join in. You may take a copy of this Consent Form to keep and refer to at any time. 
I consent to the processing of my personal information for the purposes explained to me.  I 
understand that such information will be treated as strictly confidential and will be handled in 
accordance with the terms of the UK Data Protection Act 1998. 
I understand that if I decide at any time during the research that I no longer wish to participate in 
this project, I can notify the researchers involved and withdraw from it immediately without giving 
any reason. Furthermore, I understand that I will be able to withdraw my data at any time up to 
December 2012 
I agree that the research team or other researchers may use my data for future research and 
understand that any such use of identifiable data would be reviewed and approved by a research 
ethics committee.  (In such cases, as with this project, data would not be identifiable in any report). 
I consent to my data being used in education for teaching and training. 
I consent to audio recording of my interview for research purposes 
Participant’s Statement:  
I _____________________________________________ (Participant’s name) agree that the 
research project named above has been explained to me to my satisfaction and I agree to take part 
in the study. I have read both the notes written above and the Information Sheet about the project, 
and understand what the research study involves. 
Signed_____ __________________ Date_____________  
Researcher’s signature here indicates witness to thumbprint 
Researcher’s Statement: 
Please tick  
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I ________________________________ confirm that I have carefully explained the nature, demands 
and any foreseeable risks (where applicable) of the proposed research to the participant.  
Signed ___________________________________ Date__________________ 
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Appendix 10 - Topic guides for qualitative data collection 
Interview topic guide - Intervention patients 
Introduce self again, welcome client and thank for taking part.  Explain that this is an opportunity to 
explain what it was like being in the TOPCare trial in a freer way – your own experience, in your own 
words. 
Admin: - Complete consent form, Add in ID number, ask about more questions.  
Briefly recount TOPCare trial, MOS-HIV, asked questions about emotional and physical well-being.   
Present trajectory for specific patient and discuss how it tracks psychological well being and distress 
throughout the duration of TOPCare trial.  i.e. started well, things became difficult, life got easier, 
psychological well-being remained unchanged. 
Trajectory 
Briefly, and with reference to the trajectory, how do you remember your well-being, psychologically 
and socially:   
At the start of the trial 
During the trial 
At the end 
After receiving care back in the CCC for some time? 
(If any changes reported )What do you think caused these changes? 
Do you think that your journey whilst on the trial is reflected in the trajectory? 
Before the trial 
Before the study began, how would you describe your emotional and social well-being/state of 
mind?  Talk to me about your emotional health, worries, depression, family relationships, 
community relations, spiritual well-being, adherence, sexual risk taking.  How did this affect your 
ability to work, day to day life, and your ability to function to an acceptable level.  Why was that? 
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Before the study began, how would you describe your physical well-being?   talk to me about your 
physical health, pain, symptoms.  How did this affect your ability to work, day to day life, and your 
ability to function to an acceptable level.  Why was that? 
Before the study began, how would you describe your spiritual well-being? Talk to me about your 
feelings of peace and how your health affected your ability to participate in an active spiritual life 
(attending church/mosque).  How did this affect your ability to work, day to day life, and your ability 
to function to an acceptable level.  Why was that? 
During the trial 
During the trial, how would you describe your emotional wellbeing/state of mind?  Talk to me about 
your emotional health, worries, depression, family relationships, community relations, spiritual well-
being, adherence, sexual risk taking.  How did this affect your ability to work, day to day life, and 
your ability to function to an acceptable level.  Why was that? 
During the trial, how would you describe your physical well-being?  Talk to me about your physical 
health, pain, symptoms.  How did this affect your ability to work, day to day life, and your ability to 
function to an acceptable level.  Why was that? 
During the trial, how would you describe your spiritual well-being?  Talk to me about your feelings of 
peace and how your health affected your ability to participate in an active spiritual life (attending 
church/mosque).  How did this affect your ability to work, day to day life, and your ability to function 
to an acceptable level.  Why was that? 
What would happen during the time you spent with the nurse(s)?  
What kind of questions? 
What kinds of concerns were discussed? 
What was important to you to discuss during this time? 
Do you think you got better in any way from seeing the nurse in the study? How?  
Did you get worse any way?  
Was it different in any way to the usual care you get at the clinic? 
How easy was it to answer all the questions from the researcher? 
How did it make you feel, to answer all the questions from the researcher? 
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After the trial 
After returning to the CCC and receiving care as before, do you think your experience of palliative 
care has affected you, or changed you in any way?   
Talk to me about your physical, emotional and spiritual well-being, worries, depression, family 
relationships, community relations, spiritual well-being, adherence, sexual risk taking, pain, 
symptoms. 
How did this affect your ability to work, day to day life, and your ability to function to an acceptable 
level.  Why was that? 
If change reported: What was important in this change taking place? Why/how did it happen? 
If no change reported: What do you think you need to be healthier or happier? 
For you, what was the most important thing about being on the trial – if anything, what helped you 
the most?   Is there anything that could have been done differently which would have helped you?   
Is there anything else you would like to add or tell me about your experiences of taking part in this 
research? 
Thinking back, when I very first invited you into the TOPCare study, why did you say yes?  
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Interview topic guide - Control patients 
Introduce self again, welcome client and thank for taking part.  Explain that this is an opportunity to 
explain what it was like being in the TOPCare trial in a freer way – your own experience, in your own 
words. 
Admin: - Complete consent form, Add in ID number, ask about more questions.  
Briefly recount TOPCare trial, MOS-HIV, asked questions about emotional and physical well-being.   
Trajectory 
Present trajectory for specific patient and discuss how it tracks psychological well being and distress 
throughout the duration of TOPCare trial.  i.e. started well, things became difficult, life got easier, 
psychological well-being remained unchanged.  Briefly, and with reference to the trajectory, how do 
you remember your well-being, psychologically and socially:   
At the start of the trial 
During the trial 
At the end 
(If any changes reported )What do you think caused these changes?  Do you think that your journey 
whilst on the trial is reflected in the trajectory? 
Before the study 
Before the study began, how would you describe your emotional and social well-being/state of 
mind?  Talk to me about your emotional health, worries, depression, family relationships, 
community relations, spiritual well-being, adherence, sexual risk taking.  How did this affect your 
ability to work, day to day life, and your ability to function to an acceptable level.  Why was that? 
Before the study began, how would you describe your physical well-being?  Talk to me about your 
physical health, pain, symptoms.  How did this affect your ability to work, day to day life, and your 
ability to function to an acceptable level.  Why was that? 
Before the study began, how would you describe your spiritual well-being?  Talk to me about your 
feelings of peace and how your health affected your ability to participate in an active spiritual life 
(attending church/mosque).  How did this affect your ability to work, day to day life, and your ability 
to function to an acceptable level.  Why was that? 
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During the trial  
During the trial, how would you describe your emotional wellbeing/state of mind?  Talk to me about 
your emotional health, worries, depression, family relationships, community relations, spiritual well-
being, adherence, sexual risk taking.  How did this affect your ability to work, day to day life, and 
your ability to function to an acceptable level.  Why was that? 
During the trial, how would you describe your physical well-being?  Talk to me about your physical 
health, pain, symptoms.  How did this affect your ability to work, day to day life, and your ability to 
function to an acceptable level.  Why was that? 
During the trial, how would you describe your spiritual well-being?  Talk to me about your feelings of 
peace and how your health affected your ability to participate in an active spiritual life (attending 
church/mosque).  How did this affect your ability to work, day to day life, and your ability to function 
to an acceptable level.  Why was that? 
How easy was it to answer all the questions from the researcher? 
How did it make you feel, to answer all the questions from the researcher? 
After the trial 
After finishing your time on the study, do you think your experience of being on the TOPCare trial 
has affected you, or changed you in any way?   
Talk to me about your physical, emotional and spiritual well-being, worries, depression, family 
relationships, community relations, spiritual well-being, adherence, sexual risk taking, pain, 
symptoms.  How did this affect your ability to work, day to day life, and your ability to function to an 
acceptable level.  Why was that? 
If change reported: What was important in this change taking place? Why/how did it happen? 
If no change reported: What do you think you need to be healthier or happier? 
For you, what was the most important thing about being on the trial – if anything what helped you 
the most?   Is there anything else you would like to add or tell me about your experiences of taking 
part in this research? 
Thinking back, when I very first invited you into the TOPCare study, why did you say yes?  
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Prompts and probes 
Amplification: 
 
Could you tell me a little more about that? 
Could you give me an example of that? 
When you say that, what gave you that impression? 
What exactly was it that you liked? 
How did you respond when? 
What did you feel when? 
Why do you think this is important? 
What effect did that have on you? 




What makes you say that? 




How was that 
helpful/unhelpful/important/ difficult? 
Could you explain what you mean by.....? 
Before you said...... but you also say 
.....[highlighting contradiction].   
What are the main feelings you’re left 
with? 
 
In-depth iterative probing: 
 
This may sound like an obvious question, 
but.....   
I want to make sure I’ve really 
understood you.  What was it exactly 
that you meant by.......? 
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Appendix 11 - Confidential Disclosure Agreement for Transcription and 
translation services 
This Agreement is entered into this 09 day of August, 2012 by and between xxxx  (hereinafter 
"Recipient") and Keira Lowther, with offices at King’s College London, London, UK (hereinafter 
"Discloser"). 
WHEREAS Discloser possesses certain ideas and information relating to patient and psychosocial 
care provider personal identity, demographic details and opinions of research participants that is 
confidential and proprietary to Discloser (hereinafter "Confidential Information"); and 
WHEREAS the Recipient is willing to receive disclosure of the Confidential Information pursuant to 
the terms of this Agreement for the purpose of transcription and translation of audio interviews; 
NOW THEREFORE, in consideration for the mutual undertakings of the Discloser and the Recipient 
under this Agreement, the parties agree as follows:  
1. Disclosure. Discloser agrees to disclose, and Receiver agrees to receive the Confidential 
Information. 
2. Confidentiality.  
2.1 No Use. Recipient agrees not to use the Confidential Information in any way, except for the 
purpose set forth above.  
2.2 No Disclosure. Recipient agrees to use its best efforts to prevent and protect the Confidential 
Information, or any part thereof, from disclosure to any person other than the Recipient. 
2.3 Protection of Secrecy. Recipient agrees to take all steps reasonably necessary to protect the 
secrecy of the Confidential Information, and to prevent the Confidential Information from falling 
into the public domain or into the possession of unauthorized persons. 
3. Limits on Confidential Information. Confidential Information shall not be deemed proprietary 
and the Recipient shall have no obligation with respect to such information where the information:  
(a) was known to Recipient prior to receiving any of the Confidential Information from Discloser;  
(b) has become publicly known through no wrongful act of Recipient; 
(c) was received by Recipient without breach of this Agreement from a third party without 
restriction as to the use and disclosure of the information; 
(d) was independently developed by Recipient without use of the Confidential Information; or 
(e) was ordered to be publicly released by the requirement of a government agency. 
4. Ownership of Confidential Information. Recipient agrees that all Confidential Information shall 
remain the property of Discloser, and that Discloser may use such Confidential Information for any 
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purpose without obligation to Recipient. Nothing contained herein shall be construed as granting or 
implying any transfer of rights to Recipient in the Confidential Information, or any patents or other 
intellectual property protecting or relating to the Confidential Information. 
5. Term and Termination. The obligations of this Agreement shall be continuing until the 
Confidential Information disclosed to Recipient is no longer confidential. 
6. Survival of Rights and Obligations. This Agreement shall be binding upon, inure to the benefit 
of, and be enforceable by (a) Discloser, its successors, and assigns; and (b) Recipient, its 
successors and assigns. 
IN WITNESS WHEREOF, the parties have executed this agreement effective as of the date first 
written above. 
DISCLOSER Keira Lowther  RECIPIENT   
Signed:  
 
Print Name: KEIRA LOWTHER 
Title: Ms 
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Appendix 13 – Extract of Project Journal 
30/07/2013 14:05 
All the data is coded into nodes and the intervention interviews are all checked. 
Hypotheses at the moment are that a sense of well-being may lead to a sense of social value, which 
could facilitate the rejection or active resistance to stigma messages?  The original deductive codes 
of Physical, social, psychological and spiritual have been developed to include topics which arose 
inductively such as disclosure, compassion, identity, hope, and concepts of attribution of 
improvement and content of the intervention: health education counselling and medication 
management. 
Rather than divide up the symptoms and complaints into specific psychological or physical 
symptoms, although these are sometimes decided to be relevant, it was more pertinent to 
differentiate whether these symptoms were problematic or not.  Psychological symptoms such as 
fear, shame, sadness and anxiety were also fine grain coded when more detail was provided by 
participants. 
Main themes at this moment appear to be: The therapeutic value of talking process, Stigma, 
Identity, Fear, Well-being or normality, 
I think these all need to be addressed in order to heal or become "normal" as defined by the 
participants - these are the active ingredients.  Talking and connecting with team led to increase in 
social value and reparation of identity, and ability to fulfil social role such as breadwinning or 
caretaking.   
Fear was addressed by acceptance and non judgementalism from the study team and through health 
education.  Created a tentative model for the resistence to stigma based on Goudge et al 
09/08/2013 11:41 
Following a meeting with RH, I have revised the coding framework to make it more conceptualised 
and clearer for someone external to look at.   
Is this a barrier to clear transparent analysis? Process towards developing concepts within the data.  
I have developed the code "coping" to "Living with HIV".  Do codes such as financial burden belong 
with this code - suggesting that living with HIV creates or exacerbates financial burden?  This is not 
clear from the financial burden data.  Do this population experience financial burden, regardless of 
HIV diagnosis.  
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Appendix 14 – Definition of themes and sub-themes in coding 
framework 
Each theme and subtheme is listed in this appendix with a brief definition.  They are presented 
alphabetically, with major themes in uppercase, and their sub-themes in sentence case. 
Ability to self care: Descriptions of participants take care of themselves in terms of personal hygiene 
and maintenance 
Acceptance of oneself and of status: Participants report of becoming more accepting of HIV positive 
diagnosis and self as a valid human being 
Active ingredients of intervention: Aspect of the intervention which produces the therapeutic 
benefit 
Active resistance: Response to hearing stigmatising messages or experiencing HIV-associated 
discrimination and actively resisting the stigma, through action or words 
ART adherence: Reports of taking medication, difficulties taking medication or related information 
ART adherence counselling: Descriptions of counselling given by study nurses to facilitate ART 
adherence 
Being known: Participants descriptions of benefits of feeling known by the study team, and the 
effects that this had on their mental health and well-being 
Being listened to: Descriptions of the experience of being listened to and having someone  
to talk to 
Blaming God: Reports of blaming God for their HIV positive diagnosis and the consequences 
Care taking or bread winning: Descriptions of social roles within the household 
Communication: Participant descriptions of the therapeutic benefits of effective communication 
during participation in the study. 
Compassion for others: Participant descriptions of their compassion for other people, and 
acknowledgement of their suffering 
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Compassionate care: One of the therapeutic aspects of participation, describing the approach and 
supportive way the study team interacted with participants.  Included the sub themes of being 
known and feeling treated well 
Consent: Data concerning the consent process, informed consent and reasons why participants gave 
their consent to participate in the study. 
Content of intervention: Descriptions of what happened during palliative care appointments with 
the study nurses, including counselling 
Corporate religious practice: Participant descriptions of their participation in collective religious 
experiences such as attending church, choir, prayer meetings or other events.  
Counselling: Reports of counselling as part descriptions of the content of the intervention 
Counselling for emotional support: Specific reports of counselling which was perceived by 
participants as emotionally supportive, such as management of emotional and psychological pain 
Counselling for social support:  Specific reports of counselling which provided social support, such as 
guidance on how to manage relationships 
Counselling for spiritual care: Participant descriptions of spiritual guidance and care provided by the 
study nurses, for example advising participants to attend church, or read the Bible, or praying with 
them 
Disclosure event: Participants descriptions of how, when and why they disclosed their HIV positive 
status, and to who.  This also included the decision making process of who to disclose to and why 
Effective Counselling: Active ingredient of the intervention describing the experience and effect of 
receiving counselling which met participant need 
Enacted stigma:  Descriptions of participant experience of discrimination 
Experience of healthcare: Participants’ descriptions of healthcare beyond that received as part of 
the study, including government clinics and private healthcare  
Experience of participation in research: Reports of the participants’ experiences of being recruited 
in a study: relationships with researchers and study nurses and the research process 
EXPERIENCE OF RESEARCH: Participant descriptions of their experiences of research, including 
consent, content of the intervention, participation and understanding of the research process 
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Fear:  Participant descriptions of experiencing fear or worry 
Fear for health: Participant report of fear for their future well-being, often whether they would be 
able to get better and resume their previous life  
Fear of being unable to fulfil role:  Data pertaining to the fear that the participant would not be able 
to care for their family or earn a living in the future, often due to poor health 
Fear of death: Participant reports of uncertainty in their future, and their fears that they might die 
soon, and fear for the consequences of this. 
Fear of disclosure:  Social fear of discrimination or isolation related to disclosure of HIV status, both 
accidently or inadvertently or on purpose. 
Feeling treated well: A therapeutic aspect of participation concerning the feeling of being subject to 
good hospitality, or otherwise being treated well or nicely 
Felt normative stigma: Participant descriptions of stigma which were accepted in their culture and 
community 
Financial burden: Participants descriptions of the experience of feeling financial constraint, or 
burden and of being a burden to others. 
Financial support: Descriptions of financial support as part of the content of the intervention for 
participants 
Free from mental strain: Participants descriptions of being freed from their previous mental strain 
during participation in the trial, as a source of hope 
Freedom:  Participant report of the importance of freedom in communication, that it should be 
unrestrained for full benefit 
Fulfilling role: Data describing participant social well-being in terms of their ability to fulfil their 
socially prescribed role 
Good nutrition: Participant reports of the importance of good nutrition for positive physical well-
being 
Gratitude to God: Patient descriptions of their gratitude to God for their current state of health, or 
relationships or other aspects of their lives that they were happy with 
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Growth in hope: Sub theme of hope as a part of spiritual well-being, encompassing participant 
descriptions of what cause an increase in their feelings of hope 
Health education: Data regarding information of health promoting nature, given to the participants  
Hope: Participants description of hope or other aspirations for the future, as part of spiritual well-
being, including descriptions of growth in hope and loss of hope 
Identity: Participant descriptions of how they see themselves and aspects of their personhood and 
self-image 
Increasing trust in HCP: Participants descriptions of increasing trust and the result of that trust in the 
therapeutic relationship with health care providers during receipt of the intervention 
Individual religious practice: Descriptions of prayer and devotional activities practiced alone 
Insight and understanding: An active ingredient of the intervention describing the effect of 
counselling and health education on mental health and well-being 
Interaction with healthcare professionals outside of study: Descriptions of contact participants had 
with medical or nursing staff outside of the study, usually in the CC or other hospitals such as the 
Government hospital 
Internalised stigma: Participants descriptions of negative feelings they had about themselves, which 
stemmed from the stigmatising view of their community, which they had internalised as their own, 
creating distress and inner conflict 
Judgement or rejection by God: Participants description of rationalisations they made about how 
God might be feeling negatively about them, or their actions or the situation they found themselves 
in as a PLWH, sometimes associated with internalised stigma 
Juice and biscuits: Data referring to the refreshments received by participants on arrival for an 
appointment 
Lack of social support – isolation: Participants descriptions of being isolated from family or 
community, whether self imposed or as a result of discrimination 
Light beyond being sick: Participants increase in hope due to decrease in symptoms and physical 
and psychological complaints.  This refers to participants hope for the future, and the possibilities 
they believed were not available to them 
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LIVING WITH HIV: Major theme encompassing all data relevant to the experience of life with HIV 
Long life: Participants descriptions of hoping for the future, and realising that they could live when 
previously they thought they would die imminently; a source of increasing hope. 
Lost hope: Participant’s descriptions of when they had experienced a decrease in hope 
Material support:  A therapeutic aspect of participation.  Data describing the therapeutic benefit of 
receiving material support such as refreshments and cash, rather than emotional or social support 
Medication: Participant descriptions of the therapeutic effect of appropriate medication – an active 
ingredient of the intervention 
Medication management: Participants descriptive comments about medication as content of the 
intervention 
Motivated by getting better: Participants accounts of feeling improved well-being due to previous 
improvements, which increased hope and motivation for future improvement 
Negotiation of sex: Participants descriptions of how they negotiated sex and safer sex with their 
partners, as part of sexual well-being 
No engagement with religious practice: Participant descriptions of not engaging with religious 
practice.  Sometimes due to feeling rejected by God, or just because they were not interested in 
spirituality and religion 
Nutrition counselling: Descriptions of content of the intervention regarding nutrition advice and diet 
counselling 
Open communication: Descriptive accounts of the benefits of open communication as a therapeutic 
aspect of participation in the study  
Patient perspective of intervention: Participants’ view and opinions on the relevance, value and 
effect of the study on them 
Peace: Descriptions of feeling at peace, in terms of inner peace, peace in relationships and feelings 
of reconciliation with others 
Personal strength: Descriptions of inner strength and resolve, with increases associated with 
improvements in self image 
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Physical and psychological interaction:  Descriptions of the effects of relief of physical symptoms on 
psychological symptoms and vice versa 
Physical well-being: Descriptive accounts of physical well-being, including symptoms, and nutrition 
Possibility to regain role: Data pertaining to social role fulfilment, and the hope participants express 
that they might earn money or take care of their family otherwise in the future 
Praying for a cure: Descriptions of participants praying to God to cure them of HIV 
Presence of social support: Participants descriptive accounts of the provision of social support from 
partners, families or those in their community. 
PROMS as prompts: Participant reports if using the PROMs as a prompt to self care, either as 
reflective material or as an indication of a health promotion message. 
Protected sex: Participants descriptions of negotiating, the importance of or whether they have 
protected sex with their partners 
Psychological well-being: Data pertaining to psychological symptoms and alleviation of 
psychological symptoms  
Rejection of sexuality or sexual practice: Participants decisions to not engage in sexual activity after 
their HIV positive diagnosis. 
Relationship as source of distress:  Accounts of intimate partner verbal, physical or emotional 
abuse, and how this distressed the participants 
Relationship as source of support: Accounts of partners who were supportive toward the 
participant 
Relationship counselling: Content of the intervention, descriptions of participants’ receipt of 
relationship and couples counselling 
Relief from financial burden:  Data describing the therapeutic aspect of materials support 
specifically the therapeutic aspect of relief of financial constraint 
Relief of physical symptoms:  Reports of relief of physical symptoms such as pain, pruritis or 
numbness 
Relief of psychological symptoms: Reports of relief of psychological symptoms such as worry, fear 
or sadness 
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Religious practice: Descriptive accounts of prayer, attending church or mosque 
Resistance to stigma: Participants descriptions of their internal or external resistant response to 
stigma 
Resistant thinking:  Internal mental rejection of stigmatising messages 
Restoration:  Participants descriptions of inner restoration of self-image or self perception which 
was restored to pre-HIV state 
Role: Accounts of social role, fulfilling it, being unable to fulfil it, with associated distress 
Sadness:  Participants descriptions of feeling sad, depressed or in a low mood 
Self determination:  Participants accounts of feelings of empowerment or situations where they 
were able to control their lives in ways which they had not previously 
Self image: Descriptive data of how participants saw themselves, and felt about themselves as 
human beings 
Sex as therapy: Participants descriptions of using sex with their partners as a therapeutic act, which 
they described, relieved physical symptoms 
Sexual health counselling: Descriptions of the content of the intervention including counselling on 
protected sex, and management of sexually transmitted infections 
Sexual well-being: All participants reported data pertaining to participant’s sexual health and well-
being 
Shame: Descriptions of feeling shame, or feeling shamed by others, usually due to inability to fulfil 
social role or HIV-related stigma 
Social or emotional support from study team: Descriptions of participants’ feelings of being 
supported by the study team 
Social support: As part of social well-being, the extent to which participants describe feeling 
supported by their community or not. 
Social support: Data attributing social support as a therapeutic aspect of participation, received from 
the study team religious communities or from peers. 
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Social support from peers: Participants descriptions of feeling supported through knowledge that 
they had peers, through contact with their peers, and the impact this had on participants 
Social well-being: Descriptions of social support, social role and social shame  
SOURCES OF BENEFIT: Theme containing data on active ingredients and therapeutic aspects of 
participation 
Spiritual:  Descriptive accounts of spiritual well-being, engagement with corporate or personal 
religious activity, and blaming God and receiving support from religious or spiritual practices 
Stigma: participants Descriptions of experiencing stigma or discrimination through rejection, 
isolation or persecution 
Strategic avoidance:  Participants descriptions of resistance to stigma through avoiding 
confrontation or situations where they could reasonably expect to experience stigma or 
discrimination as a results of their HIV positive diagnosis 
Stress or anxiety:  Participants descriptions of feeling anxious or stressed as a psychological 
symptoms 
Suicidal thoughts: Descriptions of suicidal thoughts, ideation and plans made by participants 
Support from religious practice:  Participants descriptions of the support they received from 
religious practice, either from the religious community or from the spiritual practices 
Symptom burden:  Sub theme of living with HIV encompassing physical, psychological, social 
spiritual and sexual well-being 
Taking time:  Participants accounts of the therapeutic effect of the study nurses taking time to talk 
during delivery of the intervention 
Talking to share and relieve burdens: Data describing the therapeutic aspect of talking and 
communication and the psychological relief that sharing emotional burdens brought 
Troubling physical symptoms: Participants accounts of persistent troubling physical symptoms 
Troubling psychological symptoms:  Participants accounts of persistent troubling psychological 
symptoms 
Trust in God: Descriptions of participants trust in God, including trust for the future, resignation that 
this was God’s plan, and fatalism and expressions of fluctuating trust. 
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Unable to fulfil role:   Participant accounts of situations where they were unable to fulfil the role 
expected of them by their community, and the impact this had on their well-being and self-image. 
Understanding of research process:  Descriptive accounts of participants’ perceptions and 
understandings of research processes, such as randomisation, consent, control group allocation and 
the approach of the researcher to data collection 
Unprotected sex:  Participants accounts of unprotected sex, negotiation and avoidance of 
unprotected sex and their knowledge of the associated risks 
Waiting time: Participants descriptions of waiting to be seen for care in the standard care clinic, 
their feelings about this and the impact that this had on their well-being  
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Appendix 15 - Preliminary bivariate analysis to address objective 1 
Data was analysed as per the analysis plan.  To present the data and demonstrate the distribution of dependent variables, data have been modified to 
simplify analysis: age has been divided into decades, time since HIV positive diagnosis into years, and time on ART into years.   
Table 0-1 Preliminary bivariative analysis for objective 1. 
 






































n/a n/a  6 (3-9) n/a n/a 2.5 (0-5) n/a n/a 5 (0-5) n/a n/a 
Males (n=23)  
Females (n=97)  
51.9 (41.8 – 
59.1) 












































































































Appendix 15 - Preliminary bivariate analysis to address objective 1 
358 
 





































Wealth quintile 1 
(n=27)  
Wealth quintile 2 
(n=21) 
 Wealth quintile 3 
(n=24) 
Wealth quintile 4 
(n=24) 



























































Never been to 
school (n=10) 
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0   (n=9) 
1   (n=12) 
2   (n=14) 
3   (n=26) 
4   (n=12) 
5   (n=20) 
6   (n=13) 
7   (n=5) 
8   (n=2) 
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0  (n=16) 
1  (n=22) 
2  (n=26)  
3  (n=20) 
4  (n=10) 
5  (n=15) 
6  (n=5) 
7  (n=4) 
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Years since HIV 
diagnosis 
0    (n=26) 
1    (n=11) 
2    (n=11) 
3    (n=17) 
4    (n=18) 
5    (n=23) 
6    (n=6) 
7    (n=4) 








































































Years on ART 
0   (n=35) 
1   (n=13) 
2   (n=20) 
3   (n=17) 
4   (n=14) 
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6   (n=4) 
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